PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
26340804-0	2015	Performance of a new 1,25-dihydroxyvitamin D fully automated assay on IDS-iSYS system.	1,25-dihydroxyvitamin D	21-44	iduronate 2-sulfatase	Homo sapiens	70-73
26071405-0	2015	1,25-Dihydroxyvitamin D regulates expression of the tryptophan hydroxylase 2 and leptin genes: implication for behavioral influences of vitamin D.	1,25-dihydroxyvitamin D	0-23	tryptophan hydroxylase 2	Homo sapiens	52-76
26287999-0	2015	1,25-Dihydroxyvitamin D Protects Intestinal Epithelial Barrier by Regulating the Myosin Light Chain Kinase Signaling Pathway.	1,25-dihydroxyvitamin D	0-23	myosin light chain kinase	Homo sapiens	81-106
26071405-0	2015	1,25-Dihydroxyvitamin D regulates expression of the tryptophan hydroxylase 2 and leptin genes: implication for behavioral influences of vitamin D.	1,25-dihydroxyvitamin D	0-23	leptin	Homo sapiens	81-87
26308451-0	2015	1,25-Dihydroxyvitamin D to PTH(1-84) Ratios Strongly Predict Cardiovascular Death in Heart Failure.	1,25-dihydroxyvitamin D	0-23	parathyroid hormone	Homo sapiens	27-30
26148725-0	2015	FGF23 gene regulation by 1,25-dihydroxyvitamin D: opposing effects in adipocytes and osteocytes.	1,25-dihydroxyvitamin D	25-48	fibroblast growth factor 23	Mus musculus	0-5
26422470-1	2015	Hereditary 1, 25-dihydroxyvitamin D-resistant rickets (HVDRR), a rare recessive disease, is caused by mutation in the VDR gene encoding the vitamin D receptor leading to the resistance to vitamin D.	1,25-dihydroxyvitamin D	11-35	vitamin D receptor	Homo sapiens	56-59
26422470-1	2015	Hereditary 1, 25-dihydroxyvitamin D-resistant rickets (HVDRR), a rare recessive disease, is caused by mutation in the VDR gene encoding the vitamin D receptor leading to the resistance to vitamin D.	1,25-dihydroxyvitamin D	11-35	vitamin D receptor	Homo sapiens	140-158
26153892-1	2015	CONTEXT: Hereditary 1,25-dihydroxyvitamin D-resistant rickets (HVDRR) is an autosomal recessive disease caused by biallelic mutations in the vitamin D receptor (VDR) gene.	1,25-dihydroxyvitamin D	20-43	vitamin D receptor	Homo sapiens	141-159
26153892-1	2015	CONTEXT: Hereditary 1,25-dihydroxyvitamin D-resistant rickets (HVDRR) is an autosomal recessive disease caused by biallelic mutations in the vitamin D receptor (VDR) gene.	1,25-dihydroxyvitamin D	20-43	vitamin D receptor	Homo sapiens	64-67
26131357-2	2015	Parathyroid hormone (PTH), secreted in response to low serum calcium, has an important role in maintaining phosphate homeostasis by influencing renal synthesis of 1,25-dihydroxyvitamin D, thereby increasing intestinal phosphate absorption.	1,25-dihydroxyvitamin D	163-186	parathyroid hormone	Homo sapiens	0-19
25846868-3	2015	These transcription factors in turn suppress vitamin D receptor (VDR) expression, resulting in loss of responsiveness to the protective anti-proliferative and anti-migratory effects of 1,25-dihydroxyvitamin D (1,25D).	1,25-dihydroxyvitamin D	185-208	vitamin D receptor	Homo sapiens	45-63
25846868-3	2015	These transcription factors in turn suppress vitamin D receptor (VDR) expression, resulting in loss of responsiveness to the protective anti-proliferative and anti-migratory effects of 1,25-dihydroxyvitamin D (1,25D).	1,25-dihydroxyvitamin D	185-208	vitamin D receptor	Homo sapiens	65-68
26131357-2	2015	Parathyroid hormone (PTH), secreted in response to low serum calcium, has an important role in maintaining phosphate homeostasis by influencing renal synthesis of 1,25-dihydroxyvitamin D, thereby increasing intestinal phosphate absorption.	1,25-dihydroxyvitamin D	163-186	parathyroid hormone	Homo sapiens	21-24
26224895-1	2015	The vitamin D receptor (VDR), a nuclear transcription factor, elicits physiological regulation of gene transcription following binding of its ligand, 1,25-dihydroxyvitamin D.	1,25-dihydroxyvitamin D	150-173	vitamin D receptor	Homo sapiens	4-22
25749414-4	2015	Multiple anatomical areas relevant to asthma contain both the enzyme responsible for producing activated vitamin D and the vitamin D receptor suggesting that activated vitamin D (1,25-dihydroxyvitamin D) may have important local effects at these sites.	1,25-dihydroxyvitamin D	179-202	vitamin D receptor	Homo sapiens	123-141
28377956-1	2015	Hereditary 1,25-dihydroxyvitamin D-resistant rickets (HVDRR) is caused by mutations in the VDR gene, and its inheritance is autosomal recessive.	1,25-dihydroxyvitamin D	11-34	vitamin D receptor	Homo sapiens	55-58
28377956-0	2015	Hereditary 1,25-dihydroxyvitamin D-resistant rickets (HVDRR) caused by a VDR mutation: A novel mechanism of dominant inheritance.	1,25-dihydroxyvitamin D	11-34	vitamin D receptor	Homo sapiens	55-58
26224895-1	2015	The vitamin D receptor (VDR), a nuclear transcription factor, elicits physiological regulation of gene transcription following binding of its ligand, 1,25-dihydroxyvitamin D.	1,25-dihydroxyvitamin D	150-173	vitamin D receptor	Homo sapiens	24-27
25446885-5	2015	Thus, in Sost knockout mice, concentrations of serum 1,25-dihydroxyvitamin D (1,25(OH)2D) are increased and concentrations of FGF-23 are decreased thereby allowing a positive calcium and phosphorus balance.	1,25-dihydroxyvitamin D	53-76	sclerostin	Mus musculus	9-13
25772922-0	2015	Relationship between 1,25-dihydroxy Vitamin D levels and homeostatic model assessment insulin resistance values in obese subjects.	1,25-dihydroxyvitamin D	21-45	insulin	Homo sapiens	86-93
25656441-4	2015	The biochemical consequence of limitations in FGF23 activity includes increased renal tubular reabsorption of phosphate, hyperphosphatemia, and increased production of 1,25-dihydroxyvitamin D.	1,25-dihydroxyvitamin D	168-191	fibroblast growth factor 23	Homo sapiens	46-51
25926572-2	2015	Fibroblast growth factor 23 (FGF23) decreases serum phosphate by inhibiting proximal tubular phosphate reabsorption and intestinal phosphate absorption through the reduction of serum 1,25-dihydroxyvitamin D [1,25 (OH) (2)D] levels.	1,25-dihydroxyvitamin D	183-206	fibroblast growth factor 23	Homo sapiens	0-27
25926572-2	2015	Fibroblast growth factor 23 (FGF23) decreases serum phosphate by inhibiting proximal tubular phosphate reabsorption and intestinal phosphate absorption through the reduction of serum 1,25-dihydroxyvitamin D [1,25 (OH) (2)D] levels.	1,25-dihydroxyvitamin D	183-206	fibroblast growth factor 23	Homo sapiens	29-34
25092518-2	2015	The resulting intracrine conversion of precursor 25-hydroxyvitamin D3 (25OHD) to active 1,25-dihydroxyvitamin D (1,25(OH)2D) can stimulate expression of antibacterial cathelicidin (CAMP).	1,25-dihydroxyvitamin D	88-111	cathelicidin antimicrobial peptide	Homo sapiens	181-185
25447737-1	2015	The active form of vitamin D (1alpha,25-dihydroxyvitamin D, 1,25(OH)2D) exerts its genomic effects via binding to a nuclear high-affinity vitamin D receptor (VDR).	1,25-dihydroxyvitamin D	30-58	vitamin D receptor	Homo sapiens	138-156
25448743-1	2015	Topical 1,25-dihydroxyvitamin D (1,25D) and other vitamin D compounds have been shown to protect skin from damage by ultraviolet radiation (UVR) in a process that requires the vitamin D receptor.	1,25-dihydroxyvitamin D	8-31	vitamin D (1,25-dihydroxyvitamin D3) receptor	Mus musculus	176-194
25597951-2	2015	In vitro, 1,25 dihydroxyvitamin D (1,25(OH)2D), suppresses beta-catenin-mediated gene transcription by inducing vitamin D receptor (VDR)-beta-catenin interactions.	1,25-dihydroxyvitamin D	10-33	catenin (cadherin associated protein), beta 1	Mus musculus	59-71
25597951-2	2015	In vitro, 1,25 dihydroxyvitamin D (1,25(OH)2D), suppresses beta-catenin-mediated gene transcription by inducing vitamin D receptor (VDR)-beta-catenin interactions.	1,25-dihydroxyvitamin D	10-33	vitamin D (1,25-dihydroxyvitamin D3) receptor	Mus musculus	112-130
25597951-2	2015	In vitro, 1,25 dihydroxyvitamin D (1,25(OH)2D), suppresses beta-catenin-mediated gene transcription by inducing vitamin D receptor (VDR)-beta-catenin interactions.	1,25-dihydroxyvitamin D	10-33	vitamin D (1,25-dihydroxyvitamin D3) receptor	Mus musculus	132-135
25597951-2	2015	In vitro, 1,25 dihydroxyvitamin D (1,25(OH)2D), suppresses beta-catenin-mediated gene transcription by inducing vitamin D receptor (VDR)-beta-catenin interactions.	1,25-dihydroxyvitamin D	10-33	catenin (cadherin associated protein), beta 1	Mus musculus	137-149
25447737-1	2015	The active form of vitamin D (1alpha,25-dihydroxyvitamin D, 1,25(OH)2D) exerts its genomic effects via binding to a nuclear high-affinity vitamin D receptor (VDR).	1,25-dihydroxyvitamin D	30-58	vitamin D receptor	Homo sapiens	158-161
25060765-2	2015	The CYP27B1 gene, which encodes the 1-alpha-hidroxylase and involved in the 1,25-dihydroxyvitamin D synthesis, was recently associated to type-1 diabetes, autoimmune disorders and treatment response in HCV.	1,25-dihydroxyvitamin D	76-99	cytochrome P450 family 27 subfamily B member 1	Homo sapiens	4-11
25716808-2	2015	Various kinds of immune cells-including macrophages, dendritic cells, T cells and B cells- express the vitamin D receptor and 1alpha-hydroxylase (CYP27B1), the enzyme necessary for the conversion of circulating 25-hydroxyvitamin D into its active form, 1,25-dihydroxyvitamin D.	1,25-dihydroxyvitamin D	253-276	cytochrome P450 family 27 subfamily B member 1	Homo sapiens	146-153
25270396-8	2015	Serum FGF-23 was significantly higher and 1,25-dihydroxyvitamin D (1,25(OH)2D3) lower in SLE patients treated with glucocorticoid and CsA than in those not taking both of them (p=0.027 and 0.002, respectively).	1,25-dihydroxyvitamin D	42-65	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	134-137
25445451-1	2015	Fibroblast growth factor 23 (FGF23), a bone-derived hormone, participates in the hormonal bone-parathyroid-kidney axis, which is modulated by PTH, 1,25-dihydroxyvitamin D, plasma phosphate (Pi), and diet.	1,25-dihydroxyvitamin D	147-170	fibroblast growth factor 23	Homo sapiens	0-27
25445451-1	2015	Fibroblast growth factor 23 (FGF23), a bone-derived hormone, participates in the hormonal bone-parathyroid-kidney axis, which is modulated by PTH, 1,25-dihydroxyvitamin D, plasma phosphate (Pi), and diet.	1,25-dihydroxyvitamin D	147-170	fibroblast growth factor 23	Homo sapiens	29-34
24939836-2	2015	Thus, the major role of the 1,25-dihydroxyvitamin D [1,25(OH)2D]/VDR system is to regulate mineral and skeletal homeostasis, although mainly after birth.	1,25-dihydroxyvitamin D	28-51	vitamin D receptor	Homo sapiens	65-68
25423921-3	2014	Recent evidence demonstrated that FGF23 levels increase early in CKD to maintain normal phosphate balance, but this results in suppression of renal production of 1,25 dihydroxyvitamin D and thereby triggers the early development of secondary hyperparathyroidism.	1,25-dihydroxyvitamin D	162-185	fibroblast growth factor 23	Homo sapiens	34-39
25451947-0	2015	Serum free 1,25-dihydroxy-vitamin D is more closely associated with fibroblast growth factor 23 than other vitamin D forms in chronic dialysis patients.	1,25-dihydroxyvitamin D	11-35	fibroblast growth factor 23	Homo sapiens	68-95
26000293-6	2015	Moreover, 1,25-dihydroxyvitamin D is implicated in NOD2-mediated expression of defensin-beta2, the latter known to play a crucial role in the pathogenesis of Crohn"s disease (IBD1 gene), and several genetic variants of the vitamin D receptor have been identified as Crohn"s disease candidate susceptibility genes.	1,25-dihydroxyvitamin D	10-33	nucleotide binding oligomerization domain containing 2	Homo sapiens	51-55
26000293-6	2015	Moreover, 1,25-dihydroxyvitamin D is implicated in NOD2-mediated expression of defensin-beta2, the latter known to play a crucial role in the pathogenesis of Crohn"s disease (IBD1 gene), and several genetic variants of the vitamin D receptor have been identified as Crohn"s disease candidate susceptibility genes.	1,25-dihydroxyvitamin D	10-33	defensin beta 4A	Homo sapiens	79-93
26000293-6	2015	Moreover, 1,25-dihydroxyvitamin D is implicated in NOD2-mediated expression of defensin-beta2, the latter known to play a crucial role in the pathogenesis of Crohn"s disease (IBD1 gene), and several genetic variants of the vitamin D receptor have been identified as Crohn"s disease candidate susceptibility genes.	1,25-dihydroxyvitamin D	10-33	nucleotide binding oligomerization domain containing 2	Homo sapiens	175-179
26000293-6	2015	Moreover, 1,25-dihydroxyvitamin D is implicated in NOD2-mediated expression of defensin-beta2, the latter known to play a crucial role in the pathogenesis of Crohn"s disease (IBD1 gene), and several genetic variants of the vitamin D receptor have been identified as Crohn"s disease candidate susceptibility genes.	1,25-dihydroxyvitamin D	10-33	vitamin D receptor	Homo sapiens	223-241
25557732-0	2015	The claudin-16 channel gene is transcriptionally inhibited by 1,25-dihydroxyvitamin D.	1,25-dihydroxyvitamin D	62-85	claudin 16	Homo sapiens	4-14
25147982-1	2014	The syndrome of hereditary 1,25-dihydroxyvitamin D-resistant rickets (HVDRR) is a genetic disease of altered mineral homeostasis due to mutations in the vitamin D receptor (VDR) gene.	1,25-dihydroxyvitamin D	27-50	vitamin D (1,25-dihydroxyvitamin D3) receptor	Mus musculus	153-171
25354043-2	2014	The discovery that immune cells express the vitamin D receptor and are capable of metabolizing circulating 25-hydroxyvitamin D into its active form, 1,25-dihydroxyvitamin D, has revolutionized the field and suggested a regulatory role on both the innate and adaptive immune systems.	1,25-dihydroxyvitamin D	149-172	vitamin D receptor	Homo sapiens	44-62
25352227-6	2014	Although FGF23 systemic actions in the kidney, and for the production of PTH and 1,25-dihydroxyvitamin-D are well established, its direct involvement in bone metabolism is currently poorly understood.	1,25-dihydroxyvitamin D	81-104	fibroblast growth factor 23	Homo sapiens	9-14
25352227-9	2014	In addition, 1,25-dihydroxyvitamin-D, synthesized locally by bone cells, may contribute to regulation of FGF23 production.	1,25-dihydroxyvitamin D	13-36	fibroblast growth factor 23	Homo sapiens	105-110
25147982-1	2014	The syndrome of hereditary 1,25-dihydroxyvitamin D-resistant rickets (HVDRR) is a genetic disease of altered mineral homeostasis due to mutations in the vitamin D receptor (VDR) gene.	1,25-dihydroxyvitamin D	27-50	vitamin D (1,25-dihydroxyvitamin D3) receptor	Mus musculus	71-74
25051439-1	2014	Fibroblast growth factor 23 (FGF23) is a hormone that inhibits renal phosphate reabsorption and 1,25-dihydroxyvitamin D biosynthesis.	1,25-dihydroxyvitamin D	96-119	fibroblast growth factor 23	Mus musculus	0-27
25051439-1	2014	Fibroblast growth factor 23 (FGF23) is a hormone that inhibits renal phosphate reabsorption and 1,25-dihydroxyvitamin D biosynthesis.	1,25-dihydroxyvitamin D	96-119	fibroblast growth factor 23	Mus musculus	29-34
24120913-1	2014	The metabolism of 25-hydroxyvitamin D (25D) to active 1alpha,25-dihydroxyvitamin D (1,25D) by endogenous expression of 25D 1-alpha hydroxylase (CYP27B1) in bone cells appears to have functional effects in both osteoclasts and osteoblasts.	1,25-dihydroxyvitamin D	54-82	cytochrome P450 family 27 subfamily B member 1	Homo sapiens	144-151
25062462-1	2014	CONTEXT: 1,25-Dihydroxyvitamin D (1,25D) administration and long-term increases in phosphate, PTH, and calcium concentrations are associated with increases in circulating fibroblast growth factor 23 (FGF23); however, whether or not acute changes in serum calcium modulate short-term FGF23 release is unknown.	1,25-dihydroxyvitamin D	9-32	fibroblast growth factor 23	Homo sapiens	171-198
25062462-1	2014	CONTEXT: 1,25-Dihydroxyvitamin D (1,25D) administration and long-term increases in phosphate, PTH, and calcium concentrations are associated with increases in circulating fibroblast growth factor 23 (FGF23); however, whether or not acute changes in serum calcium modulate short-term FGF23 release is unknown.	1,25-dihydroxyvitamin D	9-32	fibroblast growth factor 23	Homo sapiens	200-205
25062462-1	2014	CONTEXT: 1,25-Dihydroxyvitamin D (1,25D) administration and long-term increases in phosphate, PTH, and calcium concentrations are associated with increases in circulating fibroblast growth factor 23 (FGF23); however, whether or not acute changes in serum calcium modulate short-term FGF23 release is unknown.	1,25-dihydroxyvitamin D	9-32	fibroblast growth factor 23	Homo sapiens	283-288
24859502-0	2014	Hereditary 1,25-dihydroxyvitamin D-resistant rickets with alopecia in four Egyptian families: report of three novel mutations in the vitamin D receptor gene.	1,25-dihydroxyvitamin D	11-34	vitamin D receptor	Homo sapiens	133-151
24388948-3	2014	Principal among these factors are Type I and Type II interferons (IFNs); the Type II IFN, IFN-gamma, stimulates the production of 1,25-dihydroxyvitamin D (1,25(OH)2D) from 25-hydroxyvitamin D (25OHD) by the granuloma-forming disease-activated macrophage, while the Type I IFNs, IFN-alpha and IFN-beta, block the hydroxylation reaction.	1,25-dihydroxyvitamin D	130-153	interferon gamma	Homo sapiens	90-99
24388948-3	2014	Principal among these factors are Type I and Type II interferons (IFNs); the Type II IFN, IFN-gamma, stimulates the production of 1,25-dihydroxyvitamin D (1,25(OH)2D) from 25-hydroxyvitamin D (25OHD) by the granuloma-forming disease-activated macrophage, while the Type I IFNs, IFN-alpha and IFN-beta, block the hydroxylation reaction.	1,25-dihydroxyvitamin D	130-153	interferon alpha 1	Homo sapiens	278-287
24388948-3	2014	Principal among these factors are Type I and Type II interferons (IFNs); the Type II IFN, IFN-gamma, stimulates the production of 1,25-dihydroxyvitamin D (1,25(OH)2D) from 25-hydroxyvitamin D (25OHD) by the granuloma-forming disease-activated macrophage, while the Type I IFNs, IFN-alpha and IFN-beta, block the hydroxylation reaction.	1,25-dihydroxyvitamin D	130-153	interferon beta 1	Homo sapiens	292-300
24885630-2	2014	Hereditary 1,25-dihydroxyvitamin D-resistant rickets (HVDRR) patients provide a natural model to assess the role of the vitamin D receptor (VDR) in regulating human lung immune responses and airway hyperreactivity.	1,25-dihydroxyvitamin D	11-34	vitamin D receptor	Homo sapiens	120-138
24885630-2	2014	Hereditary 1,25-dihydroxyvitamin D-resistant rickets (HVDRR) patients provide a natural model to assess the role of the vitamin D receptor (VDR) in regulating human lung immune responses and airway hyperreactivity.	1,25-dihydroxyvitamin D	11-34	vitamin D receptor	Homo sapiens	55-58
23911725-1	2014	Hormonal 1,25-dihydroxyvitamin D [1,25(OH)2D] signals through the nuclear vitamin D receptor (VDR), a ligand-regulated transcription factor.	1,25-dihydroxyvitamin D	9-32	vitamin D receptor	Homo sapiens	74-92
23911725-1	2014	Hormonal 1,25-dihydroxyvitamin D [1,25(OH)2D] signals through the nuclear vitamin D receptor (VDR), a ligand-regulated transcription factor.	1,25-dihydroxyvitamin D	9-32	vitamin D receptor	Homo sapiens	94-97
24103701-4	2014	Recently we showed that 1,25-dihydroxyvitamin D (1,25(OH)2D3) modulates innate immune response by targeting the miR-155-SOCS1 axis.	1,25-dihydroxyvitamin D	24-47	microRNA 155	Mus musculus	112-119
24103701-4	2014	Recently we showed that 1,25-dihydroxyvitamin D (1,25(OH)2D3) modulates innate immune response by targeting the miR-155-SOCS1 axis.	1,25-dihydroxyvitamin D	24-47	suppressor of cytokine signaling 1	Mus musculus	120-125
24859502-1	2014	OBJECTIVE: To study the vitamin D receptor (VDR) gene in five Egyptian patients with severe rickets and the clinical features of hereditary vitamin D-resistant rickets, including hypocalcemia, hypophosphatemia, total alopecia, and elevated serum levels of 1,25-dihydroxyvitamin D.	1,25-dihydroxyvitamin D	256-279	vitamin D receptor	Homo sapiens	24-42
24859502-1	2014	OBJECTIVE: To study the vitamin D receptor (VDR) gene in five Egyptian patients with severe rickets and the clinical features of hereditary vitamin D-resistant rickets, including hypocalcemia, hypophosphatemia, total alopecia, and elevated serum levels of 1,25-dihydroxyvitamin D.	1,25-dihydroxyvitamin D	256-279	vitamin D receptor	Homo sapiens	44-47
24854954-1	2014	Vitamin D(3) belongs to the few nutritional compounds that has, via the binding of its metabolite 1alpha,25-dihydroxyvitamin D(3) (1,25(OH)(2)D(3)) to the transcription factor vitamin D receptor (VDR), a direct effect on gene regulation.	1,25-dihydroxyvitamin D	98-126	vitamin D receptor	Homo sapiens	176-194
24854954-1	2014	Vitamin D(3) belongs to the few nutritional compounds that has, via the binding of its metabolite 1alpha,25-dihydroxyvitamin D(3) (1,25(OH)(2)D(3)) to the transcription factor vitamin D receptor (VDR), a direct effect on gene regulation.	1,25-dihydroxyvitamin D	98-126	vitamin D receptor	Homo sapiens	196-199
24848934-2	2014	RECENT FINDINGS: FGF23 decreases serum phosphate and 1,25-dihydroxyvitamin D levels.	1,25-dihydroxyvitamin D	53-76	fibroblast growth factor 23	Homo sapiens	17-22
24763863-8	2014	Of note, both VDR and sclerostin immunostaining were significantly correlated with serum 1,25-dihydroxyvitamin D in IH patients (r=0.52; P=0.01 and r=0.53; P=0.02, respectively), although VDR and sclerostin expression did not differ between IH and controls.	1,25-dihydroxyvitamin D	89-112	vitamin D receptor	Homo sapiens	14-17
24763863-8	2014	Of note, both VDR and sclerostin immunostaining were significantly correlated with serum 1,25-dihydroxyvitamin D in IH patients (r=0.52; P=0.01 and r=0.53; P=0.02, respectively), although VDR and sclerostin expression did not differ between IH and controls.	1,25-dihydroxyvitamin D	89-112	sclerostin	Homo sapiens	22-32
24980727-3	2014	Parathyroid hormone stimulates the production of 1,25-dihydroxyvitamin D to enhance diet calcium absorption.	1,25-dihydroxyvitamin D	49-72	parathyroid hormone	Bos taurus	0-19
24790904-2	2014	Recent research on the various molecular activities of the vitamin D system, including the nuclear vitamin D receptor and other receptors for 1,25-dihydroxyvitamin D and vitamin D metabolism, provides evidence that the vitamin D system carries out biological activities across a wide range of tissues similar to other nuclear receptor hormones.	1,25-dihydroxyvitamin D	142-165	vitamin D receptor	Homo sapiens	99-117
24917821-3	2014	VDR and the p53/p63/p73 proteins all function typically as receptors or sensors that turn into transcriptional regulators upon stimulus, with the main difference being that the nuclear VDR is activated as a transcription factor after binding its naturally occurring ligand 1,25-dihydroxyvitamin D with high affinity while the p53 family of transcription factors, mostly in the nucleoplasm, responds to a large number of alterations in cell homeostasis commonly referred to as stress.	1,25-dihydroxyvitamin D	273-296	vitamin D (1,25-dihydroxyvitamin D3) receptor	Mus musculus	0-3
24917821-3	2014	VDR and the p53/p63/p73 proteins all function typically as receptors or sensors that turn into transcriptional regulators upon stimulus, with the main difference being that the nuclear VDR is activated as a transcription factor after binding its naturally occurring ligand 1,25-dihydroxyvitamin D with high affinity while the p53 family of transcription factors, mostly in the nucleoplasm, responds to a large number of alterations in cell homeostasis commonly referred to as stress.	1,25-dihydroxyvitamin D	273-296	transformation related protein 53, pseudogene	Mus musculus	12-15
24917821-3	2014	VDR and the p53/p63/p73 proteins all function typically as receptors or sensors that turn into transcriptional regulators upon stimulus, with the main difference being that the nuclear VDR is activated as a transcription factor after binding its naturally occurring ligand 1,25-dihydroxyvitamin D with high affinity while the p53 family of transcription factors, mostly in the nucleoplasm, responds to a large number of alterations in cell homeostasis commonly referred to as stress.	1,25-dihydroxyvitamin D	273-296	transformation related protein 63	Mus musculus	16-19
24917821-3	2014	VDR and the p53/p63/p73 proteins all function typically as receptors or sensors that turn into transcriptional regulators upon stimulus, with the main difference being that the nuclear VDR is activated as a transcription factor after binding its naturally occurring ligand 1,25-dihydroxyvitamin D with high affinity while the p53 family of transcription factors, mostly in the nucleoplasm, responds to a large number of alterations in cell homeostasis commonly referred to as stress.	1,25-dihydroxyvitamin D	273-296	transformation related protein 73	Mus musculus	20-23
24917821-3	2014	VDR and the p53/p63/p73 proteins all function typically as receptors or sensors that turn into transcriptional regulators upon stimulus, with the main difference being that the nuclear VDR is activated as a transcription factor after binding its naturally occurring ligand 1,25-dihydroxyvitamin D with high affinity while the p53 family of transcription factors, mostly in the nucleoplasm, responds to a large number of alterations in cell homeostasis commonly referred to as stress.	1,25-dihydroxyvitamin D	273-296	vitamin D (1,25-dihydroxyvitamin D3) receptor	Mus musculus	185-188
24917821-3	2014	VDR and the p53/p63/p73 proteins all function typically as receptors or sensors that turn into transcriptional regulators upon stimulus, with the main difference being that the nuclear VDR is activated as a transcription factor after binding its naturally occurring ligand 1,25-dihydroxyvitamin D with high affinity while the p53 family of transcription factors, mostly in the nucleoplasm, responds to a large number of alterations in cell homeostasis commonly referred to as stress.	1,25-dihydroxyvitamin D	273-296	transformation related protein 53, pseudogene	Mus musculus	326-329
24917821-8	2014	UV irradiation-surviving cells show significant reductions in thymine dimers in the presence of 1,25-dihydroxyvitamin D that are associated with increased nuclear p53 protein expression, and significantly reduced NO products.	1,25-dihydroxyvitamin D	96-119	transformation related protein 53, pseudogene	Mus musculus	163-166
24790904-7	2014	The three major bone cell types, which are osteoblasts, osteocytes and osteoclasts, can all respond to vitamin D via the classical nuclear vitamin D receptor and metabolize 25-hydroxyvitamin D to 1,25-dihydroxyvitamin D to activate the vitamin D receptor and modulate gene expression.	1,25-dihydroxyvitamin D	196-219	vitamin D receptor	Homo sapiens	236-254
24154811-5	2014	The VDR is expressed in all immune cells and both directly and indirectly targeted by the bioactive form of vitamin D, 1,25-Dihydroxyvitamin D (1,25[OH]2D).	1,25-dihydroxyvitamin D	119-142	vitamin D receptor	Homo sapiens	4-7
24471562-7	2014	MAIN OUTCOMES: Protein and mRNA expressions of CYP27B1, CYP24A1, and vitamin D receptor were measured in term placental tissue and related to 25-hydroxyvitamin D [25(OH)D], 1,25-dihydroxyvitamin D, PTH, serum total calcium, IL-6, leptin, and osteoprotegerin measured in maternal serum at midgestation and delivery and in umbilical cord serum at birth.	1,25-dihydroxyvitamin D	173-196	cytochrome P450 family 27 subfamily B member 1	Homo sapiens	47-54
24670704-2	2014	CXCL10 gene expression is downregulated in monocytes by metabolically active vitamin D3 (1,25dihydroxy vitamin D).	1,25-dihydroxyvitamin D	89-112	C-X-C motif chemokine ligand 10	Homo sapiens	0-6
24569459-2	2014	XLH-associated mutations in phosphate-regulating endopeptidase (PHEX) result in elevated serum FGF23, decreased renal phosphate reabsorption, and low serum concentrations of phosphate (inorganic phosphorus, Pi) and 1,25-dihydroxyvitamin D [1,25(OH)2D].	1,25-dihydroxyvitamin D	215-238	phosphate regulating endopeptidase homolog X-linked	Homo sapiens	64-68
24721620-3	2014	The relationship with PTHrP has not been determined or studied.The aim of this study is to describe and discuss the case and the pathophysiological mechanisms involved in a malignant hypercalcemia mediated by 1,25-dihydroxyvitamin D and PTHrP cosecretion in a patient with seminoma.	1,25-dihydroxyvitamin D	209-232	parathyroid hormone like hormone	Homo sapiens	22-27
24471562-7	2014	MAIN OUTCOMES: Protein and mRNA expressions of CYP27B1, CYP24A1, and vitamin D receptor were measured in term placental tissue and related to 25-hydroxyvitamin D [25(OH)D], 1,25-dihydroxyvitamin D, PTH, serum total calcium, IL-6, leptin, and osteoprotegerin measured in maternal serum at midgestation and delivery and in umbilical cord serum at birth.	1,25-dihydroxyvitamin D	173-196	vitamin D receptor	Homo sapiens	69-87
24471562-9	2014	Maternal serum 1,25-dihydroxyvitamin D concentrations at midgestation were positively correlated with term placental CYP27B1 mRNA expression (n = 49, P = .002).	1,25-dihydroxyvitamin D	15-38	cytochrome P450 family 27 subfamily B member 1	Homo sapiens	117-124
23959712-5	2014	Furthermore, we explored correlations of DBP with 25- hydroxyvitamin D (25(OH)D) and 1,25-dihydroxyvitamin D levels (1,25(OH)2D), and the effect of high-dose vitamin D3 supplementation on DBP levels in RRMS patients (n = 15).	1,25-dihydroxyvitamin D	85-108	D-box binding PAR bZIP transcription factor	Homo sapiens	41-44
23907847-2	2014	Retinoid-X receptor-alpha (RXRA) is an essential cofactor in the action of 1,25-dihydroxyvitamin D (1,25[OH]2 -vitamin D), and RXRA methylation in umbilical cord DNA has been associated with later offspring adiposity.	1,25-dihydroxyvitamin D	75-98	retinoid X receptor alpha	Homo sapiens	0-25
24641809-2	2014	The biological actions of 1, 25-dihydroxyvitamin D, are mediated through the vitamin D receptor (VDR), which heterodimerizes with retinoid X receptor, gamma (RXRG).	1,25-dihydroxyvitamin D	26-50	vitamin D receptor	Homo sapiens	77-95
24641809-2	2014	The biological actions of 1, 25-dihydroxyvitamin D, are mediated through the vitamin D receptor (VDR), which heterodimerizes with retinoid X receptor, gamma (RXRG).	1,25-dihydroxyvitamin D	26-50	vitamin D receptor	Homo sapiens	97-100
24641809-2	2014	The biological actions of 1, 25-dihydroxyvitamin D, are mediated through the vitamin D receptor (VDR), which heterodimerizes with retinoid X receptor, gamma (RXRG).	1,25-dihydroxyvitamin D	26-50	retinoid X receptor gamma	Homo sapiens	130-156
24641809-2	2014	The biological actions of 1, 25-dihydroxyvitamin D, are mediated through the vitamin D receptor (VDR), which heterodimerizes with retinoid X receptor, gamma (RXRG).	1,25-dihydroxyvitamin D	26-50	retinoid X receptor gamma	Homo sapiens	158-162
24204002-4	2014	Treatment of cultured hepatocytes or monocytes with prohormone 25-hydroxyvitamin D or active 1,25-dihydroxyvitamin D decreased expression of hepcidin mRNA by 0.5-fold, contrasting the stimulatory effect of 25-hydroxyvitamin D or 1,25-dihydroxyvitamin D on related antibacterial proteins such as cathelicidin.	1,25-dihydroxyvitamin D	93-116	hepcidin antimicrobial peptide	Homo sapiens	141-149
24204002-4	2014	Treatment of cultured hepatocytes or monocytes with prohormone 25-hydroxyvitamin D or active 1,25-dihydroxyvitamin D decreased expression of hepcidin mRNA by 0.5-fold, contrasting the stimulatory effect of 25-hydroxyvitamin D or 1,25-dihydroxyvitamin D on related antibacterial proteins such as cathelicidin.	1,25-dihydroxyvitamin D	229-252	hepcidin antimicrobial peptide	Homo sapiens	141-149
24204002-5	2014	Promoter-reporter and chromatin immunoprecipitation analyses indicated that direct transcriptional suppression of hepcidin gene (HAMP) expression mediated by 1,25-dihydroxyvitamin D binding to the vitamin D receptor caused the decrease in hepcidin mRNA levels.	1,25-dihydroxyvitamin D	158-181	hepcidin antimicrobial peptide	Homo sapiens	114-122
24204002-5	2014	Promoter-reporter and chromatin immunoprecipitation analyses indicated that direct transcriptional suppression of hepcidin gene (HAMP) expression mediated by 1,25-dihydroxyvitamin D binding to the vitamin D receptor caused the decrease in hepcidin mRNA levels.	1,25-dihydroxyvitamin D	158-181	hepcidin antimicrobial peptide	Homo sapiens	129-133
24204002-5	2014	Promoter-reporter and chromatin immunoprecipitation analyses indicated that direct transcriptional suppression of hepcidin gene (HAMP) expression mediated by 1,25-dihydroxyvitamin D binding to the vitamin D receptor caused the decrease in hepcidin mRNA levels.	1,25-dihydroxyvitamin D	158-181	vitamin D receptor	Homo sapiens	197-215
24204002-5	2014	Promoter-reporter and chromatin immunoprecipitation analyses indicated that direct transcriptional suppression of hepcidin gene (HAMP) expression mediated by 1,25-dihydroxyvitamin D binding to the vitamin D receptor caused the decrease in hepcidin mRNA levels.	1,25-dihydroxyvitamin D	158-181	hepcidin antimicrobial peptide	Homo sapiens	239-247
23907847-2	2014	Retinoid-X receptor-alpha (RXRA) is an essential cofactor in the action of 1,25-dihydroxyvitamin D (1,25[OH]2 -vitamin D), and RXRA methylation in umbilical cord DNA has been associated with later offspring adiposity.	1,25-dihydroxyvitamin D	75-98	retinoid X receptor alpha	Homo sapiens	27-31
24125760-7	2014	Multivariable linear regression adjusted for 1,25 dihydroxyvitamin D, kidney function, and parathyroid hormone revealed insulin resistance was a risk factor for greater log ctFGF-23 levels (log HOMA IR beta=0.37; 95% confidence interval 0.14 to 0.59; P=0.002).	1,25-dihydroxyvitamin D	45-68	insulin	Homo sapiens	120-127
24418271-6	2014	They then received synthetic PTH injections at 3-h intervals for 48 h. Parathyroid hormone is expected to cause an increase in plasma calcium by increasing renal production of 1,25-dihydroxyvitamin D and increasing bone calcium resorption.	1,25-dihydroxyvitamin D	176-199	parathyroid hormone	Bos taurus	71-90
25506471-2	2014	More recently hnRNP C has also been shown to function as a DNA binding protein exerting a dominant-negative effect on transcriptional responses to the vitamin D hormone,1,25-dihydroxyvitamin D (1,25(OH)2D), via interaction in cis with vitamin D response elements (VDREs).	1,25-dihydroxyvitamin D	169-192	heterogeneous nuclear ribonucleoprotein C	Homo sapiens	14-21
24423361-11	2014	CONCLUSIONS: Chronic hypercalcemia, hypercalciuria, and/or nephrolithiasis may be caused by mutations in CYP24A1 causing failure to metabolize 1,25-dihydroxyvitamin D.	1,25-dihydroxyvitamin D	143-166	cytochrome P450 family 24 subfamily A member 1	Homo sapiens	105-112
24436433-3	2014	The active metabolite of vitamin D, 1alpha,25-dihydroxyvitamin D, binds to the vitamin D receptor that regulates numerous genes involved in fundamental processes of potential relevance to cardiovascular disease, including cell proliferation and differentiation, apoptosis, oxidative stress, membrane transport, matrix homeostasis, and cell adhesion.	1,25-dihydroxyvitamin D	36-64	vitamin D receptor	Homo sapiens	79-97
24076413-0	2013	1,25-Dihydroxyvitamin D decreases HTRA1 promoter activity in the rhesus monkey--a plausible explanation for the influence of vitamin D on age-related macular degeneration?	1,25-dihydroxyvitamin D	0-23	HtrA serine peptidase 1	Macaca mulatta	34-39
24196349-5	2013	1,25-Dihydroxyvitamin D blocked LPS-induced Ang-2 expression by blocking nuclear factor-kappaB activation in human pulmonary artery endothelial cells.	1,25-dihydroxyvitamin D	0-23	angiogenin, ribonuclease A family, member 2	Mus musculus	44-49
24246681-0	2014	Vitamin D receptor mutations in patients with hereditary 1,25-dihydroxyvitamin D-resistant rickets.	1,25-dihydroxyvitamin D	57-80	vitamin D receptor	Homo sapiens	0-18
24258305-7	2014	1,25-dihydroxyvitamin D was the strongest negative predictor of I-FGF23 concentration (R(2)=18%; P=0.0006) and soluble transferrin receptor was the strongest positive predictor of C-FGF23 concentration (R(2)=33%; P<=0.0001).	1,25-dihydroxyvitamin D	0-23	fibroblast growth factor 23	Homo sapiens	66-71
25019032-1	2013	The combination of serum 25-hydroxyvitamin D (25D) and fibroblast growth factor 23 (FGF23) levels predict hard renal outcomes in patients with chronic kidney disease (CKD), independent of classical markers of mineral and bone disorders, including serum phosphorus, parathyroid hormone, 1,25-dihydroxyvitamin D levels, and active vitamin D therapy.	1,25-dihydroxyvitamin D	286-309	fibroblast growth factor 23	Homo sapiens	84-89
23965431-9	2013	Furthermore, addition of 1,25-dihydroxyvitamin D to uremic serum partially restored the serum effect on CYP3A4 expression.	1,25-dihydroxyvitamin D	25-48	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	104-110
23789983-5	2013	On the other hand, IGF-I stimulates renal production of 1,25-dihydroxyvitamin D, which increases calcium and phosphate availability in the body and suppresses PTH secretion.	1,25-dihydroxyvitamin D	56-79	insulin like growth factor 1	Homo sapiens	19-24
23789983-5	2013	On the other hand, IGF-I stimulates renal production of 1,25-dihydroxyvitamin D, which increases calcium and phosphate availability in the body and suppresses PTH secretion.	1,25-dihydroxyvitamin D	56-79	parathyroid hormone	Homo sapiens	159-162
24019880-1	2013	The mitochondrial enzyme 25-hydroxyvitamin D 1alpha-hydroxylase, which is encoded by the CYP27B1 gene, converts 25OHD to the biological active form of vitamin D, 1,25-dihydroxyvitamin D (1,25(OH)2D).	1,25-dihydroxyvitamin D	162-185	cytochrome P450, family 27, subfamily b, polypeptide 1	Mus musculus	89-96
23911750-1	2013	Vitamin D activity requires an adequate vitamin D status as indicated by the serum level of 25-hydroxyvitamin D and appropriate expression of genes coding for vitamin D receptor and 25-hydroxyvitamin D 1alpha-hydroxylase, the enzyme which converts 25-hydroxyvitamin D to 1,25-dihydroxyvitamin D.	1,25-dihydroxyvitamin D	271-294	vitamin D receptor	Homo sapiens	159-177
23911750-7	2013	Recent research demonstrates that the three major bone cell types have the capability to metabolise 25-hydroxyvitamin D to 1,25-dihydroxyvitamin D to activate the vitamin D receptor and modulate gene expression.	1,25-dihydroxyvitamin D	123-146	vitamin D receptor	Homo sapiens	163-181
23965431-10	2013	The present study suggests that the decrease of 1,25-dihydroxyvitamin D and the accumulation of uremic toxins contributed to the decreased hepatic clearance of CYP3A4 substrates in patients with end-stage renal disease.	1,25-dihydroxyvitamin D	48-71	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	160-166
23503652-0	2013	Tumor suppressor microRNAs, miR-100 and -125b, are regulated by 1,25-dihydroxyvitamin D in primary prostate cells and in patient tissue.	1,25-dihydroxyvitamin D	64-87	microRNA 100	Homo sapiens	28-45
22989482-1	2013	Human marrow stromal cells (hMSCs) are targets of 1alpha,25-dihydroxyvitamin D [1alpha,25(OH)2D3] action to promote their differentiation to osteoblasts, but they also participate in vitamin D metabolism by converting 25-dihydroxyvitamin D3 [25(OH)D3] to 1alpha,25(OH)2D3 by 1alpha-hydroxylase (CYP27B1).	1,25-dihydroxyvitamin D	50-78	cytochrome P450 family 27 subfamily B member 1	Homo sapiens	295-302
23752493-8	2013	CONCLUSIONS: Vitamin D deficiency is associated with suppression of resting cardiac autonomic activity, while low 1,25-dihydroxy vitamin D levels are associated with unfavourable cardiac autonomic activity during an acute AngII stressor, offering a potential pathophysiological mechanism that may be acting to elevate CV risk in in populations with low vitamin D status.	1,25-dihydroxyvitamin D	114-138	angiotensinogen	Homo sapiens	222-227
23362149-1	2013	When bound to the vitamin D receptor (VDR), the active form of vitamin D, 1,25-dihydroxyvitamin D (1,25D) is a potent regulator of osteoblast transcription.	1,25-dihydroxyvitamin D	74-97	vitamin D receptor	Homo sapiens	18-36
23362149-1	2013	When bound to the vitamin D receptor (VDR), the active form of vitamin D, 1,25-dihydroxyvitamin D (1,25D) is a potent regulator of osteoblast transcription.	1,25-dihydroxyvitamin D	74-97	vitamin D receptor	Homo sapiens	38-41
23856260-5	2013	Functional elements responsive to 1,25-dihydroxyvitamin D, proinflammatory cytokines, and glial cells missing-2 are present in the CASR promoters.	1,25-dihydroxyvitamin D	34-57	calcium sensing receptor	Homo sapiens	131-135
23160964-6	2013	Moreover, in adipose tissue cultures, 1,25-dihydroxyvitamin D markedly stimulated mRNA expression and secretion of leptin, but not resistin, in adipose tissues obtained from WT mice, but not from VDR-null mice, and leptin upregulation induced by 1,25-dihydroxyvitamin D was more robust in adipose tissues obtained from VDR Tg mice compared with WT mice.	1,25-dihydroxyvitamin D	38-61	leptin	Mus musculus	115-121
23423976-2	2013	Its chief circulating metabolite, 25-hydroxyvitamin D, is converted into the active hormone 1,25-dihydroxyvitamin D (1,25D) by the cytochrome P450 enzyme CYP27B1 in kidney and other tissues.	1,25-dihydroxyvitamin D	92-115	cytochrome P450 family 27 subfamily B member 1	Homo sapiens	154-161
23530237-5	2013	Eight-week-old, male sost KO mice had increased serum 1alpha,25-dihydroxyvitamin D, decreased 24,25-dihydroxyvitamin D, decreased intact fibroblast growth factor 23, and elevated inorganic phosphorus concentrations compared with age-matched WT mice.	1,25-dihydroxyvitamin D	54-82	sclerostin	Mus musculus	21-25
23344160-4	2013	Specifically, 1,25-dihydroxyvitamin D(3) (24-h pretreatment) caused a more than threefold enhancement in both ET-1-induced intracellular calcium mobilization and extracellular signal-regulated kinase (ERK) activation.	1,25-dihydroxyvitamin D	14-37	endothelin 1	Homo sapiens	110-114
23344160-4	2013	Specifically, 1,25-dihydroxyvitamin D(3) (24-h pretreatment) caused a more than threefold enhancement in both ET-1-induced intracellular calcium mobilization and extracellular signal-regulated kinase (ERK) activation.	1,25-dihydroxyvitamin D	14-37	mitogen-activated protein kinase 1	Homo sapiens	162-199
23344160-4	2013	Specifically, 1,25-dihydroxyvitamin D(3) (24-h pretreatment) caused a more than threefold enhancement in both ET-1-induced intracellular calcium mobilization and extracellular signal-regulated kinase (ERK) activation.	1,25-dihydroxyvitamin D	14-37	mitogen-activated protein kinase 1	Homo sapiens	201-204
23344160-6	2013	With the use of endothelin receptor (ETR) isoform-selective antagonists, ETRA was found to be primarily responsible for the 1,25-dihydroxyvitamin D(3)-induced ET-1 responsiveness and yet ETRA mRNA expression and protein abundance were unaltered following 1,25-dihydroxyvitamin D(3) treatment.	1,25-dihydroxyvitamin D	124-147	endothelin receptor type A	Homo sapiens	73-77
23344160-6	2013	With the use of endothelin receptor (ETR) isoform-selective antagonists, ETRA was found to be primarily responsible for the 1,25-dihydroxyvitamin D(3)-induced ET-1 responsiveness and yet ETRA mRNA expression and protein abundance were unaltered following 1,25-dihydroxyvitamin D(3) treatment.	1,25-dihydroxyvitamin D	124-147	endothelin 1	Homo sapiens	159-163
23344160-6	2013	With the use of endothelin receptor (ETR) isoform-selective antagonists, ETRA was found to be primarily responsible for the 1,25-dihydroxyvitamin D(3)-induced ET-1 responsiveness and yet ETRA mRNA expression and protein abundance were unaltered following 1,25-dihydroxyvitamin D(3) treatment.	1,25-dihydroxyvitamin D	255-278	endothelin receptor type A	Homo sapiens	73-77
23436936-0	2013	1,25-Dihydroxyvitamin D promotes negative feedback regulation of TLR signaling via targeting microRNA-155-SOCS1 in macrophages.	1,25-dihydroxyvitamin D	0-23	microRNA 155	Mus musculus	93-105
23436936-0	2013	1,25-Dihydroxyvitamin D promotes negative feedback regulation of TLR signaling via targeting microRNA-155-SOCS1 in macrophages.	1,25-dihydroxyvitamin D	0-23	suppressor of cytokine signaling 1	Mus musculus	106-111
23124514-0	2013	Interleukin-17A stimulates granulocyte-macrophage colony-stimulating factor release by murine osteoblasts in the presence of 1,25-dihydroxyvitamin D(3)  and inhibits murine osteoclast development in vitro.	1,25-dihydroxyvitamin D	125-148	interleukin 17A	Mus musculus	0-15
23124514-0	2013	Interleukin-17A stimulates granulocyte-macrophage colony-stimulating factor release by murine osteoblasts in the presence of 1,25-dihydroxyvitamin D(3)  and inhibits murine osteoclast development in vitro.	1,25-dihydroxyvitamin D	125-148	colony stimulating factor 2 (granulocyte-macrophage)	Mus musculus	27-75
22968766-4	2013	The underlying mechanisms are probably both indirect via calcium and phosphate and direct via activation of the vitamin D receptor (VDR) on muscle cells by 1,25-dihydroxyvitamin D [1,25(OH)(2)D].	1,25-dihydroxyvitamin D	156-179	vitamin D (1,25-dihydroxyvitamin D3) receptor	Mus musculus	112-130
22968766-4	2013	The underlying mechanisms are probably both indirect via calcium and phosphate and direct via activation of the vitamin D receptor (VDR) on muscle cells by 1,25-dihydroxyvitamin D [1,25(OH)(2)D].	1,25-dihydroxyvitamin D	156-179	vitamin D (1,25-dihydroxyvitamin D3) receptor	Mus musculus	132-135
23160964-6	2013	Moreover, in adipose tissue cultures, 1,25-dihydroxyvitamin D markedly stimulated mRNA expression and secretion of leptin, but not resistin, in adipose tissues obtained from WT mice, but not from VDR-null mice, and leptin upregulation induced by 1,25-dihydroxyvitamin D was more robust in adipose tissues obtained from VDR Tg mice compared with WT mice.	1,25-dihydroxyvitamin D	38-61	vitamin D (1,25-dihydroxyvitamin D3) receptor	Mus musculus	319-322
23160964-6	2013	Moreover, in adipose tissue cultures, 1,25-dihydroxyvitamin D markedly stimulated mRNA expression and secretion of leptin, but not resistin, in adipose tissues obtained from WT mice, but not from VDR-null mice, and leptin upregulation induced by 1,25-dihydroxyvitamin D was more robust in adipose tissues obtained from VDR Tg mice compared with WT mice.	1,25-dihydroxyvitamin D	246-269	leptin	Mus musculus	115-121
23160964-7	2013	These data demonstrate that 1,25-dihydroxyvitamin D stimulates adipose leptin production in a VDR-dependent manner, suggesting that vitamin D may affect energy homeostasis through direct regulation of leptin expression.	1,25-dihydroxyvitamin D	28-51	leptin	Mus musculus	71-77
23160964-7	2013	These data demonstrate that 1,25-dihydroxyvitamin D stimulates adipose leptin production in a VDR-dependent manner, suggesting that vitamin D may affect energy homeostasis through direct regulation of leptin expression.	1,25-dihydroxyvitamin D	28-51	vitamin D (1,25-dihydroxyvitamin D3) receptor	Mus musculus	94-97
23160964-7	2013	These data demonstrate that 1,25-dihydroxyvitamin D stimulates adipose leptin production in a VDR-dependent manner, suggesting that vitamin D may affect energy homeostasis through direct regulation of leptin expression.	1,25-dihydroxyvitamin D	28-51	leptin	Mus musculus	201-207
23289765-4	2013	We show that activation of human monocytes via CD40 ligand (CD40L) and IFN-gamma, alone, and in combination, induces the CYP27b1-hydroxylase, responsible for the conversion of 25-hydroxyvitamin D (25D) to the bioactive 1,25-dihydroxyvitamin D (1,25D), and the vitamin D receptor (VDR).	1,25-dihydroxyvitamin D	219-242	CD40 ligand	Homo sapiens	47-58
23289765-4	2013	We show that activation of human monocytes via CD40 ligand (CD40L) and IFN-gamma, alone, and in combination, induces the CYP27b1-hydroxylase, responsible for the conversion of 25-hydroxyvitamin D (25D) to the bioactive 1,25-dihydroxyvitamin D (1,25D), and the vitamin D receptor (VDR).	1,25-dihydroxyvitamin D	219-242	CD40 ligand	Homo sapiens	60-65
23289765-4	2013	We show that activation of human monocytes via CD40 ligand (CD40L) and IFN-gamma, alone, and in combination, induces the CYP27b1-hydroxylase, responsible for the conversion of 25-hydroxyvitamin D (25D) to the bioactive 1,25-dihydroxyvitamin D (1,25D), and the vitamin D receptor (VDR).	1,25-dihydroxyvitamin D	219-242	interferon gamma	Homo sapiens	71-80
23263654-0	2013	1,25-dihydroxyvitamin D(3) regulation of fibroblast growth factor-23 expression in bone cells: evidence for primary and secondary mechanisms modulated by leptin and interleukin-6.	1,25-dihydroxyvitamin D	0-23	fibroblast growth factor 23	Homo sapiens	41-68
26785783-8	2013	The interleukin (IL)-1beta and IL-10 release by hMDMs was clearly increased upon stimulation with 1,25-dihydroxyvitamin D.	1,25-dihydroxyvitamin D	98-121	interleukin 1 beta	Homo sapiens	4-26
26785783-8	2013	The interleukin (IL)-1beta and IL-10 release by hMDMs was clearly increased upon stimulation with 1,25-dihydroxyvitamin D.	1,25-dihydroxyvitamin D	98-121	interleukin 10	Homo sapiens	31-36
26785783-9	2013	Furthermore, the 1,25-dihydroxyvitamin D stimulation also led to elevated levels of TNF-alpha (tumor necrosis factor-alpha) and IL-12p40.	1,25-dihydroxyvitamin D	17-40	tumor necrosis factor	Homo sapiens	84-93
26785783-9	2013	Furthermore, the 1,25-dihydroxyvitamin D stimulation also led to elevated levels of TNF-alpha (tumor necrosis factor-alpha) and IL-12p40.	1,25-dihydroxyvitamin D	17-40	tumor necrosis factor	Homo sapiens	95-122
23233539-6	2013	Increases in dietary phosphorus in PTH-CaSR DKO mice markedly decreased serum 1,25-dihydroxyvitamin D(3) [1,25(OH)(2)D(3)] despite no change in FGF23, suggesting direct regulation of 1,25(OH)(2)D(3) synthesis by serum phosphorus.	1,25-dihydroxyvitamin D	78-101	calcium-sensing receptor	Mus musculus	39-43
22782502-1	2013	The hormonal metabolite of vitamin D, 1alpha,25-dihydroxyvitamin D(3) (1,25D), initiates biological responses via binding to the vitamin D receptor (VDR).	1,25-dihydroxyvitamin D	38-66	vitamin D receptor	Homo sapiens	129-147
22782502-1	2013	The hormonal metabolite of vitamin D, 1alpha,25-dihydroxyvitamin D(3) (1,25D), initiates biological responses via binding to the vitamin D receptor (VDR).	1,25-dihydroxyvitamin D	38-66	vitamin D receptor	Homo sapiens	149-152
23160964-6	2013	Moreover, in adipose tissue cultures, 1,25-dihydroxyvitamin D markedly stimulated mRNA expression and secretion of leptin, but not resistin, in adipose tissues obtained from WT mice, but not from VDR-null mice, and leptin upregulation induced by 1,25-dihydroxyvitamin D was more robust in adipose tissues obtained from VDR Tg mice compared with WT mice.	1,25-dihydroxyvitamin D	38-61	leptin	Mus musculus	215-221
24348674-0	2013	Modulatory effect of 1,25-dihydroxyvitamin D 3 on IL1 beta -induced RANKL, OPG, TNF alpha , and IL-6 expression in human rheumatoid synoviocyte MH7A.	1,25-dihydroxyvitamin D	21-44	interleukin 1 beta	Homo sapiens	50-58
23867793-1	2013	AIM: to investigate the association between vitamin D receptor polymorphisms and circulating 1,25-Dihydroxyvitamin D (1,25(OH)2D) levels with keloid scar (KS) risk.	1,25-dihydroxyvitamin D	93-116	vitamin D receptor	Homo sapiens	44-62
23879537-5	2013	The active form of vitamin D, 1,25-dihydroxyvitamin D (1,25(OH)2D) functions as a steroid hormone that, when bound to its nuclear vitamin D receptor, is able to regulate target gene expression.	1,25-dihydroxyvitamin D	30-53	vitamin D receptor	Homo sapiens	130-148
23392891-2	2013	However, whether the hormone calcitriol (1,25-dihydroxyvitamin D(3)) and retinoic acid regulate the expression of the TauT gene is unknown.	1,25-dihydroxyvitamin D	41-64	solute carrier family 6 member 6	Homo sapiens	118-122
23132743-1	2013	The vitamin D receptor (VDR) has both 1,25-dihydroxyvitamin D-dependent and -independent actions in the epidermis.	1,25-dihydroxyvitamin D	38-61	vitamin D (1,25-dihydroxyvitamin D3) receptor	Mus musculus	4-22
22986488-2	2013	Several studies suggest that dietary phosphate, serum phosphate and 1,25-dihydroxyvitamin D [1,25(OH)(2)D] are candidate regulators of FGF-23.	1,25-dihydroxyvitamin D	68-91	fibroblast growth factor 23	Homo sapiens	135-141
24348674-0	2013	Modulatory effect of 1,25-dihydroxyvitamin D 3 on IL1 beta -induced RANKL, OPG, TNF alpha , and IL-6 expression in human rheumatoid synoviocyte MH7A.	1,25-dihydroxyvitamin D	21-44	TNF superfamily member 11	Homo sapiens	68-73
23132743-1	2013	The vitamin D receptor (VDR) has both 1,25-dihydroxyvitamin D-dependent and -independent actions in the epidermis.	1,25-dihydroxyvitamin D	38-61	vitamin D (1,25-dihydroxyvitamin D3) receptor	Mus musculus	24-27
23132743-4	2013	The VDR also has immunomodulatory actions that are dependent on its ligand, 1,25-dihydroxyvitamin D.	1,25-dihydroxyvitamin D	76-99	vitamin D (1,25-dihydroxyvitamin D3) receptor	Mus musculus	4-7
24348674-0	2013	Modulatory effect of 1,25-dihydroxyvitamin D 3 on IL1 beta -induced RANKL, OPG, TNF alpha , and IL-6 expression in human rheumatoid synoviocyte MH7A.	1,25-dihydroxyvitamin D	21-44	TNF receptor superfamily member 11b	Homo sapiens	75-78
24348674-0	2013	Modulatory effect of 1,25-dihydroxyvitamin D 3 on IL1 beta -induced RANKL, OPG, TNF alpha , and IL-6 expression in human rheumatoid synoviocyte MH7A.	1,25-dihydroxyvitamin D	21-44	tumor necrosis factor	Homo sapiens	80-89
24348674-0	2013	Modulatory effect of 1,25-dihydroxyvitamin D 3 on IL1 beta -induced RANKL, OPG, TNF alpha , and IL-6 expression in human rheumatoid synoviocyte MH7A.	1,25-dihydroxyvitamin D	21-44	interleukin 6	Homo sapiens	96-100
22886720-0	2013	Fibroblast growth factor 23 inhibits extrarenal synthesis of 1,25-dihydroxyvitamin D in human monocytes.	1,25-dihydroxyvitamin D	61-84	fibroblast growth factor 23	Homo sapiens	0-27
23162103-4	2013	RESULTS: Treatment with PTH(1-84) reduced supplemental calcium requirements by 37% (P = 0.006) and 1,25-dihydroxyvitamin D requirements by 45% (P = 0.008).	1,25-dihydroxyvitamin D	99-122	parathyroid hormone	Homo sapiens	24-27
23162103-12	2013	CONCLUSIONS: PTH(1-84) treatment of hypoparathyroidism for up to 4 yr maintains the serum calcium concentration, while significantly reducing supplemental calcium and 1,25-dihydroxyvitamin D requirements.	1,25-dihydroxyvitamin D	167-190	parathyroid hormone	Homo sapiens	13-16
23128574-3	2012	SUMMARY: PTH promotes bone resorption, decreases urinary calcium excretion, enhances the conversion of 25-hydroxyvitamin D to 1, 25-dihydroxyvitamin D and increases intestinal calcium absorption and phosphate renal excretion.	1,25-dihydroxyvitamin D	126-150	parathyroid hormone	Homo sapiens	9-12
23350010-6	2013	Interestingly, production of IL-6 at 6 hours by THP-1 cells stimulated with live M. leprae and M. bovis BCG was dependent on pretreatment with 1,25-dihydroxyvitamin D(3) (VD).	1,25-dihydroxyvitamin D	143-166	interleukin 6	Homo sapiens	29-33
23350010-6	2013	Interestingly, production of IL-6 at 6 hours by THP-1 cells stimulated with live M. leprae and M. bovis BCG was dependent on pretreatment with 1,25-dihydroxyvitamin D(3) (VD).	1,25-dihydroxyvitamin D	143-166	GLI family zinc finger 2	Homo sapiens	48-53
22944250-3	2012	Here we verified the ability of the natural VDR ligand, 1,25-dihydroxyvitamin D(3) (1,25(OH)(2)D(3)) to interfere in inflammatory and T cell stimulatory capacity of macrophages, in particular within a chronic inflammatory disease features of experimental type 1 diabetes (T1D).	1,25-dihydroxyvitamin D	56-79	vitamin D (1,25-dihydroxyvitamin D3) receptor	Mus musculus	44-47
23180879-8	2013	FGF23 levels were high when 25-hydroxyvitamin D [25(OH)D] and 1,25-dihydroxyvitamin D [1,25(OH)(2)D] were deficient (P = 0.05 and P < 0.001, respectively).	1,25-dihydroxyvitamin D	62-85	fibroblast growth factor 23	Homo sapiens	0-5
23431388-5	2013	RESULTS: The serum Klotho level significantly correlated with the 1,25-dihydroxyvitamin D level and inversely correlated with the parathyroid hormone level and the fractional excretion of phosphate.	1,25-dihydroxyvitamin D	66-89	klotho	Homo sapiens	19-25
23041230-3	2012	In the current study we have examined the ability of CYP24A1, the enzyme that inactivates 1,25-dihydroxyvitamin D(3) (1,25(OH)(2)D(3)), to metabolize 20(OH)D(3).	1,25-dihydroxyvitamin D	90-113	cytochrome P450, family 24, subfamily a, polypeptide 1	Rattus norvegicus	53-60
23112173-3	2012	We show through cell- and animal-based studies and mathematical modeling that hormonal 1,25-dihydroxyvitamin D (1,25D) and the vitamin D receptor (VDR) profoundly alter, through multiple mechanisms, the balance in function of c-MYC and its antagonist the transcriptional repressor MAD1/MXD1.	1,25-dihydroxyvitamin D	87-110	myelocytomatosis oncogene	Mus musculus	228-231
23123403-6	2012	In culture, 1,25-dihydroxyvitamin D suppressed high-glucose-induced apoptosis of podocytes by blocking p38- and ERK-mediated proapoptotic pathways.	1,25-dihydroxyvitamin D	12-35	mitogen-activated protein kinase 14	Mus musculus	103-106
23123403-6	2012	In culture, 1,25-dihydroxyvitamin D suppressed high-glucose-induced apoptosis of podocytes by blocking p38- and ERK-mediated proapoptotic pathways.	1,25-dihydroxyvitamin D	12-35	mitogen-activated protein kinase 1	Mus musculus	112-115
22884583-5	2012	We found that overexpression of PPARgamma decreased 1alpha,25-dihydroxyvitamin D(3) (1,25D(3)) mediated transcriptional activity of the vitamin D target gene, CYP24A1, by 49% and the activity of VDRE-luc, a vitamin D responsive reporter, by 75% in T47D human breast cancer cells.	1,25-dihydroxyvitamin D	52-80	peroxisome proliferator activated receptor gamma	Homo sapiens	32-41
22884583-5	2012	We found that overexpression of PPARgamma decreased 1alpha,25-dihydroxyvitamin D(3) (1,25D(3)) mediated transcriptional activity of the vitamin D target gene, CYP24A1, by 49% and the activity of VDRE-luc, a vitamin D responsive reporter, by 75% in T47D human breast cancer cells.	1,25-dihydroxyvitamin D	52-80	cytochrome P450 family 24 subfamily A member 1	Homo sapiens	159-166
23112173-3	2012	We show through cell- and animal-based studies and mathematical modeling that hormonal 1,25-dihydroxyvitamin D (1,25D) and the vitamin D receptor (VDR) profoundly alter, through multiple mechanisms, the balance in function of c-MYC and its antagonist the transcriptional repressor MAD1/MXD1.	1,25-dihydroxyvitamin D	87-110	MAX dimerization protein 1	Mus musculus	281-285
23112173-3	2012	We show through cell- and animal-based studies and mathematical modeling that hormonal 1,25-dihydroxyvitamin D (1,25D) and the vitamin D receptor (VDR) profoundly alter, through multiple mechanisms, the balance in function of c-MYC and its antagonist the transcriptional repressor MAD1/MXD1.	1,25-dihydroxyvitamin D	87-110	MAX dimerization protein 1	Mus musculus	286-290
23128114-1	2012	In normal people, induction by FGF23 of renal Cyp24a1, the enzyme that degrades 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D, helps to protect from the disorders caused by excessive 1,25-dihydroxyvitamin D.	1,25-dihydroxyvitamin D	104-127	fibroblast growth factor 23	Homo sapiens	31-36
22841897-3	2012	We have previously reported that the active form of vitamin D, 1alpha,25-dihydroxyvitamin D(3) (1alpha,25-(OH)(2)D(3)), inhibits tumor necrosis factor-alpha (TNF-alpha)-induced NF-kappaB activation.	1,25-dihydroxyvitamin D	63-91	tumor necrosis factor	Homo sapiens	129-156
22841897-3	2012	We have previously reported that the active form of vitamin D, 1alpha,25-dihydroxyvitamin D(3) (1alpha,25-(OH)(2)D(3)), inhibits tumor necrosis factor-alpha (TNF-alpha)-induced NF-kappaB activation.	1,25-dihydroxyvitamin D	63-91	tumor necrosis factor	Homo sapiens	158-167
22841897-3	2012	We have previously reported that the active form of vitamin D, 1alpha,25-dihydroxyvitamin D(3) (1alpha,25-(OH)(2)D(3)), inhibits tumor necrosis factor-alpha (TNF-alpha)-induced NF-kappaB activation.	1,25-dihydroxyvitamin D	63-91	nuclear factor kappa B subunit 1	Homo sapiens	177-186
22778178-2	2012	Renal cytochrome p450 27b1 (Cyp27b1), the enzyme that catalyzes the hydrolysis to 1,25-dihydroxyvitamin D(3) (1,25(OH)(2)D(3)), is increased in klotho(-/-) mice, and a 1,25(OH)(2)D(3)-deficient diet partially normalized Ca(2+) homeostasis in these klotho(-/-) mice.	1,25-dihydroxyvitamin D	82-105	cytochrome P450, family 27, subfamily b, polypeptide 1	Mus musculus	28-35
23128114-1	2012	In normal people, induction by FGF23 of renal Cyp24a1, the enzyme that degrades 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D, helps to protect from the disorders caused by excessive 1,25-dihydroxyvitamin D.	1,25-dihydroxyvitamin D	104-127	cytochrome P450 family 24 subfamily A member 1	Homo sapiens	46-53
23128114-1	2012	In normal people, induction by FGF23 of renal Cyp24a1, the enzyme that degrades 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D, helps to protect from the disorders caused by excessive 1,25-dihydroxyvitamin D.	1,25-dihydroxyvitamin D	185-208	fibroblast growth factor 23	Homo sapiens	31-36
23128114-1	2012	In normal people, induction by FGF23 of renal Cyp24a1, the enzyme that degrades 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D, helps to protect from the disorders caused by excessive 1,25-dihydroxyvitamin D.	1,25-dihydroxyvitamin D	185-208	cytochrome P450 family 24 subfamily A member 1	Homo sapiens	46-53
23095332-1	2012	BACKGROUND: Transcription of the cathelicidin antimicrobial peptide (CAMP) gene is induced by binding of the bioactive form of vitamin D, 1,25-dihydroxyvitamin D, to the vitamin D receptor.	1,25-dihydroxyvitamin D	138-161	cathelicidin antimicrobial peptide	Homo sapiens	33-67
23095332-1	2012	BACKGROUND: Transcription of the cathelicidin antimicrobial peptide (CAMP) gene is induced by binding of the bioactive form of vitamin D, 1,25-dihydroxyvitamin D, to the vitamin D receptor.	1,25-dihydroxyvitamin D	138-161	cathelicidin antimicrobial peptide	Homo sapiens	69-73
23095332-1	2012	BACKGROUND: Transcription of the cathelicidin antimicrobial peptide (CAMP) gene is induced by binding of the bioactive form of vitamin D, 1,25-dihydroxyvitamin D, to the vitamin D receptor.	1,25-dihydroxyvitamin D	138-161	vitamin D receptor	Homo sapiens	170-188
22750284-3	2012	The active metabolite of the vitamin D endocrine system, 1,25-dihydroxyvitamin D (calcitriol), exerts pleiotropic effects through its interaction with the vitamin D receptor.	1,25-dihydroxyvitamin D	57-80	vitamin D receptor	Homo sapiens	155-173
22704696-3	2012	The purpose of this study, therefore, was to associate circulating IFN-gamma perturbations with 25(OH)D and 1,25-dihydroxyvitamin D (1,25(OH)D) alterations during inflammatory stress in young adults recovering from anterior cruciate ligament (ACL) reconstruction.	1,25-dihydroxyvitamin D	108-131	interferon gamma	Homo sapiens	67-76
22484374-1	2012	1alpha,25-Dihydroxyvitamin D(3) (1,25D3) regulates musculoskeletal cells via two different mechanisms: vitamin D receptor (VDR)-dependent gene transcription and rapid membrane-signaling via VDR as well as protein disulfide isomerase, family A, member 3 (Pdia3).	1,25-dihydroxyvitamin D	0-28	vitamin D (1,25-dihydroxyvitamin D3) receptor	Mus musculus	103-121
22484374-1	2012	1alpha,25-Dihydroxyvitamin D(3) (1,25D3) regulates musculoskeletal cells via two different mechanisms: vitamin D receptor (VDR)-dependent gene transcription and rapid membrane-signaling via VDR as well as protein disulfide isomerase, family A, member 3 (Pdia3).	1,25-dihydroxyvitamin D	0-28	vitamin D (1,25-dihydroxyvitamin D3) receptor	Mus musculus	123-126
22484374-1	2012	1alpha,25-Dihydroxyvitamin D(3) (1,25D3) regulates musculoskeletal cells via two different mechanisms: vitamin D receptor (VDR)-dependent gene transcription and rapid membrane-signaling via VDR as well as protein disulfide isomerase, family A, member 3 (Pdia3).	1,25-dihydroxyvitamin D	0-28	vitamin D (1,25-dihydroxyvitamin D3) receptor	Mus musculus	190-193
22484374-1	2012	1alpha,25-Dihydroxyvitamin D(3) (1,25D3) regulates musculoskeletal cells via two different mechanisms: vitamin D receptor (VDR)-dependent gene transcription and rapid membrane-signaling via VDR as well as protein disulfide isomerase, family A, member 3 (Pdia3).	1,25-dihydroxyvitamin D	0-28	protein disulfide isomerase associated 3	Mus musculus	205-252
22484374-1	2012	1alpha,25-Dihydroxyvitamin D(3) (1,25D3) regulates musculoskeletal cells via two different mechanisms: vitamin D receptor (VDR)-dependent gene transcription and rapid membrane-signaling via VDR as well as protein disulfide isomerase, family A, member 3 (Pdia3).	1,25-dihydroxyvitamin D	0-28	protein disulfide isomerase associated 3	Mus musculus	254-259
22647635-1	2012	Fibroblast growth factor 23 (FGF23) significantly increases with declining renal function, leading to reduced renal tubular phosphate reabsorption, decreased 1,25-dihydroxyvitamin D, and increased left ventricular hypertrophy.	1,25-dihydroxyvitamin D	158-181	fibroblast growth factor 23	Mus musculus	0-27
22576852-2	2012	Among its other biological activities, 1,25-dihydroxyvitamin D (1,25(OH)(2) D), stimulates the in vitro differentiation of human marrow stromal cells (hMSCs) to osteoblasts, which can be monitored by increases in alkaline phosphatase enzyme activity or osteocalcin gene expression.	1,25-dihydroxyvitamin D	39-62	bone gamma-carboxyglutamate protein	Homo sapiens	253-264
22647635-1	2012	Fibroblast growth factor 23 (FGF23) significantly increases with declining renal function, leading to reduced renal tubular phosphate reabsorption, decreased 1,25-dihydroxyvitamin D, and increased left ventricular hypertrophy.	1,25-dihydroxyvitamin D	158-181	fibroblast growth factor 23	Mus musculus	29-34
22562045-1	2012	Oxidative catabolism of 1alpha,25-dihydroxyvitamin D(3) [1alpha,25(OH)(2)D(3)] is mediated by either CYP24A1 or CYP3A4.	1,25-dihydroxyvitamin D	24-52	cytochrome P450 family 24 subfamily A member 1	Homo sapiens	101-108
22562045-1	2012	Oxidative catabolism of 1alpha,25-dihydroxyvitamin D(3) [1alpha,25(OH)(2)D(3)] is mediated by either CYP24A1 or CYP3A4.	1,25-dihydroxyvitamin D	24-52	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	112-118
22700885-8	2012	Enrollment fibroblast growth factor 23 correlated negatively with 25-hydroxyvitamin D (r=-0.43, P<0.001) and 1,25-dihydroxyvitamin D (r=-0.39, P=0.003) and positively with phosphate (r=0.32, P=0.02) and parathyroid hormone (r=0.37, P=0.005).	1,25-dihydroxyvitamin D	112-135	fibroblast growth factor 23	Homo sapiens	11-38
22107948-2	2012	Classically, hormonal 1,25-dihydroxyvitamin D (1,25D), produced in the kidney by CYP27B1-catalyzed 1alpha-hydroxylation from its circulating 25-hydroxy precursor, has been considered to function as a critical endocrine regulator of calcium homeostasis.	1,25-dihydroxyvitamin D	22-45	cytochrome P450 family 27 subfamily B member 1	Homo sapiens	81-88
22639294-4	2012	Initial search for a malignant process yielded no diagnosis, but an elevated 1,25-dihydroxyvitamin D level, in the setting of a suppressed PTH and undetectable PTHrP, pointed to the presence of excessive 1alpha-hydroxylase activity.	1,25-dihydroxyvitamin D	77-100	parathyroid hormone	Homo sapiens	139-142
22639294-4	2012	Initial search for a malignant process yielded no diagnosis, but an elevated 1,25-dihydroxyvitamin D level, in the setting of a suppressed PTH and undetectable PTHrP, pointed to the presence of excessive 1alpha-hydroxylase activity.	1,25-dihydroxyvitamin D	77-100	parathyroid hormone like hormone	Homo sapiens	160-165
22564539-1	2012	PURPOSE: The anti-proliferative effects of 1alpha,25-dihydroxyvitamin D(3) (1,25-D(3), calcitriol, the active form of vitamin D) are mediated by the nuclear vitamin D receptor (VDR).	1,25-dihydroxyvitamin D	43-71	vitamin D receptor	Homo sapiens	157-175
22564539-1	2012	PURPOSE: The anti-proliferative effects of 1alpha,25-dihydroxyvitamin D(3) (1,25-D(3), calcitriol, the active form of vitamin D) are mediated by the nuclear vitamin D receptor (VDR).	1,25-dihydroxyvitamin D	43-71	vitamin D receptor	Homo sapiens	177-180
22085499-3	2012	Consistent with this concept, activation of VDR by its ligand 1,25-dihydroxyvitamin D (1,25D) triggers comprehensive genomic changes in epithelial cells that contribute to maintenance of the differentiated phenotype, resistance to cellular stresses and protection of the genome.	1,25-dihydroxyvitamin D	62-85	vitamin D receptor	Homo sapiens	44-47
23197867-3	2012	We previously reported that 1alpha,25-dihydroxyvitamin D(3) (VD(3)) upregulates expression of transforming growth factor (TGF)-beta2 and alkaline phosphatase (ALP) activity, both features of hair-inducing human DPCs (hDPCs).	1,25-dihydroxyvitamin D	28-56	transforming growth factor beta 2	Homo sapiens	94-132
23197867-3	2012	We previously reported that 1alpha,25-dihydroxyvitamin D(3) (VD(3)) upregulates expression of transforming growth factor (TGF)-beta2 and alkaline phosphatase (ALP) activity, both features of hair-inducing human DPCs (hDPCs).	1,25-dihydroxyvitamin D	28-56	alkaline phosphatase, biomineralization associated	Homo sapiens	159-162
22446158-2	2012	This expression profile establishes the potential for interaction of the VDR with the product of the CYP27B1, 1,25-dihydroxyvitamin D (1,25-(OH)(2)D), in either an intracrine or paracrine mode.	1,25-dihydroxyvitamin D	110-133	vitamin D receptor	Homo sapiens	73-76
22446158-2	2012	This expression profile establishes the potential for interaction of the VDR with the product of the CYP27B1, 1,25-dihydroxyvitamin D (1,25-(OH)(2)D), in either an intracrine or paracrine mode.	1,25-dihydroxyvitamin D	110-133	cytochrome P450 family 27 subfamily B member 1	Homo sapiens	101-108
22179019-0	2012	Regulation of mouse Cyp24a1 expression via promoter-proximal and downstream-distal enhancers highlights new concepts of 1,25-dihydroxyvitamin D(3) action.	1,25-dihydroxyvitamin D	120-143	cytochrome P450, family 24, subfamily a, polypeptide 1	Mus musculus	20-27
22179019-1	2012	CYP24A1 functions in vitamin D target tissues to degrade 1,25-dihydroxyvitamin D(3) (1,25(OH)(2)D(3)).	1,25-dihydroxyvitamin D	57-80	cytochrome P450, family 24, subfamily a, polypeptide 1	Mus musculus	0-7
21995281-0	2012	Glomerular filtration rate and parathyroid hormone are associated with 1,25-dihydroxyvitamin D in men without chronic kidney disease.	1,25-dihydroxyvitamin D	71-94	parathyroid hormone	Homo sapiens	31-50
22484315-1	2012	Vitamin D, whose levels vary seasonally with sunlight, is activated to 1alpha,25-dihydroxyvitamin D(3) that binds the vitamin D receptor (VDR) and transcriptionally regulates intestinal CYP3A4 expression.	1,25-dihydroxyvitamin D	71-99	vitamin D receptor	Homo sapiens	118-136
22484315-1	2012	Vitamin D, whose levels vary seasonally with sunlight, is activated to 1alpha,25-dihydroxyvitamin D(3) that binds the vitamin D receptor (VDR) and transcriptionally regulates intestinal CYP3A4 expression.	1,25-dihydroxyvitamin D	71-99	vitamin D receptor	Homo sapiens	138-141
22484315-1	2012	Vitamin D, whose levels vary seasonally with sunlight, is activated to 1alpha,25-dihydroxyvitamin D(3) that binds the vitamin D receptor (VDR) and transcriptionally regulates intestinal CYP3A4 expression.	1,25-dihydroxyvitamin D	71-99	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	186-192
22521434-0	2012	Hepatocyte growth factor (HGF) and 1,25-dihydroxyvitamin D together stimulate human bone marrow-derived stem cells toward the osteogenic phenotype by HGF-induced up-regulation of VDR.	1,25-dihydroxyvitamin D	35-58	vitamin D receptor	Homo sapiens	179-182
22699377-1	2012	Most of the major vitamin D metabolites 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D circulates in a tightly bound state to vitamin D-binding protein (DBP), rendering this fraction unavailable for biological action.	1,25-dihydroxyvitamin D	64-87	GC vitamin D binding protein	Homo sapiens	127-152
22699377-1	2012	Most of the major vitamin D metabolites 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D circulates in a tightly bound state to vitamin D-binding protein (DBP), rendering this fraction unavailable for biological action.	1,25-dihydroxyvitamin D	64-87	D-box binding PAR bZIP transcription factor	Homo sapiens	154-157
22714041-2	2012	The physiological actions of FGF23 are to promote phosphaturia, decrease production of 1,25-dihydroxyvitamin D and suppress secretion of parathyroid hormone mediated through FGF receptors and the co-receptor Klotho.	1,25-dihydroxyvitamin D	87-110	fibroblast growth factor 23	Homo sapiens	29-34
22544628-1	2012	All cells comprising the skeleton-chondrocytes, osteoblasts, and osteoclasts-contain both the vitamin D receptor and the enzyme CYP27B1 required for producing the active metabolite of vitamin D, 1,25 dihydroxyvitamin D.	1,25-dihydroxyvitamin D	195-218	vitamin D receptor	Homo sapiens	94-112
22544628-1	2012	All cells comprising the skeleton-chondrocytes, osteoblasts, and osteoclasts-contain both the vitamin D receptor and the enzyme CYP27B1 required for producing the active metabolite of vitamin D, 1,25 dihydroxyvitamin D.	1,25-dihydroxyvitamin D	195-218	cytochrome P450 family 27 subfamily B member 1	Homo sapiens	128-135
22750930-5	2012	In addition, FGF23 seems to work to decrease 1,25-dihydroxyvitamin D while it also works to prevent the development of hyperphosphatemia by increasing urinary phosphate excretion together with PTH.	1,25-dihydroxyvitamin D	45-68	fibroblast growth factor 23	Homo sapiens	13-18
22584760-10	2012	Circulating 1,25-dihydroxyvitamin D was directly related to glomerular filtration rate (R(2) = .227; p < .001) and inversely related to interleukin 6 (R(2) = .105; p = .012).	1,25-dihydroxyvitamin D	12-35	interleukin 6	Homo sapiens	139-152
22426307-1	2012	Parathyroid hormone (PTH) increases the conversion of 25-hydroxyvitamin D [25(OH)D] to 1,25 dihydroxyvitamin D [1,25(OH)(2)D].	1,25-dihydroxyvitamin D	87-110	parathyroid hormone	Homo sapiens	0-19
22426307-1	2012	Parathyroid hormone (PTH) increases the conversion of 25-hydroxyvitamin D [25(OH)D] to 1,25 dihydroxyvitamin D [1,25(OH)(2)D].	1,25-dihydroxyvitamin D	87-110	parathyroid hormone	Homo sapiens	21-24
22520928-11	2012	In contrast, a high concentration of calcitriol (1,25-dihydroxyvitamin D(3), the active form of vitamin D(3)) or its analog MC903 upregulated total TSLP significantly but not the long-form, and did not induce the release of TSLP.	1,25-dihydroxyvitamin D	49-72	thymic stromal lymphopoietin	Homo sapiens	148-152
21995281-2	2012	We examined the associations between the levels of 25-hydroxyvitamin D (25-D) and 1,25-dihydroxyvitamin D (1,25-D) and both eGFR and PTH.	1,25-dihydroxyvitamin D	82-105	parathyroid hormone	Homo sapiens	133-136
22386975-0	2012	CYP24 inhibition preserves 1alpha,25-dihydroxyvitamin D(3) anti-proliferative signaling in lung cancer cells.	1,25-dihydroxyvitamin D	27-55	cytochrome P450 family 24 subfamily A member 1	Homo sapiens	0-5
22140123-1	2012	BACKGROUND: Fibroblast growth factor 23 (FGF23) increases renal phosphate excretion and decreases the formation of 1,25 dihydroxyvitamin D.	1,25-dihydroxyvitamin D	115-138	fibroblast growth factor 23	Homo sapiens	12-39
22140123-1	2012	BACKGROUND: Fibroblast growth factor 23 (FGF23) increases renal phosphate excretion and decreases the formation of 1,25 dihydroxyvitamin D.	1,25-dihydroxyvitamin D	115-138	fibroblast growth factor 23	Homo sapiens	41-46
22362065-7	2012	At enrollment, the increase in intact FGF23 with decreasing eGFR was the earliest among changes in MBD-related factors, followed by 1,25-dihydroxyvitamin D decrease, parathyroid hormone increase, and phosphate increase.	1,25-dihydroxyvitamin D	132-155	fibroblast growth factor 23	Homo sapiens	38-43
21874319-4	2012	The model was composed of a set of ordinary differential equations, in which the regulatory mechanism of PTH together with other key factors such as 1,25-Dihydroxyvitamin D (1,25(OH)2D) and calcium was described in the tissues including bone, the kidney, the serum, and the parathyroid glands.	1,25-dihydroxyvitamin D	149-172	parathyroid hormone	Homo sapiens	105-108
22573926-0	2012	Up-regulation of stanniocalcin 1 expression by 1,25-dihydroxy vitamin D(3) and parathyroid hormone in renal proximal tubular cells.	1,25-dihydroxyvitamin D	47-71	stanniocalcin 1	Rattus norvegicus	17-32
22592096-0	2012	Correlation of increases in 1,25-dihydroxyvitamin D during vitamin D therapy with activation of CD4+ T lymphocytes in HIV-1-infected males.	1,25-dihydroxyvitamin D	28-51	CD4 molecule	Homo sapiens	96-99
22592096-9	2012	Increases in 1,25-dihydroxyvitamin D were associated with increases in activated CD4+ T lymphocytes (P = .001) and Tregs (P = .01) in adjusted models.	1,25-dihydroxyvitamin D	13-36	CD4 molecule	Homo sapiens	81-84
22592096-13	2012	However, increases in 1,25-dihydroxyvitamin D were associated with an expansion of activated CD4+ cells and Tregs.	1,25-dihydroxyvitamin D	22-45	CD4 molecule	Homo sapiens	93-96
22716174-1	2012	Most biological activities of 1,25-dihydroxyvitamin D is mediated by the nuclear vitamin D receptor (VDR), which acts as a transcription factor activated by ligand.	1,25-dihydroxyvitamin D	30-53	vitamin D receptor	Homo sapiens	81-99
22716174-1	2012	Most biological activities of 1,25-dihydroxyvitamin D is mediated by the nuclear vitamin D receptor (VDR), which acts as a transcription factor activated by ligand.	1,25-dihydroxyvitamin D	30-53	vitamin D receptor	Homo sapiens	101-104
21937605-5	2012	However, NHE3(-/-) mice had increased serum 1,25-dihydroxyvitamin D(3).	1,25-dihydroxyvitamin D	44-67	solute carrier family 9 (sodium/hydrogen exchanger), member 3	Mus musculus	9-13
22095470-1	2012	We previously reported that 1alpha,25-dihydroxy-vitamin D(3) [1alpha,25(OH)(2)D(3)] induces non-transcriptional rapid responses through activation of Src and MAPKs in the skeletal muscle cell line C2C12.	1,25-dihydroxyvitamin D	28-57	Rous sarcoma oncogene	Mus musculus	150-153
22334725-1	2012	The X-linked hypophosphatemic (Hyp) mouse carries a loss-of-function mutation in the phex gene and is characterized by hypophosphatemia due to renal phosphate (Pi) wasting, inappropriately suppressed 1,25-dihydroxyvitamin D [1,25(OH)2D] production, and rachitic bone disease.	1,25-dihydroxyvitamin D	200-223	phosphate regulating endopeptidase homolog, X-linked	Mus musculus	85-89
22393183-9	2012	Improved vitamin D status can result in enhanced macrophage synthesis of 1,25-dihydroxyvitamin D, which increases the synthesis of the antimicrobial peptide cathelicidin (LL-37).	1,25-dihydroxyvitamin D	73-96	cathelicidin antimicrobial peptide	Homo sapiens	171-176
22285938-1	2012	The vitamin D(3) catabolizing enzyme, CYP24, is frequently over-expressed in tumors, where it may support proliferation by eliminating the growth suppressive effects of 1,25-dihydroxyvitamin D(3) (1,25(OH)(2)D(3)).	1,25-dihydroxyvitamin D	169-192	cytochrome P450 family 24 subfamily A member 1	Homo sapiens	38-43
22543147-0	2012	[Effect of 1,25-dihydroxyvitamin D(3) combined with 5-fluorouracil on IGFBP-3 expression in human esophageal carcinoma 109 cell xenograft in nude mice].	1,25-dihydroxyvitamin D	11-34	insulin like growth factor binding protein 3	Homo sapiens	70-77
22173052-13	2012	Parathyroid hormone, 1,25 dihydroxyvitamin D(3), or interleukin-6 in combination with its soluble receptor down-regulated PAR(2) mRNA expression, and fibroblast growth factor-2 or thrombin stimulated PAR(2) expression.	1,25-dihydroxyvitamin D	21-44	coagulation factor II (thrombin) receptor-like 1	Mus musculus	122-128
21845364-2	2012	Vitamin D was originally characterized for its role in calcium homeostasis, and the active form, 1,25-dihydroxyvitamin D (1,25D), can be produced in the kidney by 1alpha-hydroxylation of circulating 25-hydroxyvitamin D catalyzed by the enzyme CYP27B1.	1,25-dihydroxyvitamin D	97-120	cytochrome P450 family 27 subfamily B member 1	Homo sapiens	243-250
22393163-0	2012	1,25-Dihydroxyvitamin D(3) and extracellular inorganic phosphate activate mitogen-activated protein kinase pathway through fibroblast growth factor 23 contributing to hypertrophy and mineralization in osteoarthritic chondrocytes.	1,25-dihydroxyvitamin D	0-23	fibroblast growth factor 23	Homo sapiens	123-150
22393163-2	2012	1,25-dihydroxyvitamin D(3) (1a,25(OH)(2)D(3)) and inorganic phosphate (Pi) are two important factors that are implicated in calcium and phosphate homeostasis of bone metabolism and both can be regulated by the circulating phosphaturic factor fibroblast growth factor 23 (FGF23).	1,25-dihydroxyvitamin D	0-23	fibroblast growth factor 23	Homo sapiens	242-269
22393163-2	2012	1,25-dihydroxyvitamin D(3) (1a,25(OH)(2)D(3)) and inorganic phosphate (Pi) are two important factors that are implicated in calcium and phosphate homeostasis of bone metabolism and both can be regulated by the circulating phosphaturic factor fibroblast growth factor 23 (FGF23).	1,25-dihydroxyvitamin D	0-23	fibroblast growth factor 23	Homo sapiens	271-276
22337913-1	2012	BACKGROUND: Mutations of the CYP24A1 gene, which encodes the 1,25-dihydroxyvitamin D-24-hydroxylase cytochrome P450, Cyp24A1, are predicted to result in elevated 1,25-dihydroxyvitamin D concentrations, hypercalcemia, hypercalciuria, nephrolithiasis, and bone disease.	1,25-dihydroxyvitamin D	61-84	cytochrome P450 family 24 subfamily A member 1	Homo sapiens	29-36
22337913-1	2012	BACKGROUND: Mutations of the CYP24A1 gene, which encodes the 1,25-dihydroxyvitamin D-24-hydroxylase cytochrome P450, Cyp24A1, are predicted to result in elevated 1,25-dihydroxyvitamin D concentrations, hypercalcemia, hypercalciuria, nephrolithiasis, and bone disease.	1,25-dihydroxyvitamin D	61-84	cytochrome P450 family 24 subfamily A member 1	Homo sapiens	117-124
21870057-1	2012	Virtually all of the known biological actions of the hormonal ligand 1,25-dihydroxyvitamin D(3) (1,25(OH)(2)D(3)) are mediated by the vitamin D receptor (VDR).	1,25-dihydroxyvitamin D	69-92	vitamin D receptor	Homo sapiens	134-152
21870057-1	2012	Virtually all of the known biological actions of the hormonal ligand 1,25-dihydroxyvitamin D(3) (1,25(OH)(2)D(3)) are mediated by the vitamin D receptor (VDR).	1,25-dihydroxyvitamin D	69-92	vitamin D receptor	Homo sapiens	154-157
21932165-1	2012	1,25-dihydroxyvitamin D (1,25D), through association with the nuclear vitamin D receptor (VDR), exerts control over a novel endocrine axis consisting of the bone-derived hormone FGF23, and the kidney-expressed klotho, CYP27B1, and CYP24A1 genes, which together prevent hyperphosphatemia/ectopic calcification and govern the levels of 1,25D to maintain bone mineral integrity while promoting optimal function of other vital tissues.	1,25-dihydroxyvitamin D	0-23	vitamin D receptor	Homo sapiens	70-88
21932165-1	2012	1,25-dihydroxyvitamin D (1,25D), through association with the nuclear vitamin D receptor (VDR), exerts control over a novel endocrine axis consisting of the bone-derived hormone FGF23, and the kidney-expressed klotho, CYP27B1, and CYP24A1 genes, which together prevent hyperphosphatemia/ectopic calcification and govern the levels of 1,25D to maintain bone mineral integrity while promoting optimal function of other vital tissues.	1,25-dihydroxyvitamin D	0-23	vitamin D receptor	Homo sapiens	90-93
21932165-1	2012	1,25-dihydroxyvitamin D (1,25D), through association with the nuclear vitamin D receptor (VDR), exerts control over a novel endocrine axis consisting of the bone-derived hormone FGF23, and the kidney-expressed klotho, CYP27B1, and CYP24A1 genes, which together prevent hyperphosphatemia/ectopic calcification and govern the levels of 1,25D to maintain bone mineral integrity while promoting optimal function of other vital tissues.	1,25-dihydroxyvitamin D	0-23	fibroblast growth factor 23	Homo sapiens	178-183
21932165-1	2012	1,25-dihydroxyvitamin D (1,25D), through association with the nuclear vitamin D receptor (VDR), exerts control over a novel endocrine axis consisting of the bone-derived hormone FGF23, and the kidney-expressed klotho, CYP27B1, and CYP24A1 genes, which together prevent hyperphosphatemia/ectopic calcification and govern the levels of 1,25D to maintain bone mineral integrity while promoting optimal function of other vital tissues.	1,25-dihydroxyvitamin D	0-23	klotho	Homo sapiens	210-216
21932165-1	2012	1,25-dihydroxyvitamin D (1,25D), through association with the nuclear vitamin D receptor (VDR), exerts control over a novel endocrine axis consisting of the bone-derived hormone FGF23, and the kidney-expressed klotho, CYP27B1, and CYP24A1 genes, which together prevent hyperphosphatemia/ectopic calcification and govern the levels of 1,25D to maintain bone mineral integrity while promoting optimal function of other vital tissues.	1,25-dihydroxyvitamin D	0-23	cytochrome P450 family 27 subfamily B member 1	Homo sapiens	218-225
21932165-1	2012	1,25-dihydroxyvitamin D (1,25D), through association with the nuclear vitamin D receptor (VDR), exerts control over a novel endocrine axis consisting of the bone-derived hormone FGF23, and the kidney-expressed klotho, CYP27B1, and CYP24A1 genes, which together prevent hyperphosphatemia/ectopic calcification and govern the levels of 1,25D to maintain bone mineral integrity while promoting optimal function of other vital tissues.	1,25-dihydroxyvitamin D	0-23	cytochrome P450 family 24 subfamily A member 1	Homo sapiens	231-238
22285943-1	2012	Vitamin D receptor (VDR) is a nuclear receptor for 1alpha,25-dihydroxyvitamin D(3) (1alpha,25(OH)(2)D(3)), and is an attractive target for multiple clinical applications.	1,25-dihydroxyvitamin D	51-79	vitamin D receptor	Homo sapiens	0-18
22285943-1	2012	Vitamin D receptor (VDR) is a nuclear receptor for 1alpha,25-dihydroxyvitamin D(3) (1alpha,25(OH)(2)D(3)), and is an attractive target for multiple clinical applications.	1,25-dihydroxyvitamin D	51-79	vitamin D receptor	Homo sapiens	20-23
22396168-1	2012	Fibroblast growth factor (FGF) 23 is a hormone that acts to decrease phosphate, 1,25-dihydroxyvitamin D and parathyroid hormone levels in circulation.	1,25-dihydroxyvitamin D	80-103	fibroblast growth factor 23	Homo sapiens	0-33
22293059-11	2012	FGF23 increases renal phosphate excretion and decreases levels of 1,25-dihydroxyvitamin D.	1,25-dihydroxyvitamin D	66-89	fibroblast growth factor 23	Homo sapiens	0-5
22314609-6	2012	1-alpha,25-dihydroxyvitamin D(3) regulates the renin-angiotensin system, suppresses proliferation of vascular cell smooth muscle, improves insulin resistance and endothelial cell-dependent vasodilation, inhibits myocardial cell hypertrophy, exerts anticoagulant and antifibrotic activity, and modulates macrophage activity and cytokine generation.	1,25-dihydroxyvitamin D	0-29	insulin	Homo sapiens	139-146
22249518-2	2012	FGF-23 is secreted by osteoblasts and osteocytes in bone and principally targets the kidney to regulate the reabsorption of phosphate, the production and catabolism of 1,25-dihydroxyvitamin D and the expression of alpha-Klotho, an anti-ageing hormone.	1,25-dihydroxyvitamin D	168-191	fibroblast growth factor 23	Homo sapiens	0-6
22249518-6	2012	FGF-23 also functions as a counter-regulatory hormone for 1,25-dihydroxyvitamin D in a bone-kidney endocrine loop.	1,25-dihydroxyvitamin D	58-81	fibroblast growth factor 23	Homo sapiens	0-6
22006791-2	2012	Hypophosphatemia in XLH results from increased circulating levels of a phosphaturic hormone, fibroblast growth factor 23 (FGF23), which inhibits renal phosphate reabsorption and 1,25-dihydroxyvitamin D (calcitriol) synthesis.	1,25-dihydroxyvitamin D	178-201	fibroblast growth factor 23	Mus musculus	93-120
22006791-2	2012	Hypophosphatemia in XLH results from increased circulating levels of a phosphaturic hormone, fibroblast growth factor 23 (FGF23), which inhibits renal phosphate reabsorption and 1,25-dihydroxyvitamin D (calcitriol) synthesis.	1,25-dihydroxyvitamin D	178-201	fibroblast growth factor 23	Mus musculus	122-127
22213313-2	2012	In several cancer models, 1 alpha,25-dihydroxyvitamin D(3) (1alpha,25(OH)(2)D(3)) induces differentiation by increasing E-cadherin expression.	1,25-dihydroxyvitamin D	26-55	cadherin 1	Homo sapiens	120-130
23074704-3	2012	In this work, the free binding energy of the VDR receptor with 1,25-dihydroxyvitamin D(3) and its three potent analogs (EB 1089, KH 1060 and RO 25-9022) is calculated and compared with each other.	1,25-dihydroxyvitamin D	63-86	vitamin D receptor	Homo sapiens	45-48
22213316-1	2012	The transcription factor vitamin D receptor (VDR) is the nuclear sensor for the biologically most active metabolite of vitamin D, 1alpha,25-dihydroxyvitamin D(3) (1alpha,25(OH)(2)D(3)).	1,25-dihydroxyvitamin D	130-158	vitamin D receptor	Homo sapiens	25-43
22213316-1	2012	The transcription factor vitamin D receptor (VDR) is the nuclear sensor for the biologically most active metabolite of vitamin D, 1alpha,25-dihydroxyvitamin D(3) (1alpha,25(OH)(2)D(3)).	1,25-dihydroxyvitamin D	130-158	vitamin D receptor	Homo sapiens	45-48
22213318-1	2012	The active form of vitamin D, 1alpha,25-dihydroxyvitamin D [1alpha,25(OH)(2)D], interacts with vitamin D receptor (VDR) and induces antiproliferative, anti-invasive, proapoptotic and pro-differentiation activities in prostate cancer cells.	1,25-dihydroxyvitamin D	30-58	vitamin D receptor	Homo sapiens	95-113
22213318-1	2012	The active form of vitamin D, 1alpha,25-dihydroxyvitamin D [1alpha,25(OH)(2)D], interacts with vitamin D receptor (VDR) and induces antiproliferative, anti-invasive, proapoptotic and pro-differentiation activities in prostate cancer cells.	1,25-dihydroxyvitamin D	30-58	vitamin D receptor	Homo sapiens	115-118
22213325-3	2012	1,25-Dihydroxyvitamin D (1,25(OH)(2)D(3)) is the active form of vitamin D and exerts its actions via a specific intracellular vitamin D receptor (VDR).	1,25-dihydroxyvitamin D	0-23	vitamin D receptor	Homo sapiens	126-144
23171504-1	2012	BACKGROUND: Local production of 1,25-dihydroxyvitamin D (1,25(OH)(2)D) regulated by the CYP27B1 enzyme in monocytes contributes to the immunomodulatory effects of vitamin D.	1,25-dihydroxyvitamin D	32-55	cytochrome P450 family 27 subfamily B member 1	Homo sapiens	88-95
22213325-3	2012	1,25-Dihydroxyvitamin D (1,25(OH)(2)D(3)) is the active form of vitamin D and exerts its actions via a specific intracellular vitamin D receptor (VDR).	1,25-dihydroxyvitamin D	0-23	vitamin D receptor	Homo sapiens	146-149
21735478-7	2011	Like late osteocytes, they develop a dendritic morphology and express SOST/sclerostin and fibroblast growth factor 23 (FGF-23), regulated by parathyroid hormone (PTH) and 1,25-dihydroxyvitamin D(3).	1,25-dihydroxyvitamin D	171-194	sclerostin	Mus musculus	70-74
22168439-2	2012	These relationships link low serum 25OHD (25-hydroxyvitamin D) levels to cancer, whereas cell-based studies show that the metabolite 1,25(OH)2D (1,25-dihydroxyvitamin D) is a biologically active metabolite that works through vitamin D receptor to regulate gene transcription.	1,25-dihydroxyvitamin D	145-168	vitamin D receptor	Homo sapiens	225-243
22167381-8	2012	FGF23-mediated hypophosphatemia is characterized by inappropriately normal circulating 1,25-dihydroxyvitamin D together with renal phosphate wasting.	1,25-dihydroxyvitamin D	87-110	fibroblast growth factor 23	Homo sapiens	0-5
22298654-3	2012	PTH secreted by the parathyroid gland in response to hypocalcemia functions to maintain serum Ca(2+) levels by increasing Ca(2+) reabsorption and 1,25-dihydroxyvitamin D [1,25(OH)(2)D] production by the kidney, enhancing Ca(2+) and PO(4)(3-) intestinal absorption and increasing Ca(2+) and PO(4)(3-) efflux from bone, while maintaining neutral phosphate balance through phosphaturic effects.	1,25-dihydroxyvitamin D	146-169	parathyroid hormone	Homo sapiens	0-3
23240054-1	2012	The vitamin D receptor (VDR) mediates the physiological and pharmacological actions of 1alpha,25-dihydroxyvitamin D(3) in bone and calcium metabolism, cellular growth and differentiation, and immunity.	1,25-dihydroxyvitamin D	87-115	vitamin D (1,25-dihydroxyvitamin D3) receptor	Mus musculus	4-22
23240054-1	2012	The vitamin D receptor (VDR) mediates the physiological and pharmacological actions of 1alpha,25-dihydroxyvitamin D(3) in bone and calcium metabolism, cellular growth and differentiation, and immunity.	1,25-dihydroxyvitamin D	87-115	vitamin D (1,25-dihydroxyvitamin D3) receptor	Mus musculus	24-27
22292037-0	2012	Vitamin D binding protein and monocyte response to 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D: analysis by mathematical modeling.	1,25-dihydroxyvitamin D	75-98	GC vitamin D binding protein	Homo sapiens	0-25
22292037-1	2012	Vitamin D binding protein (DBP) plays a key role in the bioavailability of active 1,25-dihydroxyvitamin D (1,25(OH)(2)D) and its precursor 25-hydroxyvitamin D (25OHD), but accurate analysis of DBP-bound and free 25OHD and 1,25(OH)(2)D is difficult.	1,25-dihydroxyvitamin D	82-105	GC vitamin D binding protein	Homo sapiens	0-25
22292037-1	2012	Vitamin D binding protein (DBP) plays a key role in the bioavailability of active 1,25-dihydroxyvitamin D (1,25(OH)(2)D) and its precursor 25-hydroxyvitamin D (25OHD), but accurate analysis of DBP-bound and free 25OHD and 1,25(OH)(2)D is difficult.	1,25-dihydroxyvitamin D	82-105	D-box binding PAR bZIP transcription factor	Homo sapiens	27-30
22536764-3	2012	The active vitamin D metabolite, 1,25-dihydroxyvitamin D (1,25(OH)(2)D) binds to the vitamin D receptor (VDR) in the intestinal cell and stimulates the active calcium transport from the intestine to the circulation.	1,25-dihydroxyvitamin D	33-56	vitamin D receptor	Homo sapiens	85-103
22536764-3	2012	The active vitamin D metabolite, 1,25-dihydroxyvitamin D (1,25(OH)(2)D) binds to the vitamin D receptor (VDR) in the intestinal cell and stimulates the active calcium transport from the intestine to the circulation.	1,25-dihydroxyvitamin D	33-56	vitamin D receptor	Homo sapiens	105-108
22536765-6	2012	In vitro human bone cell cultures and animal model studies indicate that 25-hydroxyvitamin D can be metabolised to 1,25-dihydroxyvitamin D by each of the major bone cells to activate VDR and modulate gene expression to reduce osteoblast proliferation and stimulate osteoblast and osteoclast maturation.	1,25-dihydroxyvitamin D	115-138	vitamin D receptor	Homo sapiens	183-186
22536770-3	2012	Consistent with this concept, activation of VDR by its ligand 1,25-dihydroxyvitamin D (1,25(OH)(2)D) triggers comprehensive genomic changes in epithelial cells that contribute to maintenance of the differentiated phenotype, resistance to cellular stresses and protection of the genome.	1,25-dihydroxyvitamin D	62-85	vitamin D receptor	Homo sapiens	44-47
21664239-1	2011	The vitamin D receptor (VDR) mediates virtually all of the known biological actions of the hormonal ligand 1,25-dihydroxyvitamin D(3) (1,25(OH)(2)D(3)).	1,25-dihydroxyvitamin D	107-130	vitamin D receptor	Homo sapiens	4-22
21664239-1	2011	The vitamin D receptor (VDR) mediates virtually all of the known biological actions of the hormonal ligand 1,25-dihydroxyvitamin D(3) (1,25(OH)(2)D(3)).	1,25-dihydroxyvitamin D	107-130	vitamin D receptor	Homo sapiens	24-27
21664247-3	2011	PTH enhances vitamin D hydroxylation on carbon 1 in kidney cells thereby allowing the systemic release of 1-25-dihydroxy-vitamin D, which represents the fully active hormone.	1,25-dihydroxyvitamin D	106-130	parathyroid hormone	Homo sapiens	0-3
21664247-5	2011	Parathyroid cells express the vitamin D receptor and the 1-alpha-hydroxylase enzyme, which allows the local formation of 1-25-dihydroxy-vitamin D.	1,25-dihydroxyvitamin D	121-145	vitamin D receptor	Homo sapiens	30-48
21890490-2	2011	Here, we show that human JMJD3 expression is induced by the active vitamin D metabolite 1alpha,25-dihydroxyvitamin D(3) (1,25(OH)(2)D(3)) and that JMJD3 modulates the gene regulatory action of this hormone.	1,25-dihydroxyvitamin D	88-116	lysine demethylase 6B	Homo sapiens	25-30
21917877-1	2011	BACKGROUND: Hereditary 1,25-dihydroxyvitamin D-resistant rickets (HVDRR) is caused by mutations in the vitamin D receptor gene.	1,25-dihydroxyvitamin D	23-46	vitamin D receptor	Homo sapiens	103-121
22466564-1	2012	The active form of vitamin D, 1alpha,25-dihydroxyvitamin D(3) [1,25(OH)(2)D(3)], binds to the vitamin D receptor (VDR) and regulates various physiological and pharmacological processes.	1,25-dihydroxyvitamin D	30-58	vitamin D receptor	Homo sapiens	94-112
22466564-1	2012	The active form of vitamin D, 1alpha,25-dihydroxyvitamin D(3) [1,25(OH)(2)D(3)], binds to the vitamin D receptor (VDR) and regulates various physiological and pharmacological processes.	1,25-dihydroxyvitamin D	30-58	vitamin D receptor	Homo sapiens	114-117
22032856-4	2012	Because hormone supplementation does not include GH, dogs that have undergone hypophysectomy have low circulating concentrations of GH and IGF-1, which may result in low plasma 1,25-dihydroxy-vitamin D concentrations and consequently increased parathyroid hormone secretion.	1,25-dihydroxyvitamin D	177-201	insulin like growth factor 1	Canis lupus familiaris	139-144
22018702-4	2011	1,25-dihydroxyvitamin D inhibited proliferation and suppressed secretion of IFN-gamma and IL-17, irrespective of T cell origin and HLA restriction.	1,25-dihydroxyvitamin D	0-23	interferon gamma	Homo sapiens	76-85
22018702-4	2011	1,25-dihydroxyvitamin D inhibited proliferation and suppressed secretion of IFN-gamma and IL-17, irrespective of T cell origin and HLA restriction.	1,25-dihydroxyvitamin D	0-23	interleukin 17A	Homo sapiens	90-95
21907315-9	2011	HGF in combination with a known inducer of osteogenic differentiation, 1,25-dihydroxyvitamin D, significantly increased cell maturation/differentiation as indicated by an increase in several osteoblast markers.	1,25-dihydroxyvitamin D	71-94	hepatocyte growth factor	Homo sapiens	0-3
21907315-10	2011	Taken together these results demonstrate that HGF significantly enhances hMSC osteoblast differentiation by 1,25-dihydroxyvitamin D.	1,25-dihydroxyvitamin D	108-131	hepatocyte growth factor	Homo sapiens	46-49
22009723-6	2011	Galnt3 knockout mice in C57BL/6J had the same biochemical phenotype observed in our previous study: hyperphosphatemia, inappropriately normal 1,25-dihydroxyvitamin D level, decreased alkaline phosphatase activity, and low intact Fgf23 concentration but high Fgf23 fragments.	1,25-dihydroxyvitamin D	142-165	polypeptide N-acetylgalactosaminyltransferase 3	Mus musculus	0-6
21898591-5	2011	A microarray experiment on MC3T3-E1 murine preosteoblasts treated with 1,25-dihydroxyvitamin D(3) [1,25(OH)(2) D(3) ] revealed a cluster of genes including the cbs gene, of which the transcription was rapidly and strongly induced by 1,25(OH)(2) D(3) .	1,25-dihydroxyvitamin D	71-94	cystathionine beta-synthase	Mus musculus	160-163
21896668-2	2011	Genetic ablation of Fgf23 in mice leads to severe biochemical disorders including elevated serum 1,25-dihydroxyvitamin D [1,25(OH)2D], hypercalcemia, hyperphosphatemia, and marked decreased PTH levels.	1,25-dihydroxyvitamin D	97-120	fibroblast growth factor 23	Mus musculus	20-25
21735478-7	2011	Like late osteocytes, they develop a dendritic morphology and express SOST/sclerostin and fibroblast growth factor 23 (FGF-23), regulated by parathyroid hormone (PTH) and 1,25-dihydroxyvitamin D(3).	1,25-dihydroxyvitamin D	171-194	sclerostin	Mus musculus	75-85
21735478-7	2011	Like late osteocytes, they develop a dendritic morphology and express SOST/sclerostin and fibroblast growth factor 23 (FGF-23), regulated by parathyroid hormone (PTH) and 1,25-dihydroxyvitamin D(3).	1,25-dihydroxyvitamin D	171-194	fibroblast growth factor 23	Mus musculus	90-117
21735478-7	2011	Like late osteocytes, they develop a dendritic morphology and express SOST/sclerostin and fibroblast growth factor 23 (FGF-23), regulated by parathyroid hormone (PTH) and 1,25-dihydroxyvitamin D(3).	1,25-dihydroxyvitamin D	171-194	fibroblast growth factor 23	Mus musculus	119-125
21933904-6	2011	Treatment of cancer cells with progesterone (P4) and 1,25-dihydroxyvitamin D(3) [1,25(OH)(2)D(3)] for a period of 72 hours induced a significant upregulation of SEMA3B and SEMA3F as well as inhibited growth of cancer cells by increasing caspase-3 activity.	1,25-dihydroxyvitamin D	53-76	semaphorin 3B	Homo sapiens	161-167
21880793-8	2011	RESULTS: Serum phosphate and 1,25-dihydroxyvitamin D correlated negatively with C-terminal FGF23 and intact FGF23 in ADHR but not in controls.	1,25-dihydroxyvitamin D	29-52	fibroblast growth factor 23	Homo sapiens	91-96
21880793-8	2011	RESULTS: Serum phosphate and 1,25-dihydroxyvitamin D correlated negatively with C-terminal FGF23 and intact FGF23 in ADHR but not in controls.	1,25-dihydroxyvitamin D	29-52	fibroblast growth factor 23	Homo sapiens	108-113
21933904-6	2011	Treatment of cancer cells with progesterone (P4) and 1,25-dihydroxyvitamin D(3) [1,25(OH)(2)D(3)] for a period of 72 hours induced a significant upregulation of SEMA3B and SEMA3F as well as inhibited growth of cancer cells by increasing caspase-3 activity.	1,25-dihydroxyvitamin D	53-76	semaphorin 3F	Homo sapiens	172-178
21933904-6	2011	Treatment of cancer cells with progesterone (P4) and 1,25-dihydroxyvitamin D(3) [1,25(OH)(2)D(3)] for a period of 72 hours induced a significant upregulation of SEMA3B and SEMA3F as well as inhibited growth of cancer cells by increasing caspase-3 activity.	1,25-dihydroxyvitamin D	53-76	caspase 3	Homo sapiens	237-246
21803771-0	2011	Molecular mechanism underlying 1,25-dihydroxyvitamin D regulation of nephrin gene expression.	1,25-dihydroxyvitamin D	31-54	nephrosis 1, nephrin	Mus musculus	69-76
22081690-11	2011	They produce fibroblast growth factor-23, a hormonal regulator of renal Pi reabsorption and 1,25-dihydroxy vitamin D production.	1,25-dihydroxyvitamin D	92-116	fibroblast growth factor 23	Homo sapiens	13-40
21982773-7	2011	The phosphatemic actions of 1,25-dihydroxyvitamin D(3) are thus opposed via the combined phosphaturic effects of FGF23 and klotho, both of which are upregulated by the liganded vitamin D receptor.	1,25-dihydroxyvitamin D	28-51	fibroblast growth factor 23	Homo sapiens	113-118
21982773-7	2011	The phosphatemic actions of 1,25-dihydroxyvitamin D(3) are thus opposed via the combined phosphaturic effects of FGF23 and klotho, both of which are upregulated by the liganded vitamin D receptor.	1,25-dihydroxyvitamin D	28-51	klotho	Homo sapiens	123-129
21982773-7	2011	The phosphatemic actions of 1,25-dihydroxyvitamin D(3) are thus opposed via the combined phosphaturic effects of FGF23 and klotho, both of which are upregulated by the liganded vitamin D receptor.	1,25-dihydroxyvitamin D	28-51	vitamin D receptor	Homo sapiens	177-195
21947295-6	2011	Treatment of neonatal cardiomyocytes with 1,25-dihydroxyvitamin D partially reduced isoproterenol-induced MCIP1 mRNA and protein levels and MCIP1 gene promoter activity.	1,25-dihydroxyvitamin D	42-65	regulator of calcineurin 1	Homo sapiens	106-111
21947295-6	2011	Treatment of neonatal cardiomyocytes with 1,25-dihydroxyvitamin D partially reduced isoproterenol-induced MCIP1 mRNA and protein levels and MCIP1 gene promoter activity.	1,25-dihydroxyvitamin D	42-65	regulator of calcineurin 1	Homo sapiens	140-145
21640757-1	2011	Considering that the vitamin D receptor as well as the 1-alpha-hydroxylase enzyme that converts 25-hydroxyvitamin D (25(OH)D) to its active form 1,25-dihydroxyvitamin D have been found in tissues throughout the body, it is likely that vitamin D is important for more than the calcium balance.	1,25-dihydroxyvitamin D	145-168	vitamin D receptor	Homo sapiens	21-39
21746882-2	2011	The active form of vitamin D, 1,25-dihydroxyvitamin D(3) [1,25(OH)(2)D(3)], has a direct repressive effect on the expression of IL-17A in both human and mouse T cells.	1,25-dihydroxyvitamin D	30-53	interleukin 17A	Homo sapiens	128-134
25018912-3	2011	The link between vitamin D deficiency and death is a defective activation of the vitamin D receptor (VDR) by 1,25-dihydroxyvitamin D (calcitriol, the vitamin D hormone) to induce/repress genes that maintain mineral homeostasis and skeletal integrity, and prevent secondary hyperparathyroidism, hypertension, immune disorders, and renal and cardiovascular (CV) damage.	1,25-dihydroxyvitamin D	109-132	vitamin D receptor	Homo sapiens	81-99
25018912-3	2011	The link between vitamin D deficiency and death is a defective activation of the vitamin D receptor (VDR) by 1,25-dihydroxyvitamin D (calcitriol, the vitamin D hormone) to induce/repress genes that maintain mineral homeostasis and skeletal integrity, and prevent secondary hyperparathyroidism, hypertension, immune disorders, and renal and cardiovascular (CV) damage.	1,25-dihydroxyvitamin D	109-132	vitamin D receptor	Homo sapiens	101-104
21697289-3	2011	Vitamin D-deficient CD4(+) T cells also overproduced IL-17 in vitro and 1,25 dihydroxyvitamin D(3) inhibited the development of T(h)17 cells in CD4(+) T-cell cultures.	1,25-dihydroxyvitamin D	72-95	CD4 antigen	Mus musculus	144-147
21795053-2	2011	From X-ray analysis of these analogs with vitamin D receptor (VDR), the carboxyl groups had very unique hydrogen bonding interactions in VDR and mimicked 1alpha-hydroxy group and/or 3beta-hydroxy group of 1alpha,25-dihydroxyvitamin D(3).	1,25-dihydroxyvitamin D	205-233	vitamin D receptor	Rattus norvegicus	42-60
21795053-2	2011	From X-ray analysis of these analogs with vitamin D receptor (VDR), the carboxyl groups had very unique hydrogen bonding interactions in VDR and mimicked 1alpha-hydroxy group and/or 3beta-hydroxy group of 1alpha,25-dihydroxyvitamin D(3).	1,25-dihydroxyvitamin D	205-233	vitamin D receptor	Rattus norvegicus	62-65
21795053-2	2011	From X-ray analysis of these analogs with vitamin D receptor (VDR), the carboxyl groups had very unique hydrogen bonding interactions in VDR and mimicked 1alpha-hydroxy group and/or 3beta-hydroxy group of 1alpha,25-dihydroxyvitamin D(3).	1,25-dihydroxyvitamin D	205-233	vitamin D receptor	Rattus norvegicus	137-140
21664243-0	2011	1,25-Dihydroxyvitamin D(3) regulates PTHrP expression via transcriptional, post-transcriptional and post-translational pathways.	1,25-dihydroxyvitamin D	0-23	parathyroid hormone like hormone	Homo sapiens	37-42
21675912-6	2011	RESULTS: Sequence analysis of CYP24A1, which encodes 25-hydroxyvitamin D 24-hydroxylase, the key enzyme of 1,25-dihydroxyvitamin D(3) degradation, revealed recessive mutations in six affected children.	1,25-dihydroxyvitamin D	107-130	cytochrome P450 family 24 subfamily A member 1	Homo sapiens	30-37
21762639-8	2011	In unadjusted analyses, increased serum phosphate and parathyroid hormone (PTH) and decreased 1,25-dihydroxyvitamin D (1,25(OH)2D) levels were associated with increased hepcidin.	1,25-dihydroxyvitamin D	94-117	hepcidin antimicrobial peptide	Homo sapiens	169-177
22704269-1	2011	The bioactive vitamin D (VD) metabolite, 1,25-dihydroxyvitamin D(3) regulates essential pathways of cellular metabolism and differentiation via its nuclear receptor (VDR).	1,25-dihydroxyvitamin D	41-64	vitamin D receptor	Homo sapiens	166-169
21539305-1	2011	C15-Substituted 1alpha,25-dihydroxyvitamin D(3) analogs were synthesized for the first time to investigate the effects of the modified CD-ring on biological activity concerning the agonistic positioning of helix-3 and helix-12 of the vitamin D receptor (VDR).	1,25-dihydroxyvitamin D	16-44	placenta associated 8	Homo sapiens	0-3
21539305-1	2011	C15-Substituted 1alpha,25-dihydroxyvitamin D(3) analogs were synthesized for the first time to investigate the effects of the modified CD-ring on biological activity concerning the agonistic positioning of helix-3 and helix-12 of the vitamin D receptor (VDR).	1,25-dihydroxyvitamin D	16-44	vitamin D receptor	Homo sapiens	234-252
21244852-7	2011	Thus, our data demonstrated a synergistical role of 1,25-dihydroxyvitamin D(3) and 17beta-estradial in proliferation and differentiation of osteoblasts, and this coordinated regulation might depend on the upregulation of vitamin D receptor in osteoblasts by 17beta-estradial.	1,25-dihydroxyvitamin D	52-75	vitamin D (1,25-dihydroxyvitamin D3) receptor	Mus musculus	221-239
21472778-0	2011	Fibroblast growth factor 23 regulates renal 1,25-dihydroxyvitamin D and phosphate metabolism via the MAP kinase signaling pathway in Hyp mice.	1,25-dihydroxyvitamin D	44-67	fibroblast growth factor 23	Mus musculus	0-27
21472778-1	2011	In X-linked hypophosphatemia (XLH) and in its murine homologue, the Hyp mouse, increased circulating concentrations of fibroblast growth factor 23 (FGF-23) are critical to the pathogenesis of disordered metabolism of phosphate (P(i)) and 1,25-dihydroxyvitamin D [1,25(OH)(2)D].	1,25-dihydroxyvitamin D	238-261	fibroblast growth factor 23	Mus musculus	119-146
21472778-1	2011	In X-linked hypophosphatemia (XLH) and in its murine homologue, the Hyp mouse, increased circulating concentrations of fibroblast growth factor 23 (FGF-23) are critical to the pathogenesis of disordered metabolism of phosphate (P(i)) and 1,25-dihydroxyvitamin D [1,25(OH)(2)D].	1,25-dihydroxyvitamin D	238-261	fibroblast growth factor 23	Mus musculus	148-154
21553362-2	2011	PHEX has been identified as the gene defective in this phosphate wasting disorder leading to decreased renal phosphate reabsorption, hypophosphatemia and inappropriate concentrations of 1,25-dihydroxyvitamin D in regard to hypophosphatemia.	1,25-dihydroxyvitamin D	186-209	phosphate regulating endopeptidase homolog X-linked	Homo sapiens	0-4
21595846-2	2011	Megalin and cubilin, endocytic receptors in proximal tubule cells, are involved in the reabsorption of vitamin D binding protein from glomerular filtrates and the subsequent intracellular conversion of 25-hydroxyvitamin D(3) to biologically active 1alpha,25-dihydroxyvitamin D(3).	1,25-dihydroxyvitamin D	248-276	LDL receptor related protein 2	Homo sapiens	0-7
21595846-2	2011	Megalin and cubilin, endocytic receptors in proximal tubule cells, are involved in the reabsorption of vitamin D binding protein from glomerular filtrates and the subsequent intracellular conversion of 25-hydroxyvitamin D(3) to biologically active 1alpha,25-dihydroxyvitamin D(3).	1,25-dihydroxyvitamin D	248-276	cubilin	Homo sapiens	12-19
21595846-2	2011	Megalin and cubilin, endocytic receptors in proximal tubule cells, are involved in the reabsorption of vitamin D binding protein from glomerular filtrates and the subsequent intracellular conversion of 25-hydroxyvitamin D(3) to biologically active 1alpha,25-dihydroxyvitamin D(3).	1,25-dihydroxyvitamin D	248-276	GC vitamin D binding protein	Homo sapiens	103-128
21514270-1	2011	Numerous epidemiological data indicate that vitamin D receptor (VDR) signaling induced by its ligand or active metabolite 1alpha,25-dihydroxyvitamin D(3) (1alpha,25(OH)(2)D(3)) has anti-cancer activity in several colon cancers.	1,25-dihydroxyvitamin D	122-150	vitamin D receptor	Homo sapiens	44-62
21514270-1	2011	Numerous epidemiological data indicate that vitamin D receptor (VDR) signaling induced by its ligand or active metabolite 1alpha,25-dihydroxyvitamin D(3) (1alpha,25(OH)(2)D(3)) has anti-cancer activity in several colon cancers.	1,25-dihydroxyvitamin D	122-150	vitamin D receptor	Homo sapiens	64-67
21458526-9	2011	Inductions of osteocalcin and growth hormone promoter activities by 1,25-dihydroxyvitamin D(3) (1,25(OH)(2)D(3)) were significantly decreased when cells were co-transfected with IGFBP-6 and the VDR compared with cells transfected with the VDR only.	1,25-dihydroxyvitamin D	68-91	bone gamma-carboxyglutamate protein	Homo sapiens	14-25
21458526-9	2011	Inductions of osteocalcin and growth hormone promoter activities by 1,25-dihydroxyvitamin D(3) (1,25(OH)(2)D(3)) were significantly decreased when cells were co-transfected with IGFBP-6 and the VDR compared with cells transfected with the VDR only.	1,25-dihydroxyvitamin D	68-91	insulin like growth factor binding protein 6	Homo sapiens	178-185
21458526-9	2011	Inductions of osteocalcin and growth hormone promoter activities by 1,25-dihydroxyvitamin D(3) (1,25(OH)(2)D(3)) were significantly decreased when cells were co-transfected with IGFBP-6 and the VDR compared with cells transfected with the VDR only.	1,25-dihydroxyvitamin D	68-91	vitamin D receptor	Homo sapiens	194-197
21458526-9	2011	Inductions of osteocalcin and growth hormone promoter activities by 1,25-dihydroxyvitamin D(3) (1,25(OH)(2)D(3)) were significantly decreased when cells were co-transfected with IGFBP-6 and the VDR compared with cells transfected with the VDR only.	1,25-dihydroxyvitamin D	68-91	vitamin D receptor	Homo sapiens	239-242
21493770-7	2011	Parathyroid hormone, 1,25-OH vitamin D levels, and bone mineral density were decreased in gsk3(KI) mice, suggesting a global dysregulation of bone mineral metabolism.	1,25-dihydroxyvitamin D	21-38	glycogen synthase kinase 3 beta	Mus musculus	90-94
20928885-2	2011	Fibroblast growth factor 23 (FGF-23) is a bone-derived circulating factor that decreases serum concentrations of inorganic phosphorous (P(i)) and 1,25-dihydroxyvitamin D(3) [1,25(OH)(2)D(3)].	1,25-dihydroxyvitamin D	146-169	fibroblast growth factor 23	Homo sapiens	0-27
21438115-3	2011	In physiological conditions, bone-derived fibroblast growth factor 23 (FGF23) acts on the kidney to reduce serum phosphate and 1,25-dihydroxyvitamin D levels.	1,25-dihydroxyvitamin D	127-150	fibroblast growth factor 23	Homo sapiens	42-69
21438115-3	2011	In physiological conditions, bone-derived fibroblast growth factor 23 (FGF23) acts on the kidney to reduce serum phosphate and 1,25-dihydroxyvitamin D levels.	1,25-dihydroxyvitamin D	127-150	fibroblast growth factor 23	Homo sapiens	71-76
20928885-2	2011	Fibroblast growth factor 23 (FGF-23) is a bone-derived circulating factor that decreases serum concentrations of inorganic phosphorous (P(i)) and 1,25-dihydroxyvitamin D(3) [1,25(OH)(2)D(3)].	1,25-dihydroxyvitamin D	146-169	fibroblast growth factor 23	Homo sapiens	29-35
21139072-2	2011	Current data suggest that FGF23 targets the FGFR1c-Klotho complex to coordinately regulate phosphate transport and 1,25-dihydroxyvitamin D [1,25(OH)(2)D] production in the proximal tubule.	1,25-dihydroxyvitamin D	115-138	fibroblast growth factor 23	Mus musculus	26-31
21289245-3	2011	OBJECTIVE: To examine the effect of 1,25-dihydroxyvitamin D(3) (vitamin D(3)) on TGF-beta3-induced fibrosis-related protein expression in immortalized human uterine leiomyoma (HuLM) cells.	1,25-dihydroxyvitamin D	36-59	transforming growth factor beta 3	Homo sapiens	81-90
21139072-2	2011	Current data suggest that FGF23 targets the FGFR1c-Klotho complex to coordinately regulate phosphate transport and 1,25-dihydroxyvitamin D [1,25(OH)(2)D] production in the proximal tubule.	1,25-dihydroxyvitamin D	115-138	klotho	Mus musculus	51-57
21178642-9	2011	The in vitro study demonstrated a statistically significant increased A/P ratio of 5.27 (95% CI, 4.054-6.493) with a high concentration of 1alpha,25-dihydroxyvitamin D (10 muM) after 96 hours.	1,25-dihydroxyvitamin D	139-167	latexin	Homo sapiens	172-175
21123297-1	2011	Transcriptional regulation by hormonal 1,25-dihydroxyvitamin D(3) [1,25(OH)(2)D(3)] involves occupancy of vitamin D response elements (VDREs) by the VDRE binding protein (VDRE-BP) or 1,25(OH)(2)D(3)-bound vitamin D receptor (VDR).	1,25-dihydroxyvitamin D	39-62	vitamin D receptor	Homo sapiens	205-223
21123297-1	2011	Transcriptional regulation by hormonal 1,25-dihydroxyvitamin D(3) [1,25(OH)(2)D(3)] involves occupancy of vitamin D response elements (VDREs) by the VDRE binding protein (VDRE-BP) or 1,25(OH)(2)D(3)-bound vitamin D receptor (VDR).	1,25-dihydroxyvitamin D	39-62	vitamin D receptor	Homo sapiens	135-138
21169421-5	2011	Full suppression of PTH by the native vitamin D hormone, 1alpha,25-dihydroxyvitamin D(3) [1alpha,25 (OH)(2)D(3)], required 2 days, consistent with a transcriptional mechanism, and was reversible, indicating that reduced PTH was not attributable to cell death.	1,25-dihydroxyvitamin D	57-85	parathyroid hormone	Mus musculus	20-23
21169421-5	2011	Full suppression of PTH by the native vitamin D hormone, 1alpha,25-dihydroxyvitamin D(3) [1alpha,25 (OH)(2)D(3)], required 2 days, consistent with a transcriptional mechanism, and was reversible, indicating that reduced PTH was not attributable to cell death.	1,25-dihydroxyvitamin D	57-85	parathyroid hormone	Mus musculus	220-223
20628403-8	2011	Finally, treatment with 1alpha,25-dihydroxyvitamin D(3) (1,25(OH)(2)D(3)) significantly increased Npr-C expression in TM-BBB4 cells, as determined by liquid chromatography-tandem mass spectrometry (LC-MS/MS)-based targeted absolute proteomics.	1,25-dihydroxyvitamin D	24-52	natriuretic peptide receptor 3	Mus musculus	98-103
21164021-4	2011	Independent of changes in intestinal calcium absorption and serum calcium, 1alpha,25-dihydroxyvitamin D also represses the transcription of PTH by associating with the vitamin D receptor, which heterodimerizes with retinoic acid X receptors to bind vitamin D-response elements within the PTH gene.	1,25-dihydroxyvitamin D	75-103	parathyroid hormone	Homo sapiens	140-143
21164021-4	2011	Independent of changes in intestinal calcium absorption and serum calcium, 1alpha,25-dihydroxyvitamin D also represses the transcription of PTH by associating with the vitamin D receptor, which heterodimerizes with retinoic acid X receptors to bind vitamin D-response elements within the PTH gene.	1,25-dihydroxyvitamin D	75-103	vitamin D receptor	Homo sapiens	168-186
21164021-4	2011	Independent of changes in intestinal calcium absorption and serum calcium, 1alpha,25-dihydroxyvitamin D also represses the transcription of PTH by associating with the vitamin D receptor, which heterodimerizes with retinoic acid X receptors to bind vitamin D-response elements within the PTH gene.	1,25-dihydroxyvitamin D	75-103	parathyroid hormone	Homo sapiens	288-291
21164021-5	2011	1alpha,25-Dihydroxyvitamin D additionally regulates the expression of calcium-sensing receptors to indirectly alter PTH secretion.	1,25-dihydroxyvitamin D	0-28	parathyroid hormone	Homo sapiens	116-119
21030580-8	2011	1,25-dihydroxyvitamin D (1,25D) showed an inverse relation with FGF23.	1,25-dihydroxyvitamin D	0-23	fibroblast growth factor 23	Homo sapiens	64-69
20980705-7	2011	The effect of vitamin D (1,25-dihydroxyvitamin D, 10 nm) on anti-beta2GPI-Abs mediated TF expression was analysed by immunoblot.	1,25-dihydroxyvitamin D	25-48	apolipoprotein H	Homo sapiens	65-73
21502756-1	2011	BACKGROUND/AIMS: Fibroblast growth factor-23 (FGF23) plays a central role in the development of hypophosphatemia and inappropriately low 1,25-dihydroxyvitamin D induced by iron therapy for iron-deficiency anemia.	1,25-dihydroxyvitamin D	137-160	fibroblast growth factor 23	Homo sapiens	17-44
21502756-1	2011	BACKGROUND/AIMS: Fibroblast growth factor-23 (FGF23) plays a central role in the development of hypophosphatemia and inappropriately low 1,25-dihydroxyvitamin D induced by iron therapy for iron-deficiency anemia.	1,25-dihydroxyvitamin D	137-160	fibroblast growth factor 23	Homo sapiens	46-51
20980705-7	2011	The effect of vitamin D (1,25-dihydroxyvitamin D, 10 nm) on anti-beta2GPI-Abs mediated TF expression was analysed by immunoblot.	1,25-dihydroxyvitamin D	25-48	coagulation factor III, tissue factor	Homo sapiens	87-89
20955794-2	2011	The anticancer effects of vitamin D are mediated primarily by its active metabolite, 1,25-dihydroxyvitamin D (calcitriol), through vitamin D receptor (VDR) signaling.	1,25-dihydroxyvitamin D	85-108	vitamin D receptor	Homo sapiens	131-149
20795941-4	2011	1,25-dihydroxyvitamin D(3) interacts with its vitamin D receptor in calcium regulating tissues to regulate calcium metabolism and bone health.	1,25-dihydroxyvitamin D	0-23	vitamin D receptor	Homo sapiens	46-64
21603159-1	2011	FGF23 is a bone-derived hormone that plays an important role in the regulation of phosphate and 1,25-dihydroxy vitamin D metabolism.	1,25-dihydroxyvitamin D	96-120	fibroblast growth factor 23	Homo sapiens	0-5
21603159-2	2011	FGF23 principally acts in the kidney to induce urinary phosphate excretion and suppress 1,25-dihydroxyvitamin D synthesis in the presence of FGF receptor 1 (FGFR1) and its coreceptor Klotho.	1,25-dihydroxyvitamin D	88-111	fibroblast growth factor 23	Homo sapiens	0-5
21603159-3	2011	In patients with chronic kidney disease (CKD), circulating FGF23 levels are progressively increased to compensate for persistent phosphate retention, but this results in reduced renal production of 1,25-dihydroxyvitamin D and leads to hypersecretion of parathyroid hormone.	1,25-dihydroxyvitamin D	198-221	fibroblast growth factor 23	Homo sapiens	59-64
21941448-1	2011	INTRODUCTION: The discovery that many tissues express the vitamin D receptor and are able to transform the 25-hydroxyvitamin D into 1,25-dihydroxyvitamin D (active metabolite) has led to the hypothesis that vitamin D could have a role in the pathogenesis and prevention of diabetes mellitus.	1,25-dihydroxyvitamin D	132-155	vitamin D receptor	Homo sapiens	58-76
20955794-2	2011	The anticancer effects of vitamin D are mediated primarily by its active metabolite, 1,25-dihydroxyvitamin D (calcitriol), through vitamin D receptor (VDR) signaling.	1,25-dihydroxyvitamin D	85-108	vitamin D receptor	Homo sapiens	151-154
20739393-0	2010	Fibroblast growth factor 23 production in bone is directly regulated by 1{alpha},25-dihydroxyvitamin D, but not PTH.	1,25-dihydroxyvitamin D	72-102	fibroblast growth factor 23	Rattus norvegicus	0-27
20655141-1	2010	The purpose of this study was to determine the mechanism by which 1alpha, 25-dihydroxyvitamin D (1,25(OH)(2)D) alters hypoxia-inducible factor-1alpha (HIF-1alpha) protein in untransformed and Harvey-ras (H-ras) oncogene transfected MCF10A breast epithelial cells.	1,25-dihydroxyvitamin D	66-95	hypoxia inducible factor 1 subunit alpha	Homo sapiens	118-149
20655141-1	2010	The purpose of this study was to determine the mechanism by which 1alpha, 25-dihydroxyvitamin D (1,25(OH)(2)D) alters hypoxia-inducible factor-1alpha (HIF-1alpha) protein in untransformed and Harvey-ras (H-ras) oncogene transfected MCF10A breast epithelial cells.	1,25-dihydroxyvitamin D	66-95	hypoxia inducible factor 1 subunit alpha	Homo sapiens	151-161
20655141-1	2010	The purpose of this study was to determine the mechanism by which 1alpha, 25-dihydroxyvitamin D (1,25(OH)(2)D) alters hypoxia-inducible factor-1alpha (HIF-1alpha) protein in untransformed and Harvey-ras (H-ras) oncogene transfected MCF10A breast epithelial cells.	1,25-dihydroxyvitamin D	66-95	HRas proto-oncogene, GTPase	Homo sapiens	192-202
20655141-1	2010	The purpose of this study was to determine the mechanism by which 1alpha, 25-dihydroxyvitamin D (1,25(OH)(2)D) alters hypoxia-inducible factor-1alpha (HIF-1alpha) protein in untransformed and Harvey-ras (H-ras) oncogene transfected MCF10A breast epithelial cells.	1,25-dihydroxyvitamin D	66-95	HRas proto-oncogene, GTPase	Homo sapiens	204-209
20974859-3	2010	Treatment of mice with an active ligand of vitamin D receptor (VDR), 1,25-dihydroxyvitamin D(3) (1,25D3), ameliorated experimental autoimmune encephalomyelitis, accompanied with reduced IL-17 and IL-17F expression.	1,25-dihydroxyvitamin D	69-92	vitamin D (1,25-dihydroxyvitamin D3) receptor	Mus musculus	43-61
20974859-3	2010	Treatment of mice with an active ligand of vitamin D receptor (VDR), 1,25-dihydroxyvitamin D(3) (1,25D3), ameliorated experimental autoimmune encephalomyelitis, accompanied with reduced IL-17 and IL-17F expression.	1,25-dihydroxyvitamin D	69-92	vitamin D (1,25-dihydroxyvitamin D3) receptor	Mus musculus	63-66
20974859-3	2010	Treatment of mice with an active ligand of vitamin D receptor (VDR), 1,25-dihydroxyvitamin D(3) (1,25D3), ameliorated experimental autoimmune encephalomyelitis, accompanied with reduced IL-17 and IL-17F expression.	1,25-dihydroxyvitamin D	69-92	interleukin 17A	Mus musculus	186-191
20974859-3	2010	Treatment of mice with an active ligand of vitamin D receptor (VDR), 1,25-dihydroxyvitamin D(3) (1,25D3), ameliorated experimental autoimmune encephalomyelitis, accompanied with reduced IL-17 and IL-17F expression.	1,25-dihydroxyvitamin D	69-92	interleukin 17F	Mus musculus	196-202
20739393-1	2010	Fibroblast growth factor 23 (FGF23), which is primarily produced by osteocytes in bone, regulates renal phosphate excretion and 1alpha,25-dihydroxyvitamin D [1,25(OH)(2)D(3)] metabolism.	1,25-dihydroxyvitamin D	128-156	fibroblast growth factor 23	Rattus norvegicus	0-27
20739393-1	2010	Fibroblast growth factor 23 (FGF23), which is primarily produced by osteocytes in bone, regulates renal phosphate excretion and 1alpha,25-dihydroxyvitamin D [1,25(OH)(2)D(3)] metabolism.	1,25-dihydroxyvitamin D	128-156	fibroblast growth factor 23	Rattus norvegicus	29-34
20941510-1	2010	1alpha,25-dihydroxyvitamin D(3) [1,25(OH)(2)D(3)] induces osteoclast formation via induction of receptor activator of NF-kappaB ligand (RANKL, also called TNF-related activation-induced cytokine: TRANCE) in osteoblasts.	1,25-dihydroxyvitamin D	0-28	tumor necrosis factor (ligand) superfamily, member 11	Mus musculus	96-134
20719979-1	2010	Klotho is a membrane protein participating in the inhibitory effect of FGF23 on the formation of 1,25-dihydroxyvitamin-D(3) [1,25(OH)(2)D(3)].	1,25-dihydroxyvitamin D	97-120	klotho	Mus musculus	0-6
20719979-1	2010	Klotho is a membrane protein participating in the inhibitory effect of FGF23 on the formation of 1,25-dihydroxyvitamin-D(3) [1,25(OH)(2)D(3)].	1,25-dihydroxyvitamin D	97-120	fibroblast growth factor 23	Mus musculus	71-76
20941510-1	2010	1alpha,25-dihydroxyvitamin D(3) [1,25(OH)(2)D(3)] induces osteoclast formation via induction of receptor activator of NF-kappaB ligand (RANKL, also called TNF-related activation-induced cytokine: TRANCE) in osteoblasts.	1,25-dihydroxyvitamin D	0-28	tumor necrosis factor (ligand) superfamily, member 11	Mus musculus	136-141
20658451-1	2010	Fibroblast growth factor 23 (FGF23) is a recently identified bone-derived hormone that regulates phosphate and 1,25-dihydroxyvitamin D metabolism.	1,25-dihydroxyvitamin D	111-134	fibroblast growth factor 23	Homo sapiens	0-27
21034990-4	2010	Under the influence of parathyroid hormone, the kidney then converts 25-hydroxyvitamin D to 1,25-dihydroxyvitamin D, the biologically active, hormonal form of the nutrient that is important in the metabolism of calcium and phosphorus and is critical in building and maintaining healthy bones.	1,25-dihydroxyvitamin D	92-115	parathyroid hormone	Homo sapiens	23-42
20658451-1	2010	Fibroblast growth factor 23 (FGF23) is a recently identified bone-derived hormone that regulates phosphate and 1,25-dihydroxyvitamin D metabolism.	1,25-dihydroxyvitamin D	111-134	fibroblast growth factor 23	Homo sapiens	29-34
20658451-2	2010	FGF23 principally acts in the kidney to induce urinary phosphate excretion and suppress 1,25-dihydroxyvitamin D synthesis in the presence of FGF receptor 1 (FGFR1) and its coreceptor Klotho.	1,25-dihydroxyvitamin D	88-111	fibroblast growth factor 23	Homo sapiens	0-5
20658451-4	2010	In patients with chronic kidney disease (CKD), circulating FGF23 levels are progressively increased to compensate for persistent phosphate retention, but this results in reduced renal production of 1,25-dihydroxyvitamin D and leads to hypersecretion of parathyroid hormone.	1,25-dihydroxyvitamin D	198-221	fibroblast growth factor 23	Homo sapiens	59-64
20844473-1	2010	Circulating levels of fibroblast growth factor 23 (FGF23) are elevated in patients with early chronic kidney disease (CKD) and are postulated to cause low blood levels of 1,25-dihydroxyvitamin D, as well as normal phosphate levels.	1,25-dihydroxyvitamin D	171-194	fibroblast growth factor 23	Homo sapiens	22-49
20844473-1	2010	Circulating levels of fibroblast growth factor 23 (FGF23) are elevated in patients with early chronic kidney disease (CKD) and are postulated to cause low blood levels of 1,25-dihydroxyvitamin D, as well as normal phosphate levels.	1,25-dihydroxyvitamin D	171-194	fibroblast growth factor 23	Homo sapiens	51-56
20844473-6	2010	Hence, our study shows that FGF23 normalizes serum phosphate and decreases 1,25-dihydroxyvitamin D levels in early-stage CKD, and suggests a pathological sequence of events for the development of secondary hyperparathyroidism triggered by increased FGF23, followed by a reduction of 1,25-dihydroxyvitamin D and calcium levels, thereby increasing parathyroid hormone secretion.	1,25-dihydroxyvitamin D	75-98	fibroblast growth factor 23	Rattus norvegicus	28-33
20844473-6	2010	Hence, our study shows that FGF23 normalizes serum phosphate and decreases 1,25-dihydroxyvitamin D levels in early-stage CKD, and suggests a pathological sequence of events for the development of secondary hyperparathyroidism triggered by increased FGF23, followed by a reduction of 1,25-dihydroxyvitamin D and calcium levels, thereby increasing parathyroid hormone secretion.	1,25-dihydroxyvitamin D	283-306	fibroblast growth factor 23	Rattus norvegicus	28-33
20094706-3	2010	PTH(1-84) treatment in hypoparathyroidism significantly reduced supplemental calcium and 1,25-dihydroxyvitamin D requirements without generally altering serum and urinary calcium levels.	1,25-dihydroxyvitamin D	89-112	parathyroid hormone	Homo sapiens	0-3
20526631-1	2010	Fibroblast growth factor 23 (FGF23) is a phosphatonin that is secreted by osteocytes and osteoblasts in response to hyperphosphatemia and 1,25-dihydroxyvitamin D (1,25D).	1,25-dihydroxyvitamin D	138-161	fibroblast growth factor 23	Homo sapiens	0-27
20526631-1	2010	Fibroblast growth factor 23 (FGF23) is a phosphatonin that is secreted by osteocytes and osteoblasts in response to hyperphosphatemia and 1,25-dihydroxyvitamin D (1,25D).	1,25-dihydroxyvitamin D	138-161	fibroblast growth factor 23	Homo sapiens	29-34
20605845-2	2010	Vitamin D is modified in the liver and the kidney to its active form (1,25-dihydroxyvitamin D) by the 25-hydroxy vitamin D 1-hydroxylase enzyme (CYP27B1).	1,25-dihydroxyvitamin D	70-93	cytochrome P450 family 27 subfamily B member 1	Homo sapiens	145-152
20660032-11	2010	1,25-Dihydroxyvitamin D significantly increased from 46.8 +- 18.9 to 97.8 +- 38.3 pg/ml at 3 d (P < 0.001) and to 59.5 +- 27.3 pg/ml at 60 d (P < 0.05).	1,25-dihydroxyvitamin D	0-23	serpin family C member 1	Homo sapiens	88-94
20574434-2	2010	Topically applied 1,25-dihydroxyvitamin D(3) (1,25(OH)(2)D(3)) enhances the immunoregulatory ability of CD4+CD25+ T cells residing in the skin-draining lymph nodes (SDLNs) of mice.	1,25-dihydroxyvitamin D	18-41	CD4 antigen	Mus musculus	104-107
20733005-1	2010	Hormonal vitamin D, 1,25-dihydroxyvitamin D (1,25D), signals through the nuclear vitamin D receptor (VDR).	1,25-dihydroxyvitamin D	20-43	vitamin D receptor	Homo sapiens	81-99
20733005-1	2010	Hormonal vitamin D, 1,25-dihydroxyvitamin D (1,25D), signals through the nuclear vitamin D receptor (VDR).	1,25-dihydroxyvitamin D	20-43	vitamin D receptor	Homo sapiens	101-104
20420936-7	2010	In similarity with the effects on mRNA levels, also the endogenous enzyme activity of CYP21A2 decreased after treatment with 1alpha,25-dihydroxyvitamin D(3).	1,25-dihydroxyvitamin D	125-153	cytochrome P450 family 21 subfamily A member 2	Homo sapiens	86-93
20798257-0	2010	Reciprocal control of 1,25-dihydroxyvitamin D and FGF23 formation involving the FGF23/Klotho system.	1,25-dihydroxyvitamin D	22-45	fibroblast growth factor 23	Homo sapiens	80-85
20798257-0	2010	Reciprocal control of 1,25-dihydroxyvitamin D and FGF23 formation involving the FGF23/Klotho system.	1,25-dihydroxyvitamin D	22-45	klotho	Homo sapiens	86-92
20798257-3	2010	In a feedback loop, 1,25-dihydroxyvitamin D and phosphate intake control FGF23 production.	1,25-dihydroxyvitamin D	20-43	fibroblast growth factor 23	Homo sapiens	73-78
20450955-1	2010	The biologically active form of vitamin D, 1,25-dihydroxyvitamin D (1,25D) ligands VDR (vitamin D receptor) and binds to the vitamin D response element (VDRE) located within target genes to regulate their transcription.	1,25-dihydroxyvitamin D	43-66	vitamin D receptor	Homo sapiens	83-86
20450955-1	2010	The biologically active form of vitamin D, 1,25-dihydroxyvitamin D (1,25D) ligands VDR (vitamin D receptor) and binds to the vitamin D response element (VDRE) located within target genes to regulate their transcription.	1,25-dihydroxyvitamin D	43-66	vitamin D receptor	Homo sapiens	88-106
20947319-2	2010	More recently, the discovery that many human tissues and cells, which do not directly participate in mineral ion homeostasis, express the vitamin D receptor (VDR) and are able to convert the circulating pro-hormone 25-hydroxyvitamin D in its active form, 1,25-dihydroxyvitamin D, has provided new insights into the biological function of this peculiar endocrine system.	1,25-dihydroxyvitamin D	255-278	vitamin D receptor	Homo sapiens	138-156
20947319-2	2010	More recently, the discovery that many human tissues and cells, which do not directly participate in mineral ion homeostasis, express the vitamin D receptor (VDR) and are able to convert the circulating pro-hormone 25-hydroxyvitamin D in its active form, 1,25-dihydroxyvitamin D, has provided new insights into the biological function of this peculiar endocrine system.	1,25-dihydroxyvitamin D	255-278	vitamin D receptor	Homo sapiens	158-161
20883026-0	2010	An o-aminoanilide analogue of 1alpha,25-dihydroxyvitamin D(3) functions as a strong vitamin D receptor antagonist.	1,25-dihydroxyvitamin D	30-58	vitamin D receptor	Homo sapiens	84-102
20855882-7	2010	Interestingly, 17-beta estradiol reproduced these effects on self-reactive T cells and macrophages from male subjects, suggesting a functional synergy between 1,25-dihydroxyvitamin D(3) and 17-beta estradiol, mediated through estrogen receptor alpha.	1,25-dihydroxyvitamin D	159-182	estrogen receptor 1	Homo sapiens	226-249
20685875-0	2010	The receptor-dependent actions of 1,25-dihydroxyvitamin D are required for normal growth plate maturation in NPt2a knockout mice.	1,25-dihydroxyvitamin D	34-57	solute carrier family 34 (sodium phosphate), member 1	Mus musculus	109-114
20685875-10	2010	These studies demonstrate that the receptor-dependent actions of 1,25-dihydroxyvitamin D are required for maintenance of a normal growth plate phenotype in the Npt2a null mice.	1,25-dihydroxyvitamin D	65-88	solute carrier family 34 (sodium phosphate), member 1	Mus musculus	160-165
20593414-3	2010	FGF-23 synthesis and secretion by osteocytes and osteoblasts is upregulated through 1,25-dihydroxyvitamin D(3) [1,25(OH)(2)D(3)] and through an increased dietary phosphate intake.	1,25-dihydroxyvitamin D	84-107	fibroblast growth factor 23	Homo sapiens	0-6
20886077-3	2010	METHODOLOGY/PRINCIPAL FINDINGS: In an in vitro system using cells from mice, the active form of vitamin D(3) (1,25-dihydroxyvitamin D(3)) suppresses both interleukin (IL)-17-producing T cells (T(H)17) and regulatory T cells (Treg) differentiation via a vitamin D receptor signal.	1,25-dihydroxyvitamin D	110-133	interleukin 17A	Mus musculus	154-173
20886077-3	2010	METHODOLOGY/PRINCIPAL FINDINGS: In an in vitro system using cells from mice, the active form of vitamin D(3) (1,25-dihydroxyvitamin D(3)) suppresses both interleukin (IL)-17-producing T cells (T(H)17) and regulatory T cells (Treg) differentiation via a vitamin D receptor signal.	1,25-dihydroxyvitamin D	110-133	vitamin D (1,25-dihydroxyvitamin D3) receptor	Mus musculus	253-271
20886077-4	2010	The ability of 1,25-dihydroxyvitamin D(3) (1,25(OH)(2)D(3)) to reduce the amount of IL-2 regulates the generation of Treg cells, but not T(H)17 cells.	1,25-dihydroxyvitamin D	15-38	interleukin 2	Mus musculus	84-88
20515678-0	2010	Independent association between 1,25-dihydroxyvitamin D, 25-hydroxyvitamin D and the renin-angiotensin system: The Ludwigshafen Risk and Cardiovascular Health (LURIC) study.	1,25-dihydroxyvitamin D	32-55	renin	Homo sapiens	85-90
20515678-1	2010	BACKGROUND: Antihypertensive and tissue-protective properties of vitamin D metabolites are increasingly attributed to the inhibition of renin synthesis by 1,25-dihydroxyvitamin D [1,25(OH)2D] in the kidney.	1,25-dihydroxyvitamin D	155-178	renin	Homo sapiens	136-141
20507957-2	2010	FGF23 is a bone-derived hormone that promotes phosphaturia and decreases the synthesis of 1,25-dihydroxyvitamin D (1,25(OH)(2)D).	1,25-dihydroxyvitamin D	90-113	fibroblast growth factor 23	Homo sapiens	0-5
20393752-4	2010	Most tissues in the body have a vitamin D receptor and the enzymatic machinery to convert "nutritional" 25-hydroxyvitamin D to the active form 1,25-dihydroxyvitamin D; it is estimated that 3% of the human genome is regulated by the vitamin D endocrine system.	1,25-dihydroxyvitamin D	143-166	vitamin D receptor	Homo sapiens	32-50
20543868-2	2010	In this study, we show that SPRY2 expression in colon cancer cells is inhibited by the active vitamin D metabolite 1alpha,25-dihydroxyvitamin D(3) (1,25(OH)(2)D(3)) through E-cadherin-dependent and -independent mechanisms.	1,25-dihydroxyvitamin D	115-143	sprouty RTK signaling antagonist 2	Homo sapiens	28-33
20543868-2	2010	In this study, we show that SPRY2 expression in colon cancer cells is inhibited by the active vitamin D metabolite 1alpha,25-dihydroxyvitamin D(3) (1,25(OH)(2)D(3)) through E-cadherin-dependent and -independent mechanisms.	1,25-dihydroxyvitamin D	115-143	cadherin 1	Homo sapiens	173-183
20094706-11	2010	CONCLUSION: PTH(1-84) treatment in hypoparathyroidism significantly reduces supplemental calcium and 1,25-dihydroxyvitamin D requirements without generally altering serum and urinary calcium levels.	1,25-dihydroxyvitamin D	101-124	parathyroid hormone	Homo sapiens	12-15
20431039-1	2010	Fibroblast growth factor 23 (FGF23) modulates mineral metabolism by promoting phosphaturia and decreasing the production of 1,25-dihydroxyvitamin D(3).	1,25-dihydroxyvitamin D	124-147	fibroblast growth factor 23	Rattus norvegicus	0-27
20399919-2	2010	The active form of vitamin D, 1,25-dihydroxyvitamin D(3) [1,25(OH)(2)D(3)], is a crucial regulator of this process and increases the expression of the transient receptor potential vanilloid 6 (Trpv6) calcium channel that mediates calcium transfer across the intestinal apical membrane.	1,25-dihydroxyvitamin D	30-53	transient receptor potential cation channel, subfamily V, member 6	Mus musculus	151-191
20399919-2	2010	The active form of vitamin D, 1,25-dihydroxyvitamin D(3) [1,25(OH)(2)D(3)], is a crucial regulator of this process and increases the expression of the transient receptor potential vanilloid 6 (Trpv6) calcium channel that mediates calcium transfer across the intestinal apical membrane.	1,25-dihydroxyvitamin D	30-53	transient receptor potential cation channel, subfamily V, member 6	Mus musculus	193-198
21073129-0	2010	Two new unrelated cases of hereditary 1,25-dihydroxyvitamin D-resistant rickets with alopecia resulting from the same novel nonsense mutation in the vitamin D receptor gene.	1,25-dihydroxyvitamin D	38-61	vitamin D receptor	Homo sapiens	149-167
20585181-2	2010	FGF23 is a novel bone-derived hormone that plays an important role in the regulation of phosphate and 1,25-dihydroxy vitamin D metabolism.	1,25-dihydroxyvitamin D	102-126	fibroblast growth factor 23	Homo sapiens	0-5
20585181-3	2010	FGF23 binds to FGF receptor1 (FGFR1) -Klotho complex in the kidney and thereby induces phosphaturia and suppresses 1,25-dihydroxyvitamin D synthesis.	1,25-dihydroxyvitamin D	115-138	fibroblast growth factor 23	Homo sapiens	0-5
20585181-3	2010	FGF23 binds to FGF receptor1 (FGFR1) -Klotho complex in the kidney and thereby induces phosphaturia and suppresses 1,25-dihydroxyvitamin D synthesis.	1,25-dihydroxyvitamin D	115-138	fibroblast growth factor receptor 1	Homo sapiens	15-28
20585181-3	2010	FGF23 binds to FGF receptor1 (FGFR1) -Klotho complex in the kidney and thereby induces phosphaturia and suppresses 1,25-dihydroxyvitamin D synthesis.	1,25-dihydroxyvitamin D	115-138	fibroblast growth factor receptor 1	Homo sapiens	30-35
20585181-4	2010	In patients with chronic kidney disease (CKD) , circulating FGF23 levels are progressively increased to compensate for persistent phosphate retention, but this results in reduced renal production of 1,25-dihydroxyvitamin D and leads to secondary hyperparathyroidism.	1,25-dihydroxyvitamin D	199-222	fibroblast growth factor 23	Homo sapiens	60-65
20585181-5	2010	In patients undergoing dialysis, FGF23 levels are markedly elevated in response to hyperphosphatemia and active vitamin D therapy, which in turn cause hypophosphatemia and reduced 1,25-dihydroxyvitamin D after kidney transplantation.	1,25-dihydroxyvitamin D	180-203	fibroblast growth factor 23	Homo sapiens	33-38
20431039-1	2010	Fibroblast growth factor 23 (FGF23) modulates mineral metabolism by promoting phosphaturia and decreasing the production of 1,25-dihydroxyvitamin D(3).	1,25-dihydroxyvitamin D	124-147	fibroblast growth factor 23	Rattus norvegicus	29-34
20359533-1	2010	In the course of kidney disease, the progressive loss of renal capacity to maintain normal serum levels of 1,25-dihydroxyvitamin D (1,25(OH)2D) is a main contributor to parathyroid hyperplasia and high serum PTH.	1,25-dihydroxyvitamin D	107-130	parathyroid hormone	Homo sapiens	208-211
20564192-1	2010	Others and we previously showed that the vitamin D receptor (VDR) is subject to degradation by the 26S proteasome and that treatment with 1,25-dihydroxyvitamin D(3) (1,25D(3)) inhibited this degradation.	1,25-dihydroxyvitamin D	138-161	vitamin D receptor	Homo sapiens	41-59
20564192-1	2010	Others and we previously showed that the vitamin D receptor (VDR) is subject to degradation by the 26S proteasome and that treatment with 1,25-dihydroxyvitamin D(3) (1,25D(3)) inhibited this degradation.	1,25-dihydroxyvitamin D	138-161	vitamin D receptor	Homo sapiens	61-64
20144713-1	2010	The CYP24A1 enzyme (25-hydroxyvitamin D-24-hydroxylase) not only is involved in the catabolic breakdown of 1,25-dihydroxyvitamin D [1,25(OH)2D] but also generates the 24,25-dihydroxyvitamin D [24,25(OH)2D] metabolite.	1,25-dihydroxyvitamin D	107-130	cytochrome P450, family 24, subfamily a, polypeptide 1	Mus musculus	4-11
20407479-6	2010	The levels of FGF23 positively correlated with parathyroid hormone and phosphate concentrations and negatively with 1,25-dihydroxyvitamin D, the estimated glomerular filtration rate, and tubular phosphate reabsorption.	1,25-dihydroxyvitamin D	116-139	fibroblast growth factor 23	Homo sapiens	14-19
20412854-3	2010	Genomic profiles were also obtained in murine mammary cells that differentially express VDR that were cultured in vitro with 100 nM 1,25-dihydroxyvitamin D (1,25D).	1,25-dihydroxyvitamin D	132-155	vitamin D (1,25-dihydroxyvitamin D3) receptor	Mus musculus	88-91
20406950-3	2010	It is known that the interaction of the vitamin D metabolite 1,25-dihydroxyvitamin D(3) (1,25D) with its functional vitamin D receptor leads to differentiation, G(1) arrest, and increased cell survival in p53-null AML cells.	1,25-dihydroxyvitamin D	61-84	vitamin D receptor	Homo sapiens	116-134
20371703-1	2010	Vitamin D receptor (VDR) is activated by natural ligands, 1alpha, 25-dihydroxy-vitamin D(3) [1alpha,25(OH)(2)-D(3)] and lithocholic acid (LCA).	1,25-dihydroxyvitamin D	58-88	vitamin D receptor	Homo sapiens	0-18
20371703-1	2010	Vitamin D receptor (VDR) is activated by natural ligands, 1alpha, 25-dihydroxy-vitamin D(3) [1alpha,25(OH)(2)-D(3)] and lithocholic acid (LCA).	1,25-dihydroxyvitamin D	58-88	vitamin D receptor	Homo sapiens	20-23
20236932-1	2010	CYP24A1 expression is up-regulated by 1,25-dihydroxyvitamin D(3) (1,25(OH)(2)D(3)) via a vitamin D receptor (VDR)/retinoid X receptor (RXR) heterodimer that binds to two vitamin D response elements (VDREs) located near the proximal promoter.	1,25-dihydroxyvitamin D	38-61	cytochrome P450 family 24 subfamily A member 1	Homo sapiens	0-7
20236932-1	2010	CYP24A1 expression is up-regulated by 1,25-dihydroxyvitamin D(3) (1,25(OH)(2)D(3)) via a vitamin D receptor (VDR)/retinoid X receptor (RXR) heterodimer that binds to two vitamin D response elements (VDREs) located near the proximal promoter.	1,25-dihydroxyvitamin D	38-61	vitamin D receptor	Homo sapiens	89-107
20236932-1	2010	CYP24A1 expression is up-regulated by 1,25-dihydroxyvitamin D(3) (1,25(OH)(2)D(3)) via a vitamin D receptor (VDR)/retinoid X receptor (RXR) heterodimer that binds to two vitamin D response elements (VDREs) located near the proximal promoter.	1,25-dihydroxyvitamin D	38-61	vitamin D receptor	Homo sapiens	109-112
20236932-1	2010	CYP24A1 expression is up-regulated by 1,25-dihydroxyvitamin D(3) (1,25(OH)(2)D(3)) via a vitamin D receptor (VDR)/retinoid X receptor (RXR) heterodimer that binds to two vitamin D response elements (VDREs) located near the proximal promoter.	1,25-dihydroxyvitamin D	38-61	retinoid X receptor alpha	Homo sapiens	114-133
20236932-1	2010	CYP24A1 expression is up-regulated by 1,25-dihydroxyvitamin D(3) (1,25(OH)(2)D(3)) via a vitamin D receptor (VDR)/retinoid X receptor (RXR) heterodimer that binds to two vitamin D response elements (VDREs) located near the proximal promoter.	1,25-dihydroxyvitamin D	38-61	retinoid X receptor alpha	Homo sapiens	135-138
20511050-0	2010	The vitamin D receptor: new paradigms for the regulation of gene expression by 1,25-dihydroxyvitamin D(3).	1,25-dihydroxyvitamin D	79-102	vitamin D receptor	Homo sapiens	4-22
20511050-1	2010	The actions of the vitamin D hormone 1,25-dihydroxyvitamin D(3) (1,25(OH)(2)D(3)) are mediated by the vitamin D receptor (VDR), a ligand-activated transcription factor that functions to control gene expression.	1,25-dihydroxyvitamin D	37-60	vitamin D receptor	Homo sapiens	102-120
20511050-1	2010	The actions of the vitamin D hormone 1,25-dihydroxyvitamin D(3) (1,25(OH)(2)D(3)) are mediated by the vitamin D receptor (VDR), a ligand-activated transcription factor that functions to control gene expression.	1,25-dihydroxyvitamin D	37-60	vitamin D receptor	Homo sapiens	122-125
20406950-3	2010	It is known that the interaction of the vitamin D metabolite 1,25-dihydroxyvitamin D(3) (1,25D) with its functional vitamin D receptor leads to differentiation, G(1) arrest, and increased cell survival in p53-null AML cells.	1,25-dihydroxyvitamin D	61-84	tumor protein p53	Homo sapiens	205-208
20137773-1	2010	The analysis of rare genetic disorders affecting phosphate homeostasis led to the identification of several proteins that are essential for the renal regulation of phosphate homeostasis; for example, fibroblast growth factor 23 (FGF23), which inhibits renal phosphate reabsorption and 1,25-dihydroxyvitamin D synthesis.	1,25-dihydroxyvitamin D	285-308	fibroblast growth factor 23	Homo sapiens	200-227
20147525-4	2010	Here we show that the natural VDR agonist 1alpha,25-dihydroxyvitamin D(3) and its synthetic analog EB1089 increase expression of TMPRSS2:ERG mRNA in VCaP prostate cancer cells; this results in increased ETS-related gene (ERG) protein expression and ERG activity as demonstrated by an increase in the ERG target gene CACNA1D.	1,25-dihydroxyvitamin D	42-70	vitamin D receptor	Homo sapiens	30-33
20147525-4	2010	Here we show that the natural VDR agonist 1alpha,25-dihydroxyvitamin D(3) and its synthetic analog EB1089 increase expression of TMPRSS2:ERG mRNA in VCaP prostate cancer cells; this results in increased ETS-related gene (ERG) protein expression and ERG activity as demonstrated by an increase in the ERG target gene CACNA1D.	1,25-dihydroxyvitamin D	42-70	transmembrane serine protease 2	Homo sapiens	129-136
20147525-4	2010	Here we show that the natural VDR agonist 1alpha,25-dihydroxyvitamin D(3) and its synthetic analog EB1089 increase expression of TMPRSS2:ERG mRNA in VCaP prostate cancer cells; this results in increased ETS-related gene (ERG) protein expression and ERG activity as demonstrated by an increase in the ERG target gene CACNA1D.	1,25-dihydroxyvitamin D	42-70	ETS transcription factor ERG	Homo sapiens	137-140
20147525-4	2010	Here we show that the natural VDR agonist 1alpha,25-dihydroxyvitamin D(3) and its synthetic analog EB1089 increase expression of TMPRSS2:ERG mRNA in VCaP prostate cancer cells; this results in increased ETS-related gene (ERG) protein expression and ERG activity as demonstrated by an increase in the ERG target gene CACNA1D.	1,25-dihydroxyvitamin D	42-70	ETS transcription factor ERG	Homo sapiens	203-219
20147525-4	2010	Here we show that the natural VDR agonist 1alpha,25-dihydroxyvitamin D(3) and its synthetic analog EB1089 increase expression of TMPRSS2:ERG mRNA in VCaP prostate cancer cells; this results in increased ETS-related gene (ERG) protein expression and ERG activity as demonstrated by an increase in the ERG target gene CACNA1D.	1,25-dihydroxyvitamin D	42-70	ETS transcription factor ERG	Homo sapiens	221-224
20147525-4	2010	Here we show that the natural VDR agonist 1alpha,25-dihydroxyvitamin D(3) and its synthetic analog EB1089 increase expression of TMPRSS2:ERG mRNA in VCaP prostate cancer cells; this results in increased ETS-related gene (ERG) protein expression and ERG activity as demonstrated by an increase in the ERG target gene CACNA1D.	1,25-dihydroxyvitamin D	42-70	ETS transcription factor ERG	Homo sapiens	221-224
20147525-4	2010	Here we show that the natural VDR agonist 1alpha,25-dihydroxyvitamin D(3) and its synthetic analog EB1089 increase expression of TMPRSS2:ERG mRNA in VCaP prostate cancer cells; this results in increased ETS-related gene (ERG) protein expression and ERG activity as demonstrated by an increase in the ERG target gene CACNA1D.	1,25-dihydroxyvitamin D	42-70	ETS transcription factor ERG	Homo sapiens	221-224
20147525-4	2010	Here we show that the natural VDR agonist 1alpha,25-dihydroxyvitamin D(3) and its synthetic analog EB1089 increase expression of TMPRSS2:ERG mRNA in VCaP prostate cancer cells; this results in increased ETS-related gene (ERG) protein expression and ERG activity as demonstrated by an increase in the ERG target gene CACNA1D.	1,25-dihydroxyvitamin D	42-70	calcium voltage-gated channel subunit alpha1 D	Homo sapiens	316-323
20392230-1	2010	Mouse models with targeted deletion of the genes encoding the enzyme 25-hydroxyvitamin D 1alpha-hydroxylase [1alpha(OH)ase], and the vitamin D receptor (VDR), have provided considerable insight into the regulation of mineral and skeletal physiology by 1,25-dihydroxyvitamin D [1,25(OH)(2)D].	1,25-dihydroxyvitamin D	252-275	vitamin D (1,25-dihydroxyvitamin D3) receptor	Mus musculus	133-151
20392230-1	2010	Mouse models with targeted deletion of the genes encoding the enzyme 25-hydroxyvitamin D 1alpha-hydroxylase [1alpha(OH)ase], and the vitamin D receptor (VDR), have provided considerable insight into the regulation of mineral and skeletal physiology by 1,25-dihydroxyvitamin D [1,25(OH)(2)D].	1,25-dihydroxyvitamin D	252-275	vitamin D (1,25-dihydroxyvitamin D3) receptor	Mus musculus	153-156
20065152-1	2010	Vitamin D receptors have been detected in vascular smooth muscle cells, and 1,25-dihydroxyvitamin D inhibits the renin mRNA expression.	1,25-dihydroxyvitamin D	76-99	renin	Homo sapiens	113-118
20061412-16	2010	Surprisingly, PTHrP in the high doses studied activates 1,25 dihydroxyvitamin D production.	1,25-dihydroxyvitamin D	56-79	parathyroid hormone like hormone	Homo sapiens	14-19
20371119-1	2010	1alpha,25-Dihydroxyvitamin D(3) (VD(3)), the biologically active form of vitamin D, may have either pro- or anti-inflammatory activities because of its diverse actions on nuclear factor kappa B (NF-kappaB).	1,25-dihydroxyvitamin D	0-28	nuclear factor kappa B subunit 1	Homo sapiens	171-193
20371119-1	2010	1alpha,25-Dihydroxyvitamin D(3) (VD(3)), the biologically active form of vitamin D, may have either pro- or anti-inflammatory activities because of its diverse actions on nuclear factor kappa B (NF-kappaB).	1,25-dihydroxyvitamin D	0-28	nuclear factor kappa B subunit 1	Homo sapiens	195-204
20398021-1	2010	The bioactive form of vitamin D, 1,25-dihydroxyvitamin D(3), is a secosteroid hormone that binds to the vitamin D receptor (VDR), a member of the nuclear receptor superfamily, and modulates a variety of biological functions.	1,25-dihydroxyvitamin D	33-56	vitamin D receptor	Homo sapiens	104-122
20398021-1	2010	The bioactive form of vitamin D, 1,25-dihydroxyvitamin D(3), is a secosteroid hormone that binds to the vitamin D receptor (VDR), a member of the nuclear receptor superfamily, and modulates a variety of biological functions.	1,25-dihydroxyvitamin D	33-56	vitamin D receptor	Homo sapiens	124-127
19944755-8	2010	The synergistic effect of 25-hydroxyvitamin D(3) with 1alpha,25-dihydroxyvitamin D(3) in Cyp27b1(-/-) cells further demonstrates the agonistic action of 25-hydroxyvitamin D(3) and suggests that a synergism between 25-hydroxyvitamin D(3) and 1alpha,25-dihydroxyvitamin D(3) might be physiologically important.	1,25-dihydroxyvitamin D	54-82	cytochrome P450 family 27 subfamily B member 1	Homo sapiens	89-96
20137773-1	2010	The analysis of rare genetic disorders affecting phosphate homeostasis led to the identification of several proteins that are essential for the renal regulation of phosphate homeostasis; for example, fibroblast growth factor 23 (FGF23), which inhibits renal phosphate reabsorption and 1,25-dihydroxyvitamin D synthesis.	1,25-dihydroxyvitamin D	285-308	fibroblast growth factor 23	Homo sapiens	229-234
19952276-7	2010	1,25-Dihydroxyvitamin D levels, reduced in HYP mice, were comparably elevated in Klotho and Klotho/HYP mice, demonstrating that Klotho is necessary for FGF23"s effect on vitamin D metabolism.	1,25-dihydroxyvitamin D	0-23	fibroblast growth factor 23	Mus musculus	152-157
20586743-4	2010	Accordingly, both the vitamin D receptor and the enzymes necessary to synthesize bioactive 1,25-dihydroxyvitamin D are expressed in the brain, and hypovitaminosis D is associated with abnormal development and function of the brain.	1,25-dihydroxyvitamin D	91-114	vitamin D receptor	Homo sapiens	22-40
20010546-2	2010	One of the most important breakthroughs is the identification of fibroblastic growth factor 23 (FGF23) and its role as a key regulator of phosphate and 1,25-dihydroxyvitamin D metabolism.	1,25-dihydroxyvitamin D	152-175	fibroblast growth factor 23	Homo sapiens	65-94
20010546-2	2010	One of the most important breakthroughs is the identification of fibroblastic growth factor 23 (FGF23) and its role as a key regulator of phosphate and 1,25-dihydroxyvitamin D metabolism.	1,25-dihydroxyvitamin D	152-175	fibroblast growth factor 23	Homo sapiens	96-101
20010546-4	2010	FGF23 principally acts on the kidney to induce urinary phosphate excretion and suppresses 1,25-dihydroxyvitamin D synthesis, thereby indirectly modulating parathyroid hormone secretion.	1,25-dihydroxyvitamin D	90-113	fibroblast growth factor 23	Homo sapiens	0-5
19948723-2	2010	Here we show that hormonal vitamin D, 1,25-dihydroxyvitamin D(3), robustly stimulates expression of pattern recognition receptor NOD2/CARD15/IBD1 gene and protein in primary human monocytic and epithelial cells.	1,25-dihydroxyvitamin D	38-61	nucleotide binding oligomerization domain containing 2	Homo sapiens	129-133
19948723-2	2010	Here we show that hormonal vitamin D, 1,25-dihydroxyvitamin D(3), robustly stimulates expression of pattern recognition receptor NOD2/CARD15/IBD1 gene and protein in primary human monocytic and epithelial cells.	1,25-dihydroxyvitamin D	38-61	nucleotide binding oligomerization domain containing 2	Homo sapiens	134-140
19948723-2	2010	Here we show that hormonal vitamin D, 1,25-dihydroxyvitamin D(3), robustly stimulates expression of pattern recognition receptor NOD2/CARD15/IBD1 gene and protein in primary human monocytic and epithelial cells.	1,25-dihydroxyvitamin D	38-61	nucleotide binding oligomerization domain containing 2	Homo sapiens	141-145
19948723-5	2010	Pretreatment with 1,25-dihydroxyvitamin D(3) synergistically induced NF-kappaB function and expression of genes encoding DEFB2/HBD2 and antimicrobial peptide cathelicidin in the presence of muramyl dipeptide.	1,25-dihydroxyvitamin D	18-41	nuclear factor kappa B subunit 1	Homo sapiens	69-78
19948723-5	2010	Pretreatment with 1,25-dihydroxyvitamin D(3) synergistically induced NF-kappaB function and expression of genes encoding DEFB2/HBD2 and antimicrobial peptide cathelicidin in the presence of muramyl dipeptide.	1,25-dihydroxyvitamin D	18-41	defensin beta 4A	Homo sapiens	121-126
19948723-5	2010	Pretreatment with 1,25-dihydroxyvitamin D(3) synergistically induced NF-kappaB function and expression of genes encoding DEFB2/HBD2 and antimicrobial peptide cathelicidin in the presence of muramyl dipeptide.	1,25-dihydroxyvitamin D	18-41	defensin beta 4A	Homo sapiens	127-131
19966181-2	2010	Extrarenal conversion of 25-hydroxyvitamin D (25OHD) to the biologically active form of vitamin D, 1 alpha,25-dihydroxyvitamin D [1,25(OH)(2)D] is catalyzed in several cell types by the 1 alpha-hydroxylase (CYP27B1), but little is known about the expression or regulation of CYP27B1 in human bones.	1,25-dihydroxyvitamin D	99-128	cytochrome P450 family 27 subfamily B member 1	Homo sapiens	207-214
19966181-2	2010	Extrarenal conversion of 25-hydroxyvitamin D (25OHD) to the biologically active form of vitamin D, 1 alpha,25-dihydroxyvitamin D [1,25(OH)(2)D] is catalyzed in several cell types by the 1 alpha-hydroxylase (CYP27B1), but little is known about the expression or regulation of CYP27B1 in human bones.	1,25-dihydroxyvitamin D	99-128	cytochrome P450 family 27 subfamily B member 1	Homo sapiens	275-282
19897601-1	2010	The vitamin D receptor (VDR) mediates the endocrine actions of 1,25-dihydroxyvitamin D(3) [1,25(OH)(2)D(3)] and autoregulates the expression of its own gene in target cells.	1,25-dihydroxyvitamin D	63-86	vitamin D receptor	Homo sapiens	4-22
19897601-1	2010	The vitamin D receptor (VDR) mediates the endocrine actions of 1,25-dihydroxyvitamin D(3) [1,25(OH)(2)D(3)] and autoregulates the expression of its own gene in target cells.	1,25-dihydroxyvitamin D	63-86	vitamin D receptor	Homo sapiens	24-27
20031638-5	2009	Importantly, despite significantly higher serum calcium and 1,25-dihydroxyvitamin D levels in klotho(-/-)/NaPi2a(-/-) mice, the vascular and soft-tissue calcifications were reduced.	1,25-dihydroxyvitamin D	60-83	klotho	Mus musculus	94-100
19815438-0	2010	Hereditary 1,25-dihydroxyvitamin D-resistant rickets with alopecia resulting from a novel missense mutation in the DNA-binding domain of the vitamin D receptor.	1,25-dihydroxyvitamin D	11-34	vitamin D receptor	Homo sapiens	141-159
19815438-1	2010	The rare genetic recessive disease, hereditary vitamin D resistant rickets (HVDRR), is caused by mutations in the vitamin D receptor (VDR) that result in resistance to the active hormone 1,25-dihydroxyvitamin D(3) (1,25(OH)(2)D(3) or calcitriol).	1,25-dihydroxyvitamin D	187-210	vitamin D receptor	Homo sapiens	114-132
19815438-1	2010	The rare genetic recessive disease, hereditary vitamin D resistant rickets (HVDRR), is caused by mutations in the vitamin D receptor (VDR) that result in resistance to the active hormone 1,25-dihydroxyvitamin D(3) (1,25(OH)(2)D(3) or calcitriol).	1,25-dihydroxyvitamin D	187-210	vitamin D receptor	Homo sapiens	77-80
19753549-0	2009	1alpha,25-Dihydroxyvitamin D(3) triggered vitamin D receptor and farnesoid X receptor-like effects in rat intestine and liver in vivo.	1,25-dihydroxyvitamin D	0-28	vitamin D receptor	Rattus norvegicus	42-60
19777446-4	2009	In the current study, we have further clarified the compensatory regulation of calcium transport genes by two calcium regulating hormones, 1,25-dihydroxyvitamin D(3) (1,25(OH)(2)D(3)) and parathyroid hormone (PTH), in CaBP-9k KO mice, because the levels of these hormones differ between the KO and wild-type (WT) mice.	1,25-dihydroxyvitamin D	139-162	S100 calcium binding protein G	Mus musculus	218-225
19524013-1	2009	Synthesis of 1,25-dihydroxyvitamin D(3) (1,25(OH)(2)D(3)) is catalysed by the enzyme 25-hydroxyvitamin D(3)-1alpha-hydroxylase (CYP27B1).	1,25-dihydroxyvitamin D	13-36	cytochrome P450 family 27 subfamily B member 1	Homo sapiens	85-126
19524013-1	2009	Synthesis of 1,25-dihydroxyvitamin D(3) (1,25(OH)(2)D(3)) is catalysed by the enzyme 25-hydroxyvitamin D(3)-1alpha-hydroxylase (CYP27B1).	1,25-dihydroxyvitamin D	13-36	cytochrome P450 family 27 subfamily B member 1	Homo sapiens	128-135
19753549-1	2009	1alpha,25-Dihydroxyvitamin D(3) (1,25(OH)(2)D(3)), a natural ligand of the vitamin D receptor (VDR), was found to increase the rat ileal Asbt and bile acid absorption.	1,25-dihydroxyvitamin D	0-28	vitamin D receptor	Rattus norvegicus	75-93
19753549-1	2009	1alpha,25-Dihydroxyvitamin D(3) (1,25(OH)(2)D(3)), a natural ligand of the vitamin D receptor (VDR), was found to increase the rat ileal Asbt and bile acid absorption.	1,25-dihydroxyvitamin D	0-28	vitamin D receptor	Rattus norvegicus	95-98
19753549-1	2009	1alpha,25-Dihydroxyvitamin D(3) (1,25(OH)(2)D(3)), a natural ligand of the vitamin D receptor (VDR), was found to increase the rat ileal Asbt and bile acid absorption.	1,25-dihydroxyvitamin D	0-28	solute carrier family 10 member 2	Rattus norvegicus	137-141
19419295-1	2009	Fibroblast growth factor 23 (FGF23) promotes phosphaturia and suppresses 1,25-dihydroxyvitamin D [1,25(OH)(2)D] production.	1,25-dihydroxyvitamin D	73-96	fibroblast growth factor 23	Homo sapiens	0-27
19584304-9	2009	Moreover, in contrast to the Hyp mice, the Hyp/klotho(-/-) mice showed significantly higher serum levels of 1,25-dihydroxyvitamin D and developed extensive calcification in soft tissues and vascular walls.	1,25-dihydroxyvitamin D	108-131	klotho	Mus musculus	47-53
19666701-5	2009	PCFT mRNA levels are increased in Caco-2 cells treated with 1,25-dihydroxyvitamin D(3) (vitamin D(3)) in a dose-dependent fashion, and the duodenal rat Pcft mRNA expression is induced by vitamin D(3) ex vivo.	1,25-dihydroxyvitamin D	60-83	solute carrier family 46 member 1	Homo sapiens	0-4
19666701-5	2009	PCFT mRNA levels are increased in Caco-2 cells treated with 1,25-dihydroxyvitamin D(3) (vitamin D(3)) in a dose-dependent fashion, and the duodenal rat Pcft mRNA expression is induced by vitamin D(3) ex vivo.	1,25-dihydroxyvitamin D	60-83	solute carrier family 46 member 1	Homo sapiens	152-156
18822343-1	2009	Fibroblast growth factor 23 (FGF23) is a humoral factor that is produced by osteocytes and reduces serum phosphate and 1,25-dihydroxyvitamin D levels by acting on kidney through some FGF receptor and Klotho.	1,25-dihydroxyvitamin D	119-142	fibroblast growth factor 23	Mus musculus	0-27
18822343-1	2009	Fibroblast growth factor 23 (FGF23) is a humoral factor that is produced by osteocytes and reduces serum phosphate and 1,25-dihydroxyvitamin D levels by acting on kidney through some FGF receptor and Klotho.	1,25-dihydroxyvitamin D	119-142	fibroblast growth factor 23	Mus musculus	29-34
19523546-1	2009	OBJECTIVE: To study the vitamin D receptor (VDR) gene in a young girl with severe rickets and clinical features of hereditary vitamin D resistant rickets, including hypocalcemia, hypophosphatemia, partial alopecia, and elevated serum levels of 1,25-dihydroxyvitamin D.	1,25-dihydroxyvitamin D	244-267	vitamin D receptor	Homo sapiens	24-42
19523546-1	2009	OBJECTIVE: To study the vitamin D receptor (VDR) gene in a young girl with severe rickets and clinical features of hereditary vitamin D resistant rickets, including hypocalcemia, hypophosphatemia, partial alopecia, and elevated serum levels of 1,25-dihydroxyvitamin D.	1,25-dihydroxyvitamin D	244-267	vitamin D receptor	Homo sapiens	44-47
19615945-0	2009	Effect of 1, 25 dihydroxyvitamin D(3) on matrix metalloproteinases MMP-7, MMP-9 and the inhibitor TIMP-1 in pulmonary tuberculosis.	1,25-dihydroxyvitamin D	10-34	matrix metallopeptidase 7	Homo sapiens	67-72
19615945-0	2009	Effect of 1, 25 dihydroxyvitamin D(3) on matrix metalloproteinases MMP-7, MMP-9 and the inhibitor TIMP-1 in pulmonary tuberculosis.	1,25-dihydroxyvitamin D	10-34	matrix metallopeptidase 9	Homo sapiens	74-79
19819968-2	2009	Administration of the antiresorptive agent osteoprotegerin produced a profound reduction in bone resorption and formation in male and oophorectomized female mice, accompanied by an increase in serum levels of fibroblast growth factor 23 (FGF23) and a reduction in circulating 1,25-dihydroxyvitamin D [1,25(OH)(2)D].	1,25-dihydroxyvitamin D	276-299	tumor necrosis factor receptor superfamily, member 11b (osteoprotegerin)	Mus musculus	43-58
19819969-8	2009	The expression of RANKL and OPG in chondrocytes was regulated by several osteotropic factors including 1,25-dihydroxyvitamin D(3), PTHrP, IL-1alpha, and TNF-alpha.	1,25-dihydroxyvitamin D	103-126	tumor necrosis factor (ligand) superfamily, member 11	Mus musculus	18-23
19819969-8	2009	The expression of RANKL and OPG in chondrocytes was regulated by several osteotropic factors including 1,25-dihydroxyvitamin D(3), PTHrP, IL-1alpha, and TNF-alpha.	1,25-dihydroxyvitamin D	103-126	tumor necrosis factor receptor superfamily, member 11b (osteoprotegerin)	Mus musculus	28-31
19419295-1	2009	Fibroblast growth factor 23 (FGF23) promotes phosphaturia and suppresses 1,25-dihydroxyvitamin D [1,25(OH)(2)D] production.	1,25-dihydroxyvitamin D	73-96	fibroblast growth factor 23	Homo sapiens	29-34
19474283-2	2009	We previously reported that all-trans retinoic acid (ATRA) and 1,25-dihydroxyvitamin D(3) [1,25(OH)(2)D(3)] induced expression of nephrin in murine podocytes.	1,25-dihydroxyvitamin D	63-86	nephrosis 1, nephrin	Mus musculus	130-137
19415458-1	2009	The treatment of human promyelocytic leukemia cell lines HL-60, and to some extent NB-4, with 1alpha,25-dihydroxyvitamin D(3) (VD3) induces differentiation toward the monocytic/macrophage lineage, demonstrated by the increased expression of CD11b and CD14, and the production of opsonized zymosan particles (OZP)-stimulated reactive oxygen species (ROS).	1,25-dihydroxyvitamin D	94-122	integrin subunit alpha M	Homo sapiens	241-246
19415458-1	2009	The treatment of human promyelocytic leukemia cell lines HL-60, and to some extent NB-4, with 1alpha,25-dihydroxyvitamin D(3) (VD3) induces differentiation toward the monocytic/macrophage lineage, demonstrated by the increased expression of CD11b and CD14, and the production of opsonized zymosan particles (OZP)-stimulated reactive oxygen species (ROS).	1,25-dihydroxyvitamin D	94-122	CD14 molecule	Homo sapiens	251-255
19916908-1	2009	Dermatopontin (DPT) was recently found as a downstream target of vitamin D receptor, which is a key molecule in the 1,25-dihydroxy-vitamin D(3) anti-hepatoma proliferation pathway.	1,25-dihydroxyvitamin D	116-140	dermatopontin	Homo sapiens	0-13
19667164-3	2009	Vitamin D metabolism poses unique problems for the regulation of 1,25-dihydroxyvitamin D [1,25(OH)2D] concentrations in the tissues outside the kidney that possess 25(OH)D-1-hydroxylase [CYP27B1] and the catabolic enzyme, 1,25(OH)2D-24-hydroxylase [CYP24].	1,25-dihydroxyvitamin D	65-88	cytochrome P450 family 27 subfamily B member 1	Homo sapiens	187-194
19916908-1	2009	Dermatopontin (DPT) was recently found as a downstream target of vitamin D receptor, which is a key molecule in the 1,25-dihydroxy-vitamin D(3) anti-hepatoma proliferation pathway.	1,25-dihydroxyvitamin D	116-140	dermatopontin	Homo sapiens	15-18
19916908-1	2009	Dermatopontin (DPT) was recently found as a downstream target of vitamin D receptor, which is a key molecule in the 1,25-dihydroxy-vitamin D(3) anti-hepatoma proliferation pathway.	1,25-dihydroxyvitamin D	116-140	vitamin D receptor	Homo sapiens	65-83
19477943-1	2009	The Cyp27b1 enzyme (25-hydroxyvitamin D-1alpha-hydroxylase) that converts 25-hydroxyvitamin D into the active metabolite, 1,25-dihydroxyvitamin D(3) [1,25(OH)(2)D(3)], is expressed in kidney but also in other cell types such as chondrocytes.	1,25-dihydroxyvitamin D	122-145	cytochrome P450, family 27, subfamily b, polypeptide 1	Mus musculus	4-11
19619913-1	2009	AIMS: To investigate the relationship between Erythropoietin (EPO) and 1,25-dihydroxyvitamin D levels, and tubular damage in patients with diabetes mellitus (DM) without persistent microalbuminuria.	1,25-dihydroxyvitamin D	71-94	erythropoietin	Homo sapiens	46-60
19619913-1	2009	AIMS: To investigate the relationship between Erythropoietin (EPO) and 1,25-dihydroxyvitamin D levels, and tubular damage in patients with diabetes mellitus (DM) without persistent microalbuminuria.	1,25-dihydroxyvitamin D	71-94	erythropoietin	Homo sapiens	62-65
19619913-4	2009	Median 1,25-dihydroxyvitamin D levels were lower in Type 1 (41.0 pmol/l: p=0.001) and Type 2 DM (41.8 pmol/l: p=0.035) than in controls (56.1 pmol/l), though serum creatinine, calcium, phosphate and PTH levels did not differ.	1,25-dihydroxyvitamin D	7-30	parathyroid hormone	Homo sapiens	199-202
19483274-2	2009	FGF23 is a humoral factor that is produced by osteocytes and reduces serum phosphate and 1,25-dihydroxyvitamin D levels by binding to a complex comprised of Klotho and some FGF receptor in kidney.	1,25-dihydroxyvitamin D	89-112	fibroblast growth factor 23	Homo sapiens	0-5
18829283-1	2009	The hormone 1,25 dihydroxyvitamin D (1,25(OH)(2)D) binds to the nuclear vitamin D receptor (nVDR), which heterodimerizes with retinoid X receptor alpha (RXRalpha), and this complex interacts with specific response elements [vitamin D response elements (VDREs)] to regulate gene transcription.	1,25-dihydroxyvitamin D	12-35	vitamin D (1,25-dihydroxyvitamin D3) receptor	Mus musculus	72-90
18829283-1	2009	The hormone 1,25 dihydroxyvitamin D (1,25(OH)(2)D) binds to the nuclear vitamin D receptor (nVDR), which heterodimerizes with retinoid X receptor alpha (RXRalpha), and this complex interacts with specific response elements [vitamin D response elements (VDREs)] to regulate gene transcription.	1,25-dihydroxyvitamin D	12-35	retinoid X receptor alpha	Mus musculus	126-151
18829283-1	2009	The hormone 1,25 dihydroxyvitamin D (1,25(OH)(2)D) binds to the nuclear vitamin D receptor (nVDR), which heterodimerizes with retinoid X receptor alpha (RXRalpha), and this complex interacts with specific response elements [vitamin D response elements (VDREs)] to regulate gene transcription.	1,25-dihydroxyvitamin D	12-35	retinoid X receptor alpha	Mus musculus	153-161
19364661-5	2009	The physiological buffer for vitamin D safety is the capacity of plasma vitamin D-binding protein to bind the total of circulating 25(OH)D, vitamin D, and 1,25-dihydroxyvitamin D [1,25(OH)2D].	1,25-dihydroxyvitamin D	155-178	GC vitamin D binding protein	Homo sapiens	72-97
19519602-0	2009	1,25-dihydroxyvitamin D synthesis after renal transplantation: the role of fibroblast growth factor 23 and cyclosporine.	1,25-dihydroxyvitamin D	0-23	fibroblast growth factor 23	Homo sapiens	75-102
19502595-1	2009	Vitamin D receptor (VDR) mediates the antitumoral action of the active vitamin D metabolite 1alpha,25-dihydroxyvitamin D(3) (1,25(OH)(2)D(3)).	1,25-dihydroxyvitamin D	92-120	vitamin D receptor	Homo sapiens	0-18
19502595-1	2009	Vitamin D receptor (VDR) mediates the antitumoral action of the active vitamin D metabolite 1alpha,25-dihydroxyvitamin D(3) (1,25(OH)(2)D(3)).	1,25-dihydroxyvitamin D	92-120	vitamin D receptor	Homo sapiens	20-23
19386590-2	2009	The 1,25-dihydroxyvitamin D(3) (1,25(OH)(2)D(3)) hormone binds to the vitamin D receptor (VDR) to regulate gene expression.	1,25-dihydroxyvitamin D	4-27	vitamin D receptor	Homo sapiens	70-88
19386590-2	2009	The 1,25-dihydroxyvitamin D(3) (1,25(OH)(2)D(3)) hormone binds to the vitamin D receptor (VDR) to regulate gene expression.	1,25-dihydroxyvitamin D	4-27	vitamin D receptor	Homo sapiens	90-93
19567989-2	2009	Fibroblast growth factor (FGF) 23 is a hormone which is produced by bone and lowers serum phosphate and 1,25-dihydroxyvitamin D levels by acting on kidney.	1,25-dihydroxyvitamin D	104-127	fibroblast growth factor 23	Homo sapiens	0-33
19594554-0	2009	Podocyte injury is suppressed by 1,25-dihydroxyvitamin D via modulation of transforming growth factor-beta 1/bone morphogenetic protein-7 signalling in puromycin aminonucleoside nephropathy rats.	1,25-dihydroxyvitamin D	33-56	transforming growth factor, beta 1	Rattus norvegicus	75-108
19594554-0	2009	Podocyte injury is suppressed by 1,25-dihydroxyvitamin D via modulation of transforming growth factor-beta 1/bone morphogenetic protein-7 signalling in puromycin aminonucleoside nephropathy rats.	1,25-dihydroxyvitamin D	33-56	bone morphogenetic protein 7	Rattus norvegicus	109-137
19519602-1	2009	1,25-dihydroxyvitamin D(3) (1,25D) is tightly regulated by circulating factors, containing fibroblast growth factor 23 (FGF23).	1,25-dihydroxyvitamin D	0-23	fibroblast growth factor 23	Homo sapiens	91-118
19519602-1	2009	1,25-dihydroxyvitamin D(3) (1,25D) is tightly regulated by circulating factors, containing fibroblast growth factor 23 (FGF23).	1,25-dihydroxyvitamin D	0-23	fibroblast growth factor 23	Homo sapiens	120-125
19483274-2	2009	FGF23 is a humoral factor that is produced by osteocytes and reduces serum phosphate and 1,25-dihydroxyvitamin D levels by binding to a complex comprised of Klotho and some FGF receptor in kidney.	1,25-dihydroxyvitamin D	89-112	klotho	Homo sapiens	157-163
19225558-2	2009	Klotho knockout mice have increased expression of the sodium/phosphate cotransporter (NaPi2a) and 1alpha-hydroxylase in their kidneys, along with increased serum levels of phosphate and 1,25-dihydroxyvitamin D.	1,25-dihydroxyvitamin D	186-209	klotho	Mus musculus	0-6
19213845-7	2009	Galnt3-deficient mice also exhibited an inappropriately normal 1,25-dihydroxyvitamin D level and decreased alkaline phosphatase activity.	1,25-dihydroxyvitamin D	63-86	polypeptide N-acetylgalactosaminyltransferase 3	Mus musculus	0-6
19056306-1	2009	OBJECTIVE: Cell proliferation and gene expression regulation were studied in human fetal epiphyseal chondrocytes to ascertain the involvement of GH-IGF axis components in human fetal growth regulation by 1,25-dihydroxyvitamin D(3) (VitD) and growth hormone (GH).	1,25-dihydroxyvitamin D	204-227	growth hormone 1	Homo sapiens	145-147
19555519-3	2009	Several clinical intervention studies also support that vitamin D, or its active metabolite 1,25-dihydroxyvitamin D (1,25(OH)2D), improves insulin sensitivity, even in subjects with glucose metabolism parameters classified within normal ranges.	1,25-dihydroxyvitamin D	92-115	insulin	Homo sapiens	139-146
19164469-2	2009	The active metabolite of vitamin D, 1alpha,25-dihydroxyvitamin D(3) [1,25(OH)(2)D(3)] acting through the vitamin D receptor decreases prostate cancer cell growth and invasiveness.	1,25-dihydroxyvitamin D	36-64	vitamin D receptor	Homo sapiens	105-123
19193728-2	2009	Our previous studies demonstrated that 1,25-dihydroxyvitamin D(3) [1,25(OH)(2)D(3)] plays a renoprotective role by suppressing the RAS, with renin and angiotensinogen (AGT) as the main targets.	1,25-dihydroxyvitamin D	39-62	angiotensinogen (serpin peptidase inhibitor, clade A, member 8)	Mus musculus	168-171
18989697-4	2009	This active transcellular transport is hallmarked by the transient receptor potential vanilloid 5 (TRPV5) epithelial Ca(2+) channel, regulated by an array of events, and mediated by hormones, including 1,25-dihydroxyvitamin D(3), parathyroid hormone, and estrogen.	1,25-dihydroxyvitamin D	202-225	transient receptor potential cation channel subfamily V member 5	Oryctolagus cuniculus	57-97
18989697-4	2009	This active transcellular transport is hallmarked by the transient receptor potential vanilloid 5 (TRPV5) epithelial Ca(2+) channel, regulated by an array of events, and mediated by hormones, including 1,25-dihydroxyvitamin D(3), parathyroid hormone, and estrogen.	1,25-dihydroxyvitamin D	202-225	transient receptor potential cation channel subfamily V member 5	Oryctolagus cuniculus	99-104
19254681-7	2009	Other phenotypes were revealed when calcium metabolism was normalized in KO/TG mice: serum 1,25 dihydroxyvitamin D levels were higher in KO/TG mice than normal mice owing to reduced renal expression of the vitamin D-degrading enzyme CYP24, urinary calcium excretion was higher and associated with lower renal calcium binding protein D9k and calcium binding protein D28k than normal mice, and bone density and volume increased in KO/TG compared with normal mice owing to increased mineral apposition rate and osteoblast number.	1,25-dihydroxyvitamin D	91-114	cytochrome P450, family 24, subfamily a, polypeptide 1	Mus musculus	233-238
19383117-3	2009	PRESENTATION OF THE HYPOTHESIS: We hypothesize that low availability of 1,25-dihydroxyvitamin D, either due to vitamin D deficiency or due to polymorphisms in the vitamin D receptor or in its activating/inactivating enzymes, contributes to the appearance of IRIS.	1,25-dihydroxyvitamin D	72-95	vitamin D receptor	Homo sapiens	163-181
19329831-2	2009	Fibroblast growth factor 23 (FGF23) is a hormone which is produced by osteocytes and lowers serum phosphate and 1,25-dihydroxyvitamin D levels by binding to Klotho-FGF receptor complex in kidney.	1,25-dihydroxyvitamin D	112-135	fibroblast growth factor 23	Homo sapiens	0-27
19329831-2	2009	Fibroblast growth factor 23 (FGF23) is a hormone which is produced by osteocytes and lowers serum phosphate and 1,25-dihydroxyvitamin D levels by binding to Klotho-FGF receptor complex in kidney.	1,25-dihydroxyvitamin D	112-135	fibroblast growth factor 23	Homo sapiens	29-34
19329831-2	2009	Fibroblast growth factor 23 (FGF23) is a hormone which is produced by osteocytes and lowers serum phosphate and 1,25-dihydroxyvitamin D levels by binding to Klotho-FGF receptor complex in kidney.	1,25-dihydroxyvitamin D	112-135	klotho	Homo sapiens	157-163
19097033-0	2009	Effects of MAPK signaling on 1,25-dihydroxyvitamin D-mediated CYP24 gene expression in the enterocyte-like cell line, Caco-2.	1,25-dihydroxyvitamin D	29-52	mitogen-activated protein kinase 3	Homo sapiens	11-15
19097033-0	2009	Effects of MAPK signaling on 1,25-dihydroxyvitamin D-mediated CYP24 gene expression in the enterocyte-like cell line, Caco-2.	1,25-dihydroxyvitamin D	29-52	cytochrome P450 family 24 subfamily A member 1	Homo sapiens	62-67
19097033-1	2009	We examined the role of the extracellular signal regulated kinases (ERK) in 1,25-dihydroxyvitamin D (1,25(OH)(2)D(3))-induced gene expression in the differentiated Caco-2 cells.	1,25-dihydroxyvitamin D	76-99	mitogen-activated protein kinase 1	Homo sapiens	68-71
19049339-0	2009	Compound heterozygous mutations in the vitamin D receptor in a patient with hereditary 1,25-dihydroxyvitamin D-resistant rickets with alopecia.	1,25-dihydroxyvitamin D	87-110	vitamin D receptor	Homo sapiens	39-57
18816795-1	2009	It has previously been demonstrated that 1,25-dihydroxyvitamin D(3) [1,25(OH)(2)D(3)] administration, whether in cell cultures or in vivo to rats, increases glial cell line-derived neurotrophic factor (GDNF) expression levels, suggesting that this hormone may have beneficial effects in neurodegenerative disorders.	1,25-dihydroxyvitamin D	41-64	glial cell derived neurotrophic factor	Rattus norvegicus	157-200
19429444-1	2009	The active form of vitamin D(3), 1alpha,25-dihydroxyvitamin D(3) [1,25(OH)(2)D(3)], is a potent ligand for the nuclear receptor vitamin D receptor (VDR) and induces myeloid leukemia cell differentiation.	1,25-dihydroxyvitamin D	33-61	vitamin D receptor	Homo sapiens	128-146
19429444-1	2009	The active form of vitamin D(3), 1alpha,25-dihydroxyvitamin D(3) [1,25(OH)(2)D(3)], is a potent ligand for the nuclear receptor vitamin D receptor (VDR) and induces myeloid leukemia cell differentiation.	1,25-dihydroxyvitamin D	33-61	vitamin D receptor	Homo sapiens	148-151
18989673-4	2009	The increased osteocalcin production after 1,25-dihydroxy-vitamin D(3) stimulation of osteoporotic osteoblasts suggests a reduced, but not absent, anabolic function in senile osteoporotic osteoblasts.	1,25-dihydroxyvitamin D	43-67	bone gamma-carboxyglutamate protein	Homo sapiens	14-25
19122196-9	2009	In conclusion, 1alpha,25-dihydroxyvitamin D(3) regulates p21 transcription by inducing cyclical chromatin looping that depends on both histone deacetylation and demethylation.	1,25-dihydroxyvitamin D	15-43	cyclin dependent kinase inhibitor 1A	Homo sapiens	57-60
19005165-1	2009	The active form of vitamin D, 1,25-dihydroxyvitamin D (1,25(OH)(2)D), is a potent inducer of the antimicrobial protein cathelicidin, CAMP (LL37).	1,25-dihydroxyvitamin D	30-53	cathelicidin antimicrobial peptide	Homo sapiens	133-137
19299728-1	2009	The active form of vitamin D, 1,25-dihydroxyvitamin D (1,25(OH)(2)D) enhances innate immunity by inducing the cathelicidin antimicrobial peptide (hCAP).	1,25-dihydroxyvitamin D	30-53	cathelicidin antimicrobial peptide	Homo sapiens	110-144
19299728-1	2009	The active form of vitamin D, 1,25-dihydroxyvitamin D (1,25(OH)(2)D) enhances innate immunity by inducing the cathelicidin antimicrobial peptide (hCAP).	1,25-dihydroxyvitamin D	30-53	dermcidin	Homo sapiens	146-150
19034928-1	2009	In stimulating maturation of colonic carcinoma cells, the short chain fatty acid butyrate, and 1alpha,25-dihydroxyvitamin D(3), were shown to attenuate transcription of the cyclin D1 gene, giving rise to truncated transcripts of this locus.	1,25-dihydroxyvitamin D	95-123	cyclin D1	Homo sapiens	173-182
19157449-11	2009	In primary cultures of Sertoli"s cells the synthesis of Abca1 protein was increased by 1,25-dihydroxyvitamin D treatment but not by follicle-stimulating hormone or testosterone treatment.	1,25-dihydroxyvitamin D	87-110	ATP-binding cassette, sub-family A (ABC1), member 1	Mus musculus	56-61
19133797-6	2009	hCAP18 levels had a modest correlation with 1,25-dihydroxyvitamin D levels r = 0.23; P = .053) but not with 25-hydroxyvitamin D levels r = -0.06; P = .44).	1,25-dihydroxyvitamin D	44-67	cathelicidin antimicrobial peptide	Homo sapiens	0-6
18816795-1	2009	It has previously been demonstrated that 1,25-dihydroxyvitamin D(3) [1,25(OH)(2)D(3)] administration, whether in cell cultures or in vivo to rats, increases glial cell line-derived neurotrophic factor (GDNF) expression levels, suggesting that this hormone may have beneficial effects in neurodegenerative disorders.	1,25-dihydroxyvitamin D	41-64	glial cell derived neurotrophic factor	Rattus norvegicus	202-206
19201860-1	2009	Activation of vitamin D receptor (VDR) by 1,25-dihydroxyvitamin D(3) (1,25-vitD) reprograms dendritic cells (DC) to become tolerogenic.	1,25-dihydroxyvitamin D	42-65	vitamin D receptor	Homo sapiens	14-32
18836710-1	2009	Molecular dynamics simulation techniques have been used to study the unbinding pathways of 1alpha,25-dihydroxyvitamin D(3) from the ligand-binding pocket of the vitamin D receptor (VDR).	1,25-dihydroxyvitamin D	91-119	vitamin D receptor	Homo sapiens	161-179
19201860-1	2009	Activation of vitamin D receptor (VDR) by 1,25-dihydroxyvitamin D(3) (1,25-vitD) reprograms dendritic cells (DC) to become tolerogenic.	1,25-dihydroxyvitamin D	42-65	vitamin D receptor	Homo sapiens	34-37
18845643-6	2009	Similar effects on adipose tissue, leptin and food intake were observed in mice lacking Cyp27b1, the 1alpha-hydroxylase enzyme that generates 1,25-dihydroxyvitamin D(3), the VDR ligand.	1,25-dihydroxyvitamin D	142-165	cytochrome P450, family 27, subfamily b, polypeptide 1	Mus musculus	88-95
18836710-1	2009	Molecular dynamics simulation techniques have been used to study the unbinding pathways of 1alpha,25-dihydroxyvitamin D(3) from the ligand-binding pocket of the vitamin D receptor (VDR).	1,25-dihydroxyvitamin D	91-119	vitamin D receptor	Homo sapiens	181-184
18845643-6	2009	Similar effects on adipose tissue, leptin and food intake were observed in mice lacking Cyp27b1, the 1alpha-hydroxylase enzyme that generates 1,25-dihydroxyvitamin D(3), the VDR ligand.	1,25-dihydroxyvitamin D	142-165	vitamin D (1,25-dihydroxyvitamin D3) receptor	Mus musculus	174-177
18832097-4	2009	In the LNCaP prostate cancer cell line, induction of apoptosis and caspase-3/7 activities by staurosporine (STS) abolished [(3)H]1,25-dihydroxy vitamin D(3) binding and VDR protein, suggesting that the VDR may be targeted for inactivation by caspases during apoptosis.	1,25-dihydroxyvitamin D	129-153	caspase 3	Homo sapiens	67-76
19202327-0	2009	1,25-Dihydroxyvitamin D(3) prevents puromycin aminonucleoside-induced apoptosis of glomerular podocytes by activating the phosphatidylinositol 3-kinase/Akt-signaling pathway.	1,25-dihydroxyvitamin D	0-23	phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit beta	Rattus norvegicus	122-151
19201295-0	2009	1alpha,25-Dihydroxyvitamin D(3) to skew intratumoral levels of immune inhibitory CD34(+) progenitor cells into dendritic cells.	1,25-dihydroxyvitamin D	0-28	CD34 molecule	Homo sapiens	81-85
19201295-1	2009	OBJECTIVES: Prior studies showed that immune inhibitory CD34(+) progenitor cells, whose numbers are increased in head and neck squamous cell carcinoma (HNSCC) patients, can be differentiated into immune stimulatory dendritic cells by culture with 1alpha,25-dihydroxyvitamin D(3) (1,25[OH](2)D(3)).	1,25-dihydroxyvitamin D	247-275	CD34 molecule	Homo sapiens	56-60
18976705-5	2009	In the present study, we demonstrate that GALNT3 expression is under the regulation of a number of factors known to be associated with phosphate homeostasis, including inorganic phosphate itself, calcium and 1,25-dihydroxyvitamin D(3).	1,25-dihydroxyvitamin D	208-231	polypeptide N-acetylgalactosaminyltransferase 3	Homo sapiens	42-48
19202327-0	2009	1,25-Dihydroxyvitamin D(3) prevents puromycin aminonucleoside-induced apoptosis of glomerular podocytes by activating the phosphatidylinositol 3-kinase/Akt-signaling pathway.	1,25-dihydroxyvitamin D	0-23	AKT serine/threonine kinase 1	Rattus norvegicus	152-155
19752529-14	2009	Further prospective studies on the involvement of 1,25 dihydroxyvitamin D status in the predictive value of PTH are needed.	1,25-dihydroxyvitamin D	50-73	parathyroid hormone	Homo sapiens	108-111
20046587-9	2009	Previous reports have shown that 1,25-dihydroxyvitamin D upregulates human cathelicidin, LL-37, which has antimicrobial as well as antiendotoxin activity.	1,25-dihydroxyvitamin D	33-56	cathelicidin antimicrobial peptide	Homo sapiens	89-94
19057837-9	2009	In SDM, in the presence of recombinant RANKL, RAW 264.7 cells readily differentiated into tartrate resistant acid phosphatase (TRAP) positive multinucleated osteoclast-like cells, a process that was enhanced with the addition of 1alpha,25-dihydroxyvitamin D(3) (1,25D).	1,25-dihydroxyvitamin D	229-257	tumor necrosis factor (ligand) superfamily, member 11	Mus musculus	39-44
18726998-1	2009	We examined 1,25 dihydroxyvitamin D (1,25(OH)(2)D(3))-induced expression of 25-hydroxyvitamin D(3) 24-hydroxylase (CYP24) and apical calcium channel (TRPV6) mRNA levels in 2-, 9-, and 15-day cultures Caco-2 cells that model proliferating, post-proliferative, and differentiated enterocytes.	1,25-dihydroxyvitamin D	12-35	cytochrome P450 family 24 subfamily A member 1	Homo sapiens	115-120
18726998-1	2009	We examined 1,25 dihydroxyvitamin D (1,25(OH)(2)D(3))-induced expression of 25-hydroxyvitamin D(3) 24-hydroxylase (CYP24) and apical calcium channel (TRPV6) mRNA levels in 2-, 9-, and 15-day cultures Caco-2 cells that model proliferating, post-proliferative, and differentiated enterocytes.	1,25-dihydroxyvitamin D	12-35	transient receptor potential cation channel subfamily V member 6	Homo sapiens	150-155
19956747-4	2009	FGF23 is produced by bone and reduces serum phosphate level by suppressing phosphate reabsorption in proximal tubules and intestinal phosphate absorption through lowering 1,25-dihydroxyvitamin D level.	1,25-dihydroxyvitamin D	171-194	fibroblast growth factor 23	Homo sapiens	0-5
19056871-5	2009	The increased levels of 1,25-dihydroxyvitamin D(3) in Npt2c(-/-) mice compared with age-matched Npt2c(+/+) mice may be the result of reduced catabolism, because we observed significantly reduced expression of renal 25-hydroxyvitamin D-24-hydroxylase mRNA but no change in 1alpha-hydroxylase mRNA levels.	1,25-dihydroxyvitamin D	24-47	solute carrier family 34 (sodium phosphate), member 3	Mus musculus	54-59
18767934-1	2009	CYP27B1, encoding 25-hydroxyvitamin D-1alpha-hydroxylase, converts 25-hydroxyvitamin D to its active form, 1,25-dihydroxyvitamin D, and is expressed primarily in the kidney but also in nontraditional sites including the parathyroid glands.	1,25-dihydroxyvitamin D	107-130	cytochrome P450 family 27 subfamily B member 1	Homo sapiens	0-7
19082914-10	2009	RANKL mRNA expression induced by 1,25-dihydroxyvitamin D(3) plus prostaglandin E(2) in osteoblasts was not affected by docetaxel even at 10(-6) M. Docetaxel at 10(-6) M, but not at 10(-8) M, inhibited pit-forming activity of osteoclasts cultured on dentine.	1,25-dihydroxyvitamin D	33-56	tumor necrosis factor (ligand) superfamily, member 11	Mus musculus	0-5
18755215-2	2008	While these relationships are between serum 25 hydroxyvitamin D and cancer, cell-based studies show that the metabolite 1,25 dihydroxyvitamin D is biologically active and influences cell biology relevant to cancer through vitamin D receptor-mediated gene transcription.	1,25-dihydroxyvitamin D	120-143	vitamin D receptor	Homo sapiens	222-240
19073256-3	2009	We used primary human osteoblasts (hOBs) cells to examine the impact of 17-beta-estradiol (E2) or/and 1,25-dihydroxyvitamin D (1,25D) in OPG/RANKL system in 28 post-menopausal (PM) women; (a) with hip fracture (OP) or (b) with osteoarthritis (OA).	1,25-dihydroxyvitamin D	102-125	basic transcription factor 3 pseudogene 11	Homo sapiens	137-140
19820750-2	2009	In patients with chronic kidney disease (CKD), circulating FGF23 levels are progressively elevated to compensate for persistent phosphate retention, which result in reduced renal production of 1,25-dihydroxyvitamin D and thereby stimulate secretion of parathyroid hormone, suggesting its critical role in the pathogenesis of altered mineral homeostasis in CKD.	1,25-dihydroxyvitamin D	193-216	fibroblast growth factor 23	Homo sapiens	59-64
19127080-1	2009	Nicotinamide, the amide derivative of vitamin B(3), cooperates with retinoic acid (RA), a form of vitamin A, and 1,25-dihydroxyvitamin D(3) (D3), to regulate cell differentiation and proliferation of human myeloblastic leukemia cells.	1,25-dihydroxyvitamin D	113-136	iodothyronine deiodinase 3	Homo sapiens	141-143
18753255-1	2008	Fibroblast growth factor 23 (FGF23) is a phosphaturic factor that suppresses both sodium-dependent phosphate transport and production of 1,25-dihydroxyvitamin D [1,25(OH)(2)D] in the proximal tubule.	1,25-dihydroxyvitamin D	137-160	fibroblast growth factor 23	Mus musculus	0-27
18753255-1	2008	Fibroblast growth factor 23 (FGF23) is a phosphaturic factor that suppresses both sodium-dependent phosphate transport and production of 1,25-dihydroxyvitamin D [1,25(OH)(2)D] in the proximal tubule.	1,25-dihydroxyvitamin D	137-160	fibroblast growth factor 23	Mus musculus	29-34
19034301-6	2008	Our study shows that suppression of renin expression by 1,25-dihydroxyvitamin D in vivo is independent of parathyroid hormone and calcium.	1,25-dihydroxyvitamin D	56-79	renin	Homo sapiens	36-41
19339809-1	2009	BACKGROUND: Fibroblast growth factor 23 (FGF23) regulates renal phosphate reabsorption and 1alpha,25-dihydroxyvitamin D [1,25(OH)(2)D(3)] metabolism.	1,25-dihydroxyvitamin D	91-119	fibroblast growth factor 23	Rattus norvegicus	12-39
19339809-1	2009	BACKGROUND: Fibroblast growth factor 23 (FGF23) regulates renal phosphate reabsorption and 1alpha,25-dihydroxyvitamin D [1,25(OH)(2)D(3)] metabolism.	1,25-dihydroxyvitamin D	91-119	fibroblast growth factor 23	Rattus norvegicus	41-46
18644400-1	2008	1,25-Dihydroxyvitamin D(3) (1,25D) regulates gene transcription through a nuclear vitamin D receptor (VDR) which acts as a ligand-regulated transcription factor.	1,25-dihydroxyvitamin D	0-23	vitamin D receptor	Homo sapiens	82-100
18644400-1	2008	1,25-Dihydroxyvitamin D(3) (1,25D) regulates gene transcription through a nuclear vitamin D receptor (VDR) which acts as a ligand-regulated transcription factor.	1,25-dihydroxyvitamin D	0-23	vitamin D receptor	Homo sapiens	102-105
18694980-2	2008	The precise mode of action and the full spectrum of activities of the vitamin D hormone, 1,25-dihydroxyvitamin D [1,25-(OH)(2)D], can now be better evaluated by critical analysis of mice with engineered deletion of the vitamin D receptor (VDR).	1,25-dihydroxyvitamin D	89-112	vitamin D (1,25-dihydroxyvitamin D3) receptor	Mus musculus	219-237
19169476-0	2008	Mutations in the vitamin D receptor gene in four patients with hereditary 1,25-dihydroxyvitamin D-resistant rickets.	1,25-dihydroxyvitamin D	74-97	vitamin D receptor	Homo sapiens	17-35
18781907-7	2008	It is the parathyroid hormone suppression that causes us to postulate acute deficiency of 1,25-dihydroxyvitamin D and the consequence of this for post-burn metabolism could include derepression of the gene that controls renin production, leading to elevated levels of angiotensin II, which can contribute to insulin resistance, as can vitamin D deficiency itself.	1,25-dihydroxyvitamin D	90-113	angiotensinogen	Homo sapiens	268-282
18778589-3	2008	1,25-Dihydroxyvitamin D is a potent immunomodulator that also enhances the production and secretion of several hormones, including insulin.	1,25-dihydroxyvitamin D	0-23	insulin	Homo sapiens	131-138
18509362-1	2008	1,25-Dihydroxyvitamin D(3) (1,25(OH)(2)D(3)) is the biologically active ligand for the vitamin D receptor (VDR).	1,25-dihydroxyvitamin D	0-23	vitamin D (1,25-dihydroxyvitamin D3) receptor	Mus musculus	87-105
18509362-1	2008	1,25-Dihydroxyvitamin D(3) (1,25(OH)(2)D(3)) is the biologically active ligand for the vitamin D receptor (VDR).	1,25-dihydroxyvitamin D	0-23	vitamin D (1,25-dihydroxyvitamin D3) receptor	Mus musculus	107-110
18781907-7	2008	It is the parathyroid hormone suppression that causes us to postulate acute deficiency of 1,25-dihydroxyvitamin D and the consequence of this for post-burn metabolism could include derepression of the gene that controls renin production, leading to elevated levels of angiotensin II, which can contribute to insulin resistance, as can vitamin D deficiency itself.	1,25-dihydroxyvitamin D	90-113	insulin	Homo sapiens	308-315
18551686-12	2008	JNK phosphorylation was reduced by 126.7% with treatment of 1,25-dihydroxyvitamin D (p < 0.001).	1,25-dihydroxyvitamin D	60-83	mitogen-activated protein kinase 8	Mus musculus	0-3
18602086-10	2008	These results indicate that the induction of MDR1 by 1alpha,25-dihydroxyvitamin D(3) is mediated by VDR/RXRalpha binding to several VDREs located between -7880 and -7810bp, in which every VDRE additively contributes to the 1alpha,25-dihydroxyvitamin D(3) response.	1,25-dihydroxyvitamin D	53-81	ATP binding cassette subfamily B member 1	Homo sapiens	45-49
18602086-10	2008	These results indicate that the induction of MDR1 by 1alpha,25-dihydroxyvitamin D(3) is mediated by VDR/RXRalpha binding to several VDREs located between -7880 and -7810bp, in which every VDRE additively contributes to the 1alpha,25-dihydroxyvitamin D(3) response.	1,25-dihydroxyvitamin D	53-81	vitamin D receptor	Homo sapiens	100-103
19134349-1	2008	OBJECTIVE: To study the effects of 1, 25-dihydroxyvitamin D(3) (VD(3)) on the expression of vitamin D receptor (VDR), receptor activator of nuclear factor-kappa B ligand (RANKL) and osteoprotegerin (OPG) in human periodontal ligament cells (hPDLC) populations and to analyze the potential mechanisms.	1,25-dihydroxyvitamin D	35-59	vitamin D receptor	Homo sapiens	92-110
18602086-10	2008	These results indicate that the induction of MDR1 by 1alpha,25-dihydroxyvitamin D(3) is mediated by VDR/RXRalpha binding to several VDREs located between -7880 and -7810bp, in which every VDRE additively contributes to the 1alpha,25-dihydroxyvitamin D(3) response.	1,25-dihydroxyvitamin D	53-81	retinoid X receptor alpha	Homo sapiens	104-112
19134349-1	2008	OBJECTIVE: To study the effects of 1, 25-dihydroxyvitamin D(3) (VD(3)) on the expression of vitamin D receptor (VDR), receptor activator of nuclear factor-kappa B ligand (RANKL) and osteoprotegerin (OPG) in human periodontal ligament cells (hPDLC) populations and to analyze the potential mechanisms.	1,25-dihydroxyvitamin D	35-59	vitamin D receptor	Homo sapiens	112-115
18649741-1	2008	The active form of vitamin D, 1alpha,25-dihydroxyvitamin D (1alpha,25(OH)2D), inhibits proliferation and induces the differentiation of prostate cells in culture, attenuates tumor growth in animal models, and decreases prostate specific antigen (PSA) levels in prostate cancer patients.	1,25-dihydroxyvitamin D	30-58	kallikrein related peptidase 3	Homo sapiens	219-250
19134349-1	2008	OBJECTIVE: To study the effects of 1, 25-dihydroxyvitamin D(3) (VD(3)) on the expression of vitamin D receptor (VDR), receptor activator of nuclear factor-kappa B ligand (RANKL) and osteoprotegerin (OPG) in human periodontal ligament cells (hPDLC) populations and to analyze the potential mechanisms.	1,25-dihydroxyvitamin D	35-59	TNF superfamily member 11	Homo sapiens	118-169
19134349-1	2008	OBJECTIVE: To study the effects of 1, 25-dihydroxyvitamin D(3) (VD(3)) on the expression of vitamin D receptor (VDR), receptor activator of nuclear factor-kappa B ligand (RANKL) and osteoprotegerin (OPG) in human periodontal ligament cells (hPDLC) populations and to analyze the potential mechanisms.	1,25-dihydroxyvitamin D	35-59	TNF superfamily member 11	Homo sapiens	171-176
18687639-1	2008	BACKGROUND: Fibroblast growth factor 23 (FGF-23) is a hormone that increases the rate of urinary excretion of phosphate and inhibits renal production of 1,25-dihydroxyvitamin D, thus helping to mitigate hyperphosphatemia in patients with kidney disease.	1,25-dihydroxyvitamin D	153-176	fibroblast growth factor 23	Homo sapiens	12-39
18687639-1	2008	BACKGROUND: Fibroblast growth factor 23 (FGF-23) is a hormone that increases the rate of urinary excretion of phosphate and inhibits renal production of 1,25-dihydroxyvitamin D, thus helping to mitigate hyperphosphatemia in patients with kidney disease.	1,25-dihydroxyvitamin D	153-176	fibroblast growth factor 23	Homo sapiens	41-47
18427562-0	2008	1Alpha, 25-dihydroxyvitamin D and corticosteroid regulate adipocyte nuclear vitamin D receptor.	1,25-dihydroxyvitamin D	0-29	vitamin D receptor	Homo sapiens	76-94
18651709-0	2008	1,25-dihydroxyvitamin D(3) promotes IL-10 production in human B cells.	1,25-dihydroxyvitamin D	0-23	interleukin 10	Homo sapiens	36-41
18372326-1	2008	Mice deficient in the expression of vitamin D-binding protein (DBP) are normocalcemic despite undetectable levels of circulating 1,25-dihydroxyvitamin D(3) [1,25(OH)(2)D(3)].	1,25-dihydroxyvitamin D	129-152	vitamin D binding protein	Mus musculus	36-61
18372326-1	2008	Mice deficient in the expression of vitamin D-binding protein (DBP) are normocalcemic despite undetectable levels of circulating 1,25-dihydroxyvitamin D(3) [1,25(OH)(2)D(3)].	1,25-dihydroxyvitamin D	129-152	D site albumin promoter binding protein	Mus musculus	63-66
18660670-4	2008	A key protein in this regulatory pathway is FGF23, which is made by osteocytes and activates renal KLOTHO/FGFR1 receptor heterodimers to inhibit renal phosphate reabsorption and 1,25-dihydroxyvitamin D synthesis.	1,25-dihydroxyvitamin D	178-201	fibroblast growth factor 23	Homo sapiens	44-49
18660670-4	2008	A key protein in this regulatory pathway is FGF23, which is made by osteocytes and activates renal KLOTHO/FGFR1 receptor heterodimers to inhibit renal phosphate reabsorption and 1,25-dihydroxyvitamin D synthesis.	1,25-dihydroxyvitamin D	178-201	klotho	Homo sapiens	99-105
18660670-4	2008	A key protein in this regulatory pathway is FGF23, which is made by osteocytes and activates renal KLOTHO/FGFR1 receptor heterodimers to inhibit renal phosphate reabsorption and 1,25-dihydroxyvitamin D synthesis.	1,25-dihydroxyvitamin D	178-201	fibroblast growth factor receptor 1	Homo sapiens	106-111
18550844-1	2008	1,25-dihydroxyvitamin D(3) (1,25D) regulates gene expression by signaling through the nuclear vitamin D receptor (VDR) transcription factor and exhibits calcium homeostatic, anticancer, and immunomodulatory properties.	1,25-dihydroxyvitamin D	0-23	vitamin D receptor	Homo sapiens	94-112
18660678-5	2008	SUMMARY: The broad tissue distribution of the 25-hydroxyvitamin D 1alpha-hydroxylase enzyme and the vitamin D receptor establish a role for 1,25-dihydroxyvitamin D in the pathophysiology of various disease states and provide new therapeutic targets for vitamin D and its analogues.	1,25-dihydroxyvitamin D	140-163	vitamin D receptor	Homo sapiens	100-118
18515093-2	2008	1,25-Dihydroxyvitamin D(3) (1,25(OH)(2)D(3)), the hormonal form of vitamin D, is involved in the anti-inflammatory action through VDR.	1,25-dihydroxyvitamin D	0-23	vitamin D receptor	Homo sapiens	130-133
18550844-1	2008	1,25-dihydroxyvitamin D(3) (1,25D) regulates gene expression by signaling through the nuclear vitamin D receptor (VDR) transcription factor and exhibits calcium homeostatic, anticancer, and immunomodulatory properties.	1,25-dihydroxyvitamin D	0-23	vitamin D receptor	Homo sapiens	114-117
18358824-9	2008	Finally, the capacity of exogenous PTH to modulate extra-osseous factors such as 1,25 dihydroxyvitamin D may also modulate its potency as an anabolic agent.	1,25-dihydroxyvitamin D	81-104	parathyroid hormone	Homo sapiens	35-38
18362166-6	2008	1,25-Dihydroxy-vitamin D(3) (VD3) causes recruitment of SMRT and NCoR to a VDR target promoter.	1,25-dihydroxyvitamin D	0-24	vitamin D receptor	Homo sapiens	75-78
18362166-6	2008	1,25-Dihydroxy-vitamin D(3) (VD3) causes recruitment of SMRT and NCoR to a VDR target promoter.	1,25-dihydroxyvitamin D	0-24	nuclear receptor corepressor 2	Homo sapiens	56-60
18362166-6	2008	1,25-Dihydroxy-vitamin D(3) (VD3) causes recruitment of SMRT and NCoR to a VDR target promoter.	1,25-dihydroxyvitamin D	0-24	nuclear receptor corepressor 1	Homo sapiens	65-69
18519464-8	2008	There was a positive correlation between 1,25 dihydroxyvitamin D and parathyroid hormone, alkaline phosphatase, and urine markers for bone turnover.	1,25-dihydroxyvitamin D	41-64	parathyroid hormone	Homo sapiens	69-88
18424254-1	2008	Vitamin D requires two metabolic conversions, 25-hydroxylation in the liver and 1alpha-hydroxylation in the kidney, before its hormonal form, 1,25-dihydroxyvitamin D [1,25-(OH)2D], can bind to the vitamin D receptor (VDR) to modulate gene transcription and regulate mineral ion homeostasis.	1,25-dihydroxyvitamin D	142-165	vitamin D (1,25-dihydroxyvitamin D3) receptor	Mus musculus	197-215
18424254-1	2008	Vitamin D requires two metabolic conversions, 25-hydroxylation in the liver and 1alpha-hydroxylation in the kidney, before its hormonal form, 1,25-dihydroxyvitamin D [1,25-(OH)2D], can bind to the vitamin D receptor (VDR) to modulate gene transcription and regulate mineral ion homeostasis.	1,25-dihydroxyvitamin D	142-165	vitamin D (1,25-dihydroxyvitamin D3) receptor	Mus musculus	217-220
18311810-4	2008	The pathogenesis of tumor-induced osteomalacia involves tumor expression of fibroblast growth factor 23, a hormone that inhibits proximal renal tubular reabsorption of phosphate and down-regulates renal conversion of 25-hydroxyvitamin D to its active form, 1,25-dihydroxyvitamin D.	1,25-dihydroxyvitamin D	257-280	fibroblast growth factor 23	Homo sapiens	76-103
18180267-1	2008	1alpha,25-Dihydroxyvitamin D(3) [1,25(OH)(2)D(3)], a vitamin D receptor (VDR) ligand, regulates calcium homeostasis and also exhibits noncalcemic actions on immunity and cell differentiation.	1,25-dihydroxyvitamin D	0-28	vitamin D receptor	Homo sapiens	53-71
18180267-1	2008	1alpha,25-Dihydroxyvitamin D(3) [1,25(OH)(2)D(3)], a vitamin D receptor (VDR) ligand, regulates calcium homeostasis and also exhibits noncalcemic actions on immunity and cell differentiation.	1,25-dihydroxyvitamin D	0-28	vitamin D receptor	Homo sapiens	73-76
17786964-1	2008	Binding of 1alpha,25-dihydroxy vitamin D(3) to the C-terminal ligand-binding domain (LBD) of its receptor (VDR) induces a conformational change that enables interaction of VDR with transcriptional coactivators such as members of the p160/SRC family or the DRIP (vitamin D receptor-interacting complex)/Mediator complex.	1,25-dihydroxyvitamin D	11-40	vitamin D receptor	Homo sapiens	107-110
17786964-1	2008	Binding of 1alpha,25-dihydroxy vitamin D(3) to the C-terminal ligand-binding domain (LBD) of its receptor (VDR) induces a conformational change that enables interaction of VDR with transcriptional coactivators such as members of the p160/SRC family or the DRIP (vitamin D receptor-interacting complex)/Mediator complex.	1,25-dihydroxyvitamin D	11-40	vitamin D receptor	Homo sapiens	172-175
17786964-1	2008	Binding of 1alpha,25-dihydroxy vitamin D(3) to the C-terminal ligand-binding domain (LBD) of its receptor (VDR) induces a conformational change that enables interaction of VDR with transcriptional coactivators such as members of the p160/SRC family or the DRIP (vitamin D receptor-interacting complex)/Mediator complex.	1,25-dihydroxyvitamin D	11-40	MYB binding protein 1a	Homo sapiens	233-237
17786964-1	2008	Binding of 1alpha,25-dihydroxy vitamin D(3) to the C-terminal ligand-binding domain (LBD) of its receptor (VDR) induces a conformational change that enables interaction of VDR with transcriptional coactivators such as members of the p160/SRC family or the DRIP (vitamin D receptor-interacting complex)/Mediator complex.	1,25-dihydroxyvitamin D	11-40	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	238-241
18290715-1	2007	The vitamin D hormone, 1,25-dihydroxyvitamin D(3) [1,25(OH)(2)D(3)], binds with high affinity to the nuclear vitamin D receptor (VDR), which recruits its retinoid X receptor (RXR) heterodimeric partner to recognize vitamin D responsive elements (VDREs) in target genes.	1,25-dihydroxyvitamin D	23-46	vitamin D receptor	Homo sapiens	109-127
17932217-2	2008	We have previously shown that PTH and 1,25-dihydroxyvitamin D(3) control murine RANKL gene expression in vitro, in part, via an evolutionarily conserved transcriptional enhancer, designated the distal control region (DCR), located 76 kb upstream from the transcription start site.	1,25-dihydroxyvitamin D	38-61	tumor necrosis factor (ligand) superfamily, member 11	Mus musculus	80-85
17932217-4	2008	Deletion of the DCR reduced PTH and 1,25-dihydroxyvitamin D(3) stimulation of RANKL mRNA and osteoclast formation in primary bone marrow cultures as well as stimulation of RANKL mRNA in bone.	1,25-dihydroxyvitamin D	36-59	tumor necrosis factor (ligand) superfamily, member 11	Mus musculus	78-83
18290716-1	2007	Tissue availability of the active vitamin D metabolite, 1,25-dihydroxyvitamin D [1,25(OH)(2)D] is dependent on expression of the activating enzyme 1alpha-hydroxylase (CYP27b1) and its catabolic counterpart 24-hydroxylase (CYP24).	1,25-dihydroxyvitamin D	56-79	cytochrome P450 family 27 subfamily B member 1	Homo sapiens	167-174
18290715-1	2007	The vitamin D hormone, 1,25-dihydroxyvitamin D(3) [1,25(OH)(2)D(3)], binds with high affinity to the nuclear vitamin D receptor (VDR), which recruits its retinoid X receptor (RXR) heterodimeric partner to recognize vitamin D responsive elements (VDREs) in target genes.	1,25-dihydroxyvitamin D	23-46	vitamin D receptor	Homo sapiens	129-132
18290715-1	2007	The vitamin D hormone, 1,25-dihydroxyvitamin D(3) [1,25(OH)(2)D(3)], binds with high affinity to the nuclear vitamin D receptor (VDR), which recruits its retinoid X receptor (RXR) heterodimeric partner to recognize vitamin D responsive elements (VDREs) in target genes.	1,25-dihydroxyvitamin D	23-46	retinoid X receptor alpha	Homo sapiens	154-173
18290716-1	2007	Tissue availability of the active vitamin D metabolite, 1,25-dihydroxyvitamin D [1,25(OH)(2)D] is dependent on expression of the activating enzyme 1alpha-hydroxylase (CYP27b1) and its catabolic counterpart 24-hydroxylase (CYP24).	1,25-dihydroxyvitamin D	56-79	cytochrome P450 family 24 subfamily A member 1	Homo sapiens	222-227
18290715-1	2007	The vitamin D hormone, 1,25-dihydroxyvitamin D(3) [1,25(OH)(2)D(3)], binds with high affinity to the nuclear vitamin D receptor (VDR), which recruits its retinoid X receptor (RXR) heterodimeric partner to recognize vitamin D responsive elements (VDREs) in target genes.	1,25-dihydroxyvitamin D	23-46	retinoid X receptor alpha	Homo sapiens	175-178
17976083-2	2007	Phosphate intake and an administration of 1,25-dihydroxyvitamin D(3) (1,25(OH)(2)D(3)) increase circulating FGF-23 levels, and elevated FGF-23 prevents hyperphosphatemia and vitamin D toxicity by hyperphosphaturia and suppression of circulating 1,25(OH)(2)D level, comprising a feedback loop to maintain phosphate and vitamin D homeostasis.	1,25-dihydroxyvitamin D	42-65	fibroblast growth factor 23	Homo sapiens	108-114
18290729-2	2007	In vitro studies have shown that the VDR ligand, 1,25-dihydroxyvitamin D (1,25D), modulates key proteins involved in signaling proliferation, differentiation, and survival of normal mammary epithelial cells.	1,25-dihydroxyvitamin D	49-72	vitamin D (1,25-dihydroxyvitamin D3) receptor	Mus musculus	37-40
17906402-1	2007	Fibroblast growth factor (FGF) 23 is a humoral factor that reduces serum phosphate and 1,25-dihydroxyvitamin D [1,25 (OH)(2)D] levels at least in part by suppressing proximal tubular phosphate reabsorption and 1,25 (OH)(2)D production.	1,25-dihydroxyvitamin D	87-110	fibroblast growth factor 23	Homo sapiens	0-33
17911404-1	2007	Fibroblast growth factor-23 (FGF23) is a circulating factor that decreases serum levels of inorganic phosphate (Pi) as well as 1,25-dihydroxyvitamin D(3).	1,25-dihydroxyvitamin D	127-150	fibroblast growth factor 23	Bos taurus	0-27
17911404-1	2007	Fibroblast growth factor-23 (FGF23) is a circulating factor that decreases serum levels of inorganic phosphate (Pi) as well as 1,25-dihydroxyvitamin D(3).	1,25-dihydroxyvitamin D	127-150	fibroblast growth factor 23	Bos taurus	29-34
17904173-0	2007	PTHrP contributes to the anti-proliferative and integrin alpha6beta4-regulating effects of 1,25-dihydroxyvitamin D(3).	1,25-dihydroxyvitamin D	91-114	parathyroid hormone like hormone	Homo sapiens	0-5
17904173-2	2007	1,25-Dihydroxyvitamin D(3) [1,25(OH)(2)D(3)] suppresses PTHrP expression and exerts an anti-proliferative effect in prostate carcinoma cells.	1,25-dihydroxyvitamin D	0-23	parathyroid hormone like hormone	Homo sapiens	56-61
17917264-1	2007	Treatment of Caco-2 cells with beta-naphthoflavone (beta-NF) and 1alpha,25-dihydroxyvitamin D(3) (VD(3)) induces UDP-glucuronosyltransferases (UGTs) and cytochrome P450 (CYP) 3A4, respectively.	1,25-dihydroxyvitamin D	65-93	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	153-178
18270398-8	2007	Paricalcitol (calcitriol analogue) is as effective as 1,25-dihydroxyvitamin D in transactivating the prostatic VDR and in inhibiting the growth of prostate cancer cell lines and primary cultures of prostate cancer cells in vitro.	1,25-dihydroxyvitamin D	54-77	vitamin D receptor	Homo sapiens	111-114
17976083-2	2007	Phosphate intake and an administration of 1,25-dihydroxyvitamin D(3) (1,25(OH)(2)D(3)) increase circulating FGF-23 levels, and elevated FGF-23 prevents hyperphosphatemia and vitamin D toxicity by hyperphosphaturia and suppression of circulating 1,25(OH)(2)D level, comprising a feedback loop to maintain phosphate and vitamin D homeostasis.	1,25-dihydroxyvitamin D	42-65	fibroblast growth factor 23	Homo sapiens	136-142
17723171-3	2007	Consistent with this concept, in vitro studies have demonstrated that the VDR ligand, 1,25-dihydroxyvitamin D (1, 25D), exerts negative growth regulatory effects on mammary epithelial cells that contribute to maintenance of the differentiated phenotype.	1,25-dihydroxyvitamin D	86-109	vitamin D receptor	Homo sapiens	74-77
17412493-0	2007	1alpha,25-Dihydroxyvitamin D(3) antiproliferative actions involve vitamin D receptor-mediated activation of MAPK pathways and AP-1/p21(waf1) upregulation in human osteosarcoma.	1,25-dihydroxyvitamin D	0-28	vitamin D receptor	Homo sapiens	66-84
17412493-0	2007	1alpha,25-Dihydroxyvitamin D(3) antiproliferative actions involve vitamin D receptor-mediated activation of MAPK pathways and AP-1/p21(waf1) upregulation in human osteosarcoma.	1,25-dihydroxyvitamin D	0-28	mitogen-activated protein kinase 3	Homo sapiens	108-112
17412493-0	2007	1alpha,25-Dihydroxyvitamin D(3) antiproliferative actions involve vitamin D receptor-mediated activation of MAPK pathways and AP-1/p21(waf1) upregulation in human osteosarcoma.	1,25-dihydroxyvitamin D	0-28	cyclin dependent kinase inhibitor 1A	Homo sapiens	131-134
17412493-0	2007	1alpha,25-Dihydroxyvitamin D(3) antiproliferative actions involve vitamin D receptor-mediated activation of MAPK pathways and AP-1/p21(waf1) upregulation in human osteosarcoma.	1,25-dihydroxyvitamin D	0-28	cyclin dependent kinase inhibitor 1A	Homo sapiens	135-139
17604335-0	2007	Suppression of RelB-mediated manganese superoxide dismutase expression reveals a primary mechanism for radiosensitization effect of 1alpha,25-dihydroxyvitamin D(3) in prostate cancer cells.	1,25-dihydroxyvitamin D	132-160	RELB proto-oncogene, NF-kB subunit	Homo sapiens	15-19
17599832-0	2007	Expression of human kinase suppressor of Ras 2 (hKSR-2) gene in HL60 leukemia cells is directly upregulated by 1,25-dihydroxyvitamin D(3) and is required for optimal cell differentiation.	1,25-dihydroxyvitamin D	111-134	kinase suppressor of ras 2	Homo sapiens	20-46
17599832-0	2007	Expression of human kinase suppressor of Ras 2 (hKSR-2) gene in HL60 leukemia cells is directly upregulated by 1,25-dihydroxyvitamin D(3) and is required for optimal cell differentiation.	1,25-dihydroxyvitamin D	111-134	kinase suppressor of ras 2	Homo sapiens	48-54
17638866-1	2007	We previously showed that checkpoint kinase 1 (Chk1) and Claspin, two DNA-damage checkpoint proteins, were down-regulated by 1,25-dihydroxyvitamin D(3), a known inhibitor of cell proliferation.	1,25-dihydroxyvitamin D	125-148	checkpoint kinase 1	Homo sapiens	26-45
17638866-1	2007	We previously showed that checkpoint kinase 1 (Chk1) and Claspin, two DNA-damage checkpoint proteins, were down-regulated by 1,25-dihydroxyvitamin D(3), a known inhibitor of cell proliferation.	1,25-dihydroxyvitamin D	125-148	checkpoint kinase 1	Homo sapiens	47-51
17638866-1	2007	We previously showed that checkpoint kinase 1 (Chk1) and Claspin, two DNA-damage checkpoint proteins, were down-regulated by 1,25-dihydroxyvitamin D(3), a known inhibitor of cell proliferation.	1,25-dihydroxyvitamin D	125-148	claspin	Homo sapiens	57-64
17400175-4	2007	Elevated serum concentrations of calcium and 1,25-dihydroxyvitamin D(3) [1,25-(OH)(2)D(3)] in untreated ob/ob mice showed sharp reduction with leptin administration (4 mg/kg, i.p.	1,25-dihydroxyvitamin D	45-68	leptin	Mus musculus	143-149
17456792-2	2007	The genomic actions of 1,25-dihydroxyvitamin D(3) are mediated by the vitamin D receptor (VDR) present in target cells.	1,25-dihydroxyvitamin D	23-46	vitamin D receptor	Homo sapiens	70-88
17456792-2	2007	The genomic actions of 1,25-dihydroxyvitamin D(3) are mediated by the vitamin D receptor (VDR) present in target cells.	1,25-dihydroxyvitamin D	23-46	vitamin D receptor	Homo sapiens	90-93
18019603-1	2007	Parathyroid hormone (PTH) and 1,25-dihydroxyvitamin D [1,25-(OH)zD] participate in systemic regulation of calcium homeostasis through endocrine effects mediated via the specific receptors PTHR1 and VDR, expressed in bone, kidney, intestine and parathyroid glands.	1,25-dihydroxyvitamin D	30-53	parathyroid hormone 1 receptor	Homo sapiens	188-193
17475215-1	2007	The level of CYP24 mRNA in cultured human fibroblasts increases up to 20,000-fold in response to 1,25-dihydroxyvitamin D(3).	1,25-dihydroxyvitamin D	97-120	cytochrome P450 family 24 subfamily A member 1	Homo sapiens	13-18
18019603-1	2007	Parathyroid hormone (PTH) and 1,25-dihydroxyvitamin D [1,25-(OH)zD] participate in systemic regulation of calcium homeostasis through endocrine effects mediated via the specific receptors PTHR1 and VDR, expressed in bone, kidney, intestine and parathyroid glands.	1,25-dihydroxyvitamin D	30-53	vitamin D receptor	Homo sapiens	198-201
17440943-2	2007	The binding of 1,25-dihydroxyvitamin D to the VDR on prostatic epithelial cells prompts the regulation of cancer-related genes.	1,25-dihydroxyvitamin D	15-38	vitamin D receptor	Homo sapiens	46-49
17440943-6	2007	Plasma 1,25-dihydroxyvitamin D deficiency (< or =26 pg/ml) was associated with a threefold risk of poorly differentiated PC (P for interaction = 0.01) when comparing carriers of the Cdx2 A allele to non-carriers with normal 1,25-dihydroxyvitamin D.	1,25-dihydroxyvitamin D	7-30	caudal type homeobox 2	Homo sapiens	185-189
17397830-1	2007	1,25-dihydroxyvitamin D(3) (VD(3)) induces differentiation in a number of leukemia cell lines and under various conditions is able to either stimulate or inhibit nuclear factor kappa B (NF-kappaB) activity.	1,25-dihydroxyvitamin D	0-23	nuclear factor kappa B subunit 1	Homo sapiens	162-184
17535892-1	2007	The physiological ligand for the vitamin D receptor (VDR) is 1,25-dihydroxyvitamin D(3).	1,25-dihydroxyvitamin D	61-84	vitamin D receptor	Rattus norvegicus	33-51
17535892-1	2007	The physiological ligand for the vitamin D receptor (VDR) is 1,25-dihydroxyvitamin D(3).	1,25-dihydroxyvitamin D	61-84	vitamin D receptor	Rattus norvegicus	53-56
17395559-1	2007	Circulating 1 alpha,25-dihydroxyvitamin D(3) (1,25D) derives from renal conversion of 25-hydroxyvitamin D(3) (25D), by the 25D 1 alpha-hydroxylase (CYP27B1).	1,25-dihydroxyvitamin D	12-41	cytochrome P450 family 27 subfamily B member 1	Homo sapiens	148-155
17457012-1	2007	Fibroblast growth factor (FGF)23 is a hormone that regulates serum phosphate and 1,25-dihydroxyvitamin D levels.	1,25-dihydroxyvitamin D	81-104	fibroblast growth factor 23	Homo sapiens	0-32
17200157-2	2007	We reported (Yamauchi et al., Biochem Biophys Res Commun 331: 1353-1357, 2005) that the epithelial Ca(2+) channels TRPV5 and TRPV6 (transient receptor potential types 5 and 6) are expressed in the vestibular system and that TRPV5 expression is stimulated by 1,25-dihydroxyvitamin D(3), as also reported in kidney.	1,25-dihydroxyvitamin D	258-281	transient receptor potential cation channel, subfamily V, member 5	Mus musculus	115-120
17200157-2	2007	We reported (Yamauchi et al., Biochem Biophys Res Commun 331: 1353-1357, 2005) that the epithelial Ca(2+) channels TRPV5 and TRPV6 (transient receptor potential types 5 and 6) are expressed in the vestibular system and that TRPV5 expression is stimulated by 1,25-dihydroxyvitamin D(3), as also reported in kidney.	1,25-dihydroxyvitamin D	258-281	transient receptor potential cation channel, subfamily V, member 6	Mus musculus	125-130
17494882-2	2007	Disorders that are caused by high circulating levels of FGF23 are characterized by hypophosphatemia, decreased production of 1,25-dihydroxyvitamin D, and rickets/osteomalacia.	1,25-dihydroxyvitamin D	125-148	fibroblast growth factor 23	Mus musculus	56-61
17494882-3	2007	On the other end of the spectrum are disorders that are caused by low circulating levels of FGF23, which are characterized by hyperphosphatemia, elevated production of 1,25-dihydroxyvitamin D, soft tissue calcifications, and hyperostosis.	1,25-dihydroxyvitamin D	168-191	fibroblast growth factor 23	Mus musculus	92-97
17244893-4	2007	In any of these basal media, addition of 1,25-dihydroxyvitamin D(3), all-trans-retinoic acid or dexamethasone significantly increased activity of the nephrin promoter.	1,25-dihydroxyvitamin D	41-64	nephrosis 1, nephrin	Mus musculus	150-157
17433303-1	2007	1alpha,25-Dihydroxyvitamin D(3) (VitD(3)) increases protein and gene expression of phospholipase D1 (PLD1), but not PLD2, in HaCaT human keratinocytes.	1,25-dihydroxyvitamin D	0-28	phospholipase D1	Homo sapiens	83-99
17433303-1	2007	1alpha,25-Dihydroxyvitamin D(3) (VitD(3)) increases protein and gene expression of phospholipase D1 (PLD1), but not PLD2, in HaCaT human keratinocytes.	1,25-dihydroxyvitamin D	0-28	phospholipase D1	Homo sapiens	101-105
17397830-1	2007	1,25-dihydroxyvitamin D(3) (VD(3)) induces differentiation in a number of leukemia cell lines and under various conditions is able to either stimulate or inhibit nuclear factor kappa B (NF-kappaB) activity.	1,25-dihydroxyvitamin D	0-23	nuclear factor kappa B subunit 1	Homo sapiens	186-195
17418144-1	2007	1,25-Dihydroxyvitamin D(3) (1,25D) regulates gene transcription through the nuclear vitamin D receptor (VDR) and initiates rapid cellular responses via an unknown mechanism.	1,25-dihydroxyvitamin D	0-23	vitamin D receptor	Homo sapiens	84-102
17418144-1	2007	1,25-Dihydroxyvitamin D(3) (1,25D) regulates gene transcription through the nuclear vitamin D receptor (VDR) and initiates rapid cellular responses via an unknown mechanism.	1,25-dihydroxyvitamin D	0-23	vitamin D receptor	Homo sapiens	104-107
17372031-2	2007	Laboratory studies indicate that 1,25-dihydroxyvitamin D suppresses renin expression and vascular smooth muscle cell proliferation; clinical studies demonstrate an inverse association between ultraviolet radiation, a surrogate marker for vitamin D synthesis, and blood pressure.	1,25-dihydroxyvitamin D	33-56	renin	Homo sapiens	68-73
17157573-2	2007	Current data suggest that serum phosphate, dietary phosphate and 1,25 dihydroxyvitamin D regulate circulating FGF-23 levels in vivo.	1,25-dihydroxyvitamin D	65-88	fibroblast growth factor 23	Homo sapiens	110-116
17325131-1	2007	The vitamin D receptor (VDR) mediates the biological actions of 1,25-dihydroxyvitamin D(3) [1,25(OH)(2)D(3)], the active form of vitamin D, which regulates calcium homeostasis, immunity, cellular differentiation, and other physiological processes.	1,25-dihydroxyvitamin D	64-87	vitamin D receptor	Homo sapiens	4-22
17325131-1	2007	The vitamin D receptor (VDR) mediates the biological actions of 1,25-dihydroxyvitamin D(3) [1,25(OH)(2)D(3)], the active form of vitamin D, which regulates calcium homeostasis, immunity, cellular differentiation, and other physiological processes.	1,25-dihydroxyvitamin D	64-87	vitamin D receptor	Homo sapiens	24-27
17078924-0	2007	A unique insertion/duplication in the VDR gene that truncates the VDR causing hereditary 1,25-dihydroxyvitamin D-resistant rickets without alopecia.	1,25-dihydroxyvitamin D	89-112	vitamin D receptor	Homo sapiens	38-41
17078924-0	2007	A unique insertion/duplication in the VDR gene that truncates the VDR causing hereditary 1,25-dihydroxyvitamin D-resistant rickets without alopecia.	1,25-dihydroxyvitamin D	89-112	vitamin D receptor	Homo sapiens	66-69
17395983-3	2007	1alpha,25-dihydroxyvitamin D(3) (1,25(OH)(2)D(3)) inhibits beta-catenin signalling by inducing its binding to vitamin D receptor (VDR) and by promoting beta-catenin nuclear export.	1,25-dihydroxyvitamin D	0-28	catenin beta 1	Homo sapiens	59-71
17371189-1	2007	Vitamin D(3) needs to be activated into 1,25-dihydroxyvitamin D(3) in order to bind to vitamin D receptor (VDR) for functional responses.	1,25-dihydroxyvitamin D	40-63	vitamin D receptor	Homo sapiens	87-105
17371189-1	2007	Vitamin D(3) needs to be activated into 1,25-dihydroxyvitamin D(3) in order to bind to vitamin D receptor (VDR) for functional responses.	1,25-dihydroxyvitamin D	40-63	vitamin D receptor	Homo sapiens	107-110
17082781-1	2007	It has long been known that the active metabolite of vitamin D, 1,25 dihydroxyvitamin D(3), stimulates differentiation and inhibits proliferation in epidermal keratinocytes through interaction with the vitamin D receptor (VDR).	1,25-dihydroxyvitamin D	64-87	vitamin D receptor	Homo sapiens	222-225
17110426-0	2007	Intestinal resistance to 1,25 dihydroxyvitamin D in mice heterozygous for the vitamin D receptor knockout allele.	1,25-dihydroxyvitamin D	25-48	vitamin D (1,25-dihydroxyvitamin D3) receptor	Mus musculus	78-96
17082781-1	2007	It has long been known that the active metabolite of vitamin D, 1,25 dihydroxyvitamin D(3), stimulates differentiation and inhibits proliferation in epidermal keratinocytes through interaction with the vitamin D receptor (VDR).	1,25-dihydroxyvitamin D	64-87	vitamin D receptor	Homo sapiens	202-220
17395983-3	2007	1alpha,25-dihydroxyvitamin D(3) (1,25(OH)(2)D(3)) inhibits beta-catenin signalling by inducing its binding to vitamin D receptor (VDR) and by promoting beta-catenin nuclear export.	1,25-dihydroxyvitamin D	0-28	vitamin D receptor	Homo sapiens	110-128
17395983-3	2007	1alpha,25-dihydroxyvitamin D(3) (1,25(OH)(2)D(3)) inhibits beta-catenin signalling by inducing its binding to vitamin D receptor (VDR) and by promoting beta-catenin nuclear export.	1,25-dihydroxyvitamin D	0-28	vitamin D receptor	Homo sapiens	130-133
17395983-3	2007	1alpha,25-dihydroxyvitamin D(3) (1,25(OH)(2)D(3)) inhibits beta-catenin signalling by inducing its binding to vitamin D receptor (VDR) and by promoting beta-catenin nuclear export.	1,25-dihydroxyvitamin D	0-28	catenin beta 1	Homo sapiens	152-164
16986113-4	2007	We have identified annexin II as being specifically upregulated in mechanically stressed osteoblasts and found that increased levels of this protein are necessary for 1[alpha],25-dihydroxyvitamin D(3) mediated augmentation of the proliferative response of osteoblasts after mechanical stress.	1,25-dihydroxyvitamin D	167-197	annexin A2	Homo sapiens	19-29
17218097-1	2007	The regulatory actions of 1,25-dihydroxyvitamin D(3) (1,25(OH)(2)D(3)) on target genes are mediated by the vitamin D receptor (VDR).	1,25-dihydroxyvitamin D	26-49	vitamin D receptor	Homo sapiens	107-125
17218097-1	2007	The regulatory actions of 1,25-dihydroxyvitamin D(3) (1,25(OH)(2)D(3)) on target genes are mediated by the vitamin D receptor (VDR).	1,25-dihydroxyvitamin D	26-49	vitamin D receptor	Homo sapiens	127-130
17234401-1	2007	An essential prerequisite for the direct modulation of transcription by 1alpha,25-dihydroxy vitamin D(3) (1alpha,25(OH)(2)D(3)) is the location of at least one activated vitamin D receptor (VDR) protein close to the transcription start site of the respective primary 1alpha,25(OH)(2)D(3) target gene.	1,25-dihydroxyvitamin D	72-101	vitamin D receptor	Homo sapiens	170-188
17234401-1	2007	An essential prerequisite for the direct modulation of transcription by 1alpha,25-dihydroxy vitamin D(3) (1alpha,25(OH)(2)D(3)) is the location of at least one activated vitamin D receptor (VDR) protein close to the transcription start site of the respective primary 1alpha,25(OH)(2)D(3) target gene.	1,25-dihydroxyvitamin D	72-101	vitamin D receptor	Homo sapiens	190-193
17129178-9	2007	When kept on a regular (1% Ca(2+)) diet, Trpv6 KO mice have deficient intestinal Ca(2+) absorption, despite elevated levels of serum PTH (3.8-fold) and 1,25-dihydroxyvitamin D (2.4-fold).	1,25-dihydroxyvitamin D	152-175	transient receptor potential cation channel, subfamily V, member 6	Mus musculus	41-46
17046242-5	2007	1,25-Dihydroxyvitamin D(2) potently induced the expression of CALB3 and TRPV6 mRNA with an EC(50) of 0.3 and 1.0nM, whereas 19-nor-1,25-dihydroxyvitamin D(2) was 10-fold less potent than 1,25-dihydroxyvitamin D(2) in inducing CALB3 and TRPV6 mRNA.	1,25-dihydroxyvitamin D	0-23	S100 calcium binding protein G	Homo sapiens	62-67
17201799-2	2007	Physiologically, renal 1alpha,25-dihydroxyvitamin D [1,25(OH)(2)D] production is stimulated by PTH and phosphate deprivation, and inhibited by 1,25(OH)(2)D itself and calcium.	1,25-dihydroxyvitamin D	23-51	parathyroid hormone	Homo sapiens	95-98
17217060-2	2007	Transcriptional regulation of TRPV6 messenger RNA (mRNA) is controlled by 1,25-dihydroxyvitamin D, which is the active hormonal form of vitamin D3, and by additional calcium-dependent and vitamin D3-independent mechanisms.	1,25-dihydroxyvitamin D	74-97	transient receptor potential cation channel subfamily V member 6	Homo sapiens	30-35
17182555-7	2007	The serum level of RANKL in OPG(-/-) mice was increased by ovariectomy or administration of 1alpha,25-dihydroxyvitamin D(3).	1,25-dihydroxyvitamin D	92-120	tumor necrosis factor (ligand) superfamily, member 11	Mus musculus	19-24
17182555-7	2007	The serum level of RANKL in OPG(-/-) mice was increased by ovariectomy or administration of 1alpha,25-dihydroxyvitamin D(3).	1,25-dihydroxyvitamin D	92-120	tumor necrosis factor receptor superfamily, member 11b (osteoprotegerin)	Mus musculus	28-31
17079137-1	2007	Human placenta synthesizes and metabolizes 1,25-dihydroxyvitamin D(3) [1,25(OH)(2)D(3)/calcitriol] through the activity of 25-hydroxyvitamin D(3)-1alpha-hydroxylase (CYP27B1) and 1,25(OH)(2)D(3)-24-hydroxylase (CYP24A1), the two key enzymes for Vitamin D metabolism.	1,25-dihydroxyvitamin D	43-66	cytochrome P450 family 27 subfamily B member 1	Homo sapiens	123-164
17079137-1	2007	Human placenta synthesizes and metabolizes 1,25-dihydroxyvitamin D(3) [1,25(OH)(2)D(3)/calcitriol] through the activity of 25-hydroxyvitamin D(3)-1alpha-hydroxylase (CYP27B1) and 1,25(OH)(2)D(3)-24-hydroxylase (CYP24A1), the two key enzymes for Vitamin D metabolism.	1,25-dihydroxyvitamin D	43-66	cytochrome P450 family 27 subfamily B member 1	Homo sapiens	166-173
17079137-1	2007	Human placenta synthesizes and metabolizes 1,25-dihydroxyvitamin D(3) [1,25(OH)(2)D(3)/calcitriol] through the activity of 25-hydroxyvitamin D(3)-1alpha-hydroxylase (CYP27B1) and 1,25(OH)(2)D(3)-24-hydroxylase (CYP24A1), the two key enzymes for Vitamin D metabolism.	1,25-dihydroxyvitamin D	43-66	cytochrome P450 family 24 subfamily A member 1	Homo sapiens	211-218
18220741-1	2007	1alpha,25-Dihydroxyvitamin D(3) [1,25-(OH)(2)D(3)], the most active metabolite of vitamin D, exerts its biological effects by binding to a specific intracellular receptor (the vitamin D receptor, VDR) present in target cells.	1,25-dihydroxyvitamin D	0-28	vitamin D receptor	Homo sapiens	196-199
17046242-7	2007	These Vitamin D analogs did not change the expression of Vitamin D receptor (VDR) up to 10nM, but stimulated CYP24A1 expression in a dose-dependent manner with the potency in the order of 1,25-dihydroxyvitamin D(3)>1,25-dihydroxyvitamin D(2)=19-nor-1,25-dihydroxyvitamin D(2).	1,25-dihydroxyvitamin D	188-211	cytochrome P450 family 24 subfamily A member 1	Homo sapiens	109-116
17046242-5	2007	1,25-Dihydroxyvitamin D(2) potently induced the expression of CALB3 and TRPV6 mRNA with an EC(50) of 0.3 and 1.0nM, whereas 19-nor-1,25-dihydroxyvitamin D(2) was 10-fold less potent than 1,25-dihydroxyvitamin D(2) in inducing CALB3 and TRPV6 mRNA.	1,25-dihydroxyvitamin D	0-23	transient receptor potential cation channel subfamily V member 6	Homo sapiens	72-77
17046242-5	2007	1,25-Dihydroxyvitamin D(2) potently induced the expression of CALB3 and TRPV6 mRNA with an EC(50) of 0.3 and 1.0nM, whereas 19-nor-1,25-dihydroxyvitamin D(2) was 10-fold less potent than 1,25-dihydroxyvitamin D(2) in inducing CALB3 and TRPV6 mRNA.	1,25-dihydroxyvitamin D	0-23	S100 calcium binding protein G	Homo sapiens	226-231
17046242-5	2007	1,25-Dihydroxyvitamin D(2) potently induced the expression of CALB3 and TRPV6 mRNA with an EC(50) of 0.3 and 1.0nM, whereas 19-nor-1,25-dihydroxyvitamin D(2) was 10-fold less potent than 1,25-dihydroxyvitamin D(2) in inducing CALB3 and TRPV6 mRNA.	1,25-dihydroxyvitamin D	0-23	transient receptor potential cation channel subfamily V member 6	Homo sapiens	236-241
17507873-1	2007	Isoflavonoids exert a regulatory function on the expression of cytochrome P450 enzymes and also up-regulate the vitamin D(3) receptor (VDR) on cancer cells, which increase their sensitivity to 1,25-dihydroxyvitamin D(3) , the hormonally active form of vitamin D(3) .	1,25-dihydroxyvitamin D	193-216	vitamin D receptor	Homo sapiens	112-133
17507873-1	2007	Isoflavonoids exert a regulatory function on the expression of cytochrome P450 enzymes and also up-regulate the vitamin D(3) receptor (VDR) on cancer cells, which increase their sensitivity to 1,25-dihydroxyvitamin D(3) , the hormonally active form of vitamin D(3) .	1,25-dihydroxyvitamin D	193-216	vitamin D receptor	Homo sapiens	135-138
17507873-2	2007	Isoflavonoids are also able to raise the serum level of the active form of vitamin D(3) due to their inhibitory activity on CYP24, the enzyme involved in the degradation of 1,25-dihydroxyvitamin D(3) and its precursor 25-OH-D(3) to inactive compounds.	1,25-dihydroxyvitamin D	173-196	cytochrome P450 family 24 subfamily A member 1	Homo sapiens	124-129
17113979-1	2006	1,25-dihydroxy Vitamin D [1,25-(OH)(2)D] exerts its effects via the vitamin D receptor (VDR) that belongs to the steroid/thyroid hormone receptor superfamily leading to gene regulation which results in various biological responses.	1,25-dihydroxyvitamin D	0-24	vitamin D receptor	Homo sapiens	68-86
17071612-7	2006	Chromatin immunoprecipitation of nucleoproteins bound to the transcriptionally active 1,25-dihydroxy vitamin D-driven CYP24 promoter revealed the presence of REBiP in vitamin D-responsive human cells and indicated that the normal pattern of 1,25-dihydroxy vitamin D-initiated cyclical movement of the VDR on and off the VDRE is legislated by competitive, reciprocal occupancy of the VDRE by hnRNP C1/C2.	1,25-dihydroxyvitamin D	86-110	cytochrome P450 family 24 subfamily A member 1	Homo sapiens	118-123
17071612-7	2006	Chromatin immunoprecipitation of nucleoproteins bound to the transcriptionally active 1,25-dihydroxy vitamin D-driven CYP24 promoter revealed the presence of REBiP in vitamin D-responsive human cells and indicated that the normal pattern of 1,25-dihydroxy vitamin D-initiated cyclical movement of the VDR on and off the VDRE is legislated by competitive, reciprocal occupancy of the VDRE by hnRNP C1/C2.	1,25-dihydroxyvitamin D	86-110	vitamin D receptor	Homo sapiens	301-304
17071612-7	2006	Chromatin immunoprecipitation of nucleoproteins bound to the transcriptionally active 1,25-dihydroxy vitamin D-driven CYP24 promoter revealed the presence of REBiP in vitamin D-responsive human cells and indicated that the normal pattern of 1,25-dihydroxy vitamin D-initiated cyclical movement of the VDR on and off the VDRE is legislated by competitive, reciprocal occupancy of the VDRE by hnRNP C1/C2.	1,25-dihydroxyvitamin D	86-110	heterogeneous nuclear ribonucleoprotein C	Homo sapiens	391-402
17071612-7	2006	Chromatin immunoprecipitation of nucleoproteins bound to the transcriptionally active 1,25-dihydroxy vitamin D-driven CYP24 promoter revealed the presence of REBiP in vitamin D-responsive human cells and indicated that the normal pattern of 1,25-dihydroxy vitamin D-initiated cyclical movement of the VDR on and off the VDRE is legislated by competitive, reciprocal occupancy of the VDRE by hnRNP C1/C2.	1,25-dihydroxyvitamin D	241-265	cytochrome P450 family 24 subfamily A member 1	Homo sapiens	118-123
17163356-3	2006	The purpose of this study is to assess the relationship between 1.25-dihydroxyvitamin D levels and I/D angiotensin-converting enzyme polymorphism (ACE) in hypertensive patients.	1,25-dihydroxyvitamin D	64-87	angiotensin I converting enzyme	Homo sapiens	103-145
17163356-3	2006	The purpose of this study is to assess the relationship between 1.25-dihydroxyvitamin D levels and I/D angiotensin-converting enzyme polymorphism (ACE) in hypertensive patients.	1,25-dihydroxyvitamin D	64-87	angiotensin I converting enzyme	Homo sapiens	147-150
17113979-1	2006	1,25-dihydroxy Vitamin D [1,25-(OH)(2)D] exerts its effects via the vitamin D receptor (VDR) that belongs to the steroid/thyroid hormone receptor superfamily leading to gene regulation which results in various biological responses.	1,25-dihydroxyvitamin D	0-24	vitamin D receptor	Homo sapiens	88-91
16884396-6	2006	SUMMARY: The FGF-23 has been shown to increase urinary phosphate excretion, inhibit bone mineralization and suppress 1,25-dihydroxy vitamin D(3)[1,25(OH)(2)D(3)], the main characteristics that XLH, ADHR and TIO have in common.	1,25-dihydroxyvitamin D	117-141	fibroblast growth factor 23	Homo sapiens	13-19
17220548-7	2006	In the second part of this study, an involvement of mitogen-activated protein kinase (MAPK) and phosphatidylinositol 3-kinase (PI3-K), kinases which play a crucial role in neurodegenerative processes, in neuroprotective action of 1,25 dihydroxyvitamin D(3) and its the most potent analogue PRI-2191 has been investigated.	1,25-dihydroxyvitamin D	230-253	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta	Homo sapiens	96-125
16995819-3	2006	INTRODUCTION: 1,25-dihydroxyvitamin D(3) [1alpha,25(OH)(2)D(3)] regulates endochondral ossification in part through membrane-associated mechanisms, including protein kinase C (PKC) signaling activated by a membrane-associated 1alpha,25(OH)(2)D(3)-binding protein, ERp60.	1,25-dihydroxyvitamin D	14-37	calreticulin	Mus musculus	264-269
16995821-9	2006	A monoclonal antibody to human alpha(9) was used to block alpha(9)beta(1) on OCL precursors stimulated by 1alpha,25-dihydroxyvitamin D(3) [1alpha,25(OH)(2)D(3)] or RANKL.	1,25-dihydroxyvitamin D	106-134	occludin	Mus musculus	77-80
16787983-1	2006	CONTEXT: 25-Hydroxyvitamin D can be activated to 1,25-dihydroxyvitamin D(3) [1,25(OH)(2)D(3)] by the rate-limiting enzyme 1alpha-hydroxylase in cells of the immune system under control of immune stimuli, such as interferon-gamma (IFNgamma).	1,25-dihydroxyvitamin D	49-72	interferon gamma	Homo sapiens	212-228
16787983-1	2006	CONTEXT: 25-Hydroxyvitamin D can be activated to 1,25-dihydroxyvitamin D(3) [1,25(OH)(2)D(3)] by the rate-limiting enzyme 1alpha-hydroxylase in cells of the immune system under control of immune stimuli, such as interferon-gamma (IFNgamma).	1,25-dihydroxyvitamin D	49-72	interferon gamma	Homo sapiens	230-238
17002582-2	2006	In human duodenum, expression of the calcium channel TRPV6 was directly related to blood 1,25-dihydroxyvitamin D in men, but effects of age with lower median vitamin D receptor levels were more significant in women.	1,25-dihydroxyvitamin D	89-112	transient receptor potential cation channel subfamily V member 6	Homo sapiens	53-58
17002582-7	2006	TRPV6 expression was related in 33 subjects to other transcripts involved in calcium absorption including the vitamin D receptor (VDR) and to blood vitamin D metabolites including 1,25-dihydroxyvitamin D [1,25(OH)(2)D].	1,25-dihydroxyvitamin D	180-203	transient receptor potential cation channel subfamily V member 6	Homo sapiens	0-5
17220548-12	2006	Furthermore, these data point to differential involvement of ERK-MAPK and PI3-K in neuroprotective effects of 1,25 dihydroxyvitamin D(3) and its low-calcemic analogue - PRI-2191.	1,25-dihydroxyvitamin D	110-133	mitogen-activated protein kinase 1	Homo sapiens	61-64
16918598-1	2006	BACKGROUND: 1Alpha,25-dihydroxyvitamin D(3) [1,25(OH)(2) Vitamin D(3)] induces growth inhibition in squamous cell carcinoma (SCC) cell lines of the head and neck by arresting the cells in the G0/G1 phase of the cell cycle, probably due to an enhanced expression of p21, which could be demonstrated in other cell lines (JPPA, SCC9) before.	1,25-dihydroxyvitamin D	12-40	cyclin dependent kinase inhibitor 1A	Homo sapiens	265-268
16914732-2	2006	In osteoblasts, RANKL expression is regulated by two major calcemic hormones, 1,25-dihydroxyvitamin D(3) [1,25(OH)(2)D(3)] and parathyroid hormone (PTH), as well as by several inflammatory/osteoclastogenic cytokines; the molecular mechanisms for this regulation are unclear.	1,25-dihydroxyvitamin D	78-101	TNF superfamily member 11	Homo sapiens	16-21
16563471-2	2006	After hydroxylation in the liver into 25-hydroxyvitamin D (25(OH)D) and kidney into 1,25-dihydroxyvitamin D (1,25(OH)2D), the active metabolite can enter the cell, bind to the vitamin D-receptor and subsequently to a responsive gene such as that of calcium binding protein.	1,25-dihydroxyvitamin D	84-107	vitamin D receptor	Homo sapiens	176-194
16735491-2	2006	States of excess circulating FGF-23 are associated with renal phosphate wasting and inappropriately low serum 1,25-dihydroxyvitamin D [1,25(OH)(2)D] concentrations.	1,25-dihydroxyvitamin D	110-133	fibroblast growth factor 23	Homo sapiens	29-35
16815434-2	2006	Activated vitamin D(3) (1alpha,25-dihydroxyvitamin D(3)) or calcitriol, decreases peak force and activates protein kinase C (PKC) in isolated perfused hearts.	1,25-dihydroxyvitamin D	24-52	protein kinase C, gamma	Rattus norvegicus	107-123
16815434-2	2006	Activated vitamin D(3) (1alpha,25-dihydroxyvitamin D(3)) or calcitriol, decreases peak force and activates protein kinase C (PKC) in isolated perfused hearts.	1,25-dihydroxyvitamin D	24-52	protein kinase C, gamma	Rattus norvegicus	125-128
16815434-10	2006	Phosphorylation of the Ca(2+) regulatory proteins, phospholamban, and cardiac troponin I correlated with the accelerated relaxation observed in response to acute application of 1alpha,25-dihydroxyvitamin D(3).	1,25-dihydroxyvitamin D	177-205	troponin I3, cardiac type	Rattus norvegicus	70-88
16750418-1	2006	1,25-Dihydroxyvitamin D(3) (1,25(OH)(2)D(3)) and transforming growth factor beta (TGFbeta) potently induce 5-lipoxygenase (5-LO) in myeloid cells.	1,25-dihydroxyvitamin D	0-23	arachidonate 5-lipoxygenase	Homo sapiens	107-121
16869716-15	2006	Using the intact assay only, FGF-23 was significantly associated with serum phosphate (r = 0.39, p < 0.01), 24-h urinary phosphate (r = 0.47, p < 0.01), fractional excretion of phosphate (r = 0.29, p < 0.01), and 1,25-dihydroxyvitamin D (r = -0.30, p < 0.01).	1,25-dihydroxyvitamin D	222-245	fibroblast growth factor 23	Homo sapiens	29-35
16481392-1	2006	Transactivation of the rat apical sodium-dependent bile acid transporter (ASBT; Slc10a2) by 1alpha,25-dihydroxyvitamin D(3) [1,25(OH)(2)D(3)] via the vitamin D receptor (VDR), was studied.	1,25-dihydroxyvitamin D	92-120	solute carrier family 10 member 2	Rattus norvegicus	27-72
16362534-9	2006	CONCLUSIONS: 1,25 dihydroxyvitamin D regulates TRPV6 expression by a process that requires new mRNA and protein synthesis and the point of regulation lies likely at the transcriptional level especially since vitamin D did not increase the half life of TRPV6 mRNA.	1,25-dihydroxyvitamin D	13-36	transient receptor potential cation channel subfamily V member 6	Homo sapiens	47-52
16362534-10	2006	In addition, the prohormone form of 1,25 dihydroxyvitamin D, i. e. the 25 hydroxyvitamin D, induced TRPV6 mRNA expression in Caco-2 cells.	1,25-dihydroxyvitamin D	36-59	transient receptor potential cation channel subfamily V member 6	Homo sapiens	100-105
16775452-4	2006	Elevated intestinal and kidney vitamin D receptors suggest that increased tissue 1,25-dihydroxyvitamin D-vitamin D receptor complexes enhance 1,25-dihydroxyvitamin D actions on intestine and kidney, and vitamin D-dependent over-expression of renal calcium-sensing receptor alone can decrease tubule calcium reabsorption.	1,25-dihydroxyvitamin D	81-104	vitamin D receptor	Homo sapiens	31-49
16775452-5	2006	In TRPV5-knockout mice, ablation of the renal calcium-influx channel decreases tubular calcium reabsorption, and secondary elevations in 1,25-dihydroxyvitamin D increase intestinal calcium transport.	1,25-dihydroxyvitamin D	137-160	transient receptor potential cation channel, subfamily V, member 5	Mus musculus	3-8
16362534-0	2006	1,25-Dihydroxyvitamin D and 25-hydroxyvitamin D--mediated regulation of TRPV6 (a putative epithelial calcium channel) mRNA expression in Caco-2 cells.	1,25-dihydroxyvitamin D	0-23	transient receptor potential cation channel subfamily V member 6	Homo sapiens	72-77
16362534-2	2006	TRPV6 mRNA expression is strongly regulated by 1,25-dihydroxyvitamin D (1,25VD), the active hormonal form of vitamin D, in intestine and in Caco-2 cells, a human colon cancer cell line.	1,25-dihydroxyvitamin D	47-70	transient receptor potential cation channel subfamily V member 6	Homo sapiens	0-5
16481392-1	2006	Transactivation of the rat apical sodium-dependent bile acid transporter (ASBT; Slc10a2) by 1alpha,25-dihydroxyvitamin D(3) [1,25(OH)(2)D(3)] via the vitamin D receptor (VDR), was studied.	1,25-dihydroxyvitamin D	92-120	solute carrier family 10 member 2	Rattus norvegicus	74-78
16481392-1	2006	Transactivation of the rat apical sodium-dependent bile acid transporter (ASBT; Slc10a2) by 1alpha,25-dihydroxyvitamin D(3) [1,25(OH)(2)D(3)] via the vitamin D receptor (VDR), was studied.	1,25-dihydroxyvitamin D	92-120	solute carrier family 10 member 2	Rattus norvegicus	80-87
16481392-1	2006	Transactivation of the rat apical sodium-dependent bile acid transporter (ASBT; Slc10a2) by 1alpha,25-dihydroxyvitamin D(3) [1,25(OH)(2)D(3)] via the vitamin D receptor (VDR), was studied.	1,25-dihydroxyvitamin D	92-120	vitamin D receptor	Rattus norvegicus	150-168
16481392-1	2006	Transactivation of the rat apical sodium-dependent bile acid transporter (ASBT; Slc10a2) by 1alpha,25-dihydroxyvitamin D(3) [1,25(OH)(2)D(3)] via the vitamin D receptor (VDR), was studied.	1,25-dihydroxyvitamin D	92-120	vitamin D receptor	Rattus norvegicus	170-173
16566955-0	2006	In silico studies using Radial Distribution Function approach for predicting affinity of 1 alpha,25-dihydroxyvitamin D(3) analogues for Vitamin D receptor.	1,25-dihydroxyvitamin D	89-118	vitamin D (1,25- dihydroxyvitamin D3) receptor	Gallus gallus	136-154
16221734-3	2006	In this study, we have demonstrated that 24-h treatment of MC3T3-E1 preosteoblasts with 1,25-dihydroxyvitamin D(3) [1,25(OH)(2)D(3)], a coupling factor for bone resorption, coordinately downregulates Cav1.2 (alpha(1C)) and uniquely upregulates T-type channel Cav3.2 (alpha(1H)).	1,25-dihydroxyvitamin D	88-111	calcium voltage-gated channel subunit alpha1 C	Homo sapiens	200-206
16455676-1	2006	BACKGROUND: In a previous study we demonstrated the inhibitory effect of 1,25-dihydroxyvitamin D (1,25(OH)(2)D(3)) and its less calcaemic analog 1,24(OH)(2)D(2) on the production of tumour necrosis factor alpha (TNFalpha) by human peritoneal macrophages.	1,25-dihydroxyvitamin D	73-96	tumor necrosis factor	Homo sapiens	212-220
16597685-2	2006	It was found that administration of 1,25-dihydroxyvitamin D(3) (1,25[OH](2)D(3)) to mice rapidly increased serum FGF23 concentrations from a basal level of 90.6 +/- 8.1 to 213.8 +/- 14.6 pg/ml at 8 h (mean +/- SEM; P < 0.01) and resulted in a four-fold increase in FGF23 transcripts in bone, the predominate site of FGF23 expression.	1,25-dihydroxyvitamin D	36-59	fibroblast growth factor 23	Mus musculus	113-118
16597685-2	2006	It was found that administration of 1,25-dihydroxyvitamin D(3) (1,25[OH](2)D(3)) to mice rapidly increased serum FGF23 concentrations from a basal level of 90.6 +/- 8.1 to 213.8 +/- 14.6 pg/ml at 8 h (mean +/- SEM; P < 0.01) and resulted in a four-fold increase in FGF23 transcripts in bone, the predominate site of FGF23 expression.	1,25-dihydroxyvitamin D	36-59	fibroblast growth factor 23	Mus musculus	268-273
16597685-2	2006	It was found that administration of 1,25-dihydroxyvitamin D(3) (1,25[OH](2)D(3)) to mice rapidly increased serum FGF23 concentrations from a basal level of 90.6 +/- 8.1 to 213.8 +/- 14.6 pg/ml at 8 h (mean +/- SEM; P < 0.01) and resulted in a four-fold increase in FGF23 transcripts in bone, the predominate site of FGF23 expression.	1,25-dihydroxyvitamin D	36-59	fibroblast growth factor 23	Mus musculus	268-273
16325216-1	2006	1,25-Dihydroxyvitamin D(3) [1alpha,25(OH)(2)D(3)] acts on chondrocytes and osteoblasts through traditional nuclear Vitamin D receptor (VDR) mechanisms as well as through rapid actions on plasma membranes that initiate intracellular signaling pathways.	1,25-dihydroxyvitamin D	0-23	vitamin D (1,25-dihydroxyvitamin D3) receptor	Mus musculus	115-133
16325216-1	2006	1,25-Dihydroxyvitamin D(3) [1alpha,25(OH)(2)D(3)] acts on chondrocytes and osteoblasts through traditional nuclear Vitamin D receptor (VDR) mechanisms as well as through rapid actions on plasma membranes that initiate intracellular signaling pathways.	1,25-dihydroxyvitamin D	0-23	vitamin D (1,25-dihydroxyvitamin D3) receptor	Mus musculus	135-138
16221734-3	2006	In this study, we have demonstrated that 24-h treatment of MC3T3-E1 preosteoblasts with 1,25-dihydroxyvitamin D(3) [1,25(OH)(2)D(3)], a coupling factor for bone resorption, coordinately downregulates Cav1.2 (alpha(1C)) and uniquely upregulates T-type channel Cav3.2 (alpha(1H)).	1,25-dihydroxyvitamin D	88-111	calcium voltage-gated channel subunit alpha1 H	Homo sapiens	259-265
16358214-9	2006	Individuals of the investigated kindreds who were heterozygous for a SLC34A3 mutation frequently showed hypercalciuria, often in association with mild hypophosphatemia and/or elevations in 1,25-dihydroxyvitamin D levels.	1,25-dihydroxyvitamin D	189-212	solute carrier family 34 member 3	Homo sapiens	69-76
16395258-1	2006	Early 1,25-dihydroxyvitamin D(3) (VD(3)) therapy during the course of renal failure prevents the downregulation of VD(3) receptor (VDR), calcium-sensing receptor (CaSR) or p21, and the parathyroid (PT) growth.	1,25-dihydroxyvitamin D	6-29	vitamin D receptor	Rattus norvegicus	115-129
16395258-1	2006	Early 1,25-dihydroxyvitamin D(3) (VD(3)) therapy during the course of renal failure prevents the downregulation of VD(3) receptor (VDR), calcium-sensing receptor (CaSR) or p21, and the parathyroid (PT) growth.	1,25-dihydroxyvitamin D	6-29	vitamin D receptor	Rattus norvegicus	131-134
16395258-1	2006	Early 1,25-dihydroxyvitamin D(3) (VD(3)) therapy during the course of renal failure prevents the downregulation of VD(3) receptor (VDR), calcium-sensing receptor (CaSR) or p21, and the parathyroid (PT) growth.	1,25-dihydroxyvitamin D	6-29	calcium-sensing receptor	Rattus norvegicus	137-161
16395258-1	2006	Early 1,25-dihydroxyvitamin D(3) (VD(3)) therapy during the course of renal failure prevents the downregulation of VD(3) receptor (VDR), calcium-sensing receptor (CaSR) or p21, and the parathyroid (PT) growth.	1,25-dihydroxyvitamin D	6-29	calcium-sensing receptor	Rattus norvegicus	163-167
16395258-1	2006	Early 1,25-dihydroxyvitamin D(3) (VD(3)) therapy during the course of renal failure prevents the downregulation of VD(3) receptor (VDR), calcium-sensing receptor (CaSR) or p21, and the parathyroid (PT) growth.	1,25-dihydroxyvitamin D	6-29	KRAS proto-oncogene, GTPase	Rattus norvegicus	172-175
16955631-5	2006	25(OH)D has higher affinity for vitamin D binding protein (VDBP) than 1,25-dihydroxyvitamin D; whereas, 1,25-dihydroxyvitamin D has higher affinity for the vitamin D receptor (VDR) than 25-hydroxyvitamin D.	1,25-dihydroxyvitamin D	104-127	vitamin D receptor	Homo sapiens	156-174
16397363-3	2006	ED-71 has a longer half life than 1alpha,25-dihydroxyvitamin D(3) due to twice as high affinity with vitamin D binding protein in plasma.	1,25-dihydroxyvitamin D	34-62	GC vitamin D binding protein	Homo sapiens	101-126
16955631-5	2006	25(OH)D has higher affinity for vitamin D binding protein (VDBP) than 1,25-dihydroxyvitamin D; whereas, 1,25-dihydroxyvitamin D has higher affinity for the vitamin D receptor (VDR) than 25-hydroxyvitamin D.	1,25-dihydroxyvitamin D	104-127	vitamin D receptor	Homo sapiens	176-179
16269129-6	2005	DBP is an important carrier for the vitamin-D sterols, 25-hydroxyvitamin-D, and 1alpha,25-dihydroxyvitamin-D.	1,25-dihydroxyvitamin D	80-108	D-box binding PAR bZIP transcription factor	Homo sapiens	0-3
16207822-0	2006	Intestinal and hepatic CYP3A4 catalyze hydroxylation of 1alpha,25-dihydroxyvitamin D(3): implications for drug-induced osteomalacia.	1,25-dihydroxyvitamin D	56-84	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	23-29
16207822-2	2006	In this study, we show that the inducible enzyme CYP3A4 is a major source of oxidative metabolism of 1alpha,25-dihydroxyvitamin D(3) [1,25(OH)(2)D(3)] in human liver and small intestine and could contribute to this adverse effect.	1,25-dihydroxyvitamin D	101-129	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	49-55
16020653-1	2005	Fibroblast growth factor (FGF)23 is a phosphaturic hormone that decreases circulating 1alpha,25-dihydroxyvitamin D(3) [1,25(OH)(2)D(3)] and elicits hypophosphatemia, both of which contribute to rickets/osteomalacia.	1,25-dihydroxyvitamin D	86-114	fibroblast growth factor 23	Rattus norvegicus	0-32
16195230-4	2005	1,25-Dihydroxyvitamin D(3) (1,25(OH)(2)D(3)) or Runx2 stimulated OPN transcription (mouse OPN promoter -777/+79) 2-3-fold.	1,25-dihydroxyvitamin D	0-23	secreted phosphoprotein 1	Mus musculus	65-68
16195230-4	2005	1,25-Dihydroxyvitamin D(3) (1,25(OH)(2)D(3)) or Runx2 stimulated OPN transcription (mouse OPN promoter -777/+79) 2-3-fold.	1,25-dihydroxyvitamin D	0-23	secreted phosphoprotein 1	Mus musculus	90-93
16181450-8	2005	The active form of vitamin D, 1,25-dihydroxyvitamin D(3), exhibits antiproliferative and immunoregulatory effects via the vitamin D receptor, and thus is successfully used in the topical treatment of psoriasis.	1,25-dihydroxyvitamin D	30-53	vitamin D receptor	Homo sapiens	122-140
16317115-4	2005	The mechanisms proposed to mediate the putative effect of dietary calcium are primarily the formation of fecal fatty acid complexes to reduce fat absorption and the regulation of energy metabolism, including lipolysis from adipocytes and fatty acid oxidation, through the calciotropic hormones, parathyroid hormone, and 1,25-dihydroxyvitamin D.	1,25-dihydroxyvitamin D	320-343	parathyroid hormone	Homo sapiens	295-314
16275744-3	2005	The "phosphatonins," FGF-23 and sFRP-4, also inhibit the synthesis of 1alpha,25-dihydroxyvitamin D, leading to decreased intestinal phosphate absorption and further reduction in phosphate retention by the organism.	1,25-dihydroxyvitamin D	70-98	fibroblast growth factor 23	Homo sapiens	21-27
16275744-3	2005	The "phosphatonins," FGF-23 and sFRP-4, also inhibit the synthesis of 1alpha,25-dihydroxyvitamin D, leading to decreased intestinal phosphate absorption and further reduction in phosphate retention by the organism.	1,25-dihydroxyvitamin D	70-98	secreted frizzled related protein 4	Homo sapiens	32-38
16159932-0	2005	1,25-dihydroxyvitamin D suppresses circulating levels of parathyroid hormone in a patient with primary hyperparathyroidism and coexistent sarcoidosis.	1,25-dihydroxyvitamin D	0-23	parathyroid hormone	Homo sapiens	57-76
15998839-1	2005	FGF23 suppresses both serum phosphate and 1,25-dihydroxyvitamin D [1,25D] levels in vivo.	1,25-dihydroxyvitamin D	42-65	fibroblast growth factor 23	Mus musculus	0-5
15998839-1	2005	FGF23 suppresses both serum phosphate and 1,25-dihydroxyvitamin D [1,25D] levels in vivo.	1,25-dihydroxyvitamin D	67-72	fibroblast growth factor 23	Mus musculus	0-5
16234967-14	2005	Patient 2 showed stepwise increases in serum FGF-23 from 117 to 824 RU/ml in response to increasing serum levels of 1alpha,25-dihydroxyvitamin D (1,25-D).	1,25-dihydroxyvitamin D	116-144	fibroblast growth factor 23	Homo sapiens	45-51
16076555-1	2005	We have previously shown that concentrations of 1alpha,25-dihydroxyvitamin D(3) (1,25D) that induce G(0)/G(1) cell cycle arrest in androgen-dependent LNCaP prostate cancer cells also decrease expression of c-Myc, a proto-oncogene that stimulates progression from G(1) to S phase of the cell cycle.	1,25-dihydroxyvitamin D	48-76	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	206-211
16076940-6	2005	PTH was significantly inversely related to 25-OHD and was positively related to serum 1,25-dihydroxyvitamin D and osteocalcin.	1,25-dihydroxyvitamin D	86-109	parathyroid hormone	Homo sapiens	0-3
16046118-1	2005	1,25-Dihydroxyvitamin D(3) (1,25(OH)(2)D(3)), the biologically active metabolite of Vitamin D(3), not only regulates bone and calcium metabolism but also exerts other biological activities, including immunomodulation via the nuclear Vitamin D receptor expressed in antigen-presenting cells and activated T cells.	1,25-dihydroxyvitamin D	0-23	vitamin D receptor	Homo sapiens	233-251
16081282-2	2005	The antimitotic, prodifferentiating and proapoptotic active metabolite 1alpha,25-dihydroxyvitamin D(3) (1,25-(OH)(2)-D(3)) is synthesized also by colonocytes, since these possess Vitamin D synthesizing (CYP27B1) and catabolic (CYP24) hydroxylases similar to the kidney.	1,25-dihydroxyvitamin D	71-99	cytochrome P450 family 27 subfamily B member 1	Homo sapiens	203-210
16081282-2	2005	The antimitotic, prodifferentiating and proapoptotic active metabolite 1alpha,25-dihydroxyvitamin D(3) (1,25-(OH)(2)-D(3)) is synthesized also by colonocytes, since these possess Vitamin D synthesizing (CYP27B1) and catabolic (CYP24) hydroxylases similar to the kidney.	1,25-dihydroxyvitamin D	71-99	cytochrome P450 family 24 subfamily A member 1	Homo sapiens	227-232
15908514-1	2005	The vitamin D receptor (VDR) belongs to the superfamily of steroid/thyroid hormone receptors that is activated by 1alpha,25-dihydroxyvitamin D(3).	1,25-dihydroxyvitamin D	114-142	vitamin D receptor	Homo sapiens	24-27
16148162-8	2005	We hypothesize that an ovarian hormone inhibited CYP24A1 gene expression in the spinal cord, so the locally-produced 1,25-dihydroxyvitamin D(3) accumulated and resolved the inflammation before severe EAE developed.	1,25-dihydroxyvitamin D	117-140	cytochrome P450, family 24, subfamily a, polypeptide 1	Mus musculus	49-56
16059639-3	2005	INTRODUCTION: 1,25-Dihydroxyvitamin D-resistant rickets (HVDRR) is a rare genetic disorder caused by inactivating mutations in the vitamin D receptor (VDR).	1,25-dihydroxyvitamin D	14-37	vitamin D receptor	Homo sapiens	131-149
16059639-3	2005	INTRODUCTION: 1,25-Dihydroxyvitamin D-resistant rickets (HVDRR) is a rare genetic disorder caused by inactivating mutations in the vitamin D receptor (VDR).	1,25-dihydroxyvitamin D	14-37	vitamin D receptor	Homo sapiens	58-61
15908514-1	2005	The vitamin D receptor (VDR) belongs to the superfamily of steroid/thyroid hormone receptors that is activated by 1alpha,25-dihydroxyvitamin D(3).	1,25-dihydroxyvitamin D	114-142	vitamin D receptor	Homo sapiens	4-22
16164627-0	2005	1,25-dihydroxyvitamin D inhibits renal interstitial myofibroblast activation by inducing hepatocyte growth factor expression.	1,25-dihydroxyvitamin D	0-23	hepatocyte growth factor	Rattus norvegicus	89-113
16164627-3	2005	This study investigated the effects and potential mechanism of 1,25-dihydroxyvitamin D(3)[1,25(OH)(2)D(3)] on the regulation of myofibroblast activation from interstitial fibroblast, a critical event in generating alpha-smooth muscle actin (alphaSMA)-positive, matrix-producing effector cells in renal interstitial fibrosis.	1,25-dihydroxyvitamin D	63-86	actin gamma 2, smooth muscle	Rattus norvegicus	214-239
16141606-1	2005	To evaluate an in vitro model suitable for investigating intestinal first-pass drug metabolism, CYP3A4 and MDR1 mRNA induction by 1alpha,25-dihydroxyvitamin D(3) (VD3) was examined in two human intestinal cell lines, Caco-2 and LS180, under various culture conditions.	1,25-dihydroxyvitamin D	130-158	ATP binding cassette subfamily B member 1	Homo sapiens	107-111
15868280-0	2005	Plasma concentrations of 25-hydroxy-vitamin D and 1,25-dihydroxy-vitamin D are related to the phenotype of Gc (vitamin D-binding protein): a cross-sectional study on 595 early postmenopausal women.	1,25-dihydroxyvitamin D	50-74	GC vitamin D binding protein	Homo sapiens	111-136
15741244-5	2005	Vdr null fetuses did have threefold increased 1,25-dihydroxyvitamin D levels accompanied by increased 1alpha-hydroxylase mRNA in kidney but not placenta; a small increase was also noted in placental expression of parathyroid hormone-related protein (PTHrP).	1,25-dihydroxyvitamin D	46-69	vitamin D (1,25-dihydroxyvitamin D3) receptor	Mus musculus	0-3
15930999-9	2005	Excessive activity of FGF23 with normal renal function results in hypophosphatemia, low 1,25-dihydroxyvitamin D levels, and rickets/osteomalacia.	1,25-dihydroxyvitamin D	88-111	fibroblast growth factor 23	Homo sapiens	22-27
15930999-10	2005	By contrast, excessive FGF23 activity suppresses 1,25-dihydroxyvitamin D synthesis, but may not be sufficient to excrete the phosphate load appropriately with deteriorating renal function, both of which contribute to the development of hyperparathyroidism.	1,25-dihydroxyvitamin D	49-72	fibroblast growth factor 23	Homo sapiens	23-28
15931003-1	2005	PURPOSE OF REVIEW: Although the active metabolite of vitamin D, 1,25-dihydroxyvitamin D (1,25(OH)2D), is classically appreciated to exert its calcemic and other actions via interaction with the vitamin D receptor, thereby modulating gene transcription, some of its actions cannot be explained in this way when examined in vitro.	1,25-dihydroxyvitamin D	64-87	vitamin D (1,25-dihydroxyvitamin D3) receptor	Mus musculus	194-212
15837528-0	2005	1,25-dihydroxyvitamin D inhibits human ANP gene promoter activity.	1,25-dihydroxyvitamin D	0-23	natriuretic peptide A	Homo sapiens	39-42
15870221-2	2005	It was reported recently that type IIb sodium-dependent phosphate co-transporter (NaPi-2b) is a carrier of intestinal phosphate absorption, and that its expression level is regulated by serum 1,25-dihydroxyvitamin D [1,25(OH)(2)D] and Pi levels in normal rats.	1,25-dihydroxyvitamin D	192-215	solute carrier family 34 member 2	Rattus norvegicus	82-89
15824121-4	2005	Functional analysis of a murine Mrp3 promoter reporter construct revealed vitamin D receptor (VDR)-dependent activation by 1,25-dihydroxyvitamin D(3) (VD3), 9-cis-retinoic acid (RA), and the cholestatic secondary bile acid, lithocholic acid (LCA).	1,25-dihydroxyvitamin D	123-146	ATP-binding cassette, sub-family C (CFTR/MRP), member 3	Mus musculus	32-36
15824121-4	2005	Functional analysis of a murine Mrp3 promoter reporter construct revealed vitamin D receptor (VDR)-dependent activation by 1,25-dihydroxyvitamin D(3) (VD3), 9-cis-retinoic acid (RA), and the cholestatic secondary bile acid, lithocholic acid (LCA).	1,25-dihydroxyvitamin D	123-146	vitamin D (1,25-dihydroxyvitamin D3) receptor	Mus musculus	74-92
15824121-4	2005	Functional analysis of a murine Mrp3 promoter reporter construct revealed vitamin D receptor (VDR)-dependent activation by 1,25-dihydroxyvitamin D(3) (VD3), 9-cis-retinoic acid (RA), and the cholestatic secondary bile acid, lithocholic acid (LCA).	1,25-dihydroxyvitamin D	123-146	vitamin D (1,25-dihydroxyvitamin D3) receptor	Mus musculus	94-97
15860041-5	2005	However, the efficiency of vitamin D receptor-mediated intracellular signalling is limited by the negative effects of hypovitaminosis D on extrarenal 25-hydroxyvitamin D-1alpha-hydroxylase activity and thus on the production of 1,25-dihydroxyvitamin D(3).	1,25-dihydroxyvitamin D	228-251	vitamin D receptor	Homo sapiens	27-45
15788398-0	2005	Alternative splicing of vitamin D-24-hydroxylase: a novel mechanism for the regulation of extrarenal 1,25-dihydroxyvitamin D synthesis.	1,25-dihydroxyvitamin D	101-124	cytochrome P450 family 24 subfamily A member 1	Homo sapiens	24-48
15578590-1	2005	The vitamin D receptor (VDR) binds to and mediates the effects of the 1,25-dihydroxyvitamin D(3) (1,25(OH)(2)D(3)) hormone to alter gene transcription.	1,25-dihydroxyvitamin D	70-93	vitamin D receptor	Homo sapiens	4-22
15728261-0	2005	Superagonistic action of 14-epi-analogs of 1,25-dihydroxyvitamin D explained by vitamin D receptor-coactivator interaction.	1,25-dihydroxyvitamin D	43-66	vitamin D receptor	Homo sapiens	80-98
15781002-1	2005	Circulating levels of 1,25-dihydroxyvitamin D (1,25D) are determined by bioactivation catalyzed by the renal 25-hydroxyvitamin D 1alpha-hydroxylase (CYP27B1) and degradation through the action of the renal 25-hydroxyvitamin D 24-hydroxylase (CYP24).	1,25-dihydroxyvitamin D	22-45	cytochrome P450, family 27, subfamily b, polypeptide 1	Rattus norvegicus	149-156
15781002-1	2005	Circulating levels of 1,25-dihydroxyvitamin D (1,25D) are determined by bioactivation catalyzed by the renal 25-hydroxyvitamin D 1alpha-hydroxylase (CYP27B1) and degradation through the action of the renal 25-hydroxyvitamin D 24-hydroxylase (CYP24).	1,25-dihydroxyvitamin D	22-45	cytochrome P450, family 24, subfamily a, polypeptide 1	Rattus norvegicus	242-247
15578590-0	2005	Molecular and functional comparison of 1,25-dihydroxyvitamin D(3) and the novel vitamin D receptor ligand, lithocholic acid, in activating transcription of cytochrome P450 3A4.	1,25-dihydroxyvitamin D	39-62	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	156-175
15578590-1	2005	The vitamin D receptor (VDR) binds to and mediates the effects of the 1,25-dihydroxyvitamin D(3) (1,25(OH)(2)D(3)) hormone to alter gene transcription.	1,25-dihydroxyvitamin D	70-93	vitamin D receptor	Homo sapiens	24-27
15664452-1	2005	1,25-Dihydroxyvitamin D(3) (1,25(OH)(2)D(3)), the active form of Vitamin D, mediates gene transcription through the Vitamin D receptor (VDR), a nuclear receptor expressed in multiple normal and transformed cell types.	1,25-dihydroxyvitamin D	0-23	vitamin D receptor	Homo sapiens	116-134
15549412-2	2005	1,25-Dihydroxyvitamin D(3) [1,25(OH)(2) D(3)] decreases PTH synthesis and secretion.	1,25-dihydroxyvitamin D	0-23	parathyroid hormone	Homo sapiens	56-59
15590756-0	2005	1,25 dihydroxyvitamin d amplifies type a natriuretic peptide receptor expression and activity in target cells.	1,25-dihydroxyvitamin D	0-23	opioid related nociceptin receptor 1	Rattus norvegicus	53-69
15769857-1	2005	The vitamin D receptor (VDR) is a nuclear transcription factor responsible for mediating the biological activities of 1,25-dihydroxyvitamin D(3) [1,25(OH)(2)D(3)].	1,25-dihydroxyvitamin D	118-141	vitamin D (1,25-dihydroxyvitamin D3) receptor	Mus musculus	4-22
15769857-1	2005	The vitamin D receptor (VDR) is a nuclear transcription factor responsible for mediating the biological activities of 1,25-dihydroxyvitamin D(3) [1,25(OH)(2)D(3)].	1,25-dihydroxyvitamin D	118-141	vitamin D (1,25-dihydroxyvitamin D3) receptor	Mus musculus	24-27
15691891-1	2005	The enzyme 25-hydroxyvitamin D 1alpha-hydroxylase, or CYP27B1, is the key enzyme in the two-step activation process of vitamin D to 1,25-dihydroxyvitamin D (1,25D).	1,25-dihydroxyvitamin D	132-155	cytochrome P450 family 27 subfamily B member 1	Homo sapiens	54-61
15664452-1	2005	1,25-Dihydroxyvitamin D(3) (1,25(OH)(2)D(3)), the active form of Vitamin D, mediates gene transcription through the Vitamin D receptor (VDR), a nuclear receptor expressed in multiple normal and transformed cell types.	1,25-dihydroxyvitamin D	0-23	vitamin D receptor	Homo sapiens	136-139
15585796-3	2004	In addition, studies showed that 1,25-dihydroxyvitamin D rapidly activates signal transduction pathways in addition to the classic transcriptional activation pathways that require the vitamin D receptor.	1,25-dihydroxyvitamin D	33-56	vitamin D receptor	Homo sapiens	184-202
15581603-1	2005	Expression of the vitamin D receptor (VDR) in the kidney and intestine plays a major role in calcium homeostasis and the metabolism of 1,25-dihydroxyvitamin D(3) (1,25(OH)(2)D(3)).	1,25-dihydroxyvitamin D	135-158	vitamin D (1,25-dihydroxyvitamin D3) receptor	Mus musculus	18-36
15581603-1	2005	Expression of the vitamin D receptor (VDR) in the kidney and intestine plays a major role in calcium homeostasis and the metabolism of 1,25-dihydroxyvitamin D(3) (1,25(OH)(2)D(3)).	1,25-dihydroxyvitamin D	135-158	vitamin D (1,25-dihydroxyvitamin D3) receptor	Mus musculus	38-41
15517598-1	2005	1,25-dihydroxyvitamin D plays an important role in the regulation of osteoblast gene expression, regulating the expression of bone matrix proteins as well as that of Runx2, a key regulator of osteoblast differentiation.	1,25-dihydroxyvitamin D	0-23	runt related transcription factor 2	Mus musculus	166-171
15164161-5	2005	In multivariate regression analyses (adjusted by age, sex, presence of diabetes, glomerular filtration rate, intact parathyroid hormone, calcium, phosphate, and 1,25-dihydroxyvitamin D), OC and PINP were significantly associated with a decrease in BMD, but BAP was not.	1,25-dihydroxyvitamin D	161-184	bone gamma-carboxyglutamate protein	Homo sapiens	187-189
15630441-3	2005	provide convincing evidence that PXR can also induce vitamin D deficiency and bone disease because of its ability to cross-talk with the vitamin D-responsive gene that catabolizes 25-hydroxy-vitamin D and 1,25-dihydroxyvitamin D.	1,25-dihydroxyvitamin D	205-228	nuclear receptor subfamily 1 group I member 2	Homo sapiens	33-36
15489543-1	2005	The vitamin D receptor (VDR), a member of the nuclear receptor superfamily, mediates the biological actions of the active form of vitamin D, 1alpha,25-dihydroxyvitamin D(3).	1,25-dihydroxyvitamin D	141-169	vitamin D receptor	Homo sapiens	4-22
15489543-1	2005	The vitamin D receptor (VDR), a member of the nuclear receptor superfamily, mediates the biological actions of the active form of vitamin D, 1alpha,25-dihydroxyvitamin D(3).	1,25-dihydroxyvitamin D	141-169	vitamin D receptor	Homo sapiens	24-27
15585637-1	2004	The 25-hydroxyvitamin D(3) (25-OH-D(3)) is a nontoxic and low-affinity vitamin D receptor (VDR)-binding metabolic precursor of 1,25-dihydroxyvitamin D(3) [1,25(OH)(2)D(3)].	1,25-dihydroxyvitamin D	127-150	vitamin D receptor	Homo sapiens	71-89
15585637-1	2004	The 25-hydroxyvitamin D(3) (25-OH-D(3)) is a nontoxic and low-affinity vitamin D receptor (VDR)-binding metabolic precursor of 1,25-dihydroxyvitamin D(3) [1,25(OH)(2)D(3)].	1,25-dihydroxyvitamin D	127-150	vitamin D receptor	Homo sapiens	91-94
15564440-5	2004	The vitamin D hormone (1,25-dihydroxy vitamin D(3)) regulates T helper cell (Th1) and dendritic cell function while inducing regulatory T-cell function.	1,25-dihydroxyvitamin D	23-47	negative elongation factor complex member C/D	Homo sapiens	77-80
15337762-2	2004	We demonstrate that 1alpha-25-dihydroxyvitamin D (1,25(OH)2D3), the, active renal vitamin D metabolite, decreases PHEX mRNA in the rat osteoblastic cell line, UMR-106, as well as in mouse calvaria.	1,25-dihydroxyvitamin D	20-48	phosphate regulating endopeptidase homolog, X-linked	Rattus norvegicus	114-118
15570014-1	2004	Vitamin D is a conditionally required nutrient traditionally thought to influence physiology as the metabolite 1,25-dihydroxyvitamin D [1,25(OH)(2) D] by binding to the vitamin D receptor (VDR) and stimulating the transcription of genes through direct VDR-DNA interactions.	1,25-dihydroxyvitamin D	111-134	vitamin D receptor	Homo sapiens	169-187
15570014-1	2004	Vitamin D is a conditionally required nutrient traditionally thought to influence physiology as the metabolite 1,25-dihydroxyvitamin D [1,25(OH)(2) D] by binding to the vitamin D receptor (VDR) and stimulating the transcription of genes through direct VDR-DNA interactions.	1,25-dihydroxyvitamin D	111-134	vitamin D receptor	Homo sapiens	189-192
15570014-1	2004	Vitamin D is a conditionally required nutrient traditionally thought to influence physiology as the metabolite 1,25-dihydroxyvitamin D [1,25(OH)(2) D] by binding to the vitamin D receptor (VDR) and stimulating the transcription of genes through direct VDR-DNA interactions.	1,25-dihydroxyvitamin D	111-134	vitamin D receptor	Homo sapiens	252-255
15358113-2	2004	1,25-Dihydroxyvitamin D(3) (1,25(OH)(2)D(3)) is known to be a potent inducer of CYP3A4 in human colon carcinoma Caco-2 via vitamin D receptor (VDR).	1,25-dihydroxyvitamin D	0-23	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	80-86
15358113-2	2004	1,25-Dihydroxyvitamin D(3) (1,25(OH)(2)D(3)) is known to be a potent inducer of CYP3A4 in human colon carcinoma Caco-2 via vitamin D receptor (VDR).	1,25-dihydroxyvitamin D	0-23	vitamin D receptor	Homo sapiens	143-146
15308610-0	2004	Hereditary 1,25-dihydroxyvitamin D resistant rickets due to a mutation causing multiple defects in vitamin D receptor function.	1,25-dihydroxyvitamin D	11-34	vitamin D receptor	Homo sapiens	99-117
15308610-4	2004	From crystallographic studies of the VDR ligand-binding domain, I268 directly interacts with 1,25-dihydroxyvitamin D(3) [1,25(OH)(2)D(3)] and is involved in the hydrophobic stabilization of helix H12.	1,25-dihydroxyvitamin D	93-116	vitamin D receptor	Homo sapiens	37-40
15358113-2	2004	1,25-Dihydroxyvitamin D(3) (1,25(OH)(2)D(3)) is known to be a potent inducer of CYP3A4 in human colon carcinoma Caco-2 via vitamin D receptor (VDR).	1,25-dihydroxyvitamin D	0-23	vitamin D receptor	Homo sapiens	123-141
15205382-1	2004	1,25-Dihydroxyvitamin D(3) (1,25(OH)(2)D(3)) is known to induce the expression of cytochrome P450 3A4 (CYP3A4) in human colon carcinoma Caco-2 cells.	1,25-dihydroxyvitamin D	0-23	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	82-101
15322146-1	2004	The hormonal form of vitamin D(3), 1,25-dihydroxyvitamin D(3) (1,25(OH)(2)D(3)), is an immune system modulator and induces expression of the TLR coreceptor CD14.	1,25-dihydroxyvitamin D	35-58	CD14 molecule	Homo sapiens	156-160
15178742-2	2004	VDR is a nuclear receptor whose ligand, 1,25-dihydroxyvitamin D [1,25-(OH)(2)D] is generated after metabolic activation of vitamin D by specific vitamin D hydroxylases.	1,25-dihydroxyvitamin D	40-63	vitamin D (1,25-dihydroxyvitamin D3) receptor	Mus musculus	0-3
15199289-8	2004	Injection of recombinant fibroblast growth factor 23 induces phosphaturia, hypophosphatemia, and suppression of 1,25-dihydroxyvitamin D in animals.	1,25-dihydroxyvitamin D	112-135	fibroblast growth factor 23	Mus musculus	25-52
15199289-11	2004	The most compelling evidence derives from the fibroblast growth factor 23-knockout mouse which shows hyperphosphatemia and increased serum 1,25-dihydroxyvitamin D.	1,25-dihydroxyvitamin D	139-162	fibroblast growth factor 23	Mus musculus	46-73
15205382-1	2004	1,25-Dihydroxyvitamin D(3) (1,25(OH)(2)D(3)) is known to induce the expression of cytochrome P450 3A4 (CYP3A4) in human colon carcinoma Caco-2 cells.	1,25-dihydroxyvitamin D	0-23	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	103-109
15248822-6	2004	Serum FGF-23 correlated positively with serum calcium (P<0.0001) and intact parathyroid hormone (PTH) (P<0.01), and negatively with Ccr (P<0.001), serum phosphate (P<0.05), and serum 1,25-dihydroxyvitamin D (1,25(OH)(2)D) (P<0.05).	1,25-dihydroxyvitamin D	195-218	fibroblast growth factor 23	Homo sapiens	6-12
15211569-9	2004	Analysis by reverse transcription-polymerase chain reaction showed that expression of osteocalcin mRNA was detected in the dexamethasone-treated cells but not in the vehicle-treated cells, and dexamethasone-induced osteocalcin mRNA expression was promoted by 1,25-dihydroxyvitamin D(3).	1,25-dihydroxyvitamin D	259-282	bone gamma-carboxyglutamate protein	Homo sapiens	86-97
15211569-9	2004	Analysis by reverse transcription-polymerase chain reaction showed that expression of osteocalcin mRNA was detected in the dexamethasone-treated cells but not in the vehicle-treated cells, and dexamethasone-induced osteocalcin mRNA expression was promoted by 1,25-dihydroxyvitamin D(3).	1,25-dihydroxyvitamin D	259-282	bone gamma-carboxyglutamate protein	Homo sapiens	215-226
15100231-2	2004	Ca(2+) influx through TRPV5 is tightly controlled by modulators of Ca(2+) homeostasis, including 1,25-dihydroxyvitamin D(3) and dietary Ca(2+).	1,25-dihydroxyvitamin D	97-120	transient receptor potential cation channel subfamily V member 5	Homo sapiens	22-27
15223133-1	2004	Vitamin D 1alpha-hydroxylase (1alpha(OH)ase), which converts the circulating prohormone 25-hydroxyvitamin-D(3) (25(OH)D(3)) to the active 1alpha-25-dihydroxyvitamin-D(3) (1,25(OH)(2)D(3)), is present in normal prostatic epithelium.	1,25-dihydroxyvitamin D	138-166	cytochrome P450 family 27 subfamily B member 1	Homo sapiens	30-43
15225765-1	2004	25-hydroxyvitamin D(3)- or 1alpha,25-dihydroxyvitamin D(3)-24R-hydroxylase (cytochromeP450C24 or CYP24) has a dual role of removing 25-OH-D(3) from circulation and excess 1,25(OH)(2)D(3) from kidney.	1,25-dihydroxyvitamin D	27-55	cytochrome P450, family 24, subfamily a, polypeptide 1	Rattus norvegicus	97-102
15270777-11	2004	Finally, the enhanced gene expression of alkaline phosphatase induced by Wnt-3a could be effectively suppressed by the combined action of dexamethasone and 1,25-dihydroxyvitamin D(3).	1,25-dihydroxyvitamin D	156-179	wingless-type MMTV integration site family, member 3A	Mus musculus	73-79
15075339-0	2004	p27(Kip1) stabilization and G(1) arrest by 1,25-dihydroxyvitamin D(3) in ovarian cancer cells mediated through down-regulation of cyclin E/cyclin-dependent kinase 2 and Skp1-Cullin-F-box protein/Skp2 ubiquitin ligase.	1,25-dihydroxyvitamin D	43-66	cyclin-dependent kinase inhibitor 1B	Mus musculus	0-3
15075339-0	2004	p27(Kip1) stabilization and G(1) arrest by 1,25-dihydroxyvitamin D(3) in ovarian cancer cells mediated through down-regulation of cyclin E/cyclin-dependent kinase 2 and Skp1-Cullin-F-box protein/Skp2 ubiquitin ligase.	1,25-dihydroxyvitamin D	43-66	cyclin-dependent kinase inhibitor 1B	Mus musculus	4-8
15075339-0	2004	p27(Kip1) stabilization and G(1) arrest by 1,25-dihydroxyvitamin D(3) in ovarian cancer cells mediated through down-regulation of cyclin E/cyclin-dependent kinase 2 and Skp1-Cullin-F-box protein/Skp2 ubiquitin ligase.	1,25-dihydroxyvitamin D	43-66	cyclin-dependent kinase 2	Mus musculus	139-164
15075339-0	2004	p27(Kip1) stabilization and G(1) arrest by 1,25-dihydroxyvitamin D(3) in ovarian cancer cells mediated through down-regulation of cyclin E/cyclin-dependent kinase 2 and Skp1-Cullin-F-box protein/Skp2 ubiquitin ligase.	1,25-dihydroxyvitamin D	43-66	S-phase kinase-associated protein 1	Mus musculus	169-173
15075339-0	2004	p27(Kip1) stabilization and G(1) arrest by 1,25-dihydroxyvitamin D(3) in ovarian cancer cells mediated through down-regulation of cyclin E/cyclin-dependent kinase 2 and Skp1-Cullin-F-box protein/Skp2 ubiquitin ligase.	1,25-dihydroxyvitamin D	43-66	S-phase kinase-associated protein 2	Mus musculus	195-199
15190891-0	2004	A unique insertion/substitution in helix H1 of the vitamin D receptor ligand binding domain in a patient with hereditary 1,25-dihydroxyvitamin D-resistant rickets.	1,25-dihydroxyvitamin D	121-144	vitamin D receptor	Homo sapiens	51-69
15225738-1	2004	The new 24-phenylsulfone 4a, a low-calcemic analog of the natural hormone 1alpha,25-dihydroxyvitamin D(3), is a potent (IC(50) = 28nM) and highly selective inhibitor of the human 24-hydroxylase enzyme CYP24.	1,25-dihydroxyvitamin D	74-102	cytochrome P450 family 24 subfamily A member 1	Homo sapiens	201-206
15225739-4	2004	eight times less potent than 1alpha,25-dihydroxyvitamin D(3) (1alpha,25-(OH)(2)D(3)) (1) in binding to the rat intestinal vitamin D receptor (VDR).	1,25-dihydroxyvitamin D	29-57	vitamin D receptor	Rattus norvegicus	122-140
15225739-4	2004	eight times less potent than 1alpha,25-dihydroxyvitamin D(3) (1alpha,25-(OH)(2)D(3)) (1) in binding to the rat intestinal vitamin D receptor (VDR).	1,25-dihydroxyvitamin D	29-57	vitamin D receptor	Rattus norvegicus	142-145
15225751-1	2004	Most of the actions of 1,25-dihydroxyvitamin D(3) [1,25(OH)(2)D(3)] are mediated by binding to the Vitamin D nuclear receptor (VDR).	1,25-dihydroxyvitamin D	23-46	vitamin D receptor	Homo sapiens	99-125
15225751-1	2004	Most of the actions of 1,25-dihydroxyvitamin D(3) [1,25(OH)(2)D(3)] are mediated by binding to the Vitamin D nuclear receptor (VDR).	1,25-dihydroxyvitamin D	23-46	vitamin D receptor	Homo sapiens	127-130
15225761-1	2004	The enzyme 25-hydroxyvitamin D 1-hydroxylase (CYP27B1) is the rate limiting enzyme in the two-step activation process of Vitamin D to its active form 1,25-dihydroxyvitamin D (1,25D) and is located in the mitochondrial fraction of the proximal tubular cells of the kidney.	1,25-dihydroxyvitamin D	150-173	cytochrome P450, family 27, subfamily b, polypeptide 1	Mus musculus	46-53
15225769-3	2004	For example, NCoA62/SKIP interacts selectively with the VDR-RXR heterodimer, it forms a ternary complex with liganded VDR and steroid receptor coactivator (SRC) proteins, and it synergizes with SRCs to augment 1,25-dihydroxyvitamin D(3) [1,25-(OH)(2)D(3)]- and VDR-activated transcription.	1,25-dihydroxyvitamin D	210-233	SNW domain containing 1	Homo sapiens	13-19
15225829-0	2004	1,25-Dihydroxyvitamin D downregulation of TGFalpha/EGFR expression and growth signaling: a mechanism for the antiproliferative actions of the sterol in parathyroid hyperplasia of renal failure.	1,25-dihydroxyvitamin D	0-23	transforming growth factor alpha	Homo sapiens	42-50
15225769-3	2004	For example, NCoA62/SKIP interacts selectively with the VDR-RXR heterodimer, it forms a ternary complex with liganded VDR and steroid receptor coactivator (SRC) proteins, and it synergizes with SRCs to augment 1,25-dihydroxyvitamin D(3) [1,25-(OH)(2)D(3)]- and VDR-activated transcription.	1,25-dihydroxyvitamin D	210-233	vitamin D receptor	Homo sapiens	56-59
15225829-0	2004	1,25-Dihydroxyvitamin D downregulation of TGFalpha/EGFR expression and growth signaling: a mechanism for the antiproliferative actions of the sterol in parathyroid hyperplasia of renal failure.	1,25-dihydroxyvitamin D	0-23	epidermal growth factor receptor	Homo sapiens	51-55
15225829-8	2004	However, non-antiproliferative doses of 1,25-dihydroxyvitamin D enhance the anti-EGFR actions of EGFR-tyrosine kinase inhibitors (TKI).	1,25-dihydroxyvitamin D	40-63	epidermal growth factor receptor	Homo sapiens	81-85
15225769-3	2004	For example, NCoA62/SKIP interacts selectively with the VDR-RXR heterodimer, it forms a ternary complex with liganded VDR and steroid receptor coactivator (SRC) proteins, and it synergizes with SRCs to augment 1,25-dihydroxyvitamin D(3) [1,25-(OH)(2)D(3)]- and VDR-activated transcription.	1,25-dihydroxyvitamin D	210-233	retinoid X receptor alpha	Homo sapiens	60-63
15225829-8	2004	However, non-antiproliferative doses of 1,25-dihydroxyvitamin D enhance the anti-EGFR actions of EGFR-tyrosine kinase inhibitors (TKI).	1,25-dihydroxyvitamin D	40-63	epidermal growth factor receptor	Homo sapiens	97-101
15225769-3	2004	For example, NCoA62/SKIP interacts selectively with the VDR-RXR heterodimer, it forms a ternary complex with liganded VDR and steroid receptor coactivator (SRC) proteins, and it synergizes with SRCs to augment 1,25-dihydroxyvitamin D(3) [1,25-(OH)(2)D(3)]- and VDR-activated transcription.	1,25-dihydroxyvitamin D	210-233	vitamin D receptor	Homo sapiens	118-121
15225769-3	2004	For example, NCoA62/SKIP interacts selectively with the VDR-RXR heterodimer, it forms a ternary complex with liganded VDR and steroid receptor coactivator (SRC) proteins, and it synergizes with SRCs to augment 1,25-dihydroxyvitamin D(3) [1,25-(OH)(2)D(3)]- and VDR-activated transcription.	1,25-dihydroxyvitamin D	210-233	steroid receptor RNA activator 1	Homo sapiens	126-154
15225769-3	2004	For example, NCoA62/SKIP interacts selectively with the VDR-RXR heterodimer, it forms a ternary complex with liganded VDR and steroid receptor coactivator (SRC) proteins, and it synergizes with SRCs to augment 1,25-dihydroxyvitamin D(3) [1,25-(OH)(2)D(3)]- and VDR-activated transcription.	1,25-dihydroxyvitamin D	210-233	steroid receptor RNA activator 1	Homo sapiens	156-159
15225769-3	2004	For example, NCoA62/SKIP interacts selectively with the VDR-RXR heterodimer, it forms a ternary complex with liganded VDR and steroid receptor coactivator (SRC) proteins, and it synergizes with SRCs to augment 1,25-dihydroxyvitamin D(3) [1,25-(OH)(2)D(3)]- and VDR-activated transcription.	1,25-dihydroxyvitamin D	210-233	vitamin D receptor	Homo sapiens	118-121
15225771-2	2004	The VDR-PP1c and VDR-PP2Ac interactions were ligand independent in vivo, and 1,25-dihydroxyvitamin D(3) (1,25(OH)(2)D(3))-mediated increase in VDR-associated phosphatase activity resulted in dephosphorylation and inactivation of p70S6 kinase in colon cancer cells.	1,25-dihydroxyvitamin D	77-100	vitamin D receptor	Homo sapiens	4-7
15225771-2	2004	The VDR-PP1c and VDR-PP2Ac interactions were ligand independent in vivo, and 1,25-dihydroxyvitamin D(3) (1,25(OH)(2)D(3))-mediated increase in VDR-associated phosphatase activity resulted in dephosphorylation and inactivation of p70S6 kinase in colon cancer cells.	1,25-dihydroxyvitamin D	77-100	protein phosphatase 1 catalytic subunit gamma	Homo sapiens	8-12
15225771-2	2004	The VDR-PP1c and VDR-PP2Ac interactions were ligand independent in vivo, and 1,25-dihydroxyvitamin D(3) (1,25(OH)(2)D(3))-mediated increase in VDR-associated phosphatase activity resulted in dephosphorylation and inactivation of p70S6 kinase in colon cancer cells.	1,25-dihydroxyvitamin D	77-100	vitamin D receptor	Homo sapiens	17-20
15225771-2	2004	The VDR-PP1c and VDR-PP2Ac interactions were ligand independent in vivo, and 1,25-dihydroxyvitamin D(3) (1,25(OH)(2)D(3))-mediated increase in VDR-associated phosphatase activity resulted in dephosphorylation and inactivation of p70S6 kinase in colon cancer cells.	1,25-dihydroxyvitamin D	77-100	vitamin D receptor	Homo sapiens	17-20
14996990-5	2004	Genes regulated by 1,25-dihydroxyvitamin D included two previously known genes (25-hydroxyvitamin D-24-hydroxylase and amphiregulin) and 10 genes (sorcin, Gem, adaptin-gamma, TIG1, CEACAM6, carbonic anhydrase XII, junB, ceruloplasmin, and two unidentified sequences) that were novel.	1,25-dihydroxyvitamin D	19-42	amphiregulin	Homo sapiens	119-131
14996990-5	2004	Genes regulated by 1,25-dihydroxyvitamin D included two previously known genes (25-hydroxyvitamin D-24-hydroxylase and amphiregulin) and 10 genes (sorcin, Gem, adaptin-gamma, TIG1, CEACAM6, carbonic anhydrase XII, junB, ceruloplasmin, and two unidentified sequences) that were novel.	1,25-dihydroxyvitamin D	19-42	ceruloplasmin	Homo sapiens	220-233
14996990-7	2004	Increased protein expression was tested and confirmed in two of the novel 1,25-dihydroxyvitamin D-regulated genes, ceruloplasmin and sorcin.	1,25-dihydroxyvitamin D	74-97	ceruloplasmin	Homo sapiens	115-128
14996990-5	2004	Genes regulated by 1,25-dihydroxyvitamin D included two previously known genes (25-hydroxyvitamin D-24-hydroxylase and amphiregulin) and 10 genes (sorcin, Gem, adaptin-gamma, TIG1, CEACAM6, carbonic anhydrase XII, junB, ceruloplasmin, and two unidentified sequences) that were novel.	1,25-dihydroxyvitamin D	19-42	GTP binding protein overexpressed in skeletal muscle	Homo sapiens	155-158
14996990-5	2004	Genes regulated by 1,25-dihydroxyvitamin D included two previously known genes (25-hydroxyvitamin D-24-hydroxylase and amphiregulin) and 10 genes (sorcin, Gem, adaptin-gamma, TIG1, CEACAM6, carbonic anhydrase XII, junB, ceruloplasmin, and two unidentified sequences) that were novel.	1,25-dihydroxyvitamin D	19-42	retinoic acid receptor responder 1	Homo sapiens	175-179
14996990-5	2004	Genes regulated by 1,25-dihydroxyvitamin D included two previously known genes (25-hydroxyvitamin D-24-hydroxylase and amphiregulin) and 10 genes (sorcin, Gem, adaptin-gamma, TIG1, CEACAM6, carbonic anhydrase XII, junB, ceruloplasmin, and two unidentified sequences) that were novel.	1,25-dihydroxyvitamin D	19-42	CEA cell adhesion molecule 6	Homo sapiens	181-188
14996990-5	2004	Genes regulated by 1,25-dihydroxyvitamin D included two previously known genes (25-hydroxyvitamin D-24-hydroxylase and amphiregulin) and 10 genes (sorcin, Gem, adaptin-gamma, TIG1, CEACAM6, carbonic anhydrase XII, junB, ceruloplasmin, and two unidentified sequences) that were novel.	1,25-dihydroxyvitamin D	19-42	carbonic anhydrase 12	Homo sapiens	190-212
14996990-5	2004	Genes regulated by 1,25-dihydroxyvitamin D included two previously known genes (25-hydroxyvitamin D-24-hydroxylase and amphiregulin) and 10 genes (sorcin, Gem, adaptin-gamma, TIG1, CEACAM6, carbonic anhydrase XII, junB, ceruloplasmin, and two unidentified sequences) that were novel.	1,25-dihydroxyvitamin D	19-42	JunB proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	214-218
14755538-2	2004	We provide evidence here that KSR is upregulated in HL60 cells undergoing differentiation induced by low (0.3-3 nM) concentrations of 1,25-dihydroxyvitamin D(3) (1,25D(3)), and an antisense oligo (AS), but not a sense oligo, to KSR inhibits this differentiation.	1,25-dihydroxyvitamin D	134-157	kinase suppressor of ras 1	Homo sapiens	30-33
15040831-2	2004	FGF-23 caused a reduction in serum 1,25-dihydroxyvitamin D by altering the expressions of key enzymes for the vitamin D metabolism followed by hypophosphatemia.	1,25-dihydroxyvitamin D	35-58	fibroblast growth factor 23	Rattus norvegicus	0-6
15040831-4	2004	INTRODUCTION: The pathophysiological contribution of FGF-23 in hypophosphatemic diseases was supported by animal studies in which the long-term administration of recombinant fibroblast growth factor-23 reproduced hypophosphatemic rickets with a low serum 1,25-dihydroxyvitamin D [1,25(OH)2D] level.	1,25-dihydroxyvitamin D	255-278	fibroblast growth factor 23	Rattus norvegicus	53-59
14726489-2	2004	In the human osteoblast-like cells, hFOB, the vitamin D receptor (VDR)-mediated transcriptional potencies of Ro-26-9228 and 1,25-dihydroxyvitamin D(3) (1,25D(3)) were similar, but in the intestinal cells, Caco-2, transcriptional potency of Ro-26-9228 was 10-50 times lower.	1,25-dihydroxyvitamin D	124-147	vitamin D receptor	Homo sapiens	46-64
14726489-2	2004	In the human osteoblast-like cells, hFOB, the vitamin D receptor (VDR)-mediated transcriptional potencies of Ro-26-9228 and 1,25-dihydroxyvitamin D(3) (1,25D(3)) were similar, but in the intestinal cells, Caco-2, transcriptional potency of Ro-26-9228 was 10-50 times lower.	1,25-dihydroxyvitamin D	124-147	vitamin D receptor	Homo sapiens	66-69
14665637-1	2004	If both rapid and genomic pathways may co-exist in the same cell, the involvement of the nuclear vitamin D receptor (VDR) in the rapid effects of 1,25-dihydroxyvitamin D(3) (1,25-(OH)(2)D(3)) remains unclear.	1,25-dihydroxyvitamin D	146-169	vitamin D receptor	Homo sapiens	97-115
14665637-1	2004	If both rapid and genomic pathways may co-exist in the same cell, the involvement of the nuclear vitamin D receptor (VDR) in the rapid effects of 1,25-dihydroxyvitamin D(3) (1,25-(OH)(2)D(3)) remains unclear.	1,25-dihydroxyvitamin D	146-169	vitamin D receptor	Homo sapiens	117-120
14733920-3	2004	The transgenic mice expressing human FGF-23 reproduced the common clinical features of these diseases such as hypophosphatemia probably due to increased renal phosphate wasting, inappropriately low serum 1,25-dihydroxyvitamin D level, and rachitic bone.	1,25-dihydroxyvitamin D	204-227	fibroblast growth factor 23	Homo sapiens	37-43
15084353-1	2004	Pretreatment with 1 nM 1,25-dihydroxyvitamin D(3) (1,25), or non-hypercalcemic Vitamin D analogs, upregulated the response of creatine kinase (CK) to 17beta-estradiol (30 nM E(2)), raloxifene (3000 nM RAL) or dihydrotestosterone (300 nM DHT) in primary human bone cells.	1,25-dihydroxyvitamin D	23-46	RAS like proto-oncogene A	Homo sapiens	201-204
14966565-4	2004	We present here the evidence that FGF23 is a physiological regulator of serum phosphate and 1,25-dihydroxyvitamin D (1,25[OH]2D) by generating FGF23-null mice.	1,25-dihydroxyvitamin D	92-115	fibroblast growth factor 23	Mus musculus	34-39
14966565-4	2004	We present here the evidence that FGF23 is a physiological regulator of serum phosphate and 1,25-dihydroxyvitamin D (1,25[OH]2D) by generating FGF23-null mice.	1,25-dihydroxyvitamin D	92-115	fibroblast growth factor 23	Mus musculus	143-148
14729647-2	2004	In this study we investigated the role of the retinoblastoma protein (pRb) and the CCAAT/enhancer-binding protein (C/EBP) beta in 1,25-dihydroxyvitamin D(3) (1,25D(3))-induced monocytic differentiation of human leukemia HL60 cells.	1,25-dihydroxyvitamin D	130-153	CCAAT enhancer binding protein beta	Homo sapiens	115-126
14597768-8	2003	Removal of PTHrP from the lactating mammary glands resulted in reductions in levels of circulating PTHrP and 1,25-dihydroxy vitamin D and urinary cAMP.	1,25-dihydroxyvitamin D	109-133	parathyroid hormone-like peptide	Mus musculus	11-16
14730505-2	2004	Impaired production of 1,25-dihydroxyvitamin D (calcitriol), the hormonal form of vitamin D, is a major contributor to the generation and maintenance of parathyroid hyperplasia and increased synthesis and secretion of PTH.	1,25-dihydroxyvitamin D	23-46	parathyroid hormone	Homo sapiens	218-221
12960002-5	2003	IGF-I-deficient mice fed the normal calcium diet showed elevated PTH levels, decreased serum 1,25-dihydroxyvitamin D and serum calcium levels at baseline.	1,25-dihydroxyvitamin D	93-116	insulin-like growth factor 1	Mus musculus	0-5
14654225-9	2003	Since (1) PMA is reported to activate PLD-1 to a greater extent than PLD-2, (2) 1,25-dihydroxyvitamin D(3) increases the expression/activity of PLD-1 in keratinocytes, and (3) PLD-2 is co-localized with a glycerol channel in keratinocyte membrane microdomains, we speculate that radiolabeled PG production from radioactive glycerol is a measure of PLD-2 activation in these cells.	1,25-dihydroxyvitamin D	80-103	phospholipase D1	Mus musculus	38-43
14654225-9	2003	Since (1) PMA is reported to activate PLD-1 to a greater extent than PLD-2, (2) 1,25-dihydroxyvitamin D(3) increases the expression/activity of PLD-1 in keratinocytes, and (3) PLD-2 is co-localized with a glycerol channel in keratinocyte membrane microdomains, we speculate that radiolabeled PG production from radioactive glycerol is a measure of PLD-2 activation in these cells.	1,25-dihydroxyvitamin D	80-103	phospholipase D1	Mus musculus	144-149
14654225-9	2003	Since (1) PMA is reported to activate PLD-1 to a greater extent than PLD-2, (2) 1,25-dihydroxyvitamin D(3) increases the expression/activity of PLD-1 in keratinocytes, and (3) PLD-2 is co-localized with a glycerol channel in keratinocyte membrane microdomains, we speculate that radiolabeled PG production from radioactive glycerol is a measure of PLD-2 activation in these cells.	1,25-dihydroxyvitamin D	80-103	phospholipase D2	Mus musculus	176-181
14654225-9	2003	Since (1) PMA is reported to activate PLD-1 to a greater extent than PLD-2, (2) 1,25-dihydroxyvitamin D(3) increases the expression/activity of PLD-1 in keratinocytes, and (3) PLD-2 is co-localized with a glycerol channel in keratinocyte membrane microdomains, we speculate that radiolabeled PG production from radioactive glycerol is a measure of PLD-2 activation in these cells.	1,25-dihydroxyvitamin D	80-103	phospholipase D2	Mus musculus	176-181
12933662-4	2003	Long- and short-term adaptation to changes in dietary calcium (Ca) level and 1,25 dihydroxyvitamin D(3) [1,25(OH)(2)D(3)] injection strongly regulated duodenal calbindin D(9k) and CaT1 mRNA.	1,25-dihydroxyvitamin D	77-100	S100 calcium binding protein G	Mus musculus	160-174
14500474-6	2003	1,25-Dihydroxyvitamin D(3) differentiation of MM6 cells increased CD14 expression 12-fold but did not augment B. burgdorferi-mediated uPAR expression.	1,25-dihydroxyvitamin D	0-23	CD14 antigen	Mus musculus	66-70
12933662-4	2003	Long- and short-term adaptation to changes in dietary calcium (Ca) level and 1,25 dihydroxyvitamin D(3) [1,25(OH)(2)D(3)] injection strongly regulated duodenal calbindin D(9k) and CaT1 mRNA.	1,25-dihydroxyvitamin D	77-100	transient receptor potential cation channel, subfamily V, member 6	Mus musculus	180-184
12914530-1	2003	Critical to an understanding of the control of 1,25-dihydroxyvitamin D (1,25D) activity is a molecular appreciation of the regulation of three genes, 25-hydroxyvitamin D-1alpha-hydroxylase (CYP27B1), 25-hydroxyvitamin D-24-hydroxylase (CYP24) and vitamin D receptor (VDR).	1,25-dihydroxyvitamin D	47-70	cytochrome P450 family 27 subfamily B member 1	Homo sapiens	190-197
12914530-1	2003	Critical to an understanding of the control of 1,25-dihydroxyvitamin D (1,25D) activity is a molecular appreciation of the regulation of three genes, 25-hydroxyvitamin D-1alpha-hydroxylase (CYP27B1), 25-hydroxyvitamin D-24-hydroxylase (CYP24) and vitamin D receptor (VDR).	1,25-dihydroxyvitamin D	47-70	cytochrome P450 family 24 subfamily A member 1	Homo sapiens	236-241
12914530-1	2003	Critical to an understanding of the control of 1,25-dihydroxyvitamin D (1,25D) activity is a molecular appreciation of the regulation of three genes, 25-hydroxyvitamin D-1alpha-hydroxylase (CYP27B1), 25-hydroxyvitamin D-24-hydroxylase (CYP24) and vitamin D receptor (VDR).	1,25-dihydroxyvitamin D	47-70	vitamin D receptor	Homo sapiens	247-265
12914530-1	2003	Critical to an understanding of the control of 1,25-dihydroxyvitamin D (1,25D) activity is a molecular appreciation of the regulation of three genes, 25-hydroxyvitamin D-1alpha-hydroxylase (CYP27B1), 25-hydroxyvitamin D-24-hydroxylase (CYP24) and vitamin D receptor (VDR).	1,25-dihydroxyvitamin D	47-70	vitamin D receptor	Homo sapiens	267-270
12821938-1	2003	Vitamin D(3) upregulated protein 1 (VDUP1) is a 1,25-dihydroxyvitamin D(3) (1,25(OH)(2)D(3)) upregulated protein, and it is induced by various stresses.	1,25-dihydroxyvitamin D	48-71	thioredoxin interacting protein	Homo sapiens	0-34
12817011-5	2003	Differentiation of Caco2 and HT29 cells with 1alpha,25-dihydroxyvitamin D(3) or IFN-gamma enhances Nox1 expression and decreases cell proliferation, suggesting that Nox1 does not function as a mitogenic oxidase in colon epithelial cells.	1,25-dihydroxyvitamin D	45-73	NADPH oxidase 1	Homo sapiens	99-103
12821938-1	2003	Vitamin D(3) upregulated protein 1 (VDUP1) is a 1,25-dihydroxyvitamin D(3) (1,25(OH)(2)D(3)) upregulated protein, and it is induced by various stresses.	1,25-dihydroxyvitamin D	48-71	thioredoxin interacting protein	Homo sapiens	36-41
12782149-7	2003	Recombinant human CYP27A1 was found to convert 25-hydroxyvitamin D(3) into 1alpha,25-dihydroxyvitamin D(3), 25,27-dihydroxyvitamin D(3) and a major metabolite with the same retention time on HPLC as that formed by kidney mitochondrial cytochrome P450.	1,25-dihydroxyvitamin D	75-103	cytochrome P450 family 27 subfamily A member 1	Homo sapiens	18-25
12882707-10	2003	In group B, six clones were isolated, including cytochrome B, up-regulated by 1,25-dihydroxyvitamin D(3) (VDUP1), NADH- ubiquinone oxidoreductase 20 Kd subunit, mu-calpain large subunit, tumor protein, translationally-controlled 1 (TPT1) and COATOMER alpha subunit.	1,25-dihydroxyvitamin D	78-101	mitochondrially encoded cytochrome b	Homo sapiens	48-60
12753256-1	2003	1,25-dihydroxyvitamin D [1,25(OH)2D3], the hormonal form of vitamin D, controls serum levels of parathyroid hormone (PTH) and parathyroid hyperplasia.	1,25-dihydroxyvitamin D	0-23	parathyroid hormone	Homo sapiens	96-115
12753256-1	2003	1,25-dihydroxyvitamin D [1,25(OH)2D3], the hormonal form of vitamin D, controls serum levels of parathyroid hormone (PTH) and parathyroid hyperplasia.	1,25-dihydroxyvitamin D	0-23	parathyroid hormone	Homo sapiens	117-120
12716975-3	2003	Here we present evidence for a similar mechanism in humans via a patient with resistance to the active form of vitamin D [1,25-dihydroxyvitamin D(3) (1,25(OH)(2)D(3))] who presented with normal vitamin D receptor (VDR) expression.	1,25-dihydroxyvitamin D	122-145	vitamin D receptor	Homo sapiens	214-217
12706526-1	2003	The expression of vitamin D(3) up-regulating protein-1 (VDUP1) was up-regulated by 1alpha,25-dihydroxyvitamin D(3) (VD3) treatment in B16 mouse melanoma cells.	1,25-dihydroxyvitamin D	83-111	thioredoxin interacting protein	Mus musculus	18-54
12706526-1	2003	The expression of vitamin D(3) up-regulating protein-1 (VDUP1) was up-regulated by 1alpha,25-dihydroxyvitamin D(3) (VD3) treatment in B16 mouse melanoma cells.	1,25-dihydroxyvitamin D	83-111	thioredoxin interacting protein	Mus musculus	56-61
12759412-2	2003	1 alpha 25-dihydroxyvitamin D(3) (1 alpha 25(OH)(2)D(3)) has been identified as a major factor that inhibits the differentiation and maturation of DCs, an effect dependent upon its binding to the nuclear vitamin D receptor (VDR).	1,25-dihydroxyvitamin D	0-29	vitamin D receptor	Homo sapiens	204-222
12759412-2	2003	1 alpha 25-dihydroxyvitamin D(3) (1 alpha 25(OH)(2)D(3)) has been identified as a major factor that inhibits the differentiation and maturation of DCs, an effect dependent upon its binding to the nuclear vitamin D receptor (VDR).	1,25-dihydroxyvitamin D	0-29	vitamin D receptor	Homo sapiens	224-227
15160549-5	2003	Furthermore, in EPO-treated group, exogenous EPO doses correlated with the increments in 1,25-dihydroxy-vitamin D (r = 0.38, p < 0.05), intact osteocalcin (r = 0.42, p < 0.05) and bone alkali-phosphatase (r = 0.53, p < 0.005), but not intact parathyroid hormone (r = 0.09).	1,25-dihydroxyvitamin D	89-113	erythropoietin	Homo sapiens	16-19
12727648-2	2003	1,25-Dihydroxyvitamin D(3) [1,25-(OH)(2)D(3)] induces DCs with a tolerogenic phenotype, characterized by decreased expression of CD40, CD80, and CD86 co-stimulatory molecules, low IL-12, and enhanced IL-10 secretion.	1,25-dihydroxyvitamin D	0-23	CD40 antigen	Mus musculus	129-133
12727648-2	2003	1,25-Dihydroxyvitamin D(3) [1,25-(OH)(2)D(3)] induces DCs with a tolerogenic phenotype, characterized by decreased expression of CD40, CD80, and CD86 co-stimulatory molecules, low IL-12, and enhanced IL-10 secretion.	1,25-dihydroxyvitamin D	0-23	CD80 antigen	Mus musculus	135-139
12727648-2	2003	1,25-Dihydroxyvitamin D(3) [1,25-(OH)(2)D(3)] induces DCs with a tolerogenic phenotype, characterized by decreased expression of CD40, CD80, and CD86 co-stimulatory molecules, low IL-12, and enhanced IL-10 secretion.	1,25-dihydroxyvitamin D	0-23	CD86 antigen	Mus musculus	145-149
12727648-2	2003	1,25-Dihydroxyvitamin D(3) [1,25-(OH)(2)D(3)] induces DCs with a tolerogenic phenotype, characterized by decreased expression of CD40, CD80, and CD86 co-stimulatory molecules, low IL-12, and enhanced IL-10 secretion.	1,25-dihydroxyvitamin D	0-23	interleukin 10	Mus musculus	200-205
12577307-3	2003	The findings that 1-alpha, 25-dihydroxy-vitamin D(3) (VD3) and all-trans retinoic acid (RA) differentially alter expression of the predominant S1P(3) (Edg-3) R and S1P(2) (Edg-5) R in human breast cancer cells (BCCs) permitted analyses of their individual activities, despite a lack of selective pharmacological probes.	1,25-dihydroxyvitamin D	18-49	sphingosine-1-phosphate receptor 3	Homo sapiens	143-149
12577307-3	2003	The findings that 1-alpha, 25-dihydroxy-vitamin D(3) (VD3) and all-trans retinoic acid (RA) differentially alter expression of the predominant S1P(3) (Edg-3) R and S1P(2) (Edg-5) R in human breast cancer cells (BCCs) permitted analyses of their individual activities, despite a lack of selective pharmacological probes.	1,25-dihydroxyvitamin D	18-49	sphingosine-1-phosphate receptor 3	Homo sapiens	151-156
12577307-3	2003	The findings that 1-alpha, 25-dihydroxy-vitamin D(3) (VD3) and all-trans retinoic acid (RA) differentially alter expression of the predominant S1P(3) (Edg-3) R and S1P(2) (Edg-5) R in human breast cancer cells (BCCs) permitted analyses of their individual activities, despite a lack of selective pharmacological probes.	1,25-dihydroxyvitamin D	18-49	sphingosine-1-phosphate receptor 2	Homo sapiens	164-170
12577307-3	2003	The findings that 1-alpha, 25-dihydroxy-vitamin D(3) (VD3) and all-trans retinoic acid (RA) differentially alter expression of the predominant S1P(3) (Edg-3) R and S1P(2) (Edg-5) R in human breast cancer cells (BCCs) permitted analyses of their individual activities, despite a lack of selective pharmacological probes.	1,25-dihydroxyvitamin D	18-49	sphingosine-1-phosphate receptor 2	Homo sapiens	172-177
12732287-1	2003	In human prostate cancer cells, the availability of the steroid hormone 1,25-dihydroxyvitamin D(3) for antimitotic action is determined through the activity of the two enzymes CYP24 and CYP27B1, viz.	1,25-dihydroxyvitamin D	72-95	cytochrome P450 family 24 subfamily A member 1	Homo sapiens	176-181
12732287-1	2003	In human prostate cancer cells, the availability of the steroid hormone 1,25-dihydroxyvitamin D(3) for antimitotic action is determined through the activity of the two enzymes CYP24 and CYP27B1, viz.	1,25-dihydroxyvitamin D	72-95	cytochrome P450 family 27 subfamily B member 1	Homo sapiens	186-193
12520519-2	2003	1,25-dihydroxyvitamin D(3) [1,25(OH)(2)D(3)] induces DCs with a tolerogenic phenotype, characterized by decreased expression of CD40, CD80, and CD86 costimulatory molecules, low IL-12 and enhanced IL-10 secretion.	1,25-dihydroxyvitamin D	0-23	CD40 molecule	Homo sapiens	128-132
12520519-2	2003	1,25-dihydroxyvitamin D(3) [1,25(OH)(2)D(3)] induces DCs with a tolerogenic phenotype, characterized by decreased expression of CD40, CD80, and CD86 costimulatory molecules, low IL-12 and enhanced IL-10 secretion.	1,25-dihydroxyvitamin D	0-23	CD80 molecule	Homo sapiens	134-138
12520519-2	2003	1,25-dihydroxyvitamin D(3) [1,25(OH)(2)D(3)] induces DCs with a tolerogenic phenotype, characterized by decreased expression of CD40, CD80, and CD86 costimulatory molecules, low IL-12 and enhanced IL-10 secretion.	1,25-dihydroxyvitamin D	0-23	CD86 molecule	Homo sapiens	144-148
12520519-2	2003	1,25-dihydroxyvitamin D(3) [1,25(OH)(2)D(3)] induces DCs with a tolerogenic phenotype, characterized by decreased expression of CD40, CD80, and CD86 costimulatory molecules, low IL-12 and enhanced IL-10 secretion.	1,25-dihydroxyvitamin D	0-23	interleukin 10	Homo sapiens	197-202
12520520-1	2003	The 25-hydroxyvitamin D(3)-24-hydroxylase mRNA is tightly and reciprocally regulated by 1,25-dihydroxyvitamin D(3) (1,25(OH)(2)D(3)) and parathyroid hormone (PTH).	1,25-dihydroxyvitamin D	88-111	cytochrome P450, family 24, subfamily a, polypeptide 1	Rattus norvegicus	4-41
12520520-1	2003	The 25-hydroxyvitamin D(3)-24-hydroxylase mRNA is tightly and reciprocally regulated by 1,25-dihydroxyvitamin D(3) (1,25(OH)(2)D(3)) and parathyroid hormone (PTH).	1,25-dihydroxyvitamin D	88-111	parathyroid hormone	Rattus norvegicus	158-161
12520523-1	2003	The vitamin D receptor (VDR) is known to mediate the biological actions of 1,25-dihydroxyvitamin D(3) (1,25(OH)(2)D(3)) through its ability to regulate cellular programs of gene expression.	1,25-dihydroxyvitamin D	75-98	vitamin D receptor	Homo sapiens	4-22
12520523-1	2003	The vitamin D receptor (VDR) is known to mediate the biological actions of 1,25-dihydroxyvitamin D(3) (1,25(OH)(2)D(3)) through its ability to regulate cellular programs of gene expression.	1,25-dihydroxyvitamin D	75-98	vitamin D receptor	Homo sapiens	24-27
12710998-2	2003	Elucidation of Vitamin D(3) receptor (VDR) regulation may reveal strategies to sensitize cancer cells to the effects of 1,25-dihydroxyvitamin D(3) and Vitamin D(3) analogs.	1,25-dihydroxyvitamin D	120-143	vitamin D receptor	Homo sapiens	15-36
12710998-2	2003	Elucidation of Vitamin D(3) receptor (VDR) regulation may reveal strategies to sensitize cancer cells to the effects of 1,25-dihydroxyvitamin D(3) and Vitamin D(3) analogs.	1,25-dihydroxyvitamin D	120-143	vitamin D receptor	Homo sapiens	38-41
12710998-9	2003	Because resveratrol could up-regulate VDR without increasing breast cancer cell growth, we hypothesized that resveratrol mediated increase in VDR expression would sensitize breast cancer cells to the effects of 1,25-dihydroxyvitamin D(3) and Vitamin D(3) analogs.	1,25-dihydroxyvitamin D	211-234	vitamin D receptor	Homo sapiens	142-145
12674325-1	2003	Mice homozygous for the disrupted renal type IIa sodium/phosphate (Na/Pi) cotransporter gene (Npt2-/-) exhibit renal Pi wasting, hypophosphatemia, and an adaptive increase in the serum concentration of 1,25-dihydroxyvitamin D with associated hypercalcemia and hypercalciuria.	1,25-dihydroxyvitamin D	202-225	solute carrier family 34 (sodium phosphate), member 1	Mus musculus	67-87
12674325-1	2003	Mice homozygous for the disrupted renal type IIa sodium/phosphate (Na/Pi) cotransporter gene (Npt2-/-) exhibit renal Pi wasting, hypophosphatemia, and an adaptive increase in the serum concentration of 1,25-dihydroxyvitamin D with associated hypercalcemia and hypercalciuria.	1,25-dihydroxyvitamin D	202-225	solute carrier family 34 (sodium phosphate), member 1	Mus musculus	94-98
12577303-1	2003	The biologically active metabolite of vitamin D, 1,25-dihydroxyvitamin D(3) (1,25(OH)(2)D(3)) is a secosteroid whose genomic mechanism of action is similar to that of other steroid hormones and is mediated by stereospecific interaction of 1,25(OH)(2)D(3) with the vitamin D receptor (VDR) which heterodimerizes with the retinoid X receptor (RXR).	1,25-dihydroxyvitamin D	49-72	vitamin D (1,25-dihydroxyvitamin D3) receptor	Mus musculus	264-282
12577303-1	2003	The biologically active metabolite of vitamin D, 1,25-dihydroxyvitamin D(3) (1,25(OH)(2)D(3)) is a secosteroid whose genomic mechanism of action is similar to that of other steroid hormones and is mediated by stereospecific interaction of 1,25(OH)(2)D(3) with the vitamin D receptor (VDR) which heterodimerizes with the retinoid X receptor (RXR).	1,25-dihydroxyvitamin D	49-72	vitamin D (1,25-dihydroxyvitamin D3) receptor	Mus musculus	284-287
15160549-7	2003	CONCLUSION: The present data provide evidence that EPO may modulate the production of 1,25-dihydroxy-vitamin D in HD patients.	1,25-dihydroxyvitamin D	86-110	erythropoietin	Homo sapiens	51-54
15160549-5	2003	Furthermore, in EPO-treated group, exogenous EPO doses correlated with the increments in 1,25-dihydroxy-vitamin D (r = 0.38, p < 0.05), intact osteocalcin (r = 0.42, p < 0.05) and bone alkali-phosphatase (r = 0.53, p < 0.005), but not intact parathyroid hormone (r = 0.09).	1,25-dihydroxyvitamin D	89-113	erythropoietin	Homo sapiens	45-48
12899521-1	2003	The 25-hydroxyvitamin D-1alpha-OHase (1alpha-OHase) is responsible for producing the active form of vitamin D, 1alpha,25-dihydroxyvitamin D.	1,25-dihydroxyvitamin D	111-139	cytochrome P450 family 27 subfamily B member 1	Homo sapiens	22-36
12899521-1	2003	The 25-hydroxyvitamin D-1alpha-OHase (1alpha-OHase) is responsible for producing the active form of vitamin D, 1alpha,25-dihydroxyvitamin D.	1,25-dihydroxyvitamin D	111-139	cytochrome P450 family 27 subfamily B member 1	Homo sapiens	24-36
12364326-8	2002	CREB activity was also required for full stimulation of RANKL by oncostatin M or 1,25-dihydroxyvitamin D(3).	1,25-dihydroxyvitamin D	81-104	cAMP responsive element binding protein 1	Homo sapiens	0-4
12470639-1	2002	The nuclear vitamin D receptor (VDR) mediates the effects of 1,25-dihydroxyvitamin D(3) (1,25D(3)) to alter intestinal gene transcription and promote calcium absorption.	1,25-dihydroxyvitamin D	61-84	vitamin D receptor	Homo sapiens	12-30
12470639-1	2002	The nuclear vitamin D receptor (VDR) mediates the effects of 1,25-dihydroxyvitamin D(3) (1,25D(3)) to alter intestinal gene transcription and promote calcium absorption.	1,25-dihydroxyvitamin D	61-84	vitamin D receptor	Homo sapiens	32-35
12464272-7	2002	We conclude that 1alpha,25-dihydroxyvitamin D(3) functions to suppress EAE through the well-known VDR and not through an undiscovered receptor or through a "nongenomic" mechanism.	1,25-dihydroxyvitamin D	17-45	vitamin D (1,25-dihydroxyvitamin D3) receptor	Mus musculus	98-101
12364326-8	2002	CREB activity was also required for full stimulation of RANKL by oncostatin M or 1,25-dihydroxyvitamin D(3).	1,25-dihydroxyvitamin D	81-104	TNF superfamily member 11	Homo sapiens	56-61
12650704-1	2002	1,25-Dihydroxyvitamin D(3) (1,25(OH)(2)D(3)) interacts with the Vitamin D(3) receptor (VDR) to modulate proliferation and apoptosis in a variety of cell types, including breast cancer cells.	1,25-dihydroxyvitamin D	0-23	vitamin D (1,25-dihydroxyvitamin D3) receptor	Mus musculus	64-85
12507934-1	2002	1,25-Dihydroxyvitamin D(3) (1,25D(3)) is the biologically active form of vitamin D(3) that interacts with the nuclear vitamin D(3) receptor (VDR) to modulate gene expression in a tissue-specific fashion.	1,25-dihydroxyvitamin D	0-23	vitamin D (1,25-dihydroxyvitamin D3) receptor	Mus musculus	118-139
12507934-1	2002	1,25-Dihydroxyvitamin D(3) (1,25D(3)) is the biologically active form of vitamin D(3) that interacts with the nuclear vitamin D(3) receptor (VDR) to modulate gene expression in a tissue-specific fashion.	1,25-dihydroxyvitamin D	0-23	vitamin D (1,25-dihydroxyvitamin D3) receptor	Mus musculus	141-144
12498308-4	2002	Hormonal responsiveness was characterized by measuring the capacity of 1,25-dihydroxyvitamin D [1,25(OH)2D], the hormonal form of vitamin D, to increase mRNA levels of the intestinal 24-hydroxylase cytochrome P-450 (CYP24).	1,25-dihydroxyvitamin D	71-94	cytochrome P450, family 2, subfamily g, polypeptide 1	Rattus norvegicus	198-214
12498308-4	2002	Hormonal responsiveness was characterized by measuring the capacity of 1,25-dihydroxyvitamin D [1,25(OH)2D], the hormonal form of vitamin D, to increase mRNA levels of the intestinal 24-hydroxylase cytochrome P-450 (CYP24).	1,25-dihydroxyvitamin D	71-94	cytochrome P450, family 24, subfamily a, polypeptide 1	Rattus norvegicus	216-221
12650704-1	2002	1,25-Dihydroxyvitamin D(3) (1,25(OH)(2)D(3)) interacts with the Vitamin D(3) receptor (VDR) to modulate proliferation and apoptosis in a variety of cell types, including breast cancer cells.	1,25-dihydroxyvitamin D	0-23	vitamin D (1,25-dihydroxyvitamin D3) receptor	Mus musculus	87-90
12403843-0	2002	A novel mutation in helix 12 of the vitamin D receptor impairs coactivator interaction and causes hereditary 1,25-dihydroxyvitamin D-resistant rickets without alopecia.	1,25-dihydroxyvitamin D	109-132	vitamin D receptor	Homo sapiens	36-54
12444900-2	2002	Active vitamin D, 1,25-dihydroxyvitamin D(3) (1,25-(OH)(2)D(3)), with the vitamin D receptor (VDR) is involved in regulation of the calcium homeostasis together with PTH.	1,25-dihydroxyvitamin D	18-41	vitamin D receptor	Homo sapiens	74-92
12444900-2	2002	Active vitamin D, 1,25-dihydroxyvitamin D(3) (1,25-(OH)(2)D(3)), with the vitamin D receptor (VDR) is involved in regulation of the calcium homeostasis together with PTH.	1,25-dihydroxyvitamin D	18-41	vitamin D receptor	Homo sapiens	94-97
12444900-2	2002	Active vitamin D, 1,25-dihydroxyvitamin D(3) (1,25-(OH)(2)D(3)), with the vitamin D receptor (VDR) is involved in regulation of the calcium homeostasis together with PTH.	1,25-dihydroxyvitamin D	18-41	parathyroid hormone	Homo sapiens	166-169
12468277-0	2002	A novel nonsense mutation in the ligand binding domain of the vitamin D receptor causes hereditary 1,25-dihydroxyvitamin D-resistant rickets.	1,25-dihydroxyvitamin D	99-122	vitamin D receptor	Homo sapiens	62-80
12468277-1	2002	Hereditary 1,25-dihydroxyvitamin D resistant rickets (HVDRR) is a genetic disorder most often caused by mutations in the vitamin D receptor (VDR).	1,25-dihydroxyvitamin D	11-34	vitamin D receptor	Homo sapiens	121-139
12468277-1	2002	Hereditary 1,25-dihydroxyvitamin D resistant rickets (HVDRR) is a genetic disorder most often caused by mutations in the vitamin D receptor (VDR).	1,25-dihydroxyvitamin D	11-34	vitamin D receptor	Homo sapiens	55-58
12431791-3	2002	For example, deleterious mutations in the VDR gene cause 1,25-dihydroxyvitamin D-resistant rickets, a rare monogenetic disease.	1,25-dihydroxyvitamin D	57-80	vitamin D receptor	Homo sapiens	42-45
12387822-6	2002	In cocultures of E1 cells and mouse bone marrow cells, histamine stimulated osteoclastogenesis in the presence of 1,25-dihydroxyvitamin D(3) and this effect was blocked by preincubation with neutralizing antibody against ODF/RANKL.	1,25-dihydroxyvitamin D	114-137	tumor necrosis factor (ligand) superfamily, member 11	Mus musculus	221-224
12386916-2	2002	25-hydroxyvitamin D(3) 1-alpha-hydroxylase, the enzyme that catalyzes the final step of vitamin D synthesis, converting 25-hydroxyvitamin D(3) to 1,25-dihydroxyvitamin D(3), is expressed in the prostate.	1,25-dihydroxyvitamin D	146-169	cytochrome P450 family 27 subfamily B member 1	Homo sapiens	0-42
12372434-3	2002	CYP24 is also involved in the breakdown of 1alpha,25-dihydroxyvitamin D(3) [1alpha,25(OH)(2)D(3)], the active form of vitamin D(3).	1,25-dihydroxyvitamin D	43-71	cytochrome P450, family 24, subfamily a, polypeptide 1	Rattus norvegicus	0-5
12181310-0	2002	1,25-Dihydroxyvitamin D down-regulates cell membrane growth- and nuclear growth-promoting signals by the epidermal growth factor receptor.	1,25-dihydroxyvitamin D	0-23	epidermal growth factor receptor	Homo sapiens	105-137
12211444-0	2002	Tryptophan missense mutation in the ligand-binding domain of the vitamin D receptor causes severe resistance to 1,25-dihydroxyvitamin D.	1,25-dihydroxyvitamin D	112-135	vitamin D receptor	Homo sapiens	65-83
12324654-5	2002	Ectopic expression of blr1 caused no significant cell cycle or differentiation changes, but caused the U937/blr1 cells to differentiate faster when treated with either retinoic acid or 1alpha,25-dihydroxyvitamin D(3).	1,25-dihydroxyvitamin D	185-213	C-X-C motif chemokine receptor 5	Homo sapiens	22-26
12125095-0	2002	1alpha,25-Dihydroxyvitamin D(3) inhibits rat liver ultrastructural changes and the development of gamma-glutamyltranspeptidase-positive foci in diethylnitrosamine-initiated and streptozotocin-induced diabetes-promoted hepatocarcinogenesis.	1,25-dihydroxyvitamin D	0-28	gamma-glutamyltransferase 1	Rattus norvegicus	98-126
12125099-0	2002	Transcriptional activation of the human insulin receptor gene by 1,25-dihydroxyvitamin D(3).	1,25-dihydroxyvitamin D	65-88	insulin receptor	Homo sapiens	40-56
12086963-8	2002	For VDR protein levels, the best-fit model (P = 0.006) gave TaqI genotype (P = 0.005) and circulating 1,25-dihydroxyvitamin-D levels (P = 0.03) as independent determinants.	1,25-dihydroxyvitamin D	102-125	vitamin D receptor	Homo sapiens	4-7
12036954-1	2002	Vitamin D response elements in promoters P1 and P2 confer transcriptional responsiveness to 1,25-dihydroxyvitamin D.	1,25-dihydroxyvitamin D	92-115	crystallin gamma F, pseudogene	Homo sapiens	41-50
12127065-0	2002	Protein synthesis is required for optimal induction of 25-hydroxyvitamin D(3)-24-hydroxylase, osteocalcin, and osteopontin mRNA by 1,25-dihydroxyvitamin D(3).	1,25-dihydroxyvitamin D	131-154	cytochrome P450, family 24, subfamily a, polypeptide 1	Rattus norvegicus	55-92
12127065-0	2002	Protein synthesis is required for optimal induction of 25-hydroxyvitamin D(3)-24-hydroxylase, osteocalcin, and osteopontin mRNA by 1,25-dihydroxyvitamin D(3).	1,25-dihydroxyvitamin D	131-154	bone gamma-carboxyglutamate protein	Rattus norvegicus	94-105
12127065-0	2002	Protein synthesis is required for optimal induction of 25-hydroxyvitamin D(3)-24-hydroxylase, osteocalcin, and osteopontin mRNA by 1,25-dihydroxyvitamin D(3).	1,25-dihydroxyvitamin D	131-154	secreted phosphoprotein 1	Rattus norvegicus	111-122
12127065-1	2002	The regulation of the 25-hydroxyvitamin D(3)-24-hydroxylase gene by 1,25-dihydroxyvitamin D(3) (1,25(OH)(2)D(3)) has been extensively studied.	1,25-dihydroxyvitamin D	68-91	cytochrome P450, family 24, subfamily a, polypeptide 1	Rattus norvegicus	22-59
12130576-2	2002	SB203580, an inhibitor of p38 MAPK, blocked osteoclast formation induced by 1alpha,25-dihydroxyvitamin D(3) and prostaglandin E(2) in cocultures of mouse osteoblasts and bone marrow cells.	1,25-dihydroxyvitamin D	76-104	mitogen-activated protein kinase 14	Mus musculus	26-34
12070083-3	2002	The vitamin D(3) receptor (VDR), whose ligand 1,25-dihydroxyvitamin D(3) is the biologically active form of vitamin D(3), has been implicated in control of differentiation, cell cycle and apoptosis of mammary cells in culture, but little is known about the physiological relevance of the vitamin D(3) endocrine system in the developing gland.	1,25-dihydroxyvitamin D	46-69	vitamin D (1,25-dihydroxyvitamin D3) receptor	Mus musculus	4-25
12070083-3	2002	The vitamin D(3) receptor (VDR), whose ligand 1,25-dihydroxyvitamin D(3) is the biologically active form of vitamin D(3), has been implicated in control of differentiation, cell cycle and apoptosis of mammary cells in culture, but little is known about the physiological relevance of the vitamin D(3) endocrine system in the developing gland.	1,25-dihydroxyvitamin D	46-69	vitamin D (1,25-dihydroxyvitamin D3) receptor	Mus musculus	27-30
12198242-1	2002	Parathyroid hormone (PTH) or activators of protein kinase A (PKA) up-regulate the vitamin D receptor (VDR) and augment the induction by 1,25-dihydroxyvitamin D(3) of the expression of target genes (24-hydroxylase and osteopontin) in osteoblastic cells.	1,25-dihydroxyvitamin D	136-159	parathyroid hormone	Rattus norvegicus	21-24
12198242-1	2002	Parathyroid hormone (PTH) or activators of protein kinase A (PKA) up-regulate the vitamin D receptor (VDR) and augment the induction by 1,25-dihydroxyvitamin D(3) of the expression of target genes (24-hydroxylase and osteopontin) in osteoblastic cells.	1,25-dihydroxyvitamin D	136-159	protein kinase cAMP-activated catalytic subunit alpha	Rattus norvegicus	43-59
12198242-1	2002	Parathyroid hormone (PTH) or activators of protein kinase A (PKA) up-regulate the vitamin D receptor (VDR) and augment the induction by 1,25-dihydroxyvitamin D(3) of the expression of target genes (24-hydroxylase and osteopontin) in osteoblastic cells.	1,25-dihydroxyvitamin D	136-159	protein kinase cAMP-activated catalytic subunit alpha	Rattus norvegicus	61-64
12198242-1	2002	Parathyroid hormone (PTH) or activators of protein kinase A (PKA) up-regulate the vitamin D receptor (VDR) and augment the induction by 1,25-dihydroxyvitamin D(3) of the expression of target genes (24-hydroxylase and osteopontin) in osteoblastic cells.	1,25-dihydroxyvitamin D	136-159	secreted phosphoprotein 1	Rattus norvegicus	217-228
12107506-1	2002	1,25-Dihydroxyvitamin D(3) through its receptor (vitamin D receptor; VDR) has important physiological effects such as calcium transport and cell growth and differentiation.	1,25-dihydroxyvitamin D	0-23	vitamin D receptor	Rattus norvegicus	49-67
11893738-2	2002	The bone-specific activation and 1,25-dihydroxyvitamin D(3) enhancement of osteocalcin (OC) gene transcription are both functionally linked to modifications in nucleosomal organization.	1,25-dihydroxyvitamin D	33-56	bone gamma-carboxyglutamate protein	Rattus norvegicus	75-86
11893738-2	2002	The bone-specific activation and 1,25-dihydroxyvitamin D(3) enhancement of osteocalcin (OC) gene transcription are both functionally linked to modifications in nucleosomal organization.	1,25-dihydroxyvitamin D	33-56	bone gamma-carboxyglutamate protein	Rattus norvegicus	88-90
12107506-1	2002	1,25-Dihydroxyvitamin D(3) through its receptor (vitamin D receptor; VDR) has important physiological effects such as calcium transport and cell growth and differentiation.	1,25-dihydroxyvitamin D	0-23	vitamin D receptor	Rattus norvegicus	69-72
11978632-4	2002	Thus, a short treatment of adult NOD mice with an analog of 1,25-dihydroxyvitamin D(3) inhibits IL-12 production, blocks pancreatic infiltration of Th1 cells, enhances CD4(+)CD25(+) regulatory cells, and arrests the progression of type 1 diabetes, suggesting its possible application in the treatment of human autoimmune diabetes.	1,25-dihydroxyvitamin D	60-83	CD4 antigen	Mus musculus	168-171
12137801-0	2002	Sensitivity to growth suppression by 1alpha,25-dihydroxyvitamin D(3) among MCF-7 clones correlates with Vitamin D receptor protein induction.	1,25-dihydroxyvitamin D	37-65	vitamin D receptor	Homo sapiens	104-122
12111243-1	2002	The renal sodium-sulfate cotransporter, NaS(i)-1, a protein implicated to control serum sulfate levels, has been shown to be regulated in vivo by 1,25-dihydroxyvitamin D(3) (1,25-(OH)(2)D(3)) and tri-iodothyronine (T(3)).	1,25-dihydroxyvitamin D	146-169	solute carrier family 13 (sodium/sulfate symporters), member 1	Mus musculus	40-48
12054486-1	2002	The synthesis of 1,25-dihydroxyvitamin D(3) (1,25-(OH)(2)D(3)) is most strongly regulated by dietary calcium and the action of parathyroid hormone to increase 1alpha-hydroxylase (1alpha-OHase) and decrease 24-hydroxylase (24-OHase) in kidney proximal tubules.	1,25-dihydroxyvitamin D	17-40	cytochrome P450, family 24, subfamily a, polypeptide 1	Rattus norvegicus	222-230
12002390-7	2002	A stepwise regression analysis adjusting for observation time, serum concentration of calcium and 1,25-Dihydroxyvitamin D, urinary excretion of calcium, and urinary calcium crystals showed that sCa2+, together with angiotensin-converting enzyme activity in serum, was the most contributory variable to decrease in renal function in sarcoidosis patients (R2 = 0.391, p < 0.0001).	1,25-dihydroxyvitamin D	98-121	ataxin 2	Homo sapiens	194-198
11834737-2	2002	Two major VDRE-containing and thus 1,25-dihydroxyvitamin D(3) (1,25-(OH)(2)D(3))-regulated genes are the two non-collagenous, osteoblast-derived bone matrix proteins osteocalcin and osteopontin.	1,25-dihydroxyvitamin D	35-58	bone gamma-carboxyglutamate protein	Rattus norvegicus	166-177
11834737-2	2002	Two major VDRE-containing and thus 1,25-dihydroxyvitamin D(3) (1,25-(OH)(2)D(3))-regulated genes are the two non-collagenous, osteoblast-derived bone matrix proteins osteocalcin and osteopontin.	1,25-dihydroxyvitamin D	35-58	secreted phosphoprotein 1	Rattus norvegicus	182-193
11913978-0	2002	Regulation of calbindin-D9k expression by 1,25-dihydroxyvitamin D(3) and parathyroid hormone in mouse primary renal tubular cells.	1,25-dihydroxyvitamin D	42-65	S100 calcium binding protein G	Mus musculus	14-27
11956247-1	2002	The vitamin D receptor (VDR) is a transcription factor that mediates the actions of its ligand, 1,25-dihydroxyvitamin D(3) [1,25(OH)(2)D(3)], which can promote monocyte/macrophage differentiation and inhibit proliferation and cytokine production by activated T lymphocytes.	1,25-dihydroxyvitamin D	96-119	vitamin D (1,25-dihydroxyvitamin D3) receptor	Mus musculus	4-22
11956247-1	2002	The vitamin D receptor (VDR) is a transcription factor that mediates the actions of its ligand, 1,25-dihydroxyvitamin D(3) [1,25(OH)(2)D(3)], which can promote monocyte/macrophage differentiation and inhibit proliferation and cytokine production by activated T lymphocytes.	1,25-dihydroxyvitamin D	96-119	vitamin D (1,25-dihydroxyvitamin D3) receptor	Mus musculus	24-27
11920955-1	2002	BACKGROUND: 1,25-dihydroxyvitamin D, the active form of vitamin D, exerts antiproliferative effect on prostatic cells, mediated through the vitamin D receptor.	1,25-dihydroxyvitamin D	12-35	vitamin D receptor	Homo sapiens	140-158
11890700-1	2002	1,25-Dihydroxyvitamin D(3) [1,25(OH)(2) D(3)] exerts its biological effects by binding to the vitamin D receptor (VDR), which binds in turn to the vitamin D response elements located in the target gene"s promoter.	1,25-dihydroxyvitamin D	0-23	vitamin D receptor	Homo sapiens	94-112
11890700-1	2002	1,25-Dihydroxyvitamin D(3) [1,25(OH)(2) D(3)] exerts its biological effects by binding to the vitamin D receptor (VDR), which binds in turn to the vitamin D response elements located in the target gene"s promoter.	1,25-dihydroxyvitamin D	0-23	vitamin D receptor	Homo sapiens	114-117
11980618-0	2002	Diurnal rhythm of plasma 1,25-dihydroxyvitamin D and vitamin D-binding protein in postmenopausal women: relationship to plasma parathyroid hormone and calcium and phosphate metabolism.	1,25-dihydroxyvitamin D	25-48	parathyroid hormone	Homo sapiens	127-146
11909970-0	2002	Stat1-vitamin D receptor interactions antagonize 1,25-dihydroxyvitamin D transcriptional activity and enhance stat1-mediated transcription.	1,25-dihydroxyvitamin D	49-72	signal transducer and activator of transcription 1	Homo sapiens	0-5
11909970-0	2002	Stat1-vitamin D receptor interactions antagonize 1,25-dihydroxyvitamin D transcriptional activity and enhance stat1-mediated transcription.	1,25-dihydroxyvitamin D	49-72	vitamin D receptor	Homo sapiens	6-24
11779200-4	2002	Whereas ZK 156718 at the concentration [10(-8) M] was as potent as 10(-6) M 1,25-dihydroxyvitamin D(3) in inducing differentiation and p21(Waf1/Cip1) expression, it was even more effective in inhibiting cell growth and stimulating p27(Kip1) expression than 1,25-dihydroxyvitamin D(3) itself.	1,25-dihydroxyvitamin D	76-99	cyclin dependent kinase inhibitor 1A	Homo sapiens	135-138
11796525-0	2002	Mediation of unusually high concentrations of 1,25-dihydroxyvitamin D in homozygous klotho mutant mice by increased expression of renal 1alpha-hydroxylase gene.	1,25-dihydroxyvitamin D	46-69	klotho	Mus musculus	84-90
11857931-3	2002	Hereditary 1,25-dihydroxyvitamin D resistant rickets (HVDRR) known as vitamin D dependent rickets type II is a rare autosomal recessive disease that arises as a result of mutations in the gene encoding the VDR.	1,25-dihydroxyvitamin D	11-34	vitamin D receptor	Homo sapiens	55-58
11706027-8	2002	1,25-dihydroxyvitamin D(3) and transforming growth factor-beta (TGFbeta), potent inducers of the 5-LO pathway in myeloid cell lines, increased 5-LO RNA expression in HL-60TB and U937 cells, but co-treatment with AdC was required to achieve 5-LO expression levels in HL-60TB cells that were comparable with wild-type HL-60 cells.	1,25-dihydroxyvitamin D	0-23	arachidonate 5-lipoxygenase	Homo sapiens	97-101
11706027-8	2002	1,25-dihydroxyvitamin D(3) and transforming growth factor-beta (TGFbeta), potent inducers of the 5-LO pathway in myeloid cell lines, increased 5-LO RNA expression in HL-60TB and U937 cells, but co-treatment with AdC was required to achieve 5-LO expression levels in HL-60TB cells that were comparable with wild-type HL-60 cells.	1,25-dihydroxyvitamin D	0-23	arachidonate 5-lipoxygenase	Homo sapiens	143-147
11706027-8	2002	1,25-dihydroxyvitamin D(3) and transforming growth factor-beta (TGFbeta), potent inducers of the 5-LO pathway in myeloid cell lines, increased 5-LO RNA expression in HL-60TB and U937 cells, but co-treatment with AdC was required to achieve 5-LO expression levels in HL-60TB cells that were comparable with wild-type HL-60 cells.	1,25-dihydroxyvitamin D	0-23	arachidonate 5-lipoxygenase	Homo sapiens	143-147
11801653-3	2002	It has been established that the fat-soluble vitamin D(3) metabolite 1,25-dihydroxyvitamin D(3) (1,25(OH)(2)D(3)) and its nuclear receptor, the vitamin D receptor, play an important role in the immune system primarily through the transcriptional inhibition of cytokine genes that either are required for Th1 differentiation or are products of differentiated Th1 cells.	1,25-dihydroxyvitamin D	69-92	vitamin D (1,25-dihydroxyvitamin D3) receptor	Mus musculus	144-162
11801653-3	2002	It has been established that the fat-soluble vitamin D(3) metabolite 1,25-dihydroxyvitamin D(3) (1,25(OH)(2)D(3)) and its nuclear receptor, the vitamin D receptor, play an important role in the immune system primarily through the transcriptional inhibition of cytokine genes that either are required for Th1 differentiation or are products of differentiated Th1 cells.	1,25-dihydroxyvitamin D	69-92	negative elongation factor complex member C/D, Th1l	Mus musculus	304-307
11801653-3	2002	It has been established that the fat-soluble vitamin D(3) metabolite 1,25-dihydroxyvitamin D(3) (1,25(OH)(2)D(3)) and its nuclear receptor, the vitamin D receptor, play an important role in the immune system primarily through the transcriptional inhibition of cytokine genes that either are required for Th1 differentiation or are products of differentiated Th1 cells.	1,25-dihydroxyvitamin D	69-92	negative elongation factor complex member C/D, Th1l	Mus musculus	358-361
12055341-2	2002	Bioactivation occurs through the sequential actions of cytochromes P450C25 and P450C1, resulting in synthesis of the pleiotropic hormone 1,25-dihydroxyvitamin D (1,25VD), which regulates over 60 genes whose actions include those associated with calcium homeostasis and immune responses as well as cellular growth, differentiation, and apoptosis.	1,25-dihydroxyvitamin D	137-160	cytochrome P450 family 27 subfamily B member 1	Homo sapiens	79-85
11779200-4	2002	Whereas ZK 156718 at the concentration [10(-8) M] was as potent as 10(-6) M 1,25-dihydroxyvitamin D(3) in inducing differentiation and p21(Waf1/Cip1) expression, it was even more effective in inhibiting cell growth and stimulating p27(Kip1) expression than 1,25-dihydroxyvitamin D(3) itself.	1,25-dihydroxyvitamin D	76-99	cyclin dependent kinase inhibitor 1A	Homo sapiens	139-143
11751606-6	2002	Human (h) PTH-(7-84) (300 nM) reduced basal 72-h release of preincorporated (45)Ca from neonatal mouse calvariae by 50% (9.6 +/- 1.9% vs. 17.8 +/- 5.7%; P < 0.001) and similarly inhibited resorption induced by hPTH-(1-84), hPTH-(1-34), 1,25-dihydroxyvitamin D(3) (VitD), PGE(2), or IL-11.	1,25-dihydroxyvitamin D	239-262	parathyroid hormone	Homo sapiens	10-13
11801529-0	2002	Expression of toll-like receptors 2 and 4 and CD14 during differentiation of HL-60 cells induced by phorbol 12-myristate 13-acetate and 1 alpha, 25-dihydroxy-vitamin D(3).	1,25-dihydroxyvitamin D	136-167	toll like receptor 2	Homo sapiens	14-41
11801529-0	2002	Expression of toll-like receptors 2 and 4 and CD14 during differentiation of HL-60 cells induced by phorbol 12-myristate 13-acetate and 1 alpha, 25-dihydroxy-vitamin D(3).	1,25-dihydroxyvitamin D	136-167	CD14 molecule	Homo sapiens	46-50
12386267-2	2002	BACKGROUND: 1,25-Dihydroxy-22-oxavitamin D(3) (22-oxacalcitriol, OCT) is an analogue of 1,25-dihydroxyvitamin D(3) (1,25(OH)(2)D(3), calcitriol) with less calcaemic activity, thus more suitable than 1,25(OH)(2)D(3) for the control of parathyroid hormone (PTH) secretion in chronic dialysis patients.	1,25-dihydroxyvitamin D	88-111	plexin A2	Homo sapiens	65-68
11851870-1	2002	The active vitamin D metabolite, 1,25-dihydroxyvitamin D, acting through the vitamin D receptor, regulates the expression of genes in a variety of vitamin D-responsive tissues, including the epidermis.	1,25-dihydroxyvitamin D	33-56	vitamin D (1,25-dihydroxyvitamin D3) receptor	Mus musculus	77-95
12386267-2	2002	BACKGROUND: 1,25-Dihydroxy-22-oxavitamin D(3) (22-oxacalcitriol, OCT) is an analogue of 1,25-dihydroxyvitamin D(3) (1,25(OH)(2)D(3), calcitriol) with less calcaemic activity, thus more suitable than 1,25(OH)(2)D(3) for the control of parathyroid hormone (PTH) secretion in chronic dialysis patients.	1,25-dihydroxyvitamin D	88-111	parathyroid hormone	Homo sapiens	234-253
12386262-2	2002	In addition to classic stimuli for parathyroid hormone (PTH) such as decreased concentrations of ionized calcium and 1,25-dihydroxyvitamin D(3) (1,25(OH)(2)D(3), calcitriol), several mechanisms have been suggested.	1,25-dihydroxyvitamin D	117-140	parathyroid hormone	Homo sapiens	35-54
12386267-2	2002	BACKGROUND: 1,25-Dihydroxy-22-oxavitamin D(3) (22-oxacalcitriol, OCT) is an analogue of 1,25-dihydroxyvitamin D(3) (1,25(OH)(2)D(3), calcitriol) with less calcaemic activity, thus more suitable than 1,25(OH)(2)D(3) for the control of parathyroid hormone (PTH) secretion in chronic dialysis patients.	1,25-dihydroxyvitamin D	88-111	parathyroid hormone	Homo sapiens	255-258
12386262-2	2002	In addition to classic stimuli for parathyroid hormone (PTH) such as decreased concentrations of ionized calcium and 1,25-dihydroxyvitamin D(3) (1,25(OH)(2)D(3), calcitriol), several mechanisms have been suggested.	1,25-dihydroxyvitamin D	117-140	parathyroid hormone	Homo sapiens	56-59
12386263-2	2002	Vitamin D levels decline in the early phase of renal failure, however, through a compensatory mechanism parathyroid hormone (PTH) stimulates the production of 1,25-dihydroxyvitamin D(3) (1,25(OH)(2)D(3), calcitriol) to return it to normal circulating concentrations.	1,25-dihydroxyvitamin D	159-182	parathyroid hormone	Homo sapiens	125-128
12386268-0	2002	A comparison between 1,25-dihydroxy-22-oxavitamin D(3) and 1,25-dihydroxyvitamin D(3) regarding suppression of parathyroid hormone secretion and calcaemic action.	1,25-dihydroxyvitamin D	59-82	parathyroid hormone	Rattus norvegicus	111-130
12386270-1	2002	1,25-Dihydroxy-22-oxavitamin D(3) (22-oxacalcitriol, OCT), is a new synthetic analogue of 1,25-dihydroxyvitamin D(3) (1,25(OH)(2)D(3), calcitriol), to be used in the treatment of secondary hyperparathyroidism.	1,25-dihydroxyvitamin D	90-113	plexin A2	Homo sapiens	53-56
11711287-1	2001	1Alpha,25-dihydroxyvitamin D(3), an endogenous ligand with the highest affinity for the vitamin D receptor (VDR), was labeled with 11C for use in biological experiments.	1,25-dihydroxyvitamin D	0-28	vitamin D receptor	Homo sapiens	88-106
11741335-2	2001	Vitamin D-responsive elements (VDRE) were detected in the promoter sequence of human ECaC1 and regulation of ECaC by the steroid hormone 1,25-dihydroxyvitamin D(3) (1,25-(OH)(2)D(3)) has been postulated.	1,25-dihydroxyvitamin D	137-160	transient receptor potential cation channel subfamily V member 5	Homo sapiens	85-90
11711287-1	2001	1Alpha,25-dihydroxyvitamin D(3), an endogenous ligand with the highest affinity for the vitamin D receptor (VDR), was labeled with 11C for use in biological experiments.	1,25-dihydroxyvitamin D	0-28	vitamin D receptor	Homo sapiens	108-111
11751517-0	2001	Combination of 1alpha,25-dihydroxyvitamin D(3) with dexamethasone enhances cell cycle arrest and apoptosis: role of nuclear receptor cross-talk and Erk/Akt signaling.	1,25-dihydroxyvitamin D	15-43	thymoma viral proto-oncogene 1	Mus musculus	152-155
11751517-0	2001	Combination of 1alpha,25-dihydroxyvitamin D(3) with dexamethasone enhances cell cycle arrest and apoptosis: role of nuclear receptor cross-talk and Erk/Akt signaling.	1,25-dihydroxyvitamin D	15-43	mitogen-activated protein kinase 1	Mus musculus	148-151
11721090-7	2001	Recently discovered 64.5 kDa protein from chick epithelium, which specifically binds 1,25-dihydroxyvitamin D(3) and is responsible for some rapid cellular actions of 1,25-dihydroxyvitamin D(3) is a candidate for mVDR.	1,25-dihydroxyvitamin D	85-108	vitamin D (1,25-dihydroxyvitamin D3) receptor	Mus musculus	212-216
11704292-4	2001	Our prior work had shown that the differentiation inducer 1alpha,25-dihydroxyvitamin D(3) could drive the differentiation of CD34(+) cells isolated from HNSCC patients into dendritic cells.	1,25-dihydroxyvitamin D	58-86	CD34 molecule	Homo sapiens	125-129
11525796-0	2001	Rag-1-dependent cells are necessary for 1,25-dihydroxyvitamin D(3) prevention of experimental autoimmune encephalomyelitis.	1,25-dihydroxyvitamin D	40-63	recombination activating 1	Mus musculus	0-5
11577149-3	2001	The results in this paper show that the mechanism of stimulation by porins of THP-1 cells enriched in CD14 receptor after treatment with 1,25-dihydroxyvitamin D(3) (vitamin D(3)) is independent of this receptor, but is partially dependent on CD11a/18 integrins.	1,25-dihydroxyvitamin D	137-160	CD14 molecule	Homo sapiens	102-106
11710940-0	2001	Inhibition of 1,25-dihydroxyvitamin-D-induced keratinocyte differentiation by blocking the expression of phospholipase C-gamma1.	1,25-dihydroxyvitamin D	14-37	phospholipase C gamma 1	Homo sapiens	105-127
11455592-0	2001	Model of three-dimensional structure of vitamin D receptor and its binding mechanism with 1alpha,25-dihydroxyvitamin D(3).	1,25-dihydroxyvitamin D	90-118	vitamin D receptor	Homo sapiens	40-58
11557366-0	2001	Parathyroid hormone-stimulated resorption in calvaria cultured in serum-free medium is enhanced by the calcium-mobilizing activity of 1,25-dihydroxyvitamin D(3).	1,25-dihydroxyvitamin D	134-157	parathyroid hormone	Rattus norvegicus	0-19
11500311-8	2001	These data demonstrate that renal CaBP-D9k, but not CaBP-D28k, is highly regulated by the VDR-mediated action of 1,25-dihydroxyvitamin D(3).	1,25-dihydroxyvitamin D	113-136	S100 calcium binding protein G	Mus musculus	34-42
11500311-8	2001	These data demonstrate that renal CaBP-D9k, but not CaBP-D28k, is highly regulated by the VDR-mediated action of 1,25-dihydroxyvitamin D(3).	1,25-dihydroxyvitamin D	113-136	vitamin D (1,25-dihydroxyvitamin D3) receptor	Mus musculus	90-93
11591891-11	2001	Selective expression of RIZ1 was also induced by 12-O-tetradecanoyl-phorbol-13-acetate in the U937 and HL60 cell lines and by 1,25-dihydroxyvitamin D(3) only in HL60 cells.	1,25-dihydroxyvitamin D	126-149	PR/SET domain 2	Homo sapiens	24-28
11478855-3	2001	Further, in HL60 cells induced to differentiate with 1,25-dihydroxyvitamin D(3) raf-1 and p90RSK, but not ERK1/2, are coregulated, and their expression as well as monocytic differentiation is inhibited in parallel by PD 098059.	1,25-dihydroxyvitamin D	53-76	Raf-1 proto-oncogene, serine/threonine kinase	Homo sapiens	80-85
11478855-3	2001	Further, in HL60 cells induced to differentiate with 1,25-dihydroxyvitamin D(3) raf-1 and p90RSK, but not ERK1/2, are coregulated, and their expression as well as monocytic differentiation is inhibited in parallel by PD 098059.	1,25-dihydroxyvitamin D	53-76	ribosomal protein S6 kinase A1	Homo sapiens	90-96
11591891-15	2001	CONCLUSIONS: The correlation between the selective expression of RIZ1 induced by retinoic acid, 12-O-tetradecanoyl-phorbol-13-acetate, or 1,25-dihydroxyvitamin D(3) and differentiation suggested that RIZ protein was involved in myeloid cell differentiation induced by these agents.	1,25-dihydroxyvitamin D	138-161	PR/SET domain 2	Homo sapiens	65-69
11591891-15	2001	CONCLUSIONS: The correlation between the selective expression of RIZ1 induced by retinoic acid, 12-O-tetradecanoyl-phorbol-13-acetate, or 1,25-dihydroxyvitamin D(3) and differentiation suggested that RIZ protein was involved in myeloid cell differentiation induced by these agents.	1,25-dihydroxyvitamin D	138-161	PR/SET domain 2	Homo sapiens	65-68
11410870-0	2001	Sensitization to TNF-induced apoptosis by 1,25-dihydroxy vitamin D(3) involves up-regulation of the TNF receptor 1 and cathepsin B.	1,25-dihydroxyvitamin D	42-66	tumor necrosis factor	Homo sapiens	17-20
11410870-0	2001	Sensitization to TNF-induced apoptosis by 1,25-dihydroxy vitamin D(3) involves up-regulation of the TNF receptor 1 and cathepsin B.	1,25-dihydroxyvitamin D	42-66	tumor necrosis factor	Homo sapiens	100-103
11410870-0	2001	Sensitization to TNF-induced apoptosis by 1,25-dihydroxy vitamin D(3) involves up-regulation of the TNF receptor 1 and cathepsin B.	1,25-dihydroxyvitamin D	42-66	cathepsin B	Homo sapiens	119-130
11472889-4	2001	Pooling the results from knee and hip hOB cell cultures, we found that secreted osteocalcin was higher in hOB cells from the younger donors, compared with that in older donors, and peaked after stimulation with 10(-6)--10(-8) mol/L 1,25-dihydroxyvitamin D(3) [1,25(OH)(2)D(3)].	1,25-dihydroxyvitamin D	232-255	bone gamma-carboxyglutamate protein	Homo sapiens	80-91
11382925-4	2001	Furthermore, we show that AP-1 binding activity, mainly composed of Fra-2 and JunD, is induced by treatment of bone marrow cultures with the osteoclastogenic hormone 1,25 dihydroxyvitamin D(3).	1,25-dihydroxyvitamin D	166-189	JunD proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	26-30
11382925-4	2001	Furthermore, we show that AP-1 binding activity, mainly composed of Fra-2 and JunD, is induced by treatment of bone marrow cultures with the osteoclastogenic hormone 1,25 dihydroxyvitamin D(3).	1,25-dihydroxyvitamin D	166-189	FOS like 2, AP-1 transcription factor subunit	Homo sapiens	68-73
11382925-4	2001	Furthermore, we show that AP-1 binding activity, mainly composed of Fra-2 and JunD, is induced by treatment of bone marrow cultures with the osteoclastogenic hormone 1,25 dihydroxyvitamin D(3).	1,25-dihydroxyvitamin D	166-189	JunD proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	78-82
11416220-1	2001	The active form of vitamin D, 1alpha,25-dihydroxyvitamin D [1alpha,25(OH)2D], is synthesized from its precursor 25 hydroxyvitamin D [25(OH)D] via the catalytic action of the 25(OH)D-1alpha-hydroxylase [1alpha(OH)ase] enzyme.	1,25-dihydroxyvitamin D	30-58	cytochrome P450, family 27, subfamily b, polypeptide 1	Mus musculus	174-200
11416220-1	2001	The active form of vitamin D, 1alpha,25-dihydroxyvitamin D [1alpha,25(OH)2D], is synthesized from its precursor 25 hydroxyvitamin D [25(OH)D] via the catalytic action of the 25(OH)D-1alpha-hydroxylase [1alpha(OH)ase] enzyme.	1,25-dihydroxyvitamin D	30-58	cytochrome P450, family 27, subfamily b, polypeptide 1	Mus musculus	202-215
11376130-1	2001	AIMS: The human ccn1 (hccn; hcyr61) gene has been identified previously at the mRNA and protein level as a 1,25-dihydroxyvitamin D(3) and growth factor regulated gene in human osteoblasts.	1,25-dihydroxyvitamin D	107-130	cellular communication network factor 1	Homo sapiens	16-20
11432806-2	2001	The functions of 1,25-dihydroxyvitamin D(3) are mediated through the vitamin D(3) receptor (VDR); therefore, an understanding of the regulation of VDR expression is important when considering the molecular mechanisms of differentiation induced by vitamin D(3) and its analogues.	1,25-dihydroxyvitamin D	17-40	vitamin D receptor	Homo sapiens	69-90
11432806-2	2001	The functions of 1,25-dihydroxyvitamin D(3) are mediated through the vitamin D(3) receptor (VDR); therefore, an understanding of the regulation of VDR expression is important when considering the molecular mechanisms of differentiation induced by vitamin D(3) and its analogues.	1,25-dihydroxyvitamin D	17-40	vitamin D receptor	Homo sapiens	92-95
11432806-2	2001	The functions of 1,25-dihydroxyvitamin D(3) are mediated through the vitamin D(3) receptor (VDR); therefore, an understanding of the regulation of VDR expression is important when considering the molecular mechanisms of differentiation induced by vitamin D(3) and its analogues.	1,25-dihydroxyvitamin D	17-40	vitamin D receptor	Homo sapiens	147-150
11386849-1	2001	Mutations in the vitamin D receptor (VDR) cause hereditary vitamin D-resistant rickets (HVDRR), an autosomal recessive disease resulting in target organ resistance to 1,25-dihydroxyvitamin D(3) [1,25(OH)(2)D(3)].	1,25-dihydroxyvitamin D	167-190	vitamin D receptor	Homo sapiens	17-35
11386849-1	2001	Mutations in the vitamin D receptor (VDR) cause hereditary vitamin D-resistant rickets (HVDRR), an autosomal recessive disease resulting in target organ resistance to 1,25-dihydroxyvitamin D(3) [1,25(OH)(2)D(3)].	1,25-dihydroxyvitamin D	167-190	vitamin D receptor	Homo sapiens	37-40
11389974-4	2001	We found that I-mfa is expressed at a low level in an osteoblast-like cell line, MC3T3E1, and a pluripotent differentiation modulator, 1,25-dihydroxyvitamin D(3), specifically enhanced I-mfa mRNA expression.	1,25-dihydroxyvitamin D	135-158	MyoD family inhibitor	Mus musculus	14-19
11389974-4	2001	We found that I-mfa is expressed at a low level in an osteoblast-like cell line, MC3T3E1, and a pluripotent differentiation modulator, 1,25-dihydroxyvitamin D(3), specifically enhanced I-mfa mRNA expression.	1,25-dihydroxyvitamin D	135-158	MyoD family inhibitor	Mus musculus	185-190
11389974-7	2001	I-mfa expression was also observed in primary mouse calvaria cells and ROS17/2.8 cells and 1,25-dihydroxyvitamin D(3) enhanced I-mfa expression in these cells.	1,25-dihydroxyvitamin D	91-114	MyoD family inhibitor	Mus musculus	127-132
11389974-8	2001	These data indicate that I-mfa is a novel transcriptional regulator gene expressed in osteoblasts and that its level is under the control of 1,25-dihydroxyvitamin D(3).	1,25-dihydroxyvitamin D	141-164	MyoD family inhibitor	Mus musculus	25-30
11316765-9	2001	Up-regulation of these binding proteins has been observed in association with actions of 1,25-dihydroxyvitamin D(3) in prostate cancer cells, and the data suggest a role for IGFBP-3 and IGFBP-6 in the suppression of prostate tumor cell growth.	1,25-dihydroxyvitamin D	89-112	insulin-like growth factor binding protein 3	Mus musculus	174-181
11316765-9	2001	Up-regulation of these binding proteins has been observed in association with actions of 1,25-dihydroxyvitamin D(3) in prostate cancer cells, and the data suggest a role for IGFBP-3 and IGFBP-6 in the suppression of prostate tumor cell growth.	1,25-dihydroxyvitamin D	89-112	insulin-like growth factor binding protein 6	Mus musculus	186-193
11275949-1	2001	OBJECTIVE: A novel assay was employed to study the free 1,25-dihydroxyvitamin D (1,25(OH)2D) concentrations in various populations with different levels of 1,25(OH)2D and vitamin D binding protein (DBP).	1,25-dihydroxyvitamin D	56-79	D-box binding PAR bZIP transcription factor	Homo sapiens	198-201
11400164-1	2001	Monocytic differentiation of HL60 cells induced by 1,25-dihydroxyvitamin D(3) (1,25 D(3)) has been recently shown (Exp Cell Res 258, 425, 2000) to be enhanced by an exposure to SB203580 or to SB202190, specific inhibitors of p38MAP kinase, with concomitant up-regulation of the c-jun N terminal kinase (JNK) pathway.	1,25-dihydroxyvitamin D	51-74	mitogen-activated protein kinase 14	Homo sapiens	225-238
11400164-1	2001	Monocytic differentiation of HL60 cells induced by 1,25-dihydroxyvitamin D(3) (1,25 D(3)) has been recently shown (Exp Cell Res 258, 425, 2000) to be enhanced by an exposure to SB203580 or to SB202190, specific inhibitors of p38MAP kinase, with concomitant up-regulation of the c-jun N terminal kinase (JNK) pathway.	1,25-dihydroxyvitamin D	51-74	mitogen-activated protein kinase 8	Homo sapiens	278-301
11400164-1	2001	Monocytic differentiation of HL60 cells induced by 1,25-dihydroxyvitamin D(3) (1,25 D(3)) has been recently shown (Exp Cell Res 258, 425, 2000) to be enhanced by an exposure to SB203580 or to SB202190, specific inhibitors of p38MAP kinase, with concomitant up-regulation of the c-jun N terminal kinase (JNK) pathway.	1,25-dihydroxyvitamin D	51-74	mitogen-activated protein kinase 8	Homo sapiens	303-306
11250921-4	2001	In the bone marrow stromal cell line ST2 and preosteoblastic cell line MC3T3-E1, all three RANKL isoforms were detected, but the expression of RANKL 2 was preferentially suppressed by treatment with 1alpha,25-dihydroxyvitamin D(3) and dexamethasone.	1,25-dihydroxyvitamin D	199-227	tumor necrosis factor (ligand) superfamily, member 11	Mus musculus	91-96
11250921-4	2001	In the bone marrow stromal cell line ST2 and preosteoblastic cell line MC3T3-E1, all three RANKL isoforms were detected, but the expression of RANKL 2 was preferentially suppressed by treatment with 1alpha,25-dihydroxyvitamin D(3) and dexamethasone.	1,25-dihydroxyvitamin D	199-227	tumor necrosis factor (ligand) superfamily, member 11	Mus musculus	143-148
11344183-1	2001	In vitro studies and animal experiments suggest that the production of 1,25-dihydroxyvitamin D [1,25-(OH)(2)D] and 24,25-(OH)(2)D is reciprocally controlled by 1,25-(OH)(2)D. To investigate the role of the vitamin D receptor (VDR) in controlling vitamin D metabolism in humans, we studied 10 patients with vitamin D-dependent rickets type II due to a defective VDR.	1,25-dihydroxyvitamin D	71-94	vitamin D receptor	Homo sapiens	206-224
11344183-1	2001	In vitro studies and animal experiments suggest that the production of 1,25-dihydroxyvitamin D [1,25-(OH)(2)D] and 24,25-(OH)(2)D is reciprocally controlled by 1,25-(OH)(2)D. To investigate the role of the vitamin D receptor (VDR) in controlling vitamin D metabolism in humans, we studied 10 patients with vitamin D-dependent rickets type II due to a defective VDR.	1,25-dihydroxyvitamin D	71-94	vitamin D receptor	Homo sapiens	226-229
11344183-1	2001	In vitro studies and animal experiments suggest that the production of 1,25-dihydroxyvitamin D [1,25-(OH)(2)D] and 24,25-(OH)(2)D is reciprocally controlled by 1,25-(OH)(2)D. To investigate the role of the vitamin D receptor (VDR) in controlling vitamin D metabolism in humans, we studied 10 patients with vitamin D-dependent rickets type II due to a defective VDR.	1,25-dihydroxyvitamin D	71-94	vitamin D receptor	Homo sapiens	361-364
11158001-14	2001	Serum 1,25-dihydroxyvitamin D levels increased in response to PTH infusion before leuprolide therapy (P = 0.022), but there was no difference in the rate of increase before or after leuprolide therapy (P = 0.66).	1,25-dihydroxyvitamin D	6-29	parathyroid hormone	Homo sapiens	62-65
11257709-1	2001	PURPOSE: We determined that insulin-like growth factor binding protein 3 (IGFBP-3) induction by 1,25-dihydroxyvitamin D(3) (1,25-(OH)(2)D(3)) is a necessary component of 1,25-(OH)(2)D(3) mediated growth inhibition of the LNCaP human prostate cancer cell line.	1,25-dihydroxyvitamin D	96-119	insulin like growth factor binding protein 3	Homo sapiens	28-72
11257709-1	2001	PURPOSE: We determined that insulin-like growth factor binding protein 3 (IGFBP-3) induction by 1,25-dihydroxyvitamin D(3) (1,25-(OH)(2)D(3)) is a necessary component of 1,25-(OH)(2)D(3) mediated growth inhibition of the LNCaP human prostate cancer cell line.	1,25-dihydroxyvitamin D	96-119	insulin like growth factor binding protein 3	Homo sapiens	74-81
11231340-2	2001	To identify potential mechanisms mediating these opposing effects of dietary P on PT growth, this study first focused on p21(WAF1) (p21) because high P reduces while low P enhances serum 1,25-dihydroxyvitamin D, whose potent antiproliferative properties result from the induction of p21.	1,25-dihydroxyvitamin D	187-210	KRAS proto-oncogene, GTPase	Rattus norvegicus	132-135
11179724-1	2001	The nuclear actions of 1,25-dihydroxyvitamin D(3) [1alpha,25(OH)(2)D(3)] are mediated by the vitamin D receptor (VDR).	1,25-dihydroxyvitamin D	23-46	vitamin D receptor	Homo sapiens	93-111
11050081-3	2001	This is predominantly mediated by the nuclear receptor for 1,25-dihydroxyvitamin D(3), the vitamin D receptor (VDR).	1,25-dihydroxyvitamin D	59-82	vitamin D receptor	Homo sapiens	91-109
11050081-3	2001	This is predominantly mediated by the nuclear receptor for 1,25-dihydroxyvitamin D(3), the vitamin D receptor (VDR).	1,25-dihydroxyvitamin D	59-82	vitamin D receptor	Homo sapiens	111-114
11050081-12	2001	Thus, induction of VDR by WT1 leads to an enhanced response to 1,25-dihydroxyvitamin D(3).	1,25-dihydroxyvitamin D	63-86	vitamin D receptor	Homo sapiens	19-22
11050081-12	2001	Thus, induction of VDR by WT1 leads to an enhanced response to 1,25-dihydroxyvitamin D(3).	1,25-dihydroxyvitamin D	63-86	WT1 transcription factor	Homo sapiens	26-29
11179724-1	2001	The nuclear actions of 1,25-dihydroxyvitamin D(3) [1alpha,25(OH)(2)D(3)] are mediated by the vitamin D receptor (VDR).	1,25-dihydroxyvitamin D	23-46	vitamin D receptor	Homo sapiens	113-116
11158062-1	2001	The mitochondrial enzyme 25-hydroxyvitamin D(3)-1 alpha-hydroxylase (1 alpha-hydroxylase) plays an important role in calcium homeostasis by catalyzing synthesis of the active form of vitamin D, 1,25-dihydroxyvitamin D(3), in the kidney.	1,25-dihydroxyvitamin D	194-217	cytochrome P450 family 27 subfamily B member 1	Homo sapiens	25-67
11545681-9	2001	CaT1 mRNA expression is rapidly up regulated (4-fold increase at 4 h and 10-fold at 24 h) by treatment with 1,25-dihydroxyvitamin D (10(-7) moles/L).	1,25-dihydroxyvitamin D	108-131	transient receptor potential cation channel subfamily V member 6	Homo sapiens	0-4
11035059-9	2000	These TGF-beta effects were also observed in cultures of unfractionated bone cells, and anti-TGF-beta blocked the stimulatory effect of 1, 25-dihydroxyvitamin D(3).	1,25-dihydroxyvitamin D	136-160	transforming growth factor, beta 1	Mus musculus	6-14
11104746-0	2000	1alpha,25-dihydroxyvitamin D(3) and its potent synthetic analogs downregulate tissue factor and upregulate thrombomodulin expression in monocytic cells, counteracting the effects of tumor necrosis factor and oxidized LDL.	1,25-dihydroxyvitamin D	0-28	coagulation factor III, tissue factor	Homo sapiens	78-91
11104746-0	2000	1alpha,25-dihydroxyvitamin D(3) and its potent synthetic analogs downregulate tissue factor and upregulate thrombomodulin expression in monocytic cells, counteracting the effects of tumor necrosis factor and oxidized LDL.	1,25-dihydroxyvitamin D	0-28	thrombomodulin	Homo sapiens	107-121
11062020-0	2000	The promoter region of the human PMCA1 gene mediates transcriptional downregulation by 1,25-dihydroxyvitamin D(3).	1,25-dihydroxyvitamin D	87-110	ATPase plasma membrane Ca2+ transporting 1	Homo sapiens	33-38
11050002-6	2000	Studies on the mechanism of KS tumor growth inhibition by 1alpha,25 dihydroxyvitamin D(3) showed that production of autocrine growth factors interleukin (IL)-6 and IL-8 was reduced in a dose-dependent manner, whereas no effect was observed on vascular endothelial growth factor and basic fibroblast growth factor.	1,25-dihydroxyvitamin D	58-86	C-X-C motif chemokine ligand 8	Homo sapiens	164-168
11080724-17	2000	When 1,25-dihydroxyvitamin D(3) was combined with dexamethasone, IL-5 and IL-13 production was increased compared with dexamethasone alone (P <.001).	1,25-dihydroxyvitamin D	5-28	interleukin 5	Homo sapiens	65-69
11080724-17	2000	When 1,25-dihydroxyvitamin D(3) was combined with dexamethasone, IL-5 and IL-13 production was increased compared with dexamethasone alone (P <.001).	1,25-dihydroxyvitamin D	5-28	interleukin 13	Homo sapiens	74-79
11064245-0	2000	Epidermal change can alter mechanical properties of hairless mouse skin topically treated with 1alpha, 25-dihydroxyvitamin D(3).	1,25-dihydroxyvitamin D	95-124	lysine demethylase and nuclear receptor corepressor	Mus musculus	52-60
11074597-0	2000	Binding of 1alpha,25-dihydroxyvitamin D(3) to annexin II: effect of vitamin D metabolites and calcium.	1,25-dihydroxyvitamin D	11-39	annexin A2	Homo sapiens	46-56
11035059-9	2000	These TGF-beta effects were also observed in cultures of unfractionated bone cells, and anti-TGF-beta blocked the stimulatory effect of 1, 25-dihydroxyvitamin D(3).	1,25-dihydroxyvitamin D	136-160	transforming growth factor, beta 1	Mus musculus	93-101
10922312-2	2000	Several inflammatory cytokines involved in malnutrition, including interleukin-1, interleukin-6, and tumor necrosis factor-alpha, are modulated by 1,25-dihydroxyvitamin D(3) [1,25-(OH)(2)D(3)], of which synthesis is impaired in end-stage renal disease.	1,25-dihydroxyvitamin D	147-170	interleukin 1 alpha	Homo sapiens	67-80
11039126-3	2000	Expression of the OC gene is enhanced by 1,25-dihydroxyvitamin D (1,25(OH)2D) in experimental models.	1,25-dihydroxyvitamin D	41-64	bone gamma-carboxyglutamate protein	Homo sapiens	18-20
10996858-1	2000	We have previously shown that the steroid hormone 1, 25-dihydroxy-vitamin D(3) [1,25(OH)(2)D(3)] stimulates total cell protein kinase C (PKC) activity in rat duodenum, an effect that is severely impaired in old animals.	1,25-dihydroxyvitamin D	50-75	protein kinase C, alpha	Rattus norvegicus	137-140
11000289-0	2000	Bcl-2 transfected HaCaT keratinocytes resist apoptotic signals of ceramides, tumor necrosis factor alpha and 1 alpha, 25-dihydroxyvitamin D(3).	1,25-dihydroxyvitamin D	109-139	BCL2 apoptosis regulator	Homo sapiens	0-5
11003603-4	2000	Treatment of A375 cells with increasing concentrations of 1, 25-dihydroxyvitamin D(3) [1,25-(OH)(2)D(3)] or its low-calcemic analog EB-1089 revealed that EB-1089 was 10-fold more potent than 1, 25-(OH)(2)D(3) on inhibition of both cell proliferation and PTHrP expression.	1,25-dihydroxyvitamin D	58-82	parathyroid hormone like hormone	Homo sapiens	254-259
11071463-1	2000	We studied the serum levels of 1,25-dihydroxyvitamin D [1,25(OH)2D (Vit D)] in patients with renal cell carcinoma (RCC) and the influence of 1,25(OH)2D3 (Vit D3) on gap junctional intercellular communication (GJIC) during carcinogenesis.	1,25-dihydroxyvitamin D	31-54	vitrin	Homo sapiens	68-71
11033763-1	2000	The disorders of vitamin D metabolism are inherited metabolic abnormalities involving mutations of the vitamin D receptor or enzymes involved in the metabolism of vitamin D to its biologically active form 1,25-dihydroxyvitamin D.	1,25-dihydroxyvitamin D	205-228	vitamin D receptor	Homo sapiens	103-121
10922312-2	2000	Several inflammatory cytokines involved in malnutrition, including interleukin-1, interleukin-6, and tumor necrosis factor-alpha, are modulated by 1,25-dihydroxyvitamin D(3) [1,25-(OH)(2)D(3)], of which synthesis is impaired in end-stage renal disease.	1,25-dihydroxyvitamin D	147-170	interleukin 6	Homo sapiens	82-95
10922312-2	2000	Several inflammatory cytokines involved in malnutrition, including interleukin-1, interleukin-6, and tumor necrosis factor-alpha, are modulated by 1,25-dihydroxyvitamin D(3) [1,25-(OH)(2)D(3)], of which synthesis is impaired in end-stage renal disease.	1,25-dihydroxyvitamin D	147-170	tumor necrosis factor	Homo sapiens	101-128
10875271-1	2000	The 25-hydroxyvitamin D-24-hydroxylase enzyme (24-OHase) is responsible for the catabolic breakdown of 1,25-dihydroxyvitamin D [1,25(OH)2D], the active form of vitamin D.	1,25-dihydroxyvitamin D	103-126	cytochrome P450, family 24, subfamily a, polypeptide 1	Mus musculus	47-55
10896794-4	2000	SB 203580 and SB 202190, specific inhibitors of a signaling protein p38 MAP kinase, were found to markedly accelerate monocytic differentiation of HL60 cells induced by low concentrations of 1,25-dihydroxyvitamin D(3) (1,25D(3)).	1,25-dihydroxyvitamin D	191-214	mitogen-activated protein kinase 14	Homo sapiens	68-71
10891379-0	2000	Human leukemic (HMC-1) mast cells are responsive to 1alpha, 25-dihydroxyvitamin D(3): selective promotion of ICAM-3 expression and constitutive presence of vitamin D(3) receptor.	1,25-dihydroxyvitamin D	52-81	intercellular adhesion molecule 3	Homo sapiens	109-115
10891379-0	2000	Human leukemic (HMC-1) mast cells are responsive to 1alpha, 25-dihydroxyvitamin D(3): selective promotion of ICAM-3 expression and constitutive presence of vitamin D(3) receptor.	1,25-dihydroxyvitamin D	52-81	vitamin D receptor	Homo sapiens	156-177
10900268-9	2000	In contrast, transient overexpression of RORalpha overrides the activation of the osteocalcin promoter by 1alpha,25-dihydroxyvitamin D(3).	1,25-dihydroxyvitamin D	106-134	RAR-related orphan receptor alpha	Mus musculus	41-49
10877839-1	2000	The vitamin D receptor (VDR) is a transcription factor that transmits incoming 1,25-dihydroxyvitamin D(3) (1alpha,25(OH)(2)D(3)) signaling via combined contact with coactivator proteins and specific DNA binding sites (VDREs), which ultimately results in activation of transcription.	1,25-dihydroxyvitamin D	79-102	vitamin D receptor	Homo sapiens	4-22
10877839-1	2000	The vitamin D receptor (VDR) is a transcription factor that transmits incoming 1,25-dihydroxyvitamin D(3) (1alpha,25(OH)(2)D(3)) signaling via combined contact with coactivator proteins and specific DNA binding sites (VDREs), which ultimately results in activation of transcription.	1,25-dihydroxyvitamin D	79-102	vitamin D receptor	Homo sapiens	24-27
10873580-6	2000	Interleukin-6-inducing activities of the active glycolipids from 1,25-dihydroxy vitamin D(3)-differentiated human monocytic leukemia cells, THP-1, were inhibited by anti-CD14 mAbs in a dose-dependent manner.	1,25-dihydroxyvitamin D	65-89	interleukin 6	Homo sapiens	0-13
10912528-4	2000	In proliferative chondrocytes, growth hormone (GH) and the calciotropic hormones parathyroid hormone (PTH) and 1,25-dihydroxyvitamin D [1alpha,25(OH)2D3] increase cell proliferation via stimulation of paracrine insulin-like growth factor-I (IGF-I) secretion.	1,25-dihydroxyvitamin D	111-134	insulin like growth factor 1	Homo sapiens	211-239
10912528-4	2000	In proliferative chondrocytes, growth hormone (GH) and the calciotropic hormones parathyroid hormone (PTH) and 1,25-dihydroxyvitamin D [1alpha,25(OH)2D3] increase cell proliferation via stimulation of paracrine insulin-like growth factor-I (IGF-I) secretion.	1,25-dihydroxyvitamin D	111-134	insulin like growth factor 1	Homo sapiens	241-246
10873580-6	2000	Interleukin-6-inducing activities of the active glycolipids from 1,25-dihydroxy vitamin D(3)-differentiated human monocytic leukemia cells, THP-1, were inhibited by anti-CD14 mAbs in a dose-dependent manner.	1,25-dihydroxyvitamin D	65-89	GLI family zinc finger 2	Homo sapiens	140-145
10873580-6	2000	Interleukin-6-inducing activities of the active glycolipids from 1,25-dihydroxy vitamin D(3)-differentiated human monocytic leukemia cells, THP-1, were inhibited by anti-CD14 mAbs in a dose-dependent manner.	1,25-dihydroxyvitamin D	65-89	CD14 molecule	Homo sapiens	170-174
10775452-0	2000	In vivo upregulation of interleukin-4 is one mechanism underlying the immunoregulatory effects of 1,25-dihydroxyvitamin D(3).	1,25-dihydroxyvitamin D	98-121	interleukin 4	Mus musculus	24-37
10830290-5	2000	PGE2, PTH, or 1,25 dihydroxyvitamin D increased TRAP+ MNC in 7-day cultures of bone marrow cells from EP2 +/+ mice.	1,25-dihydroxyvitamin D	14-37	prostaglandin E receptor 2 (subtype EP2)	Mus musculus	102-105
10830290-6	2000	In cultures from EP2 -/- animals, responses to PGE2, PTH, and 1,25 dihydroxyvitamin D were reduced by 86%, 58%, and 50%, respectively.	1,25-dihydroxyvitamin D	62-85	prostaglandin E receptor 2 (subtype EP2)	Mus musculus	17-20
10825392-1	2000	The vitamin D receptor (VDR) is the nuclear receptor for 1, 25-dihydroxyvitamin D(3) [1alpha,25(OH)(2)D(3)] that acts as a ligand-dependent transcription factor via combined contact with coactivator proteins (steroid receptor coactivator-1, transcriptional intermediary factor 2, and receptor associated coactivator 3) and specific DNA binding sites [vitamin D response elements (VDREs)].	1,25-dihydroxyvitamin D	57-81	vitamin D receptor	Homo sapiens	4-22
10825392-1	2000	The vitamin D receptor (VDR) is the nuclear receptor for 1, 25-dihydroxyvitamin D(3) [1alpha,25(OH)(2)D(3)] that acts as a ligand-dependent transcription factor via combined contact with coactivator proteins (steroid receptor coactivator-1, transcriptional intermediary factor 2, and receptor associated coactivator 3) and specific DNA binding sites [vitamin D response elements (VDREs)].	1,25-dihydroxyvitamin D	57-81	vitamin D receptor	Homo sapiens	24-27
10825392-1	2000	The vitamin D receptor (VDR) is the nuclear receptor for 1, 25-dihydroxyvitamin D(3) [1alpha,25(OH)(2)D(3)] that acts as a ligand-dependent transcription factor via combined contact with coactivator proteins (steroid receptor coactivator-1, transcriptional intermediary factor 2, and receptor associated coactivator 3) and specific DNA binding sites [vitamin D response elements (VDREs)].	1,25-dihydroxyvitamin D	57-81	nuclear receptor coactivator 2	Homo sapiens	241-278
10825392-1	2000	The vitamin D receptor (VDR) is the nuclear receptor for 1, 25-dihydroxyvitamin D(3) [1alpha,25(OH)(2)D(3)] that acts as a ligand-dependent transcription factor via combined contact with coactivator proteins (steroid receptor coactivator-1, transcriptional intermediary factor 2, and receptor associated coactivator 3) and specific DNA binding sites [vitamin D response elements (VDREs)].	1,25-dihydroxyvitamin D	57-81	nuclear receptor coactivator 3	Homo sapiens	284-317
10843160-1	2000	Insulin-like growth factor I (IGF-I) stimulates renal and placental 1,25-dihydroxyvitamin D [1,25-(OH)2D] and is considered an important regulator of fetal growth.	1,25-dihydroxyvitamin D	68-91	insulin like growth factor 1	Homo sapiens	0-28
10794753-15	2000	In patients with progressive renal failure, I-PTH was related to Ca(2+) (r = -0.66; P <0.0001), CrCl (r = -0.61; P <0.001), 1,25-dihydroxyvitamin D (r = -0.40; P <0.05), and 25-hydroxyvitamin D (r = -0.49; P <0.01) by simple linear regression.	1,25-dihydroxyvitamin D	130-153	parathyroid hormone	Homo sapiens	46-49
10843160-1	2000	Insulin-like growth factor I (IGF-I) stimulates renal and placental 1,25-dihydroxyvitamin D [1,25-(OH)2D] and is considered an important regulator of fetal growth.	1,25-dihydroxyvitamin D	68-91	insulin like growth factor 1	Homo sapiens	30-35
10698704-5	2000	After vitamin-induced differentiation in vitro with retinoic acid (RA) and 1,25-dihydroxy vitamin D(3) (VD), termed RA/VD, we observed that THP1 RA/VD cells became more resistant to NO-mediated cytotoxicity whereas the susceptibility of U937 cells was not modified.	1,25-dihydroxyvitamin D	75-99	GLI family zinc finger 2	Homo sapiens	140-144
10797570-1	2000	1alpha,25-dihydroxyvitamin D(3) (1alpha,25(OH)(2)D(3)), the active metabolite of vitamin D, mediates many of its effects through the intranuclear vitamin D receptor (VDR, NR1I1), that belongs to the large superfamily of nuclear receptors.	1,25-dihydroxyvitamin D	0-28	vitamin D receptor	Homo sapiens	146-164
10797570-1	2000	1alpha,25-dihydroxyvitamin D(3) (1alpha,25(OH)(2)D(3)), the active metabolite of vitamin D, mediates many of its effects through the intranuclear vitamin D receptor (VDR, NR1I1), that belongs to the large superfamily of nuclear receptors.	1,25-dihydroxyvitamin D	0-28	vitamin D receptor	Homo sapiens	166-169
10797570-1	2000	1alpha,25-dihydroxyvitamin D(3) (1alpha,25(OH)(2)D(3)), the active metabolite of vitamin D, mediates many of its effects through the intranuclear vitamin D receptor (VDR, NR1I1), that belongs to the large superfamily of nuclear receptors.	1,25-dihydroxyvitamin D	0-28	vitamin D receptor	Homo sapiens	171-176
10666315-3	2000	As expected from previous work, the total T lymphocyte population contains VDR whose levels are increased when activated and treated with 1, 25-dihydroxyvitamin D(3).	1,25-dihydroxyvitamin D	138-162	vitamin D receptor	Homo sapiens	75-78
10684662-0	2000	Metabolism of 1alpha,25-dihydroxyvitamin D(3) in vitamin D receptor-ablated mice in vivo.	1,25-dihydroxyvitamin D	14-42	vitamin D (1,25-dihydroxyvitamin D3) receptor	Mus musculus	49-67
10720046-23	2000	The marked and sustained elevation of PTH, more pronounced in the postmenopausal women, during the first year of treatment of hyperthyroidism seems to play a pivotal role in maintaining a relatively high rate of bone turnover despite euthyroidism, and in the conservation of calcium by reducing renal calcium excretion and increasing calcium absorption (via 1,25-dihydroxyvitamin D).	1,25-dihydroxyvitamin D	358-381	parathyroid hormone	Homo sapiens	38-41
10666315-6	2000	Cells of the monocyte/macrophage lineage possess small amounts of VDR that are not affected by activation but are increased by treatment with 1, 25-dihydroxyvitamin D(3).	1,25-dihydroxyvitamin D	142-166	vitamin D receptor	Homo sapiens	66-69
10666315-7	2000	These results suggest that CD8 lymphocytes may be a major site of 1,25-dihydroxyvitamin D(3) action, while B lymphocytes are likely not directly regulated by 1, 25-dihydroxyvitamin D(3).	1,25-dihydroxyvitamin D	66-89	CD8a molecule	Homo sapiens	27-30
10662714-1	2000	We investigated the effects of 1,25-dihydroxyvitamin D(3) [25(OH)(2)D(3)] on tissue plasminogen activator (tPA) secretion from primary cultures of rat heart microvascular cells.	1,25-dihydroxyvitamin D	31-54	plasminogen activator, tissue type	Rattus norvegicus	77-105
10671205-0	2000	Inhibition of Th1 development and treatment of chronic-relapsing experimental allergic encephalomyelitis by a non-hypercalcemic analogue of 1,25-dihydroxyvitamin D(3).	1,25-dihydroxyvitamin D	140-163	negative elongation factor complex member C/D, Th1l	Mus musculus	14-17
10640427-6	2000	blr1 mRNA also is induced by other differentiation-inducing agents, 1alpha,25-dihydroxyvitamin D(3) and DMSO.	1,25-dihydroxyvitamin D	68-96	C-X-C motif chemokine receptor 5	Homo sapiens	0-4
10671205-1	2000	1alpha,25-dihydroxyvitamin D(3) [1,25(OH)(2)D(3)] inhibits production of IL-12, a cytokine involved in the development of Th1 cells and in the pathogenesis of Th1-mediated autoimmune diseases.	1,25-dihydroxyvitamin D	0-28	negative elongation factor complex member C/D, Th1l	Mus musculus	122-125
10671205-1	2000	1alpha,25-dihydroxyvitamin D(3) [1,25(OH)(2)D(3)] inhibits production of IL-12, a cytokine involved in the development of Th1 cells and in the pathogenesis of Th1-mediated autoimmune diseases.	1,25-dihydroxyvitamin D	0-28	negative elongation factor complex member C/D, Th1l	Mus musculus	159-162
10587460-1	1999	The vitamin D receptor (VDR) binds 1,25-dihydroxyvitamin D(3) and mediates its actions on gene transcription by heterodimerizing with retinoid X receptors (RXRs) on direct repeat (DR+3) vitamin D responsive elements (VDREs) located in target genes.	1,25-dihydroxyvitamin D	35-58	vitamin D receptor	Homo sapiens	4-22
10673374-3	2000	VIP(170) may be a coactivator because it interacts only with 1,25-dihydroxyvitamin D(3) (1,25(OH)(2)D(3)) ligand-bound hVDR and because a mutation (E420A) in the activation function-2 (AF-2) of hVDR abolishes both receptor-mediated transactivation and VIP(170) binding.	1,25-dihydroxyvitamin D	61-84	vasoactive intestinal peptide	Homo sapiens	0-3
10572247-0	1999	Regulation of estrogen receptor-alpha gene expression by 1, 25-dihydroxyvitamin D in MCF-7 cells.	1,25-dihydroxyvitamin D	57-81	estrogen receptor 1	Homo sapiens	14-37
10572247-1	1999	This report describes an investigation of the role of 1, 25-dihydroxyvitamin D (VD(3)) in the regulation of estrogen receptor-alpha (ER) in the ER-positive breast cancer cell line, MCF-7.	1,25-dihydroxyvitamin D	54-78	estrogen receptor 1	Homo sapiens	108-131
10587349-1	1999	1alpha,25-dihydroxyvitamin D(3) (D(3)) promotes the maturation of myeloid cells and surface expressions of CD14 and CD11b, markers of cell differentiation in response to D(3).	1,25-dihydroxyvitamin D	0-28	CD14 molecule	Homo sapiens	107-111
10587349-1	1999	1alpha,25-dihydroxyvitamin D(3) (D(3)) promotes the maturation of myeloid cells and surface expressions of CD14 and CD11b, markers of cell differentiation in response to D(3).	1,25-dihydroxyvitamin D	0-28	integrin subunit alpha M	Homo sapiens	116-121
10620374-2	2000	In the present investigation we probed the vitamin D sterol-binding pocket of human DBP with affinity labeling analogs of 25-hydroxyvitamin D(3) ?25-OH-D(3) and 1, 25-dihydroxyvitamin D(3) ?1,25(OH)(2)D(3) containing bromoacetate alkylating probe at C-3 (A-ring), C-6 (triene), C-11 (C-ring), and C-19 (exocyclic methylene) of the parent sterol.	1,25-dihydroxyvitamin D	161-185	D-box binding PAR bZIP transcription factor	Homo sapiens	84-87
11211092-4	2000	Exposure to 1,25-dihydroxy vitamin D (Vit.	1,25-dihydroxyvitamin D	12-36	vitrin	Rattus norvegicus	38-41
11436712-2	2000	Elevated circulating levels of 1.25-OH vitamin D lead to increased efficiency of maternal intestinal calcium absorption and possibly lead to hypersecretion of calcitonin.	1,25-dihydroxyvitamin D	31-48	calcitonin related polypeptide alpha	Homo sapiens	159-169
10769434-10	2000	In men both 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D showed pairwise correlation with LEP (r = 0.24; p = 0.0004/r = 0.14; p = 0.045).	1,25-dihydroxyvitamin D	36-59	leptin	Homo sapiens	93-96
10587460-1	1999	The vitamin D receptor (VDR) binds 1,25-dihydroxyvitamin D(3) and mediates its actions on gene transcription by heterodimerizing with retinoid X receptors (RXRs) on direct repeat (DR+3) vitamin D responsive elements (VDREs) located in target genes.	1,25-dihydroxyvitamin D	35-58	vitamin D receptor	Homo sapiens	24-27
10542279-0	1999	Analysis of the molecular mechanism for the antagonistic action of a novel 1alpha,25-dihydroxyvitamin D(3) analogue toward vitamin D receptor function.	1,25-dihydroxyvitamin D	75-103	vitamin D receptor	Homo sapiens	123-141
10633456-3	1999	PTH gene expression is regulated by calcium, phosphate and 1,25-dihydroxy vitamin D (1,25(OH)2D).	1,25-dihydroxyvitamin D	59-83	parathyroid hormone	Rattus norvegicus	0-3
10536369-2	1999	However, it was reported [Schrader et al., 1994] that, on putative vitamin D response elements (VDREs) within the rat 9k and mouse 28k calcium binding protein genes (rCaBP 9k and mCaBP 28k), VDR and thyroid hormone receptor (TR) form heterodimers that transactivate in response to both 1,25-dihydroxyvitamin D(3) (1,25(OH)(2)D(3)) and triiodothyronine (T(3)).	1,25-dihydroxyvitamin D	286-309	vitamin D (1,25-dihydroxyvitamin D3) receptor	Mus musculus	96-99
10540876-1	1999	Action of 1,25-dihydroxyvitamin D, the most active metabolite of vitamin D, is exerted by the nuclear vitamin D receptor (VDR) mediated gene expression.	1,25-dihydroxyvitamin D	10-33	vitamin D receptor	Homo sapiens	102-120
10544252-0	1999	1,25-Dihydroxyvitamin D(3) induction of the tissue-type plasminogen activator gene is mediated through its multihormone-responsive enhancer.	1,25-dihydroxyvitamin D	0-23	plasminogen activator, tissue type	Homo sapiens	44-77
10544252-2	1999	In the present study, 1,25-dihydroxyvitamin D(3) [1,25(OH)(2)D(3)] was found to stimulate t-PA gene expression in ROS17/2.8 osteosarcoma cells.	1,25-dihydroxyvitamin D	22-45	plasminogen activator, tissue type	Rattus norvegicus	90-94
10508929-0	1999	Regulation by 1alpha,25-dihydroxyvitamin D(3) of expression of stanniocalcin messages in the rat kidney and ovary.	1,25-dihydroxyvitamin D	14-42	stanniocalcin 1	Rattus norvegicus	63-76
10540876-1	1999	Action of 1,25-dihydroxyvitamin D, the most active metabolite of vitamin D, is exerted by the nuclear vitamin D receptor (VDR) mediated gene expression.	1,25-dihydroxyvitamin D	10-33	vitamin D receptor	Homo sapiens	122-125
10540876-2	1999	Toward the expression of vitamin D function, several steps including 1,25-dihydroxyvitamin D production, tissue specific expression of VDR and transcription of target gene by VDR are involved.	1,25-dihydroxyvitamin D	69-92	vitamin D receptor	Homo sapiens	175-178
10441375-6	1999	Also, mRNA and protein levels of calbindin-D9k were similar in vitamin D-deficient wild-type and op/op mice as well as in wild-type and op/op mice treated with 1, 25-dihydroxyvitamin D(3).	1,25-dihydroxyvitamin D	160-184	S100 calcium binding protein G	Mus musculus	33-46
10488123-0	1999	Molecular characterization of peptidylarginine deiminase in HL-60 cells induced by retinoic acid and 1alpha,25-dihydroxyvitamin D(3).	1,25-dihydroxyvitamin D	101-129	peptidyl arginine deiminase 4	Homo sapiens	30-56
10421806-1	1999	The aim of the present study was to assess the effects of insulin-like growth factor I (IGF-I) upon the synthesis of 1, 25-dihydroxyvitamin D(3) [1,25-(OH)(2)D(3)] by human placenta trophoblasts in culture.	1,25-dihydroxyvitamin D	117-141	insulin like growth factor 1	Homo sapiens	58-86
10421806-1	1999	The aim of the present study was to assess the effects of insulin-like growth factor I (IGF-I) upon the synthesis of 1, 25-dihydroxyvitamin D(3) [1,25-(OH)(2)D(3)] by human placenta trophoblasts in culture.	1,25-dihydroxyvitamin D	117-141	insulin like growth factor 1	Homo sapiens	88-93
10419473-11	1999	Treatment of HL-60 cells with 1alpha, 25-dihydroxyvitamin D(3) caused an increase of TBP-2/VDUP1 expression and down-regulation of the expression and the reducing activity of TRX.	1,25-dihydroxyvitamin D	30-59	thioredoxin interacting protein	Homo sapiens	85-90
10419473-11	1999	Treatment of HL-60 cells with 1alpha, 25-dihydroxyvitamin D(3) caused an increase of TBP-2/VDUP1 expression and down-regulation of the expression and the reducing activity of TRX.	1,25-dihydroxyvitamin D	30-59	thioredoxin interacting protein	Homo sapiens	91-96
10419473-11	1999	Treatment of HL-60 cells with 1alpha, 25-dihydroxyvitamin D(3) caused an increase of TBP-2/VDUP1 expression and down-regulation of the expression and the reducing activity of TRX.	1,25-dihydroxyvitamin D	30-59	thioredoxin	Homo sapiens	175-178
9637715-6	1998	Serum levels of PTH and 1, 25-dihydroxyvitamin D were substantially increased above the normal low fetal levels by disruption of the CaSR.	1,25-dihydroxyvitamin D	24-48	calcium-sensing receptor	Mus musculus	133-137
10416587-1	1999	EB1089, an analogue of 1,25 dihydroxyvitamin D with low calcemic activity is a potent inhibitor of parathyroid hormone-related peptide (PTHRP) production in vitro.	1,25-dihydroxyvitamin D	23-46	parathyroid hormone like hormone	Homo sapiens	99-134
10416587-1	1999	EB1089, an analogue of 1,25 dihydroxyvitamin D with low calcemic activity is a potent inhibitor of parathyroid hormone-related peptide (PTHRP) production in vitro.	1,25-dihydroxyvitamin D	23-46	parathyroid hormone like hormone	Homo sapiens	136-141
10381152-10	1999	GH significantly further increased serum 1,25-dihydroxyvitamin D (1,25(OH)2D) and further decreased intact PTH (from 10 +/- 1 to 6 +/- 1 pg/mL).	1,25-dihydroxyvitamin D	41-64	growth hormone 1	Homo sapiens	0-2
10320521-1	1999	Pseudovitamin D-defiency rickets (PDDR) is an autosomal recessive disorder characterized by hypocalcemia, rickets (which are resistant to treatment with vitamin D), and low or undetectable serum levels of 1,25-dihydroxyvitamin D (1,25(OH)2D).	1,25-dihydroxyvitamin D	205-228	cytochrome P450 family 27 subfamily B member 1	Homo sapiens	34-38
9927335-0	1999	Stimulation of osteoclast formation by 1,25-dihydroxyvitamin D requires its binding to vitamin D receptor (VDR) in osteoblastic cells: studies using VDR knockout mice.	1,25-dihydroxyvitamin D	39-62	vitamin D (1,25-dihydroxyvitamin D3) receptor	Mus musculus	87-105
9927335-0	1999	Stimulation of osteoclast formation by 1,25-dihydroxyvitamin D requires its binding to vitamin D receptor (VDR) in osteoblastic cells: studies using VDR knockout mice.	1,25-dihydroxyvitamin D	39-62	vitamin D (1,25-dihydroxyvitamin D3) receptor	Mus musculus	107-110
9927335-0	1999	Stimulation of osteoclast formation by 1,25-dihydroxyvitamin D requires its binding to vitamin D receptor (VDR) in osteoblastic cells: studies using VDR knockout mice.	1,25-dihydroxyvitamin D	39-62	vitamin D (1,25-dihydroxyvitamin D3) receptor	Mus musculus	149-152
11056661-1	1999	INTRODUCTION: 1alpha,25-dihydroxyvitamin D(3)[1alpha,25(OH)(2)D(3)], the biologically active metabolite of vitamin D3, acts through an intracellular vitamin D receptor (VDR) and has several immunostimulatory effects.	1,25-dihydroxyvitamin D	14-42	vitamin D receptor	Homo sapiens	149-167
11056661-1	1999	INTRODUCTION: 1alpha,25-dihydroxyvitamin D(3)[1alpha,25(OH)(2)D(3)], the biologically active metabolite of vitamin D3, acts through an intracellular vitamin D receptor (VDR) and has several immunostimulatory effects.	1,25-dihydroxyvitamin D	14-42	vitamin D receptor	Homo sapiens	169-172
10052739-0	1999	Effectiveness of 1,25-dihydroxyvitamin D supplementation on blood pressure reduction in a pseudohypoparathyroidism patient with high renin activity.	1,25-dihydroxyvitamin D	17-40	renin	Homo sapiens	133-138
9696350-11	1998	Thus, ascorbic acid may be causing amplification of the vitamin D receptor-dependent genomic response to 1,25-dihydroxyvitamin D, resulting in promotion of terminal differentiation.	1,25-dihydroxyvitamin D	105-128	vitamin D receptor	Homo sapiens	56-74
9610787-1	1998	Prostatic cells express vitamin D receptor (VDR), which mediates the functions of 1,25-dihydroxyvitamin D.	1,25-dihydroxyvitamin D	82-105	vitamin D receptor	Homo sapiens	24-42
9570827-1	1998	Most of the total circulating 1,25-dihydroxyvitamin D (1,25(OH)2D) is bound to plasma proteins, mainly vitamin D-binding protein (DBP) and albumin.	1,25-dihydroxyvitamin D	30-53	GC vitamin D binding protein	Homo sapiens	103-128
9570827-1	1998	Most of the total circulating 1,25-dihydroxyvitamin D (1,25(OH)2D) is bound to plasma proteins, mainly vitamin D-binding protein (DBP) and albumin.	1,25-dihydroxyvitamin D	30-53	D-box binding PAR bZIP transcription factor	Homo sapiens	130-133
9610787-1	1998	Prostatic cells express vitamin D receptor (VDR), which mediates the functions of 1,25-dihydroxyvitamin D.	1,25-dihydroxyvitamin D	82-105	vitamin D receptor	Homo sapiens	44-47
9507497-0	1998	Regulation of the parathyroid hormone gene by calcium, phosphate and 1,25-dihydroxyvitamin D.	1,25-dihydroxyvitamin D	69-92	parathyroid hormone	Homo sapiens	18-37
9560283-3	1998	Homozygous mutants (Npt2(-/-)) exhibit increased urinary Pi excretion, hypophosphatemia, an appropriate elevation in the serum concentration of 1,25-dihydroxyvitamin D with attendant hypercalcemia, hypercalciuria and decreased serum parathyroid hormone levels, and increased serum alkaline phosphatase activity.	1,25-dihydroxyvitamin D	144-167	solute carrier family 34 (sodium phosphate), member 1	Mus musculus	20-24
9587402-0	1998	Capacity of 1,25-dihydroxyvitamin D to stimulate expression of calbindin D changes with age in the rat.	1,25-dihydroxyvitamin D	12-35	calbindin 1	Rattus norvegicus	63-72
9510866-6	1998	Plasma concentrations of 1,25-dihydroxyvitamin D correlated positively with AUCs (P < 0.01) when normalized to the plasma concentration of PTH.	1,25-dihydroxyvitamin D	25-48	parathyroid hormone	Homo sapiens	142-145
9495519-0	1998	Hereditary 1,25-dihydroxyvitamin D-resistant rickets due to an opal mutation causing premature termination of the vitamin D receptor.	1,25-dihydroxyvitamin D	11-34	vitamin D receptor	Homo sapiens	114-132
9405025-9	1997	In spite of this presence of IGFBPs, IGFs could be responsible for the local biosynthesis of 1.25-dihydroxyvitamin D (1,25-(OH)2D) since pleural fluid levels of both IGF-I and IGF-II significantly correlated with those of 1,25-(OH)2D.	1,25-dihydroxyvitamin D	93-116	insulin like growth factor 1	Homo sapiens	166-171
9398125-2	1997	Low serum levels of 1,25-dihydroxyvitamin D in uremic patients are postulated by some as having a role in permitting higher parathyroid hormone (PTH) secretion.	1,25-dihydroxyvitamin D	20-43	parathyroid hormone	Homo sapiens	124-143
9405025-9	1997	In spite of this presence of IGFBPs, IGFs could be responsible for the local biosynthesis of 1.25-dihydroxyvitamin D (1,25-(OH)2D) since pleural fluid levels of both IGF-I and IGF-II significantly correlated with those of 1,25-(OH)2D.	1,25-dihydroxyvitamin D	93-116	insulin like growth factor 2	Homo sapiens	176-182
9165053-0	1997	In vivo regulation of chromogranin A messenger ribonucleic acid in the parathyroid by 1,25-dihydroxyvitamin D: studies in normal rats and in chronic renal insufficiency.	1,25-dihydroxyvitamin D	86-109	chromogranin A	Rattus norvegicus	22-36
9312396-0	1997	Increased serum 1,25-dihydroxyvitamin D after growth hormone administration is not parathyroid hormone-mediated.	1,25-dihydroxyvitamin D	16-39	growth hormone 1	Homo sapiens	46-60
9312396-1	1997	To assess the effects of growth hormone (GH) on serum 1,25-dihydroxyvitamin D [1,25(OH)2D], we performed the following prospective crossover study in six healthy, young, adult, white men.	1,25-dihydroxyvitamin D	54-79	growth hormone 1	Homo sapiens	41-43
9169351-0	1997	Association between intestinal vitamin D receptor, calcium absorption, and serum 1,25 dihydroxyvitamin D in normal young and elderly women.	1,25-dihydroxyvitamin D	81-104	vitamin D receptor	Homo sapiens	31-49
9075099-0	1997	Deficiency of a parathyroid hormone fragment containing the midportion and 1,25-dihydroxyvitamin D in serum of patients with slipped capital femoral epiphysis.	1,25-dihydroxyvitamin D	75-98	parathyroid hormone	Homo sapiens	16-35
9166109-0	1997	Induction of 24-hydroxylase cytochrome P450 mRNA by 1,25-dihydroxyvitamin D and phorbol esters in normal rat kidney (NRK-52E) cells.	1,25-dihydroxyvitamin D	52-75	cytochrome P450, family 2, subfamily g, polypeptide 1	Rattus norvegicus	28-43
9062504-6	1997	PTHrP-(1-36) administered sc in three doses (0.82, 1.64, and 3.28 micrograms/kg) to 21 normal women produced increases in circulating PTHrP-(1-36), reductions in serum phosphorus and the renal phosphorus threshold, increments in fractional calcium excretion and nephrogenous cAMP excretion, and increases in plasma 1,25-dihydroxyvitamin D.	1,25-dihydroxyvitamin D	315-338	parathyroid hormone like hormone	Homo sapiens	0-5
9037126-0	1997	Growth hormone increases serum 1,25-dihydroxyvitamin D levels and decreases 24,25-dihydroxyvitamin D levels in children with growth hormone deficiency.	1,25-dihydroxyvitamin D	31-54	growth hormone 1	Homo sapiens	0-14
9005998-1	1997	Mutations in the vitamin D receptor (VDR) result in target organ resistance to 1alpha,25-dihydroxyvitamin D [1,25(OH)2D3], the active form of vitamin D, and cause hereditary 1,25-dihydroxyvitamin D resistant rickets (HVDRR).	1,25-dihydroxyvitamin D	174-197	vitamin D receptor	Homo sapiens	17-35
9005998-1	1997	Mutations in the vitamin D receptor (VDR) result in target organ resistance to 1alpha,25-dihydroxyvitamin D [1,25(OH)2D3], the active form of vitamin D, and cause hereditary 1,25-dihydroxyvitamin D resistant rickets (HVDRR).	1,25-dihydroxyvitamin D	174-197	vitamin D receptor	Homo sapiens	37-40
8675579-0	1996	A novel mutation in the deoxyribonucleic acid-binding domain of the vitamin D receptor causes hereditary 1,25-dihydroxyvitamin D-resistant rickets.	1,25-dihydroxyvitamin D	105-128	vitamin D receptor	Homo sapiens	68-86
8709404-8	1996	Furthermore, elevated PTHrP levels were negatively and significantly associated (P<.01) over time with bone mineral density change at both the spine and the femoral neck, even after accounting for prolactin levels, breast-feeding status, return of menstruation, estradiol levels, PTH levels, 1,25-dihydroxyvitamin D levels, dietary calcium intake, physical activity, and body size.	1,25-dihydroxyvitamin D	295-318	parathyroid hormone like hormone	Homo sapiens	22-27
8709404-8	1996	Furthermore, elevated PTHrP levels were negatively and significantly associated (P<.01) over time with bone mineral density change at both the spine and the femoral neck, even after accounting for prolactin levels, breast-feeding status, return of menstruation, estradiol levels, PTH levels, 1,25-dihydroxyvitamin D levels, dietary calcium intake, physical activity, and body size.	1,25-dihydroxyvitamin D	295-318	parathyroid hormone	Homo sapiens	22-25
8889838-0	1996	Effect of parathyroid hormone (hPTH[1-34]) infusion on serum 1,25-dihydroxyvitamin D and parathyroid hormone in normal women.	1,25-dihydroxyvitamin D	61-84	parathyroid hormone	Homo sapiens	10-29
8889838-0	1996	Effect of parathyroid hormone (hPTH[1-34]) infusion on serum 1,25-dihydroxyvitamin D and parathyroid hormone in normal women.	1,25-dihydroxyvitamin D	61-84	parathyroid hormone	Homo sapiens	31-35
9084657-6	1996	1,25-dihydroxyvitamin D increased MT induction.	1,25-dihydroxyvitamin D	0-23	metallothionein 4	Gallus gallus	34-36
8612483-0	1996	1,25-Dihydroxyvitamin D induces lipoprotein lipase expression in 3T3-L1 cells in association with adipocyte differentiation.	1,25-dihydroxyvitamin D	0-23	lipoprotein lipase	Mus musculus	32-50
8861731-3	1996	1,25-Dihydroxyvitamin D(3), through VDR, may perform significant functions in the development of neuronal cells.	1,25-dihydroxyvitamin D	0-23	vitamin D receptor	Rattus norvegicus	36-39
8852951-8	1996	In contrast, alkaline phosphatase activity and osteocalcin production by osteoblastic cells cultured in basal conditions and after stimulation with 1,25-dihydroxyvitamin D (1,25[OH]2D3), were 53-74% higher in fused sutures compared with cells isolated from normal sutures in the same patients.	1,25-dihydroxyvitamin D	148-171	bone gamma-carboxyglutamate protein	Homo sapiens	47-58
8557238-2	1995	1,25 dihydroxyvitamin D (1,25[OH]2D) and Dexamethasone (DEX) have been shown to decrease PTHrP mRNA expression in several cell lines.	1,25-dihydroxyvitamin D	0-23	parathyroid hormone-like hormone	Rattus norvegicus	89-94
8717533-11	1996	However, both Hyp and Gy mice fed the medium and low diets were elevated in serum 1,25-dihydroxyvitamin D over normal mice.	1,25-dihydroxyvitamin D	82-105	phosphate regulating endopeptidase homolog, X-linked	Mus musculus	14-17
8717533-12	1996	Serum PTH levels were correlated to serum 1,25-dihydroxyvitamin D levels with Hyp and Gy mice lying on the same line (r = 0.86; p < 0.0001).	1,25-dihydroxyvitamin D	42-65	parathyroid hormone	Mus musculus	6-9
8717533-12	1996	Serum PTH levels were correlated to serum 1,25-dihydroxyvitamin D levels with Hyp and Gy mice lying on the same line (r = 0.86; p < 0.0001).	1,25-dihydroxyvitamin D	42-65	phosphate regulating endopeptidase homolog, X-linked	Mus musculus	78-81
8717533-13	1996	In summary, when Hyp and Gy mice are studied on the same genetic background and fed the same diet, similar responses are seen in PTH levels and 1,25-dihydroxyvitamin D levels.	1,25-dihydroxyvitamin D	144-167	phosphate regulating endopeptidase homolog, X-linked	Mus musculus	17-20
8807622-1	1996	In man, parathyroid hormone (PTH) is one of the main regulators of 1,25-dihydroxyvitamin D (1,25(OH)2D) production.	1,25-dihydroxyvitamin D	67-90	parathyroid hormone	Homo sapiens	8-27
8807622-1	1996	In man, parathyroid hormone (PTH) is one of the main regulators of 1,25-dihydroxyvitamin D (1,25(OH)2D) production.	1,25-dihydroxyvitamin D	67-90	parathyroid hormone	Homo sapiens	29-32
7626465-1	1995	The gene encoding parathyroid hormone-related protein (PTHrP), an autocrine/paracrine inhibitor of vascular and nonvascular smooth muscle contractility, is regulated by hormonal steroids including estrogens (E2), 1,25-dihydroxy vitamin D (Vit D3) and glucocorticoids.	1,25-dihydroxyvitamin D	213-237	parathyroid hormone-like hormone	Rattus norvegicus	18-53
7626465-1	1995	The gene encoding parathyroid hormone-related protein (PTHrP), an autocrine/paracrine inhibitor of vascular and nonvascular smooth muscle contractility, is regulated by hormonal steroids including estrogens (E2), 1,25-dihydroxy vitamin D (Vit D3) and glucocorticoids.	1,25-dihydroxyvitamin D	213-237	parathyroid hormone-like hormone	Rattus norvegicus	55-60
7626465-1	1995	The gene encoding parathyroid hormone-related protein (PTHrP), an autocrine/paracrine inhibitor of vascular and nonvascular smooth muscle contractility, is regulated by hormonal steroids including estrogens (E2), 1,25-dihydroxy vitamin D (Vit D3) and glucocorticoids.	1,25-dihydroxyvitamin D	213-237	vitrin	Rattus norvegicus	239-242
7776978-9	1995	These findings indicate that the mouse calbindin-D28k promoter is capable of conferring estrogen responsiveness, which may be mediated by several imperfect half-palindromic estrogen-responsive elements, and suggest, in light of previous studies concerning 1,25-dihydroxyvitamin D regulation, multiple steroid regulation of the calbindin-D28k gene.	1,25-dihydroxyvitamin D	256-279	calbindin 1	Mus musculus	39-53
21153172-1	1995	Vitamin D(3), 25-hydroxyvitamin D(3) (25OHD(3)) and 1alpha,25-dihydroxyvitamin D(3) (1alpha,25(OH)(2)D(3)) bind to the vitamin D binding protein (DBP) in the serum.	1,25-dihydroxyvitamin D	52-80	GC, vitamin D binding protein	Rattus norvegicus	119-144
21153172-1	1995	Vitamin D(3), 25-hydroxyvitamin D(3) (25OHD(3)) and 1alpha,25-dihydroxyvitamin D(3) (1alpha,25(OH)(2)D(3)) bind to the vitamin D binding protein (DBP) in the serum.	1,25-dihydroxyvitamin D	52-80	D-box binding PAR bZIP transcription factor	Rattus norvegicus	146-149
7530647-4	1995	The OHS-4 cells exhibit type I collagen production, 1,25-Dihydroxyvitamin D-inducible osteocalcin, and mineralization of the extracellular matrix.	1,25-dihydroxyvitamin D	52-75	bone gamma-carboxyglutamate protein	Homo sapiens	86-97
21153232-4	1995	The levels of PTN mRNA in these cells was significantly reduced by treatment with 10(-8) M: 1alpha,25-dihydroxyvitamin D(3) (1,25(OH)(2)D(3)) for 24 h. However, PTN mRNA levels were increased when the non-osteoblastic cell line, ROS 25/1, was treated with 1,25(OH)(2)D(3).	1,25-dihydroxyvitamin D	92-120	pleiotrophin	Rattus norvegicus	14-17
21153145-1	1995	The goal of the present work was to use IEC-6 cells to investigate the possible mechanisms underlying the regulation of alkaline phosphatase (ALP) activity (ALPA) by 1alpha, 25-dihydroxyvitamin D(3) (1,25(OH)(2)D(3)) and retinoids.	1,25-dihydroxyvitamin D	166-195	PDZ and LIM domain 3	Rattus norvegicus	142-145
21153232-4	1995	The levels of PTN mRNA in these cells was significantly reduced by treatment with 10(-8) M: 1alpha,25-dihydroxyvitamin D(3) (1,25(OH)(2)D(3)) for 24 h. However, PTN mRNA levels were increased when the non-osteoblastic cell line, ROS 25/1, was treated with 1,25(OH)(2)D(3).	1,25-dihydroxyvitamin D	92-120	pleiotrophin	Rattus norvegicus	161-164
7947935-1	1994	In rat calvarial osteoblast-like cells and in clonal osteogenic sarcoma cells (UMR 106-01), 1,25-dihydroxyvitamin D-3 (1,25(OH)2D3) enhanced plasminogen activator (PA) activity and decreased PA inhibitor-1 (PAI-1) production over the same concentration range.	1,25-dihydroxyvitamin D	92-115	serpin family E member 1	Rattus norvegicus	191-205
7947935-1	1994	In rat calvarial osteoblast-like cells and in clonal osteogenic sarcoma cells (UMR 106-01), 1,25-dihydroxyvitamin D-3 (1,25(OH)2D3) enhanced plasminogen activator (PA) activity and decreased PA inhibitor-1 (PAI-1) production over the same concentration range.	1,25-dihydroxyvitamin D	92-115	serpin family E member 1	Rattus norvegicus	207-212
7850990-1	1994	Concentrations of serum phosphate and parathyroid hormone (PTH) are well known regulators of the production of 1,25-dihydroxyvitamin D (1,25-(OH)2D) and acidosis is known to affect the serum concentration of 1,25-(OH)2D.	1,25-dihydroxyvitamin D	111-134	parathyroid hormone	Homo sapiens	38-57
7850990-1	1994	Concentrations of serum phosphate and parathyroid hormone (PTH) are well known regulators of the production of 1,25-dihydroxyvitamin D (1,25-(OH)2D) and acidosis is known to affect the serum concentration of 1,25-(OH)2D.	1,25-dihydroxyvitamin D	111-134	parathyroid hormone	Homo sapiens	59-62
7918114-6	1994	These data suggest that pyridoxal 5"-phosphate may be related to 1,25-dihydroxyvitamin D retention in the nuclei, possibly through interaction of the pyridoxal 5"-phosphate with the vitamin D receptor protein in the nuclei.	1,25-dihydroxyvitamin D	65-88	vitamin D receptor	Rattus norvegicus	182-200
7929846-0	1994	Local action of phosphate depletion and insulin-like growth factor 1 on in vitro production of 1,25-dihydroxyvitamin D by cultured mammalian kidney cells.	1,25-dihydroxyvitamin D	95-118	insulin like growth factor 1	Homo sapiens	40-68
8084286-1	1994	The immunosuppressive agent cyclosporine A (CsA) produces in vivo in the rat marked osteopenia and elevation of serum bone gla protein (BGP) that reflects the high bone turnover and increased circulating levels of 1,25-dihydroxyvitamin D [1,25(OH)2D].	1,25-dihydroxyvitamin D	214-237	bone gamma-carboxyglutamate protein	Rattus norvegicus	118-134
8084286-1	1994	The immunosuppressive agent cyclosporine A (CsA) produces in vivo in the rat marked osteopenia and elevation of serum bone gla protein (BGP) that reflects the high bone turnover and increased circulating levels of 1,25-dihydroxyvitamin D [1,25(OH)2D].	1,25-dihydroxyvitamin D	214-237	bone gamma-carboxyglutamate protein	Rattus norvegicus	136-139
8086474-1	1994	A novel cDNA clone (VDUP1) has been isolated from a cDNA library constructed from mRNA obtained from HL-60 cells stimulated by 1,25-dihydroxyvitamin D-3.	1,25-dihydroxyvitamin D	127-150	thioredoxin interacting protein	Homo sapiens	20-25
7939190-3	1994	Although exceptional, pseudo-deficiency rickets type II has enabled studies which led to the description of several alterations in the vitamin D receptor chromosomal gene responsible for tissue resistance to 1,25-dihydroxyvitamin D.	1,25-dihydroxyvitamin D	208-231	vitamin D receptor	Homo sapiens	135-153
7815245-4	1994	We hypothesized that in winter-born infants, the bone mineral content is low and serum osteocalcin is high, related to increased bone turnover and high serum 1,25-dihydroxyvitamin D [1,25(OH)2D].	1,25-dihydroxyvitamin D	158-181	bone gamma-carboxyglutamate protein	Homo sapiens	87-98
8119183-9	1994	Exposure of the differentiated cultures of 1,25-dihydroxyvitamin D (10 nM) for 2 days markedly stimulated osteocalcin mRNA while having no effect on tPA.	1,25-dihydroxyvitamin D	43-66	bone gamma-carboxyglutamate protein	Rattus norvegicus	106-117
8180120-4	1994	Only vitamin D3 sulfate and 1 alpha 25-dihydroxyvitamin D inhibited the estrone sulfatase activity in human placental microsomes, albeit at high concentration (32 and 37% inhibition, respectively with 50 microns each inhibitor).	1,25-dihydroxyvitamin D	28-57	steroid sulfatase	Homo sapiens	72-89
8106618-0	1994	Hereditary 1 alpha,25-dihydroxyvitamin D-resistant rickets resulting from a mutation in the vitamin D receptor deoxyribonucleic acid-binding domain.	1,25-dihydroxyvitamin D	11-40	vitamin D receptor	Homo sapiens	92-110
8106618-1	1994	Hereditary 1 alpha,25-dihydroxyvitamin D-resistant rickets (HVDRR) is a genetic disease that results from mutations in the gene encoding the vitamin D receptor (VDR).	1,25-dihydroxyvitamin D	11-40	vitamin D receptor	Homo sapiens	141-159
8106618-1	1994	Hereditary 1 alpha,25-dihydroxyvitamin D-resistant rickets (HVDRR) is a genetic disease that results from mutations in the gene encoding the vitamin D receptor (VDR).	1,25-dihydroxyvitamin D	11-40	vitamin D receptor	Homo sapiens	61-64
8377475-7	1993	RESULTS: Epidermal growth factor, cholera toxin, calcium, 1,25-dihydroxyvitamin D, ionomycin, trans-retinoic acid, transforming growth factor-beta 1 and hydrocortisone stimulated production of PTHrP by SCC 2/88 cells to various degrees.	1,25-dihydroxyvitamin D	58-81	parathyroid hormone like hormone	Canis lupus familiaris	193-198
8301857-5	1993	DAT patients showed significant decreases in serum Ca and Ca2+ ion, increase in serum parathyroid hormone, and decrease in serum 1,25-dihydroxyvitamin D, a tendency towards decrease in serum calcitonin, and a tendency towards increase in urinary Ca.	1,25-dihydroxyvitamin D	129-152	solute carrier family 6 member 3	Homo sapiens	0-3
8229062-8	1993	The early clinical onset of HAM/TSP may be due to PTH receptor anomaly and a low level of 1,25-dihydroxyvitamin D, which is deficient in PHP and is involved in the regulation of the immune response.	1,25-dihydroxyvitamin D	90-113	thrombospondin 1	Homo sapiens	32-35
8227216-6	1993	Addition of 1,25-dihydroxyvitamin D to the diet, which is known to reduce the incidence of dyschondroplasia, resulted in an increase in c-myc production.	1,25-dihydroxyvitamin D	12-35	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	136-141
8472307-6	1993	Osteocalcin production was increased after stimulation with 10 nM 1,25 dihydroxyvitamin D (1,25(OH)2 D) and the response to 1,25(OH)2 D was similar at all ages.	1,25-dihydroxyvitamin D	66-89	bone gamma-carboxyglutamate protein	Rattus norvegicus	0-11
7859016-3	1993	Such studies have emphasized the steep, inverse sigmoidal relationship between circulating intact parathyroid hormone and serum ionized Ca2+ concentrations, which can be modulated in a reciprocal fashion by 1,25 dihydroxyvitamin D.	1,25-dihydroxyvitamin D	207-230	parathyroid hormone	Homo sapiens	98-117
7859016-6	1993	Finally, the regulation of parathyroid hormone gene expression by extracellular Ca2+ and 1,25 dihydroxyvitamin D has been clarified at a molecular level by the description of specific motifs in the upstream region of the parathyroid hormone gene that mediate binding of specific inhibitory nuclear factors.	1,25-dihydroxyvitamin D	89-112	parathyroid hormone	Homo sapiens	27-46
7859016-6	1993	Finally, the regulation of parathyroid hormone gene expression by extracellular Ca2+ and 1,25 dihydroxyvitamin D has been clarified at a molecular level by the description of specific motifs in the upstream region of the parathyroid hormone gene that mediate binding of specific inhibitory nuclear factors.	1,25-dihydroxyvitamin D	89-112	parathyroid hormone	Homo sapiens	221-240
8385999-0	1993	The necessity for calcium for increased renal vitamin D receptor in response to 1,25-dihydroxyvitamin D.	1,25-dihydroxyvitamin D	80-103	vitamin D receptor	Rattus norvegicus	46-64
8429446-10	1993	We suggest that reduced uteroplacental blood flow in SGA infants may result in reduced fetal-placental production of 1,25-dihydroxyvitamin D, which results in low BMC and low serum osteocalcin values; fetal serum parathyroid hormone values may be relatively elevated because of reduced placental mineral supply.	1,25-dihydroxyvitamin D	117-140	bone gamma-carboxyglutamate protein	Homo sapiens	181-192
8381803-0	1993	A new point mutation in the deoxyribonucleic acid-binding domain of the vitamin D receptor in a kindred with hereditary 1,25-dihydroxyvitamin D-resistant rickets.	1,25-dihydroxyvitamin D	120-143	vitamin D receptor	Homo sapiens	72-90
8445039-1	1993	We investigated in humoral hypercalcemia of malignancy whether parathyroid hormone-related protein (PTHrP) elevation causes a rise in 1,25-dihydroxyvitamin D (1,25-(OH)2 D) serum levels.	1,25-dihydroxyvitamin D	134-157	parathyroid hormone like hormone	Homo sapiens	63-98
8445039-1	1993	We investigated in humoral hypercalcemia of malignancy whether parathyroid hormone-related protein (PTHrP) elevation causes a rise in 1,25-dihydroxyvitamin D (1,25-(OH)2 D) serum levels.	1,25-dihydroxyvitamin D	134-157	parathyroid hormone like hormone	Homo sapiens	100-105
8439572-0	1993	1,25-Dihydroxyvitamin D-3 destabilizes c-myc mRNA in HL-60 leukemic cells.	1,25-dihydroxyvitamin D	0-23	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	39-44
22217851-7	1992	1,25-Dihydroxyvitamin D, the active metabolite of vitamin D, markedly stimulates renal P450cc24 mRNA and 24-hydroxylase activity in the intact animal and in renal cell lines.	1,25-dihydroxyvitamin D	0-23	cytochrome P450, family 24, subfamily a, polypeptide 1	Rattus norvegicus	87-95
8569602-0	1993	Effect of calcium and 1,25 dihydroxyvitamin D on the level of parathyroid hormone in patients with secondary hyperparathyroidism due to chronic renal insufficiency.	1,25-dihydroxyvitamin D	22-45	parathyroid hormone	Homo sapiens	62-81
8569602-6	1993	Serum PTH values were lower in group of patients who received 1,25 dihydroxyvitamin D (p < 0.05).	1,25-dihydroxyvitamin D	62-85	parathyroid hormone	Homo sapiens	6-9
8569602-8	1993	Suppression of PTH secretion with calcium rose in group of patients who received 1,25 dihydroxyvitamin D for two years.	1,25-dihydroxyvitamin D	81-104	parathyroid hormone	Homo sapiens	15-18
1615756-0	1992	Intermittent administration of bovine PTH-(1-34) increases serum 1,25-dihydroxyvitamin D concentrations and spinal bone density in senile (23 month) rats.	1,25-dihydroxyvitamin D	65-88	parathyroid hormone	Rattus norvegicus	38-41
1328752-1	1992	Patients who have nephrotic syndrome and normal renal function are hypocalcemic in spite of the elevated levels of serum parathyroid hormone (PTH) caused by a low serum concentration of 1,25-dihydroxyvitamin D[1,25(OH)2D], presumably because of its loss in urine.	1,25-dihydroxyvitamin D	186-209	parathyroid hormone	Rattus norvegicus	121-140
1615756-6	1992	PTH administration resulted in significantly increased serum 1,25-dihydroxyvitamin D concentrations in the senile and young male animals (both, p less than 0.05) and the final mean serum 1,25-dihydroxyvitamin D concentrations were not statistically different (68 +/- 9 versus 85 +/- 6 pg/ml respectively; p = NS).	1,25-dihydroxyvitamin D	61-84	parathyroid hormone	Rattus norvegicus	0-3
1615756-6	1992	PTH administration resulted in significantly increased serum 1,25-dihydroxyvitamin D concentrations in the senile and young male animals (both, p less than 0.05) and the final mean serum 1,25-dihydroxyvitamin D concentrations were not statistically different (68 +/- 9 versus 85 +/- 6 pg/ml respectively; p = NS).	1,25-dihydroxyvitamin D	187-210	parathyroid hormone	Rattus norvegicus	0-3
1615756-7	1992	Serum 1,25-dihydroxyvitamin D concentrations were significantly (p less than 0.05) higher in the PTH-treated senile female rats than the sex-matched, vehicle-treated controls.	1,25-dihydroxyvitamin D	6-29	parathyroid hormone	Rattus norvegicus	97-100
1539040-0	1992	1,25-Dihydroxyvitamin D and not calcium is the major regulator of calbindin-D 9-kDa mRNA levels in vivo.	1,25-dihydroxyvitamin D	0-23	calbindin 1	Rattus norvegicus	66-75
1566788-9	1992	We conclude that 1,25-dihydroxyvitamin D is reduced in preeclampsia and may lead to hypocalciuria by causing decreased intestinal absorption of calcium, stimulation of parathyroid hormone, and increased distal renal tubular resorption of calcium.	1,25-dihydroxyvitamin D	17-40	parathyroid hormone	Homo sapiens	168-187
1539040-4	1992	These results strongly support the idea that 1,25-dihydroxyvitamin D is directly responsible for the induction of calbindin-D 9-kDa.	1,25-dihydroxyvitamin D	45-68	calbindin 1	Rattus norvegicus	114-123
1542549-7	1992	The increase in serum Gla concentrations, birth to 1 wk, were significantly correlated with the simultaneous increase in 1,25-dihydroxyvitamin D concentrations.	1,25-dihydroxyvitamin D	121-144	galactosidase alpha	Homo sapiens	22-25
1344039-2	1992	1,25 di-hydroxy Vitamin D and gamma interferon, factors which are present in vivo in both tuberculosis and sarcoidosis, enhance the ability of macrophages to release TNF in vitro.	1,25-dihydroxyvitamin D	0-25	tumor necrosis factor	Homo sapiens	166-169
1757627-9	1991	Because parathyroid hormone regulates both bone Ca resorption and renal 1,25-dihydroxyvitamin D production, these data suggest that prepartal diets high in cations decrease the ability of bone and renal tissues to respond to parathyroid hormone.	1,25-dihydroxyvitamin D	72-95	parathyroid hormone	Bos taurus	225-244
1757627-7	1991	Plasma 1,25-dihydroxyvitamin D concentration was correlated inversely with plasma Ca and related directly to plasma parathyroid hormone in both groups of cows.	1,25-dihydroxyvitamin D	7-30	parathyroid hormone	Bos taurus	116-135
1653516-1	1991	We have previously shown that 1,25-dihydroxyvitamin D [1,25-(OH)2D3] and glucocorticoid modulate adenylate cyclase activation by PTH in osteoblast-like cells.	1,25-dihydroxyvitamin D	30-53	parathyroid hormone	Rattus norvegicus	129-132
1757627-8	1991	However, the magnitude of the response (the amount of 1,25-dihydroxyvitamin D produced per unit increase in parathyroid hormone) was reduced greatly in cows fed the high cation diet.	1,25-dihydroxyvitamin D	54-77	parathyroid hormone	Bos taurus	108-127
1757627-9	1991	Because parathyroid hormone regulates both bone Ca resorption and renal 1,25-dihydroxyvitamin D production, these data suggest that prepartal diets high in cations decrease the ability of bone and renal tissues to respond to parathyroid hormone.	1,25-dihydroxyvitamin D	72-95	parathyroid hormone	Bos taurus	8-27
2065286-0	1991	The role of 1,25-dihydroxyvitamin D in the maintenance of hypercalcemia in a patient with an ovarian carcinoma producing parathyroid hormone-related protein.	1,25-dihydroxyvitamin D	12-35	parathyroid hormone like hormone	Homo sapiens	121-156
2065286-3	1991	A patient is reported with HHM from a clear cell ovarian carcinoma and elevated serum immunoreactive PTHRP (about five times the upper limit of normal) in whom serum 1,25-DHD concentrations were abnormally high (200 pmol/l) and associated with increased intestinal calcium absorption.	1,25-dihydroxyvitamin D	166-174	parathyroid hormone like hormone	Homo sapiens	101-106
1675987-0	1991	Tumor necrosis factor-alpha regulation of 1,25-dihydroxyvitamin D production by human keratinocytes.	1,25-dihydroxyvitamin D	42-65	tumor necrosis factor	Homo sapiens	0-27
2035567-1	1991	We measured serum concentrations of calcium-regulating hormones and osteocalcin in 20 women longitudinally throughout pregnancy, 1,25-Dihydroxyvitamin D levels were high early in pregnancy and increased with advancing gestation.	1,25-dihydroxyvitamin D	129-152	bone gamma-carboxyglutamate protein	Homo sapiens	68-79
2035567-5	1991	The synthesis of osteocalcin by osteoblasts is stimulated by the action of 1,25-dihydroxyvitamin D, and serum osteocalcin levels are also related to the levels of parathyroid hormone.	1,25-dihydroxyvitamin D	75-98	bone gamma-carboxyglutamate protein	Homo sapiens	17-28
2035567-6	1991	During early and mid pregnancy, the stimulatory effect of 1,25-dihydroxyvitamin D on the synthesis of osteocalcin may be overridden by the inhibitory effect of declining parathyroid hormone levels.	1,25-dihydroxyvitamin D	58-81	bone gamma-carboxyglutamate protein	Homo sapiens	102-113
2035567-7	1991	The increase in osteocalcin level in late pregnancy may be a consequence of increasing levels of both parathyroid hormone and 1,25-dihydroxyvitamin D.	1,25-dihydroxyvitamin D	126-149	bone gamma-carboxyglutamate protein	Homo sapiens	16-27
1850633-3	1991	The 7-34 PTHrP analog also antagonized the PTHrP-(1-34)NH2-induced hypercalcemia and rises in blood 1,25-dihydroxyvitamin D concentrations.	1,25-dihydroxyvitamin D	100-123	parathyroid hormone-like hormone	Rattus norvegicus	9-14
1826305-0	1991	Effects of diabetes mellitus on parathyroid hormone-stimulated protein kinase activity, ferredoxin phosphorylation, and renal 1,25-dihydroxyvitamin D production.	1,25-dihydroxyvitamin D	126-149	parathyroid hormone	Rattus norvegicus	32-51
1846874-0	1991	Human umbilical cord blood monocytes express calcitonin receptors in culture in the presence of 1,25 dihydroxyvitamin D.	1,25-dihydroxyvitamin D	96-119	calcitonin related polypeptide alpha	Homo sapiens	45-55
1846874-12	1991	In conclusion, CT receptors can be induced on newborn cord monocytes in the presence of 1,25-dihydroxyvitamin D.	1,25-dihydroxyvitamin D	88-111	calcitonin related polypeptide alpha	Homo sapiens	15-17
2099369-0	1990	Plasma osteocalcin in preparturient and postparturient cows: correlation with plasma 1,25-dihydroxyvitamin D, calcium, and inorganic phosphorus.	1,25-dihydroxyvitamin D	85-108	bone gamma-carboxyglutamate protein	Bos taurus	7-18
1984564-0	1991	Calcitonin stimulates 1,25-dihydroxyvitamin D production in diabetic rat kidney.	1,25-dihydroxyvitamin D	22-45	calcitonin-related polypeptide alpha	Rattus norvegicus	0-10
2081010-6	1990	It is postulated that the increase in dietary sodium led to an increase in serum 1,25-dihydroxyvitamin D concentration, which may have contributed to an increase in intracellular calcium concentration, a decrease in renal secretion of renin, and a fall in plasma renin activity.	1,25-dihydroxyvitamin D	81-104	renin	Homo sapiens	235-240
2081010-6	1990	It is postulated that the increase in dietary sodium led to an increase in serum 1,25-dihydroxyvitamin D concentration, which may have contributed to an increase in intracellular calcium concentration, a decrease in renal secretion of renin, and a fall in plasma renin activity.	1,25-dihydroxyvitamin D	81-104	renin	Homo sapiens	263-268
2081010-8	1990	Therefore, 1,25-dihydroxyvitamin D may be a mediator in the response of high renin hypertension to increased sodium intake.	1,25-dihydroxyvitamin D	11-34	renin	Homo sapiens	77-82
1782101-9	1991	The immediate response to 1,25-dihydroxyvitamin D administration on the biochemical markers of formative bone cells was a marked increase in the serum level of osteocalcin (BGP), (p less than 0.002) with a gradually fall during the next weeks.	1,25-dihydroxyvitamin D	26-49	bone gamma-carboxyglutamate protein	Homo sapiens	160-171
1782101-9	1991	The immediate response to 1,25-dihydroxyvitamin D administration on the biochemical markers of formative bone cells was a marked increase in the serum level of osteocalcin (BGP), (p less than 0.002) with a gradually fall during the next weeks.	1,25-dihydroxyvitamin D	26-49	bone gamma-carboxyglutamate protein	Homo sapiens	173-176
1986022-7	1991	Biochemical parameters of bone formation, serum alkaline phosphatase and osteocalcin, showed a slight increase during the first month after stimulation of the parathyroids and a corresponding increase in serum 1,25-dihydroxyvitamin D.	1,25-dihydroxyvitamin D	210-233	bone gamma-carboxyglutamate protein	Homo sapiens	73-84
2081010-0	1990	Interaction of 1,25-dihydroxyvitamin D and plasma renin activity in high renin essential hypertension.	1,25-dihydroxyvitamin D	15-38	renin	Homo sapiens	50-55
2081010-0	1990	Interaction of 1,25-dihydroxyvitamin D and plasma renin activity in high renin essential hypertension.	1,25-dihydroxyvitamin D	15-38	renin	Homo sapiens	73-78
2167815-5	1990	Serum concentrations of 1,25-dihydroxyvitamin D (1,25-(OH)2D) were significantly higher in pGH-treated pigs than in control pigs at all time points following initiation of treatment, with the greatest difference observed at day 28 (42.4 +/- 4.9 pg/ml in controls vs. 65.4 +/- 4.7 pg/ml in pGH-treated pigs).	1,25-dihydroxyvitamin D	24-47	somatotropin	Sus scrofa	91-94
2167815-5	1990	Serum concentrations of 1,25-dihydroxyvitamin D (1,25-(OH)2D) were significantly higher in pGH-treated pigs than in control pigs at all time points following initiation of treatment, with the greatest difference observed at day 28 (42.4 +/- 4.9 pg/ml in controls vs. 65.4 +/- 4.7 pg/ml in pGH-treated pigs).	1,25-dihydroxyvitamin D	24-47	somatotropin	Sus scrofa	289-292
2299496-5	1990	These results suggest that calcium-dependent, parathyroid hormone-independent regulation of 1,25-dihydroxyvitamin D production may exist in human beings.	1,25-dihydroxyvitamin D	92-115	parathyroid hormone	Homo sapiens	46-65
2159833-0	1990	Response of plasma 1,25-dihydroxyvitamin D in the human PTH(1-34) infusion test: an improved index for the diagnosis of idiopathic hypoparathyroidism and pseudohypoparathyroidism.	1,25-dihydroxyvitamin D	19-42	parathyroid hormone	Homo sapiens	56-59
2159833-2	1990	The response of plasma levels of 1,25-dihydroxyvitamin D (1,25(OH)2D) in parathyroid hormone (PTH) infusion test was studied as a new criterion for the differential diagnosis of idiopathic hypoparathyroidism (IHP) and pseudohypoparathyroidism (PHP).	1,25-dihydroxyvitamin D	33-56	parathyroid hormone	Homo sapiens	73-92
2159833-2	1990	The response of plasma levels of 1,25-dihydroxyvitamin D (1,25(OH)2D) in parathyroid hormone (PTH) infusion test was studied as a new criterion for the differential diagnosis of idiopathic hypoparathyroidism (IHP) and pseudohypoparathyroidism (PHP).	1,25-dihydroxyvitamin D	33-56	parathyroid hormone	Homo sapiens	94-97
2168795-2	1990	The results showed that vitamin D deficiency rickets (VDR) were still present in some infants when vitamin D was sufficient, because of deficiency of 1,25-dihydroxyvitamin D (1,25-(OH)2D3).	1,25-dihydroxyvitamin D	150-173	vitamin D receptor	Homo sapiens	54-57
2153516-1	1990	The biological actions of 1,25-dihydroxyvitamin D [1,25-(OH)2D] are mediated by specific binding of the hormone with an intracellular vitamin D receptor, which ultimately regulates expression of genes within the target tissues.	1,25-dihydroxyvitamin D	26-49	vitamin D receptor	Rattus norvegicus	134-152
2163713-2	1990	Recent evidence suggests that intracellular phosphate (Pi) retention in CRF plays a major role in decreasing serum 1,25-dihydroxyvitamin D (1,25(OH)2D) levels, which are responsible for the progressive rise in serum parathyroid hormone (PTH) concentrations through the direct action of 1,25(OH)2D on the parathyroid gland.	1,25-dihydroxyvitamin D	115-138	parathyroid hormone	Homo sapiens	216-235
2163713-2	1990	Recent evidence suggests that intracellular phosphate (Pi) retention in CRF plays a major role in decreasing serum 1,25-dihydroxyvitamin D (1,25(OH)2D) levels, which are responsible for the progressive rise in serum parathyroid hormone (PTH) concentrations through the direct action of 1,25(OH)2D on the parathyroid gland.	1,25-dihydroxyvitamin D	115-138	parathyroid hormone	Homo sapiens	237-240
2159486-3	1990	The PTH-induced rise in serum 1,25-dihydroxyvitamin-D was significantly smaller in the hyperparathyroid patients than in either the controls or the hypercalciuric patients.	1,25-dihydroxyvitamin D	30-53	parathyroid hormone	Homo sapiens	4-7
2156649-10	1990	In contrast, in the haemodialysis patients previously treated with 1,25-dihydroxyvitamin D, acetazolamide increased serum inorganic phosphorus, bone isoenzyme of alkaline phosphatase, parathyroid hormone and serum calcium.	1,25-dihydroxyvitamin D	67-90	parathyroid hormone	Homo sapiens	184-203
34757587-2	2021	The principal actions of FGF23 are to reduce serum phosphate levels by decreasing kidney phosphate reabsorption and 1,25-dihydroxyvitamin D synthesis.	1,25-dihydroxyvitamin D	116-139	fibroblast growth factor 23	Homo sapiens	25-30
33767635-1	2021	Fibroblast growth factor-23 (FGF)-23 is a phosphaturic hormone involved in mineral bone metabolism that helps control phosphate homeostasis and reduces 1,25-dihydroxyvitamin D synthesis.	1,25-dihydroxyvitamin D	152-175	fibroblast growth factor 23	Homo sapiens	0-36
34890768-0	2022	Inhibition of Nrf2 degradation alleviates age-related osteoporosis induced by 1,25-Dihydroxyvitamin D deficiency.	1,25-dihydroxyvitamin D	78-101	nuclear factor, erythroid derived 2, like 2	Mus musculus	14-18
34950835-1	2021	The presence of the vitamin D receptor (VDR) in mammary gland and breast cancer has long been recognized, and multiple preclinical studies have demonstrated that its ligand, 1,25-dihydroxyvitamin D (1,25D), modulates normal mammary gland development and inhibits growth of breast tumors in animal models.	1,25-dihydroxyvitamin D	174-197	vitamin D receptor	Homo sapiens	20-38
34950835-1	2021	The presence of the vitamin D receptor (VDR) in mammary gland and breast cancer has long been recognized, and multiple preclinical studies have demonstrated that its ligand, 1,25-dihydroxyvitamin D (1,25D), modulates normal mammary gland development and inhibits growth of breast tumors in animal models.	1,25-dihydroxyvitamin D	174-197	vitamin D receptor	Homo sapiens	40-43
34887675-0	2021	1,25-Dihydroxyvitamin D Inhibits Osteoarthritis by Modulating Interaction Between Vitamin D Receptor and NLRP3 in Macrophages.	1,25-dihydroxyvitamin D	0-23	vitamin D (1,25-dihydroxyvitamin D3) receptor	Mus musculus	82-100
34887675-0	2021	1,25-Dihydroxyvitamin D Inhibits Osteoarthritis by Modulating Interaction Between Vitamin D Receptor and NLRP3 in Macrophages.	1,25-dihydroxyvitamin D	0-23	NLR family, pyrin domain containing 3	Mus musculus	105-110
34523743-2	2021	In XLH, increased circulating fibroblast growth factor 23 (FGF23) levels cause renal phosphate wasting and low concentrations of 1,25-dihydroxyvitamin D, leading to an early clinical manifestation of rickets.	1,25-dihydroxyvitamin D	129-152	fibroblast growth factor 23	Mus musculus	30-57
34523743-2	2021	In XLH, increased circulating fibroblast growth factor 23 (FGF23) levels cause renal phosphate wasting and low concentrations of 1,25-dihydroxyvitamin D, leading to an early clinical manifestation of rickets.	1,25-dihydroxyvitamin D	129-152	fibroblast growth factor 23	Mus musculus	59-64
34249156-15	2021	The NF is a bioavailable source of the biologically active metabolite of vitamin D, i.e. 1,25-dihydroxyvitamin D.	1,25-dihydroxyvitamin D	89-112	neurofascin	Homo sapiens	4-6
34799645-9	2021	MPC cells secreted intact (iFGF23) and C-terminal (cFGF23) forms of the endocrine hormone FGF23, which was upregulated by 1,25 dihydroxy vitamin D (1,25D).	1,25-dihydroxyvitamin D	122-146	fibroblast growth factor 23	Mus musculus	90-95
34950831-2	2021	Cells of the immune and cardiovascular systems and lungs can express the vitamin D receptor, and overall these cells respond in a coherent fashion when exposed to 1,25-dihydroxyvitamin D, the main metabolite of the VDES.	1,25-dihydroxyvitamin D	163-186	vitamin D receptor	Homo sapiens	73-91
34519274-1	2021	Low serum 1,25-dihydroxyvitamin D (1,25(OH)2D) in end stage renal disease (ESRD) is considered a consequence of elevated fibroblast growth factor 23 (FGF23) and concomitant reduced activity of renal 1alpha-hydroxylase (CYP27B1).	1,25-dihydroxyvitamin D	10-33	fibroblast growth factor 23	Homo sapiens	121-148
34519274-1	2021	Low serum 1,25-dihydroxyvitamin D (1,25(OH)2D) in end stage renal disease (ESRD) is considered a consequence of elevated fibroblast growth factor 23 (FGF23) and concomitant reduced activity of renal 1alpha-hydroxylase (CYP27B1).	1,25-dihydroxyvitamin D	10-33	fibroblast growth factor 23	Homo sapiens	150-155
34519274-1	2021	Low serum 1,25-dihydroxyvitamin D (1,25(OH)2D) in end stage renal disease (ESRD) is considered a consequence of elevated fibroblast growth factor 23 (FGF23) and concomitant reduced activity of renal 1alpha-hydroxylase (CYP27B1).	1,25-dihydroxyvitamin D	10-33	cytochrome P450 family 27 subfamily B member 1	Homo sapiens	219-226
34504604-2	2021	Abnormally elevated levels of 1,25-dihydroxyvitamin D cause osteocytes to secrete FGF23, which subsequently induces phosphaturia.	1,25-dihydroxyvitamin D	30-53	fibroblast growth factor 23	Homo sapiens	82-87
34322901-5	2021	Two VDR gene polymorphisms (rs851998024 and rs852900542) were detected by specific TaqMan real-time polymerase chain reaction assay, and their relationship with serum 1,25-dihydroxyvitamin D, serum and urinary electrolyte concentrations was evaluated.	1,25-dihydroxyvitamin D	167-190	vitamin D receptor	Canis lupus familiaris	4-7
34203792-3	2021	Typical biochemical findings include elevated serum levels of bioactive/intact fibroblast growth factor 23 (FGF23) which lead to (i) low serum phosphate levels, (ii) increased fractional excretion of phosphate, and (iii) inappropriately low or normal 1,25-dihydroxyvitamin D (1,25-vitD).	1,25-dihydroxyvitamin D	251-274	fibroblast growth factor 23	Homo sapiens	79-106
34203792-3	2021	Typical biochemical findings include elevated serum levels of bioactive/intact fibroblast growth factor 23 (FGF23) which lead to (i) low serum phosphate levels, (ii) increased fractional excretion of phosphate, and (iii) inappropriately low or normal 1,25-dihydroxyvitamin D (1,25-vitD).	1,25-dihydroxyvitamin D	276-285	fibroblast growth factor 23	Homo sapiens	108-113
34203792-3	2021	Typical biochemical findings include elevated serum levels of bioactive/intact fibroblast growth factor 23 (FGF23) which lead to (i) low serum phosphate levels, (ii) increased fractional excretion of phosphate, and (iii) inappropriately low or normal 1,25-dihydroxyvitamin D (1,25-vitD).	1,25-dihydroxyvitamin D	251-274	fibroblast growth factor 23	Homo sapiens	108-113
34203792-8	2021	Burosumab binds circulating intact FGF23 and blocks its biological effects in target tissues, resulting in increased serum inorganic phosphate (Pi) concentrations and increased conversion of inactive vitamin D to active 1,25-vitD.	1,25-dihydroxyvitamin D	220-229	fibroblast growth factor 23	Homo sapiens	35-40
34203792-3	2021	Typical biochemical findings include elevated serum levels of bioactive/intact fibroblast growth factor 23 (FGF23) which lead to (i) low serum phosphate levels, (ii) increased fractional excretion of phosphate, and (iii) inappropriately low or normal 1,25-dihydroxyvitamin D (1,25-vitD).	1,25-dihydroxyvitamin D	276-285	fibroblast growth factor 23	Homo sapiens	79-106
34066482-3	2021	Moreover, the active form of vitamin D, i.e., 1,25-dihydroxyvitamin D, exerts various effects via its interaction with the vitamin D receptor on the innate and adaptive immune system, which could be relevant in the onset of tumors.	1,25-dihydroxyvitamin D	46-69	vitamin D receptor	Homo sapiens	123-141
2510826-4	1989	The mitogenic effect of 1,25-dihydroxyvitamin D-3 was correlated with an increase in c-myc mRNA and a decrease in c-fos mRNA levels, whereas its inhibitory action on DNA synthesis was accompanied by increased myofibrillar and microsomal protein synthesis and an elevation of creatine kinase activity, the latter suggesting a stimulation of muscle cell differentiation by the sterol.	1,25-dihydroxyvitamin D	24-47	v-myc avian myelocytomatosis viral oncogene homolog	Gallus gallus	85-90
35468986-1	2022	The active form of vitamin D, 1,25-dihydroxyvitamin D (1,25D), and its analogues signal through the nuclear vitamin D receptor (VDR), a ligand-regulated transcription factor, and have been extensively investigated as anticancer agents.	1,25-dihydroxyvitamin D	55-60	vitamin D receptor	Homo sapiens	128-131
35065959-1	2022	Levels of the Vitamin D Receptor (VDR) are highest in the intestine where it mediates 1,25 dihydroxyvitamin D-induced gene expression.	1,25-dihydroxyvitamin D	86-109	vitamin D (1,25-dihydroxyvitamin D3) receptor	Mus musculus	14-32
35065959-1	2022	Levels of the Vitamin D Receptor (VDR) are highest in the intestine where it mediates 1,25 dihydroxyvitamin D-induced gene expression.	1,25-dihydroxyvitamin D	86-109	vitamin D (1,25-dihydroxyvitamin D3) receptor	Mus musculus	34-37
35595176-3	2022	The mechanisms that underpin the link between low 25(OH)D3 and sarcopenia are yet to be fully understood but several lines of evidence have highlighted the importance of both genomic and non-genomic effects of active vitamin D (1,25-dihydroxyvitamin D (1,25(OH)2D3)) and its nuclear vitamin D receptor (VDR), in skeletal muscle functioning.	1,25-dihydroxyvitamin D	228-251	vitamin D receptor	Homo sapiens	283-301
35595176-3	2022	The mechanisms that underpin the link between low 25(OH)D3 and sarcopenia are yet to be fully understood but several lines of evidence have highlighted the importance of both genomic and non-genomic effects of active vitamin D (1,25-dihydroxyvitamin D (1,25(OH)2D3)) and its nuclear vitamin D receptor (VDR), in skeletal muscle functioning.	1,25-dihydroxyvitamin D	228-251	vitamin D receptor	Homo sapiens	303-306
35482362-8	2022	The next hydroxylation step occurs in the renal proximal tubule via the 1-alphahydroxylase enzyme (encoded by CYP27B1) thereby generating 1,25-dihydroxyvitamin D, that is, calcitriol.	1,25-dihydroxyvitamin D	138-161	cytochrome P450 family 27 subfamily B member 1	Homo sapiens	110-117
35468986-1	2022	The active form of vitamin D, 1,25-dihydroxyvitamin D (1,25D), and its analogues signal through the nuclear vitamin D receptor (VDR), a ligand-regulated transcription factor, and have been extensively investigated as anticancer agents.	1,25-dihydroxyvitamin D	30-53	vitamin D receptor	Homo sapiens	108-126
35468986-1	2022	The active form of vitamin D, 1,25-dihydroxyvitamin D (1,25D), and its analogues signal through the nuclear vitamin D receptor (VDR), a ligand-regulated transcription factor, and have been extensively investigated as anticancer agents.	1,25-dihydroxyvitamin D	30-53	vitamin D receptor	Homo sapiens	128-131
35468986-1	2022	The active form of vitamin D, 1,25-dihydroxyvitamin D (1,25D), and its analogues signal through the nuclear vitamin D receptor (VDR), a ligand-regulated transcription factor, and have been extensively investigated as anticancer agents.	1,25-dihydroxyvitamin D	55-60	vitamin D receptor	Homo sapiens	108-126
35196255-3	2022	Thus, serum 25-hydroxyvitamin D (25D) can be converted to hormonal 1,25-dihydroxyvitamin D (1,25D) within immune cells, and then interact with VDR and promote transcriptional and epigenomic responses in the same or neighbouring cells.	1,25-dihydroxyvitamin D	67-90	vitamin D receptor	Homo sapiens	143-146
34985728-3	2022	The active form of vitamin D, 1,25-dihydroxyvitamin D (1,25(OH)D), has been shown to induce the CAMP gene expression through promoter activation.	1,25-dihydroxyvitamin D	30-53	cathelicidin antimicrobial peptide	Homo sapiens	96-100
2541129-8	1989	Untreated cells produced high levels of osteocalcin, a bone-specific protein, and they responded to 1,25(OH) vitamin D by increasing osteocalcin synthesis in a dose-dependent manner.	1,25-dihydroxyvitamin D	100-118	bone gamma-carboxyglutamate protein	Homo sapiens	133-144
2544409-11	1989	4) EGF at the maximally effective dose produced a small (30%) but statistically significant (P less than 0.005) increase in serum 1,25-dihydroxyvitamin D.	1,25-dihydroxyvitamin D	130-153	epidermal growth factor like 1	Rattus norvegicus	3-6
2745825-7	1989	Parathyroid hormone administration increased plasma concentrations of 1,25-dihydroxyvitamin D and hydroxyproline prior to parturition, suggesting that both intestinal Ca absorption and bone calcium resorption were increased by administration of the hormone.	1,25-dihydroxyvitamin D	70-93	parathyroid hormone	Bos taurus	0-19
2588000-0	1989	1,25-dihydroxyvitamin D-responsive element and glucocorticoid repression in the osteocalcin gene.	1,25-dihydroxyvitamin D	0-23	bone gamma-carboxyglutamate protein	Homo sapiens	80-91
2537175-6	1989	Collectively, these data indicate that abnormal regulation of 1,25-dihydroxyvitamin D production in Hyp mice results from aberrant intracellular regulation of 25OHD-1 alpha-hydroxylase, a defect probably related to deranged phosphate transport in the renal tubule.	1,25-dihydroxyvitamin D	62-85	cytochrome P450, family 27, subfamily b, polypeptide 1	Mus musculus	159-184
2703535-0	1989	Parathyroid hormone suppression by intravenous 1,25-dihydroxyvitamin D.	1,25-dihydroxyvitamin D	47-70	parathyroid hormone	Homo sapiens	0-19
2703535-2	1989	Numerous in vitro studies in experimental animals have demonstrated a direct suppressive effect of 1,25-dihydroxyvitamin D (1,25(OH)2D) on parathyroid hormone (PTH) synthesis.	1,25-dihydroxyvitamin D	99-122	parathyroid hormone	Homo sapiens	139-158
2703535-2	1989	Numerous in vitro studies in experimental animals have demonstrated a direct suppressive effect of 1,25-dihydroxyvitamin D (1,25(OH)2D) on parathyroid hormone (PTH) synthesis.	1,25-dihydroxyvitamin D	99-122	parathyroid hormone	Homo sapiens	160-163
2764803-2	1989	The patient responded to exogenous PTH by an increase in urinary cAMP excretion and by several post cyclase parameters including an increase in serum calcium and 1,25-dihydroxyvitamin D, an increase in urinary phosphate excretion and a decrease in urinary calcium.	1,25-dihydroxyvitamin D	162-185	parathyroid hormone	Homo sapiens	35-38
3027149-5	1986	Concentrations of vitamin D, 25-hydroxyvitamin D, 24,25-dihydroxyvitamin D, and 1,25-dihydroxyvitamin D in milk of the control cows were 372 +/- 24, 264 +/- 68, 68 +/- 26, and 21 +/- 3 ng/L, respectively.	1,25-dihydroxyvitamin D	80-103	Weaning weight-maternal milk	Bos taurus	107-111
2463902-1	1989	Greater than 99% of the total circulating 1,25-dihydroxyvitamin D [1,25-(OH)2D] is bound to proteins such as the vitamin D-binding protein (DBP) and albumin; in the normal human only 0.4% of the circulating 1,25-(OH)2D is free.	1,25-dihydroxyvitamin D	42-65	GC vitamin D binding protein	Homo sapiens	113-138
2463903-0	1989	Regulation of 1,25-dihydroxyvitamin D production in human keratinocytes by interferon-gamma.	1,25-dihydroxyvitamin D	14-37	interferon gamma	Homo sapiens	75-91
2786986-4	1989	Osteocalcin levels were significantly low as compared to normal values (5.0 +/- 3.0 ng/ml vs 14.3 +/- 5.2 ng/ml, p less than 0.01) as well as urinary calcium excretion (0.02 +/- 1.01 vs 0.08 +/- 0.06, p less than 0.05); 1,25-dihydroxyvitamin D values were low only in 4 patients.	1,25-dihydroxyvitamin D	220-243	bone gamma-carboxyglutamate protein	Homo sapiens	0-11
3145795-13	1988	These changes parallel the malabsorption of calcium in young Hyp mice and reflect the lowered plasma 1,25-dihydroxyvitamin D (1,25(OH)2D) levels of young Hyp mice.	1,25-dihydroxyvitamin D	101-124	phosphate regulating endopeptidase homolog, X-linked	Mus musculus	154-157
2835240-0	1988	Evidence that calcitonin plays a role in the postnatal increase of serum 1 alpha,25-dihydroxyvitamin D.	1,25-dihydroxyvitamin D	73-102	calcitonin related polypeptide alpha	Homo sapiens	14-24
2892002-1	1987	The syndrome of humoral hypercalcaemia of malignancy (HHM) is characterised by end-organ manifestations of parathyroid-hormone (PTH)-like effects such as abnormalities of renal tubular calcium and phosphate transport, increased nephrogenous cyclic AMP and 1,25 dihydroxyvitamin D production, and increased osteoclastic bone resorption.	1,25-dihydroxyvitamin D	256-279	parathyroid hormone	Homo sapiens	107-126
2892002-1	1987	The syndrome of humoral hypercalcaemia of malignancy (HHM) is characterised by end-organ manifestations of parathyroid-hormone (PTH)-like effects such as abnormalities of renal tubular calcium and phosphate transport, increased nephrogenous cyclic AMP and 1,25 dihydroxyvitamin D production, and increased osteoclastic bone resorption.	1,25-dihydroxyvitamin D	256-279	parathyroid hormone	Homo sapiens	128-131
3124987-1	1987	For this sensitive RIA for 1 alpha,25-dihydroxyvitamin D, we used antibodies to 1 alpha,25-dihydroxycholecalciferol-3-hemisuccinate conjugated to bovine serum albumin, raised in eggs by immunization of chickens.	1,25-dihydroxyvitamin D	27-56	albumin	Gallus gallus	153-166
3311717-1	1987	To evaluate the role of insulin in 1,25-dihydroxyvitamin D [1,25(OH)2D] production in response to PTH, 25-hydroxyvitamin D-1 alpha-hydroxylase activity in kidney homogenates as well as serum 1,25(OH)2D concentration was measured both after dietary calcium (Ca) deprivation and after PTH infusion in control and streptozotocin-diabetic rats.	1,25-dihydroxyvitamin D	35-58	parathyroid hormone	Rattus norvegicus	98-101
3495547-7	1987	The rise in serum osteocalcin correlated significantly with the concomitant increase in serum 1,25-dihydroxyvitamin D concentrations.	1,25-dihydroxyvitamin D	94-117	bone gamma-carboxyglutamate protein	Homo sapiens	18-29
3495547-12	1987	APD can modulate the release of osteocalcin, possibly through stimulation of 1,25-dihydroxyvitamin D production, although other factors may be involved.	1,25-dihydroxyvitamin D	77-100	bone gamma-carboxyglutamate protein	Homo sapiens	32-43
2644746-3	1989	Before initiation of therapy, the hyperparathyroid subjects showed lower serum levels of 1,25-dihydroxyvitamin D in relation to PTH or calcium when compared with age- and sex-matched controls.	1,25-dihydroxyvitamin D	89-112	parathyroid hormone	Homo sapiens	128-131
3135085-5	1988	A significant correlation (P less than 0.001) was found between the concentration of CaBP and s-1,25-dihydroxyvitamin D (1,25(OH)2D).	1,25-dihydroxyvitamin D	94-119	S100 calcium binding protein G	Homo sapiens	85-89
3430963-0	1987	Role of 1,25-dihydroxyvitamin D on the skeletal resistance to parathyroid hormone.	1,25-dihydroxyvitamin D	8-31	parathyroid hormone	Canis lupus familiaris	62-81
2825934-2	1987	We have established a 6 hour infusion of human PTH (1-34) which identifies PTH-resistant hypoparathyroid subjects on the basis of serum 1,25-dihydroxyvitamin D (1,25(OH)2D) and calcium responses.	1,25-dihydroxyvitamin D	136-159	parathyroid hormone	Homo sapiens	47-50
2825934-2	1987	We have established a 6 hour infusion of human PTH (1-34) which identifies PTH-resistant hypoparathyroid subjects on the basis of serum 1,25-dihydroxyvitamin D (1,25(OH)2D) and calcium responses.	1,25-dihydroxyvitamin D	136-159	parathyroid hormone	Homo sapiens	75-78
2825934-3	1987	1,25-Dihydroxyvitamin D levels increased by at least 58 pmol/liter and serum calcium by at least 0.1 mmol/liter in PTH-responsive hypoparathyroid subjects (n = 6), whereas in pseudohypoparathyroid subjects (n = 5) these levels rose by less than 22 pmol/liter and 0.06 mmol/liter respectively.	1,25-dihydroxyvitamin D	0-23	parathyroid hormone	Homo sapiens	115-118
2820733-7	1987	The two PTH administrations caused a significant but variable rise of serum 1,25-dihydroxy-vitamin D in all four adults.	1,25-dihydroxyvitamin D	76-100	parathyroid hormone	Homo sapiens	8-11
3786038-0	1986	Idiopathic hypoparathyroidism: a case study on the interactions between exogenous parathyroid hormone infusion and 1,25-dihydroxyvitamin D.	1,25-dihydroxyvitamin D	115-138	parathyroid hormone	Homo sapiens	82-101
3459646-1	1986	The vitamin D-dependent calcium-binding protein (CaBP), cholecalcin or calbindin, is one of the best documented molecular expressions of 1,25-dihydroxyvitamin D, the hormonal metabolite of vitamin D.	1,25-dihydroxyvitamin D	137-160	hippocalcin	Rattus norvegicus	24-47
3782584-1	1986	Intravenous infusion of synthetic bovine parathyroid hormone for 96 h increased 1,25-dihydroxyvitamin D, Mg, Ca, and hydroxyproline in plasma of pregnant cows within 16, 24, 48, and 72 h, respectively.	1,25-dihydroxyvitamin D	80-103	parathyroid hormone	Bos taurus	41-60
3782584-3	1986	Plasma concentration of 1,25-dihydroxyvitamin D at 96 h was twice that before parathyroid hormone infusion, indicating that parathyroid hormone stimulated 1,25-dihydroxyvitamin D production in the presence of hypercalcemia.	1,25-dihydroxyvitamin D	24-47	parathyroid hormone	Bos taurus	124-143
3782584-3	1986	Plasma concentration of 1,25-dihydroxyvitamin D at 96 h was twice that before parathyroid hormone infusion, indicating that parathyroid hormone stimulated 1,25-dihydroxyvitamin D production in the presence of hypercalcemia.	1,25-dihydroxyvitamin D	155-178	parathyroid hormone	Bos taurus	124-143
3013322-4	1986	1,25-dihydroxyvitamin D-3 blunted also the cAMP response to parathyroid hormone in cells incubated with the glucocorticoid dexamethasone, where a higher activity of the adenylate cyclase catalytic unit was observed.	1,25-dihydroxyvitamin D	0-23	parathyroid hormone	Rattus norvegicus	60-79
3465901-1	1986	To test the possible impairment of vitamin D metabolism in hypertension, we studied the effect of parathyroid hormone (PTH) on the renal production of 1,25-dihydroxyvitamin D [1,25(OH)2D] in spontaneously hypertensive rats (SHR) before (at 4 weeks of age) and after (at 12 weeks of age) the onset of hypertension.	1,25-dihydroxyvitamin D	151-174	parathyroid hormone	Rattus norvegicus	98-117
3755445-4	1986	At the highest dose taken by each man (1200 mg/day in six, 900 mg/day in one, and 600 mg/day in two), serum levels of 1,25-dihydroxyvitamin D fell significantly compared to baseline [14 +/- 1 (+/- SEM) vs. 39 +/- 3 pg/ml; P less than 0.001), but there was no change in serum levels of 25-hydroxyvitamin D, PTH, calcium, phosphate, or alkaline phosphatase.	1,25-dihydroxyvitamin D	118-141	parathyroid hormone	Homo sapiens	306-309
3459646-1	1986	The vitamin D-dependent calcium-binding protein (CaBP), cholecalcin or calbindin, is one of the best documented molecular expressions of 1,25-dihydroxyvitamin D, the hormonal metabolite of vitamin D.	1,25-dihydroxyvitamin D	137-160	hippocalcin	Rattus norvegicus	49-53
3459646-1	1986	The vitamin D-dependent calcium-binding protein (CaBP), cholecalcin or calbindin, is one of the best documented molecular expressions of 1,25-dihydroxyvitamin D, the hormonal metabolite of vitamin D.	1,25-dihydroxyvitamin D	137-160	S100 calcium binding protein G	Rattus norvegicus	56-67
3459646-1	1986	The vitamin D-dependent calcium-binding protein (CaBP), cholecalcin or calbindin, is one of the best documented molecular expressions of 1,25-dihydroxyvitamin D, the hormonal metabolite of vitamin D.	1,25-dihydroxyvitamin D	137-160	calbindin 1	Rattus norvegicus	71-80
3030793-1	1986	The capacity of parathyroid hormone (PTH) to stimulate the renal production of 1,25-dihydroxyvitamin D declines with age.	1,25-dihydroxyvitamin D	79-102	parathyroid hormone	Rattus norvegicus	16-35
3484482-2	1986	In the glucocorticoid-treated patients, the mean OC level was approximately 50% less than that in the control group (P less than 0.001), and there was a direct correlation between serum OC and 1,25-dihydroxyvitamin D [1,25-(OH)2D; r = 0.71; P less than 0.001].	1,25-dihydroxyvitamin D	193-216	bone gamma-carboxyglutamate protein	Homo sapiens	186-188
3753677-7	1986	When 1,25-dihydroxyvitamin D was administered to vitamin D-deficient chicks, the binding of CaM to the 102K CaM-binding protein appeared to increase more rapidly in BBMV from cells near the tip of the villus than in cells from more basal regions, comparable to our previously reported data for 1,25-dihydroxyvitamin D-stimulated calcium accumulation by similarly prepared BBMV.	1,25-dihydroxyvitamin D	5-28	calmodulin 1	Homo sapiens	92-95
3753677-7	1986	When 1,25-dihydroxyvitamin D was administered to vitamin D-deficient chicks, the binding of CaM to the 102K CaM-binding protein appeared to increase more rapidly in BBMV from cells near the tip of the villus than in cells from more basal regions, comparable to our previously reported data for 1,25-dihydroxyvitamin D-stimulated calcium accumulation by similarly prepared BBMV.	1,25-dihydroxyvitamin D	5-28	calmodulin 1	Homo sapiens	108-111
3753677-7	1986	When 1,25-dihydroxyvitamin D was administered to vitamin D-deficient chicks, the binding of CaM to the 102K CaM-binding protein appeared to increase more rapidly in BBMV from cells near the tip of the villus than in cells from more basal regions, comparable to our previously reported data for 1,25-dihydroxyvitamin D-stimulated calcium accumulation by similarly prepared BBMV.	1,25-dihydroxyvitamin D	294-317	calmodulin 1	Homo sapiens	92-95
3030793-1	1986	The capacity of parathyroid hormone (PTH) to stimulate the renal production of 1,25-dihydroxyvitamin D declines with age.	1,25-dihydroxyvitamin D	79-102	parathyroid hormone	Rattus norvegicus	37-40
2578454-1	1985	To study regulation of the parathyroid hormone (PTH)-responsive adenylate cyclase of osteoblast-like cells by 1,25-dihydroxyvitamin D (1,25(OH)2D), cAMP levels and adenylate cyclase activity were assayed in the hormone-responsive ROS 17/2.8 rat osteosarcoma cell line.	1,25-dihydroxyvitamin D	110-133	parathyroid hormone	Rattus norvegicus	27-46
2999175-0	1986	Receptor-positive hereditary resistance to 1,25-dihydroxyvitamin D: chromatography of hormone-receptor complexes on deoxyribonucleic acid-cellulose shows two classes of mutation.	1,25-dihydroxyvitamin D	43-66	nuclear receptor subfamily 4 group A member 1	Homo sapiens	86-102
2856782-4	1985	We observed renin-linked, heterogeneous deviations in circulating levels of the divalent cations, magnesium and ionized calcium, in addition to deviations in the calcium-regulating hormones, parathyroid hormone (PTH), calcitonin (CT), and 1,25 dihydroxyvitamin D (1,25 D).	1,25-dihydroxyvitamin D	239-262	renin	Homo sapiens	12-17
3924117-12	1985	These results indicate that, in JTC-12 cells, 1,25-dihydroxyvitamin D-3 stimulates 24-hydroxylase in a dose- and time-dependent manner by increasing the Vmax of the enzyme through a mechanism dependent upon new protein synthesis, and suggest that PTH1-34 inhibits the 1,25-dihydroxyvitamin D-3-induced stimulation of 24-hydroxylase through its effect on cyclic AMP production.	1,25-dihydroxyvitamin D	46-69	parathyroid hormone	Homo sapiens	247-251
2578454-1	1985	To study regulation of the parathyroid hormone (PTH)-responsive adenylate cyclase of osteoblast-like cells by 1,25-dihydroxyvitamin D (1,25(OH)2D), cAMP levels and adenylate cyclase activity were assayed in the hormone-responsive ROS 17/2.8 rat osteosarcoma cell line.	1,25-dihydroxyvitamin D	110-133	parathyroid hormone	Rattus norvegicus	48-51
6333810-0	1984	25-Hydroxyvitamin D and 1,25-dihydroxyvitamin D of D2 and D3 origin in maternal and umbilical cord serum after vitamin D2 supplementation in human pregnancy.	1,25-dihydroxyvitamin D	24-47	immunoglobulin heavy diversity 2-15	Homo sapiens	51-60
3838086-1	1985	For this sensitive RIA for 1 alpha,25-dihydroxyvitamin D, we used antibodies to 1 alpha,25-dihydroxycholecalciferol-3-hemisuccinate conjugated to bovine serum albumin, raised in rabbits.	1,25-dihydroxyvitamin D	27-56	albumin	Homo sapiens	153-166
6333810-1	1984	Serum concentrations of 25-hydroxyvitamin D (25-OHD) and 1,25-dihydroxyvitamin D [1,25-(OH)2D] of vitamin D2 and D3 origin were determined separately in 10 women before vitamin intake in early pregnancy, and repeated in maternal and cord serum obtained at delivery after 20 to 30 wk of vitamin D2 supplementation in a dose of 400 IU/day.	1,25-dihydroxyvitamin D	57-80	immunoglobulin heavy diversity 2-15	Homo sapiens	106-115
6541227-5	1984	The serum concentration of 1 alpha,25-dihydroxyvitamin D (1 alpha,25-(OH)2-Vit D) did not change in children and younger adults, being 42.0 +/- 1.4 (SE) pg/ml, but it significantly decreased to 31.4 +/- 1.9 pg/ml in older adults (P less than 0.01).	1,25-dihydroxyvitamin D	27-56	vitrin	Homo sapiens	75-78
6276432-0	1982	Parathyroid hormone effects on serum 1,25-dihydroxyvitamin D levels in patients with X-linked hypophosphatemic rickets: evidence for abnormal 25-hydroxyvitamin D-1-hydroxylase activity.	1,25-dihydroxyvitamin D	37-60	parathyroid hormone	Homo sapiens	0-19
6141381-8	1984	It is postulated that with increasing age 1,25-dihydroxyvitamin D levels fall, causing a rise in iPTH and thus in bone turnover, which is reflected by a rise in BGP levels.	1,25-dihydroxyvitamin D	42-65	bone gamma-carboxyglutamate protein	Homo sapiens	161-164
6600459-1	1983	The increasing serum concentrations of various hormones (PTH, PRL, estrogens, and human placental lactogen) are hypothesized to regulate 1,25-dihydroxyvitamin D [1,25(OH)2D] and possibly 24,25-dihydroxyvitamin D [24,25(OH)2D] production during pregnancy.	1,25-dihydroxyvitamin D	137-160	parathyroid hormone	Homo sapiens	57-60
6600459-1	1983	The increasing serum concentrations of various hormones (PTH, PRL, estrogens, and human placental lactogen) are hypothesized to regulate 1,25-dihydroxyvitamin D [1,25(OH)2D] and possibly 24,25-dihydroxyvitamin D [24,25(OH)2D] production during pregnancy.	1,25-dihydroxyvitamin D	137-160	prolactin	Homo sapiens	62-65
6294581-0	1983	Effect of parathyroid hormone on cAMP and 1,25-dihydroxyvitamin D formation and renal handling of phosphate in vitamin D-dependent rickets.	1,25-dihydroxyvitamin D	42-65	parathyroid hormone	Homo sapiens	10-29
6547914-0	1984	Calmodulin may mediate 1,25-dihydroxyvitamin D-stimulated intestinal calcium transport.	1,25-dihydroxyvitamin D	23-46	calmodulin 2	Gallus gallus	0-10
6611007-1	1984	We previously reported increased mean serum 1,25-dihydroxyvitamin D (1,25-(OH)2D) and increased trabecular bone remodelling in patients with medullary thyroid carcinoma (MCT) and hypercalcitoninaemia.	1,25-dihydroxyvitamin D	44-67	solute carrier family 16 member 1	Homo sapiens	170-173
6699136-3	1984	Plasma 25-hydroxyvitamin D concentrations were normal in both groups, but plasma 1,25-dihydroxyvitamin D levels in FHH were significantly lower than control (P less than 0.0025) or hyperparathyroid (P less than 0.01) values.	1,25-dihydroxyvitamin D	81-104	calcium sensing receptor	Homo sapiens	115-118
6546544-0	1984	Infusions of parathyroid hormone in ruminants: hypercalcemia and reduced plasma 1,25-dihydroxyvitamin D concentrations.	1,25-dihydroxyvitamin D	80-103	parathyroid hormone	Bos taurus	13-32
6549067-0	1984	The role of calmodulin in 1,25-dihydroxyvitamin D regulation of calcium transport across the intestinal brush border membrane.	1,25-dihydroxyvitamin D	26-49	calmodulin 1	Homo sapiens	12-22
6302126-0	1983	Effects of growth hormone replacement therapy on 1,25-dihydroxyvitamin D and calcium metabolism.	1,25-dihydroxyvitamin D	49-72	growth hormone 1	Homo sapiens	11-25
6687520-0	1983	Normocalcemia in a hypoparathyroid patient with sarcoidosis: evidence for parathyroid-hormone-independent synthesis of 1,25 dihydroxyvitamin D.	1,25-dihydroxyvitamin D	119-142	parathyroid hormone	Homo sapiens	74-93
6274485-5	1981	The authors hypothesize that the reduction in 1,25-dihydroxyvitamin D, recently reported in postmenopausal osteoporotic women, might be responsible for the increased serum levels of 25-hydroxyvitamin D through an inadequate product inhibition of liver vitamin D 25-hydroxylase.	1,25-dihydroxyvitamin D	46-69	cytochrome P450 family 2 subfamily R member 1	Homo sapiens	252-276
6249837-0	1980	Effect of growth hormone administration: reciprocal changes in serum 1 alpha,25-dihydroxyvitamin D and intestinal calcium absorption.	1,25-dihydroxyvitamin D	69-98	growth hormone 1	Homo sapiens	10-24
6255001-0	1980	Effect of parathyroid hormone on 1,25-dihydroxyvitamin D formation in type I pseudohypoparathyroidism.	1,25-dihydroxyvitamin D	33-56	parathyroid hormone	Homo sapiens	10-29
6255001-1	1980	The role of parathyroid hormone (PTH) and cAMP in the hydroxylation of 25-hydroxyvitamin D to 1,25-dihydroxyvitamin D [1,25-(OH)2D] was explored in two young male volunteers and a patient with pseudohypoparathyroidism type I.	1,25-dihydroxyvitamin D	94-117	parathyroid hormone	Homo sapiens	12-31
6250405-0	1980	Calcium-dependent, parathyroid hormone-independent regulation of 1,25-dihydroxyvitamin D.	1,25-dihydroxyvitamin D	65-88	parathyroid hormone	Rattus norvegicus	19-38
6250405-1	1980	The increase of plasma 1,25-dihydroxyvitamin D (1,25(OH)2D) in response to Ca restriction has been suggested to be essentially mediated by parathyroid hormone (PTH).	1,25-dihydroxyvitamin D	23-46	parathyroid hormone	Rattus norvegicus	139-158
6250405-1	1980	The increase of plasma 1,25-dihydroxyvitamin D (1,25(OH)2D) in response to Ca restriction has been suggested to be essentially mediated by parathyroid hormone (PTH).	1,25-dihydroxyvitamin D	23-46	parathyroid hormone	Rattus norvegicus	160-163
6101809-0	1980	Acute response of plasma 1,25-dihydroxyvitamin D to parathyroid hormone.	1,25-dihydroxyvitamin D	25-48	parathyroid hormone	Homo sapiens	52-71
7352735-0	1980	Parathyroid hormone effect on 1,25-dihydroxyvitamin D in hypoparathyroidism.	1,25-dihydroxyvitamin D	30-53	parathyroid hormone	Homo sapiens	0-19
1004133-0	1976	Circulating 1alpha,25-dihydroxyvitamin D in the chicken: enhancement by injection of prolactin and during egg laying.	1,25-dihydroxyvitamin D	12-40	prolactin	Gallus gallus	85-94
6243383-0	1980	The effect of elevated prolactin levels on plasma 1,25-dihydroxyvitamin D and intestinal absorption of calcium.	1,25-dihydroxyvitamin D	50-73	prolactin	Homo sapiens	23-32
6243383-1	1980	Because of evidence in experimental animals that prolactin stimulates production of 1,25-dihydroxyvitamin D, we evaluated several indices of calcium metabolism in patients who had hyperprolactinemia due to functioning pituitary adenomas and in normal age-matched controls.	1,25-dihydroxyvitamin D	84-107	prolactin	Homo sapiens	49-58
489718-0	1979	A patient with pseudohypoparathyroidism with increased serum calcium and 1 alpha, 25-dihydroxyvitamin D after exogenous parathyroid hormone administration.	1,25-dihydroxyvitamin D	73-103	parathyroid hormone	Homo sapiens	120-139
33608491-4	2021	All three cells lines showed intracellular DBP, with increased expression and nuclear localisation of DBP in cells treated with the active form of vitamin D, 1,25-dihydroxyvitamin D (1,25D).	1,25-dihydroxyvitamin D	158-181	D-box binding PAR bZIP transcription factor	Homo sapiens	102-105
31291127-2	2021	The activated form of vitamin D (1 alpha,25-dihydroxyvitamin D) binds to vitamin D receptor which regulates genes that control cell proliferation, differentiation and apoptosis.	1,25-dihydroxyvitamin D	33-62	vitamin D receptor	Homo sapiens	73-91
33368246-8	2021	We further functionally validated our model by demonstrating that the endogenous VDR agonist 1,25-dihydroxyvitamin D activated all tested tdTomato+ neurons in the paraventricular hypothalamus but had no effect on neurons without tdTomato fluorescence.	1,25-dihydroxyvitamin D	93-116	vitamin D (1,25-dihydroxyvitamin D3) receptor	Mus musculus	81-84
33906518-1	2021	Mutations in the PHEX gene lead to X-linked hypophosphatemia (XLH), a form of inherited rickets featuring elevated fibroblast growth factor 23 (FGF23), reduced 1,25-dihydroxyvitamin D (1,25D), and hypophosphatemia.	1,25-dihydroxyvitamin D	160-183	phosphate regulating endopeptidase homolog, X-linked	Mus musculus	17-21
33785437-1	2021	The active form of vitamin D, 1,25-dihydroxyvitamin D (1,25D) is a potent regulator of immune function, promoting anti-inflammatory, tolerogenic T cell responses by modulating antigen presentation by dendritic cells (DC).	1,25-dihydroxyvitamin D	30-53	decorin	Mus musculus	217-219
33492302-2	2021	Patients with end-stage kidney disease (ESKD) receive large amounts of calcitriol, i.e., 1,25 -dihydroxy vitamin D [1-25(OH)2D], for suppression of parathyroid hormone (PTH).	1,25-dihydroxyvitamin D	89-114	parathyroid hormone	Homo sapiens	148-167
33436077-2	2021	The active form of vitamin D, i.e., 1,25-dihydroxyvitamin D, through the interaction with vitamin D receptor, exerts different activities on the innate and adaptive immune system, among which suppression of inflammation and promotion of tolerogenic responses.	1,25-dihydroxyvitamin D	36-59	vitamin D receptor	Homo sapiens	90-108
33706890-2	2021	PTH enhances calcium reabsorption while inhibiting phosphate reabsorption in the kidneys, increases the synthesis of 1,25-dihydroxyvitamin D, which then increases gastrointestinal absorption of calcium, and increases bone resorption to increase calcium and phosphate.	1,25-dihydroxyvitamin D	117-140	parathyroid hormone	Homo sapiens	0-3
33249469-2	2021	Hormonal 1,25-dihydroxyvitamin D (1,25D) signals through the nuclear vitamin D receptor, and large-scale expression profiling has provided numerous insights into its diverse physiological roles.	1,25-dihydroxyvitamin D	9-32	vitamin D receptor	Homo sapiens	69-87
33492302-2	2021	Patients with end-stage kidney disease (ESKD) receive large amounts of calcitriol, i.e., 1,25 -dihydroxy vitamin D [1-25(OH)2D], for suppression of parathyroid hormone (PTH).	1,25-dihydroxyvitamin D	89-114	parathyroid hormone	Homo sapiens	169-172
33230698-4	2021	FGF23 inhibits the activation of 1,25-dihydroxyvitamin D that is a potent suppressor of renin biosynthesis.	1,25-dihydroxyvitamin D	33-56	fibroblast growth factor 23	Homo sapiens	0-5
33553988-0	2021	Vitamin D Receptor Mediates a Myriad of Biological Actions Dependent on Its 1,25-Dihydroxyvitamin D Ligand: Distinct Regulatory Themes Revealed by Induction of Klotho and Fibroblast Growth Factor-23.	1,25-dihydroxyvitamin D	76-99	vitamin D (1,25-dihydroxyvitamin D3) receptor	Mus musculus	0-18
33230698-4	2021	FGF23 inhibits the activation of 1,25-dihydroxyvitamin D that is a potent suppressor of renin biosynthesis.	1,25-dihydroxyvitamin D	33-56	renin	Homo sapiens	88-93
32299030-0	2020	1,25-Dihydroxyvitamin D attenuates diabetic cardiac autophagy and damage by vitamin D receptor-mediated suppression of FoxO1 translocation.	1,25-dihydroxyvitamin D	0-23	vitamin D receptor	Rattus norvegicus	76-94
33204932-2	2020	Hypophosphatemia in XLH is caused by loss of function mutations in the phosphate-regulating endopeptidase homolog X-linked (PHEX) gene, resulting in excess levels of the phosphate-regulating hormone fibroblast growth factor 23 (FGF23), which leads to renal phosphate wasting and decreased serum 1,25-dihydroxyvitamin D production.	1,25-dihydroxyvitamin D	295-318	phosphate regulating endopeptidase homolog X-linked	Homo sapiens	71-122
33204932-2	2020	Hypophosphatemia in XLH is caused by loss of function mutations in the phosphate-regulating endopeptidase homolog X-linked (PHEX) gene, resulting in excess levels of the phosphate-regulating hormone fibroblast growth factor 23 (FGF23), which leads to renal phosphate wasting and decreased serum 1,25-dihydroxyvitamin D production.	1,25-dihydroxyvitamin D	295-318	phosphate regulating endopeptidase homolog X-linked	Homo sapiens	124-128
33204932-2	2020	Hypophosphatemia in XLH is caused by loss of function mutations in the phosphate-regulating endopeptidase homolog X-linked (PHEX) gene, resulting in excess levels of the phosphate-regulating hormone fibroblast growth factor 23 (FGF23), which leads to renal phosphate wasting and decreased serum 1,25-dihydroxyvitamin D production.	1,25-dihydroxyvitamin D	295-318	fibroblast growth factor 23	Homo sapiens	199-226
33204932-2	2020	Hypophosphatemia in XLH is caused by loss of function mutations in the phosphate-regulating endopeptidase homolog X-linked (PHEX) gene, resulting in excess levels of the phosphate-regulating hormone fibroblast growth factor 23 (FGF23), which leads to renal phosphate wasting and decreased serum 1,25-dihydroxyvitamin D production.	1,25-dihydroxyvitamin D	295-318	fibroblast growth factor 23	Homo sapiens	228-233
32619592-1	2020	X-linked hypophosphatemia (XLH) caused by PHEX mutations results in elevated serum FGF23 levels, renal phosphate wasting and low 1,25-dihydroxyvitamin D.	1,25-dihydroxyvitamin D	129-152	phosphate regulating endopeptidase homolog X-linked	Homo sapiens	42-46
32872475-1	2020	(1) Background: Vitamin D receptor (VDR) is present in multiple types of blood cells, and its ligand, 1,25-dihydroxyvitamin D (1,25D), is important for the proper functioning of the immune system.	1,25-dihydroxyvitamin D	102-125	vitamin D receptor	Homo sapiens	16-34
32872475-1	2020	(1) Background: Vitamin D receptor (VDR) is present in multiple types of blood cells, and its ligand, 1,25-dihydroxyvitamin D (1,25D), is important for the proper functioning of the immune system.	1,25-dihydroxyvitamin D	102-125	vitamin D receptor	Homo sapiens	36-39
32635656-1	2020	Vitamin D is a fat-soluble vitamin that is metabolized by the liver into 25-hydroxyvitamin D [25(OH)D] and then by the kidney into 1,25-dihydroxyvitamin D [1,25(OH)2D], which activates the vitamin D receptor expressed in various cells, including immune cells, for an overall immunostimulatory effect.	1,25-dihydroxyvitamin D	131-154	vitamin D (1,25-dihydroxyvitamin D3) receptor	Mus musculus	189-207
32409924-0	2020	Effect of prolactin and estrogen on the serum level of 1,25-dihydroxy vitamin D and FGF23 in female rats.	1,25-dihydroxyvitamin D	55-79	prolactin	Rattus norvegicus	10-19
32140785-8	2020	RIS treatment also suppressed the elevation of FGF23, which was associated with increased 1,25-dihydroxyvitamin D.	1,25-dihydroxyvitamin D	90-113	fibroblast growth factor 23	Rattus norvegicus	47-52
32140785-10	2020	RIS treatment also suppressed the elevation of FGF23, which may explain the increased 1,25-dihydroxyvitamin D production during the treatment.	1,25-dihydroxyvitamin D	86-109	fibroblast growth factor 23	Rattus norvegicus	47-52
32140858-5	2020	FGF23 reduces serum Pi level by inhibiting both renal phosphate reabsorption and intestinal phosphate absorption via reduction of serum 1,25-dihydroxyvitamin D level.	1,25-dihydroxyvitamin D	136-159	fibroblast growth factor 23	Homo sapiens	0-5
32299030-0	2020	1,25-Dihydroxyvitamin D attenuates diabetic cardiac autophagy and damage by vitamin D receptor-mediated suppression of FoxO1 translocation.	1,25-dihydroxyvitamin D	0-23	forkhead box O1	Rattus norvegicus	119-124
32283207-1	2020	Intestinal calcium (Ca) absorption depends upon vitamin D signaling through the vitamin D receptor (VDR) in the proximal and distal intestine while lower VDR content causes intestinal resistance to 1,25 dihydroxyvitamin D (1,25(OH)2 D) action.	1,25-dihydroxyvitamin D	198-221	vitamin D (1,25-dihydroxyvitamin D3) receptor	Mus musculus	154-157
31783150-2	2020	The active form of vitamin D, 1,25 dihydroxyvitamin D (1,25(OH)2D), regulates myeloid cell biology and previous research showed that in mouse models 1,25(OH)2D reduced the tumor level of CD34+ cells, an MDSC precursor, and reduced metastasis.	1,25-dihydroxyvitamin D	30-53	CD34 antigen	Mus musculus	187-191
32351560-1	2020	Parathyroid glands contain the vitamin D receptor (VDR) and 25-hydroxyvitamin D-1alpha-hydroxylase (CYP27B1) and 24-hydroxylase (CYP24A1), which catalyze the production and degradation of 1,25-dihydroxyvitamin D [1,25(OH)2D], respectively.	1,25-dihydroxyvitamin D	188-211	vitamin D receptor	Homo sapiens	31-49
32351560-1	2020	Parathyroid glands contain the vitamin D receptor (VDR) and 25-hydroxyvitamin D-1alpha-hydroxylase (CYP27B1) and 24-hydroxylase (CYP24A1), which catalyze the production and degradation of 1,25-dihydroxyvitamin D [1,25(OH)2D], respectively.	1,25-dihydroxyvitamin D	188-211	vitamin D receptor	Homo sapiens	51-54
32351560-1	2020	Parathyroid glands contain the vitamin D receptor (VDR) and 25-hydroxyvitamin D-1alpha-hydroxylase (CYP27B1) and 24-hydroxylase (CYP24A1), which catalyze the production and degradation of 1,25-dihydroxyvitamin D [1,25(OH)2D], respectively.	1,25-dihydroxyvitamin D	188-211	cytochrome P450 family 27 subfamily B member 1	Homo sapiens	100-107
32351560-1	2020	Parathyroid glands contain the vitamin D receptor (VDR) and 25-hydroxyvitamin D-1alpha-hydroxylase (CYP27B1) and 24-hydroxylase (CYP24A1), which catalyze the production and degradation of 1,25-dihydroxyvitamin D [1,25(OH)2D], respectively.	1,25-dihydroxyvitamin D	188-211	cytochrome P450 family 24 subfamily A member 1	Homo sapiens	129-136
31881310-2	2020	Transepithelial intestinal Ca absorption is mediated by 1,25-dihydroxyvitamin D (1,25(OH)2D, calcitriol) through the vitamin D receptor (VDR).	1,25-dihydroxyvitamin D	56-79	vitamin D (1,25-dihydroxyvitamin D3) receptor	Mus musculus	137-140
31965544-2	2020	In this condition, the hormone fibroblast growth factor 23 (FGF23) is produced in excessive amounts for still unknown reasons, and causes renal phosphate wasting and suppression of 1,25-dihydroxyvitamin D, leading to low serum phosphate concentrations.	1,25-dihydroxyvitamin D	181-204	fibroblast growth factor 23	Homo sapiens	31-58
31965544-2	2020	In this condition, the hormone fibroblast growth factor 23 (FGF23) is produced in excessive amounts for still unknown reasons, and causes renal phosphate wasting and suppression of 1,25-dihydroxyvitamin D, leading to low serum phosphate concentrations.	1,25-dihydroxyvitamin D	181-204	fibroblast growth factor 23	Homo sapiens	60-65
32045827-2	2020	FGF23 production is stimulated by 1alpha,25-dihydroxyvitamin D in osteocytes.	1,25-dihydroxyvitamin D	34-62	fibroblast growth factor 23	Mus musculus	0-5
32045827-5	2020	We also investigated differences in the induction of FGF23 by 1alpha,25-dihydroxyvitamin D and various vitamin D analogs.	1,25-dihydroxyvitamin D	62-90	fibroblast growth factor 23	Mus musculus	53-58
32918225-3	2020	While the p53 clan, mostly in the nucleoplasm, responds to a large and still growing number of alterations in cellular homeostasis commonly referred to as stress, the nuclear VDR is transcriptionally activated after binding its naturally occurring biologically active ligand 1,25-dihydroxyvitamin D with high affinity.	1,25-dihydroxyvitamin D	275-298	transformation related protein 53, pseudogene	Mus musculus	10-13
31468534-3	2020	Real-time polymerase chain reaction and western-blot analysis were used to study the effect of CUR or 1,25-dihydroxyvitamin D (1,25(OH)2 D3 ) on the expression of H19, miR-675, and VDR.	1,25-dihydroxyvitamin D	102-125	H19 imprinted maternally expressed transcript	Homo sapiens	163-166
31468534-3	2020	Real-time polymerase chain reaction and western-blot analysis were used to study the effect of CUR or 1,25-dihydroxyvitamin D (1,25(OH)2 D3 ) on the expression of H19, miR-675, and VDR.	1,25-dihydroxyvitamin D	102-125	microRNA 675	Homo sapiens	168-175
31468534-3	2020	Real-time polymerase chain reaction and western-blot analysis were used to study the effect of CUR or 1,25-dihydroxyvitamin D (1,25(OH)2 D3 ) on the expression of H19, miR-675, and VDR.	1,25-dihydroxyvitamin D	102-125	vitamin D receptor	Homo sapiens	181-184
31926093-1	2020	Background Hereditary vitamin D resistant rickets (HVDRR) is a bone disorder characterized by a phenotype of rickets with onset at early stage of life with elevated alkaline phosphatase, hypocalcemia, hypophosphatemia, hyperparathyroidism and elevated levels of 1,25-dihydroxyvitamin D (calcitriol) as a consequence of the resistance of the vitamin D receptor (VDR).	1,25-dihydroxyvitamin D	262-285	vitamin D receptor	Homo sapiens	52-55
32053638-8	2020	Women with lower calcitriol (1,25-dihydroxyvitamin D), the active form of vitamin D, were more likely to have an infant with congenital (OR 12.2 [95% CI 1.61-92.2] P = 0.02) and peri/postnatal (OR 9.84 [95% CI 2.63-36.8] P = 0.0007) infections in multivariate analyses, independent of maternal HIV viral load and CD4 count.	1,25-dihydroxyvitamin D	29-52	CD4 molecule	Homo sapiens	313-316
31880094-0	2020	1,25-Dihydroxyvitamin D protects against age-related osteoporosis by a novel VDR-Ezh2-p16 signal axis.	1,25-dihydroxyvitamin D	0-23	vitamin D (1,25-dihydroxyvitamin D3) receptor	Mus musculus	77-80
31880094-0	2020	1,25-Dihydroxyvitamin D protects against age-related osteoporosis by a novel VDR-Ezh2-p16 signal axis.	1,25-dihydroxyvitamin D	0-23	enhancer of zeste 2 polycomb repressive complex 2 subunit	Mus musculus	81-85
31880094-0	2020	1,25-Dihydroxyvitamin D protects against age-related osteoporosis by a novel VDR-Ezh2-p16 signal axis.	1,25-dihydroxyvitamin D	0-23	cyclin dependent kinase inhibitor 2A	Mus musculus	86-89
32918225-3	2020	While the p53 clan, mostly in the nucleoplasm, responds to a large and still growing number of alterations in cellular homeostasis commonly referred to as stress, the nuclear VDR is transcriptionally activated after binding its naturally occurring biologically active ligand 1,25-dihydroxyvitamin D with high affinity.	1,25-dihydroxyvitamin D	275-298	vitamin D (1,25-dihydroxyvitamin D3) receptor	Mus musculus	175-178
32918225-7	2020	A second level of interaction is characterized by binding of VDR and p53 protein, an observation that may be of relevance for the ability of 1,25-dihydroxyvitamin D to increase the survival of skin cells after UV irradiation.	1,25-dihydroxyvitamin D	141-164	vitamin D (1,25-dihydroxyvitamin D3) receptor	Mus musculus	61-64
32918225-7	2020	A second level of interaction is characterized by binding of VDR and p53 protein, an observation that may be of relevance for the ability of 1,25-dihydroxyvitamin D to increase the survival of skin cells after UV irradiation.	1,25-dihydroxyvitamin D	141-164	transformation related protein 53, pseudogene	Mus musculus	69-72
32918225-8	2020	UV irradiation-surviving cells show significant reductions in thymine dimers in the presence of 1,25-dihydroxyvitamin D that are associated with increased nuclear p53 protein expression and significantly reduced NO products.	1,25-dihydroxyvitamin D	96-119	transformation related protein 53, pseudogene	Mus musculus	163-166
31102703-1	2020	CYP24A1, Vitamin D 24-hydroxylase catabolizes 25-hydroxyvitamin D (25(OH)D) and 1,25-dihydroxyvitamin D to 24-hydroxylated vitamin D products.	1,25-dihydroxyvitamin D	80-103	cytochrome P450 family 24 subfamily A member 1	Homo sapiens	0-7
31792685-6	2020	FGF23 also decreases 1,25-dihydroxyvitamin D levels by regulating the expression of vitamin D-metabolizing enzymes, which results in reduced intestinal phosphate absorption.	1,25-dihydroxyvitamin D	21-44	fibroblast growth factor 23	Homo sapiens	0-5
32001956-0	2020	Association of increased renal Cyp24a1 gene expression with low plasma 1,25-dihydroxyvitamin D levels in rats with streptozotocin-induced diabetes.	1,25-dihydroxyvitamin D	71-94	cytochrome P450, family 24, subfamily a, polypeptide 1	Rattus norvegicus	31-38
31949415-10	2019	However, serum hepcidin levels were correlated with 1,25-dihydroxyvitamin D and interleukin-6 levels (p=0.013 and p=0.002, respectively).	1,25-dihydroxyvitamin D	52-75	hepcidin antimicrobial peptide	Homo sapiens	15-23
31792685-8	2020	In contrast, deficient actions of FGF23 result in hyperphosphatemic tumoral calcinosis with high 1,25-dihydroxyvitamin D levels.	1,25-dihydroxyvitamin D	97-120	fibroblast growth factor 23	Homo sapiens	34-39
31102703-1	2020	CYP24A1, Vitamin D 24-hydroxylase catabolizes 25-hydroxyvitamin D (25(OH)D) and 1,25-dihydroxyvitamin D to 24-hydroxylated vitamin D products.	1,25-dihydroxyvitamin D	80-103	cytochrome P450 family 24 subfamily A member 1	Homo sapiens	9-33
31768494-6	2019	Moreover, SGLT2is may induce an increase in serum phosphate, FGF-23, and PTH; reduce 1,25-dihydroxyvitamin D; and generate normal serum calcium.	1,25-dihydroxyvitamin D	85-108	solute carrier family 5 member 2	Homo sapiens	10-15
31369697-1	2019	In adults with X-linked hypophosphatemia (XLH), excess FGF23 impairs renal phosphate reabsorption and suppresses production of 1,25-dihydroxyvitamin D, resulting in chronic hypophosphatemia and persistent osteomalacia.	1,25-dihydroxyvitamin D	127-150	fibroblast growth factor 23	Homo sapiens	55-60
31729682-3	2019	Biological studies were remarkable for PTH-independent severe hypercalcemia with low 25-hydroxyvitamin D and a paradoxically elevated 1,25-dihydroxyvitamin D.	1,25-dihydroxyvitamin D	134-157	parathyroid hormone	Homo sapiens	39-42
31805709-1	2019	The protein 1alpha-hydroxylase (CYP27B1) was expressed in liver and omega-3 fatty acid (FA) elevated 1,25-dihydroxyvitamin D [1,25(OH)2D] levels in dialysis patients.	1,25-dihydroxyvitamin D	101-124	cytochrome P450 family 27 subfamily B member 1	Homo sapiens	32-39
31237611-0	2019	1,25-Dihydroxyvitamin D Maintains Brush Border Membrane NaPi2a and Attenuates Phosphaturia in Hyp Mice.	1,25-dihydroxyvitamin D	0-23	solute carrier family 34 (sodium phosphate), member 1	Mus musculus	56-62
30484255-0	2019	Resveratrol and 1,25-dihydroxyvitamin D co-administration protects the heart against D-galactose-induced aging in rats: evaluation of serum and cardiac levels of klotho.	1,25-dihydroxyvitamin D	16-39	Klotho	Rattus norvegicus	162-168
31104216-11	2019	In monocyte and T lymphocyte cell lines, TNF-alpha suppressed VDR expression, whereas 1,25-dihydroxyvitamin D blocked TNF-alpha-induced VDR downregulation.	1,25-dihydroxyvitamin D	86-109	tumor necrosis factor	Homo sapiens	118-127
31104216-11	2019	In monocyte and T lymphocyte cell lines, TNF-alpha suppressed VDR expression, whereas 1,25-dihydroxyvitamin D blocked TNF-alpha-induced VDR downregulation.	1,25-dihydroxyvitamin D	86-109	vitamin D receptor	Homo sapiens	136-139
31237611-5	2019	Long-term treatment of Hyp mice with 1,25-dihydroxyvitamin D (1,25D) or 1,25D analogues has been shown to improve renal phosphate wasting in the setting of increased FGF23 mRNA expression.	1,25-dihydroxyvitamin D	37-60	fibroblast growth factor 23	Mus musculus	166-171
31891001-2	2019	CYP24A1-mediated vitamin D clearance, calculated as the ratio of serum 24,25-dihydroxyvitamin D3 to 25-hydroxyvitamin D3 (the vitamin D metabolic ratio, VDMR), is induced by 1,25-dihydroxyvitamin D and may assess tissue-level activity.	1,25-dihydroxyvitamin D	174-197	cytochrome P450 family 24 subfamily A member 1	Homo sapiens	0-7
30765103-1	2019	Mutations in the SLC34A3 gene, encoding the sodium/phosphate cotransporter 2C (NPTIIc), induce decreased renal phosphate reabsorption, hypophosphatemia, decreased fibroblast growth factor 23 and parathyroid hormone, and increased 1,25-dihydroxyvitamin D (1,25[OH]2D) levels.	1,25-dihydroxyvitamin D	230-253	solute carrier family 34 member 3	Homo sapiens	17-24
30995974-9	2019	This effect might be mediated by increased colonic Cyp27b1 levels, leading to upregulation of local 1,25-dihydroxy vitamin D production.	1,25-dihydroxyvitamin D	100-124	cytochrome P450, family 27, subfamily b, polypeptide 1	Mus musculus	51-58
30907059-0	2019	1,25-Dihydroxyvitamin D exerts an antiaging role by activation of Nrf2-antioxidant signaling and inactivation of p16/p53-senescence signaling.	1,25-dihydroxyvitamin D	0-23	nuclear factor, erythroid derived 2, like 2	Mus musculus	66-70
30907059-0	2019	1,25-Dihydroxyvitamin D exerts an antiaging role by activation of Nrf2-antioxidant signaling and inactivation of p16/p53-senescence signaling.	1,25-dihydroxyvitamin D	0-23	cytochrome P450, family 2, subfamily b, polypeptide 10	Mus musculus	113-116
30907059-0	2019	1,25-Dihydroxyvitamin D exerts an antiaging role by activation of Nrf2-antioxidant signaling and inactivation of p16/p53-senescence signaling.	1,25-dihydroxyvitamin D	0-23	transformation related protein 53, pseudogene	Mus musculus	117-120
30765103-1	2019	Mutations in the SLC34A3 gene, encoding the sodium/phosphate cotransporter 2C (NPTIIc), induce decreased renal phosphate reabsorption, hypophosphatemia, decreased fibroblast growth factor 23 and parathyroid hormone, and increased 1,25-dihydroxyvitamin D (1,25[OH]2D) levels.	1,25-dihydroxyvitamin D	230-253	solute carrier family 34 member 3	Homo sapiens	79-85
30915443-5	2019	Calcium transport in these tissues is regulated by a sophisticated homeostatic hormonal system that involves parathyroid hormone, and 1,25-dihydroxyvitamin D in response to decreased serum ionized calcium, detected by the calcium-sensing receptor (1).	1,25-dihydroxyvitamin D	134-157	calcium sensing receptor	Homo sapiens	222-246
30395535-4	2018	The biological activity of vitamin D occurs via two pathways: non-genomic and genomic responses, both of which involve binding of 1,25-dihydroxyvitamin D (1,25(OH)2D), the active metabolite of vitamin D binding to the vitamin D receptor (VDR).	1,25-dihydroxyvitamin D	130-153	vitamin D receptor	Homo sapiens	218-236
30959822-0	2019	Transcriptomic Response to 1,25-Dihydroxyvitamin D in Human Fibroblasts with or without a Functional Vitamin D Receptor (VDR): Novel Target Genes and Insights into VDR Basal Transcriptional Activity.	1,25-dihydroxyvitamin D	27-50	vitamin D receptor	Homo sapiens	101-119
30959822-0	2019	Transcriptomic Response to 1,25-Dihydroxyvitamin D in Human Fibroblasts with or without a Functional Vitamin D Receptor (VDR): Novel Target Genes and Insights into VDR Basal Transcriptional Activity.	1,25-dihydroxyvitamin D	27-50	vitamin D receptor	Homo sapiens	121-124
30959822-0	2019	Transcriptomic Response to 1,25-Dihydroxyvitamin D in Human Fibroblasts with or without a Functional Vitamin D Receptor (VDR): Novel Target Genes and Insights into VDR Basal Transcriptional Activity.	1,25-dihydroxyvitamin D	27-50	vitamin D receptor	Homo sapiens	164-167
30959822-2	2019	While VDR activation by 1,25-dihydroxyvitamin D (1,25D) leads to robust transcriptional regulation, less is known about VDR actions in the absence of 1,25D.	1,25-dihydroxyvitamin D	24-47	vitamin D receptor	Homo sapiens	6-9
31029431-1	2019	OBJECTIVE: To study the reproductive history of patients with hereditary 1,25-dihydroxyvitamin D-resistant rickets (HVDRR) who have a nonfunctioning vitamin D receptor (VDR).	1,25-dihydroxyvitamin D	73-96	vitamin D receptor	Homo sapiens	149-167
31029431-1	2019	OBJECTIVE: To study the reproductive history of patients with hereditary 1,25-dihydroxyvitamin D-resistant rickets (HVDRR) who have a nonfunctioning vitamin D receptor (VDR).	1,25-dihydroxyvitamin D	73-96	vitamin D receptor	Homo sapiens	117-120
31218207-2	2019	Elevated serum phosphorus and 1,25dihydroxyvitaminD stimulates FGF23 production to promote renal phosphate excretion and decrease 1,25dihydroxyvitaminD synthesis.	1,25-dihydroxyvitamin D	30-51	fibroblast growth factor 23	Homo sapiens	63-68
31218207-2	2019	Elevated serum phosphorus and 1,25dihydroxyvitaminD stimulates FGF23 production to promote renal phosphate excretion and decrease 1,25dihydroxyvitaminD synthesis.	1,25-dihydroxyvitamin D	130-151	fibroblast growth factor 23	Homo sapiens	63-68
31258606-1	2019	Objective: This study was conducted to explore the relationship between 1,25-dihydroxy vitamin D (1,25(OH)2D) and Vitamin-D binding protein (DBP) in patients with periodontitis and healthy controls.	1,25-dihydroxyvitamin D	72-96	GC vitamin D binding protein	Homo sapiens	114-139
31258606-1	2019	Objective: This study was conducted to explore the relationship between 1,25-dihydroxy vitamin D (1,25(OH)2D) and Vitamin-D binding protein (DBP) in patients with periodontitis and healthy controls.	1,25-dihydroxyvitamin D	72-96	GC vitamin D binding protein	Homo sapiens	141-144
30513912-1	2018	In chronic kidney disease (CKD), hyperphosphatemia induces fibroblast growth factor-23 (FGF-23) expression that disturbs renal 1,25-dihydroxy vitamin D (1,25D) synthesis; thereby increasing parathyroid hormone (PTH) production.	1,25-dihydroxyvitamin D	127-151	fibroblast growth factor 23	Homo sapiens	59-86
30513912-1	2018	In chronic kidney disease (CKD), hyperphosphatemia induces fibroblast growth factor-23 (FGF-23) expression that disturbs renal 1,25-dihydroxy vitamin D (1,25D) synthesis; thereby increasing parathyroid hormone (PTH) production.	1,25-dihydroxyvitamin D	127-151	fibroblast growth factor 23	Homo sapiens	88-94
30395535-4	2018	The biological activity of vitamin D occurs via two pathways: non-genomic and genomic responses, both of which involve binding of 1,25-dihydroxyvitamin D (1,25(OH)2D), the active metabolite of vitamin D binding to the vitamin D receptor (VDR).	1,25-dihydroxyvitamin D	130-153	vitamin D receptor	Homo sapiens	238-241
30364037-1	2018	The biologically active form of vitamin D, 1,25 dihydroxyvitamin D (1,25(OH)2D) and its receptor, the vitamin D receptor (VDR), play roles in maintaining oral immunity and the integrity of the periodontium.	1,25-dihydroxyvitamin D	43-66	vitamin D receptor	Homo sapiens	102-120
30136086-0	2018	Low 1,25-dihydroxyvitamin D level is associated with erythropoietin deficiency and endogenous erythropoietin resistance in patients with chronic kidney disease.	1,25-dihydroxyvitamin D	4-27	erythropoietin	Homo sapiens	53-67
30136086-0	2018	Low 1,25-dihydroxyvitamin D level is associated with erythropoietin deficiency and endogenous erythropoietin resistance in patients with chronic kidney disease.	1,25-dihydroxyvitamin D	4-27	erythropoietin	Homo sapiens	94-108
29933504-0	2018	Unique Variant of NOD2 Pediatric Granulomatous Arthritis With Severe 1,25-Dihydroxyvitamin D-Mediated Hypercalcemia and Generalized Osteosclerosis.	1,25-dihydroxyvitamin D	69-92	nucleotide binding oligomerization domain containing 2	Homo sapiens	18-22
30233662-2	2018	Therefore, the aim of the current study was to explore the effect of the active metabolite of vitamin D, 1,25-dihydroxyvitamin D (1,25-D3) on thyroid cancer cells following the downregulation of CYP24A1.	1,25-dihydroxyvitamin D	105-128	cytochrome P450 family 24 subfamily A member 1	Homo sapiens	195-202
30217807-7	2018	The SNP with the strongest association, rs17216707 (P=3.0x10-24), lies upstream of CYP24A1, which encodes the primary catabolic enzyme for 1,25-dihydroxyvitamin D and 25-hydroxyvitamin D.	1,25-dihydroxyvitamin D	139-162	cytochrome P450 family 24 subfamily A member 1	Homo sapiens	83-90
29446010-6	2018	FGF23 also inhibits production of 1alpha,25-dihydroxyvitamin D which is inappropriately low or normal in the context of hypophosphatemia.	1,25-dihydroxyvitamin D	34-62	fibroblast growth factor 23	Homo sapiens	0-5
30364037-1	2018	The biologically active form of vitamin D, 1,25 dihydroxyvitamin D (1,25(OH)2D) and its receptor, the vitamin D receptor (VDR), play roles in maintaining oral immunity and the integrity of the periodontium.	1,25-dihydroxyvitamin D	43-66	vitamin D receptor	Homo sapiens	122-125
30008960-0	2018	Optimal vitamin D spurs serotonin: 1,25-dihydroxyvitamin D represses serotonin reuptake transport (SERT) and degradation (MAO-A) gene expression in cultured rat serotonergic neuronal cell lines.	1,25-dihydroxyvitamin D	35-58	solute carrier family 6 member 4	Rattus norvegicus	99-103
30236113-1	2018	BACKGROUND: Fibroblast growth factor 23 (FGF23) regulates phosphate metabolism by increasing renal phosphate excretion and decreasing 1.25-dihydroxyvitamin D synthesis.	1,25-dihydroxyvitamin D	134-157	fibroblast growth factor 23	Homo sapiens	12-39
30236113-1	2018	BACKGROUND: Fibroblast growth factor 23 (FGF23) regulates phosphate metabolism by increasing renal phosphate excretion and decreasing 1.25-dihydroxyvitamin D synthesis.	1,25-dihydroxyvitamin D	134-157	fibroblast growth factor 23	Homo sapiens	41-46
30208925-14	2018	There was an interaction between CYP27A1 methylation level and 1,25-dihydroxyvitamin D concentration associated with the risk of TB (ORinteraction = 4.11, 95% CI 1.26-13.36, P = 0.019).	1,25-dihydroxyvitamin D	63-86	cytochrome P450 family 27 subfamily A member 1	Homo sapiens	33-40
29548779-5	2018	Parathyroid hormone was suppressed (15 pg/mL), associated with a low-normal 25-hydroxyvitamin D (26 ng/mL) concentration but high 1,25-dihydroxyvitamin D concentration (92 pg/mL).	1,25-dihydroxyvitamin D	130-153	parathyroid hormone	Homo sapiens	0-19
29183808-6	2018	In addition, 1alpha, 25 dihydroxyvitamin D (1,25(OH)2D3) promotes VDR binding to the nuclear matrix.	1,25-dihydroxyvitamin D	13-42	vitamin D3 receptor	Cricetulus griseus	66-69
29949513-0	2018	Hereditary 1,25-dihydroxyvitamin D-resistant rickets (HVDRR): clinical heterogeneity and long-term efficacious management of eight patients from four unrelated Arab families with a loss of function VDR mutation.	1,25-dihydroxyvitamin D	11-34	vitamin D receptor	Homo sapiens	55-58
29949513-2	2018	The circulating active form of vitamin D, 1,25-dihydroxyvitamin D, binds to the vitamin D receptor (VDR), which heterodimerizes with the retinoid X receptor to regulate the expression of target genes.	1,25-dihydroxyvitamin D	42-65	vitamin D receptor	Homo sapiens	80-98
29949513-2	2018	The circulating active form of vitamin D, 1,25-dihydroxyvitamin D, binds to the vitamin D receptor (VDR), which heterodimerizes with the retinoid X receptor to regulate the expression of target genes.	1,25-dihydroxyvitamin D	42-65	vitamin D receptor	Homo sapiens	100-103
29949513-2	2018	The circulating active form of vitamin D, 1,25-dihydroxyvitamin D, binds to the vitamin D receptor (VDR), which heterodimerizes with the retinoid X receptor to regulate the expression of target genes.	1,25-dihydroxyvitamin D	42-65	retinoid X receptor alpha	Homo sapiens	137-156
29575677-1	2018	The active form of vitamin D (1alpha,25-dihydroxyvitamin D) acts as a steroid hormone and binds to the vitamin D receptor.	1,25-dihydroxyvitamin D	30-58	vitamin D receptor	Homo sapiens	103-121
30008960-0	2018	Optimal vitamin D spurs serotonin: 1,25-dihydroxyvitamin D represses serotonin reuptake transport (SERT) and degradation (MAO-A) gene expression in cultured rat serotonergic neuronal cell lines.	1,25-dihydroxyvitamin D	35-58	monoamine oxidase A	Rattus norvegicus	122-127
30057603-1	2018	Objective: 1,25-Dihydroxyvitamin D (1,25([OH]2D) is considered to be a negative endogenous regulator of the renin-angiotensin-aldosterone system (RAAS), but the effect of vitamin D supplementation on the RAAS is inconclusive.	1,25-dihydroxyvitamin D	11-34	renin	Homo sapiens	108-113
30283909-2	2018	Activation of vitamin D by renal 1alpha-hydroxylation is dependent on protein binding because 1,25-dihydroxyvitamin D (1,25(OH)2D3) is formed after megalin-mediated reabsorption of 25-hydroxyvitamin D (25OHD) bound to vitamin D binding protein (DBP).	1,25-dihydroxyvitamin D	94-117	LDL receptor related protein 2	Homo sapiens	148-155
29796622-2	2018	During pregnancy, both gestational age and serum 25-hydroxyvitamin D [25(OH)D] concentrations may influence the concentrations of 1,25-dihydroxyvitamin D [1,25(OH)2D], 24,25-dihydroxyvitamin D [24,25(OH)2D], and parathyroid hormone (PTH).	1,25-dihydroxyvitamin D	130-153	parathyroid hormone	Homo sapiens	212-231
30283909-2	2018	Activation of vitamin D by renal 1alpha-hydroxylation is dependent on protein binding because 1,25-dihydroxyvitamin D (1,25(OH)2D3) is formed after megalin-mediated reabsorption of 25-hydroxyvitamin D (25OHD) bound to vitamin D binding protein (DBP).	1,25-dihydroxyvitamin D	94-117	GC vitamin D binding protein	Homo sapiens	218-243
30283909-2	2018	Activation of vitamin D by renal 1alpha-hydroxylation is dependent on protein binding because 1,25-dihydroxyvitamin D (1,25(OH)2D3) is formed after megalin-mediated reabsorption of 25-hydroxyvitamin D (25OHD) bound to vitamin D binding protein (DBP).	1,25-dihydroxyvitamin D	94-117	D-box binding PAR bZIP transcription factor	Homo sapiens	245-248
29536989-0	2018	Corrigendum: 1,25-Dihydroxyvitamin D Inhibits LPS-Induced High-Mobility Group Box 1 (HMGB1) Secretion via Targeting the NF-E2-Related Factor 2-Hemeoxygenase-1-HMGB1 Pathway in Macrophages.	1,25-dihydroxyvitamin D	13-36	high mobility group box 1	Homo sapiens	58-83
29461981-4	2018	In vitro, the mutant CYP3A4 oxidized 1,25-dihydroxyvitamin D with 10-fold greater activity than WT CYP3A4 and 2-fold greater activity than CYP24A1, the principal inactivator of vitamin D metabolites.	1,25-dihydroxyvitamin D	37-60	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	21-27
29461981-4	2018	In vitro, the mutant CYP3A4 oxidized 1,25-dihydroxyvitamin D with 10-fold greater activity than WT CYP3A4 and 2-fold greater activity than CYP24A1, the principal inactivator of vitamin D metabolites.	1,25-dihydroxyvitamin D	37-60	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	99-105
29461981-4	2018	In vitro, the mutant CYP3A4 oxidized 1,25-dihydroxyvitamin D with 10-fold greater activity than WT CYP3A4 and 2-fold greater activity than CYP24A1, the principal inactivator of vitamin D metabolites.	1,25-dihydroxyvitamin D	37-60	cytochrome P450 family 24 subfamily A member 1	Homo sapiens	139-146
29669938-9	2018	The increase in plasma FGF23 was correlated with the increase in serum phosphorus, and the decrease in plasma 1,25-dihydroxyvitamin D was correlated with the increase in plasma FGF23.	1,25-dihydroxyvitamin D	110-133	fibroblast growth factor 23	Homo sapiens	177-182
29536989-0	2018	Corrigendum: 1,25-Dihydroxyvitamin D Inhibits LPS-Induced High-Mobility Group Box 1 (HMGB1) Secretion via Targeting the NF-E2-Related Factor 2-Hemeoxygenase-1-HMGB1 Pathway in Macrophages.	1,25-dihydroxyvitamin D	13-36	high mobility group box 1	Homo sapiens	85-90
29536989-0	2018	Corrigendum: 1,25-Dihydroxyvitamin D Inhibits LPS-Induced High-Mobility Group Box 1 (HMGB1) Secretion via Targeting the NF-E2-Related Factor 2-Hemeoxygenase-1-HMGB1 Pathway in Macrophages.	1,25-dihydroxyvitamin D	13-36	high mobility group box 1	Homo sapiens	159-164
29307660-1	2018	BACKGROUND AND AIMS: The nature of the link (causal vs non-causal) between low 1,25-OH vitamin D and insulin resistance (IR) in patients with chronic kidney disease (CKD) remains elusive.	1,25-dihydroxyvitamin D	79-96	insulin	Homo sapiens	101-108
29083055-3	2018	X-linked hypophosphatemia (XLH) is characterized by elevated serum fibroblast growth factor 23 (FGF23) levels, resulting in hypophosphatemia and decreased production of 1,25 dihydroxyvitamin D (1,25D).	1,25-dihydroxyvitamin D	169-192	fibroblast growth factor 23	Mus musculus	67-94
29083055-3	2018	X-linked hypophosphatemia (XLH) is characterized by elevated serum fibroblast growth factor 23 (FGF23) levels, resulting in hypophosphatemia and decreased production of 1,25 dihydroxyvitamin D (1,25D).	1,25-dihydroxyvitamin D	169-192	fibroblast growth factor 23	Mus musculus	96-101
29515522-2	2018	FGF23 reduces serum phosphate by suppressing intestinal phosphate absorption through reducing 1,25-dihydroxyvitamin D and proximal tubular phosphate reabsorption.	1,25-dihydroxyvitamin D	94-117	fibroblast growth factor 23	Homo sapiens	0-5
30041203-2	2018	In a negative endocrine feedback loop, 1,25-dihydroxyvitamin D also stimulates FGF23 secretion.	1,25-dihydroxyvitamin D	39-62	fibroblast growth factor 23	Homo sapiens	79-84
29271617-2	2017	Fibroblast growth factor 23 is a bone-derived hormone that regulates phosphate and 1,25-dihydroxyvitamin D homeostasis as a counter regulatory factor.	1,25-dihydroxyvitamin D	83-106	fibroblast growth factor 23	Homo sapiens	0-27
29116467-2	2018	1,25-dihydroxyvitamin D (1,25(OH)2D), the active metabolite of vitamin D, is known to inhibit expression of CYP27B1, which is very similar in structure and function to CYP27A1, the synthesizing enzyme of 27HC.	1,25-dihydroxyvitamin D	0-23	cytochrome P450 family 27 subfamily B member 1	Homo sapiens	108-115
29116467-2	2018	1,25-dihydroxyvitamin D (1,25(OH)2D), the active metabolite of vitamin D, is known to inhibit expression of CYP27B1, which is very similar in structure and function to CYP27A1, the synthesizing enzyme of 27HC.	1,25-dihydroxyvitamin D	0-23	cytochrome P450 family 27 subfamily A member 1	Homo sapiens	168-175
29371756-0	2018	The age-related changes of dietary phosphate responsiveness in plasma 1,25-dihydroxyvitamin D levels and renal Cyp27b1 and Cyp24a1 gene expression is associated with renal alpha-Klotho gene expression in mice.	1,25-dihydroxyvitamin D	70-93	klotho	Mus musculus	178-184
29371756-4	2018	In fact, plasma 1,25-dihydroxyvitamin D levels showed a significant correlation with vitamin D metabolism gene Cyp27b1 and Cyp24a1 mRNA expression in the high phosphate group.	1,25-dihydroxyvitamin D	16-39	cytochrome P450, family 27, subfamily b, polypeptide 1	Mus musculus	111-118
29371756-4	2018	In fact, plasma 1,25-dihydroxyvitamin D levels showed a significant correlation with vitamin D metabolism gene Cyp27b1 and Cyp24a1 mRNA expression in the high phosphate group.	1,25-dihydroxyvitamin D	16-39	cytochrome P450, family 24, subfamily a, polypeptide 1	Mus musculus	123-130
29371756-6	2018	Furthermore, alpha-Klotho mRNA expression showed a significant negative correlation with plasma 1,25-dihydroxyvitamin D levels in the high phosphate group.	1,25-dihydroxyvitamin D	96-119	klotho	Mus musculus	19-25
29024812-0	2017	Inhibition of pyruvate carboxylase by 1alpha,25-dihydroxyvitamin D promotes oxidative stress in early breast cancer progression.	1,25-dihydroxyvitamin D	38-66	pyruvate carboxylase	Homo sapiens	14-34
29061851-4	2017	Here, we show that hormonal 1,25-dihydroxyvitamin D (1,25D) is a direct transcriptional inducer of the human genes encoding PD-L1 and PD-L2 through the vitamin D receptor, a ligand-regulated transcription factor.	1,25-dihydroxyvitamin D	28-51	CD274 molecule	Homo sapiens	124-129
29061851-4	2017	Here, we show that hormonal 1,25-dihydroxyvitamin D (1,25D) is a direct transcriptional inducer of the human genes encoding PD-L1 and PD-L2 through the vitamin D receptor, a ligand-regulated transcription factor.	1,25-dihydroxyvitamin D	28-51	programmed cell death 1 ligand 2	Homo sapiens	134-139
29061851-4	2017	Here, we show that hormonal 1,25-dihydroxyvitamin D (1,25D) is a direct transcriptional inducer of the human genes encoding PD-L1 and PD-L2 through the vitamin D receptor, a ligand-regulated transcription factor.	1,25-dihydroxyvitamin D	28-51	vitamin D receptor	Homo sapiens	152-170
29271617-3	2017	1,25-Dihydroxyvitamin D stimulates fibroblast growth factor 23 synthesis in bone, while fibroblast growth factor 23 suppresses 1,25-dihydroxyvitamin D production in the kidney.	1,25-dihydroxyvitamin D	0-23	fibroblast growth factor 23	Homo sapiens	35-62
29271617-3	2017	1,25-Dihydroxyvitamin D stimulates fibroblast growth factor 23 synthesis in bone, while fibroblast growth factor 23 suppresses 1,25-dihydroxyvitamin D production in the kidney.	1,25-dihydroxyvitamin D	127-150	fibroblast growth factor 23	Homo sapiens	88-115
29085368-0	2017	1,25-Dihydroxyvitamin D Inhibits LPS-Induced High-Mobility Group Box 1 (HMGB1) Secretion via Targeting the NF-E2-Related Factor 2-Hemeoxygenase-1-HMGB1 Pathway in Macrophages.	1,25-dihydroxyvitamin D	0-23	high mobility group box 1	Homo sapiens	146-151
29029014-0	2017	1,25-Dihydroxyvitamin D Regulation of Glutamine Synthetase and Glutamine Metabolism in Human Mammary Epithelial Cells.	1,25-dihydroxyvitamin D	0-23	glutamate-ammonia ligase	Homo sapiens	38-58
29029014-1	2017	Genomic profiling has identified a subset of metabolic genes that are altered by 1,25-dihydroxyvitamin D (1,25D) in breast cells, including GLUL, the gene that encodes glutamine synthetase (GS).	1,25-dihydroxyvitamin D	81-104	glutamate-ammonia ligase	Homo sapiens	140-144
29029014-1	2017	Genomic profiling has identified a subset of metabolic genes that are altered by 1,25-dihydroxyvitamin D (1,25D) in breast cells, including GLUL, the gene that encodes glutamine synthetase (GS).	1,25-dihydroxyvitamin D	81-104	glutamate-ammonia ligase	Homo sapiens	168-188
29085368-0	2017	1,25-Dihydroxyvitamin D Inhibits LPS-Induced High-Mobility Group Box 1 (HMGB1) Secretion via Targeting the NF-E2-Related Factor 2-Hemeoxygenase-1-HMGB1 Pathway in Macrophages.	1,25-dihydroxyvitamin D	0-23	high mobility group box 1	Homo sapiens	45-70
29085368-0	2017	1,25-Dihydroxyvitamin D Inhibits LPS-Induced High-Mobility Group Box 1 (HMGB1) Secretion via Targeting the NF-E2-Related Factor 2-Hemeoxygenase-1-HMGB1 Pathway in Macrophages.	1,25-dihydroxyvitamin D	0-23	high mobility group box 1	Homo sapiens	72-77
29085368-0	2017	1,25-Dihydroxyvitamin D Inhibits LPS-Induced High-Mobility Group Box 1 (HMGB1) Secretion via Targeting the NF-E2-Related Factor 2-Hemeoxygenase-1-HMGB1 Pathway in Macrophages.	1,25-dihydroxyvitamin D	0-23	NFE2 like bZIP transcription factor 2	Homo sapiens	107-129
28600887-2	2017	FGF23 inhibits phosphate reabsorption and suppresses 1alpha,25-dihydroxyvitamin D (1,25D) biosynthesis, analytes that differentially contribute to bone integrity and deleterious soft-tissue mineralization.	1,25-dihydroxyvitamin D	53-81	fibroblast growth factor 23	Mus musculus	0-5
28104492-0	2017	Constitutively active RAS signaling reduces 1,25 dihydroxyvitamin D-mediated gene transcription in intestinal epithelial cells by reducing vitamin D receptor expression.	1,25-dihydroxyvitamin D	44-67	vitamin D (1,25-dihydroxyvitamin D3) receptor	Mus musculus	139-157
28635660-0	2017	Diverse Regulation of Vitamin D Receptor Gene Expression by 1,25-Dihydroxyvitamin D and ATRA in Murine and Human Blood Cells at Early Stages of Their Differentiation.	1,25-dihydroxyvitamin D	60-83	vitamin D (1,25-dihydroxyvitamin D3) receptor	Mus musculus	22-40
27473561-3	2017	The 1alpha-hydroxylation of 25(OH)D in the kidney by CYP27B1 generates the fully active vitamin D metabolite, 1,25-dihydroxyvitamin D (1,25(OH)2D).	1,25-dihydroxyvitamin D	110-133	cytochrome P450 family 27 subfamily B member 1	Homo sapiens	53-60
28768705-2	2017	In CKD, vitamin D metabolism is complicated by decreased conversion of 25-hydroxyvitamin D to 1,25-dihydroxyvitamin D by CYP27B1 and possibly decreased conversion of 25-hydroxyvitamin D to 24,25-dihydroxyvitamin D by CYP24A1.	1,25-dihydroxyvitamin D	94-117	cytochrome P450 family 27 subfamily B member 1	Homo sapiens	121-128
28944088-2	2017	The known anti-proliferative and pro-apoptotic actions of the active metabolite of vitamin D, 1,25-dihydroxy-vitamin D [1,25(OH)2D] are mediated through binding to the vitamin D receptor (VDR).	1,25-dihydroxyvitamin D	94-118	vitamin D receptor	Homo sapiens	168-186
28944088-2	2017	The known anti-proliferative and pro-apoptotic actions of the active metabolite of vitamin D, 1,25-dihydroxy-vitamin D [1,25(OH)2D] are mediated through binding to the vitamin D receptor (VDR).	1,25-dihydroxyvitamin D	94-118	vitamin D receptor	Homo sapiens	188-191
28367941-1	2017	Vitamin D-dependent rickets type 2A (VDDR2A) is a rare inherited disorder with decreased tissue responsiveness to 1,25-dihydroxyvitamin D [1,25(OH)2D], caused by loss of function mutations in the vitamin D receptor (VDR) gene.	1,25-dihydroxyvitamin D	114-137	vitamin D receptor	Homo sapiens	196-214
28367941-1	2017	Vitamin D-dependent rickets type 2A (VDDR2A) is a rare inherited disorder with decreased tissue responsiveness to 1,25-dihydroxyvitamin D [1,25(OH)2D], caused by loss of function mutations in the vitamin D receptor (VDR) gene.	1,25-dihydroxyvitamin D	114-137	vitamin D receptor	Homo sapiens	216-219
28339837-3	2017	Here, we determined if 1,25-dihydroxyvitamin D (calcitriol) inhibits FGF23-induced cardiac signaling and LVH.	1,25-dihydroxyvitamin D	23-46	fibroblast growth factor 23	Rattus norvegicus	69-74
28698609-1	2017	Hereditary 1,25-dihydroxyvitamin D-resistant rickets (HVDRR) is a rare disorder, caused by bialellic mutations of the vitamin D receptor (VDR) gene, sometimes associated with alopecia.	1,25-dihydroxyvitamin D	11-34	vitamin D receptor	Homo sapiens	118-136
28698609-1	2017	Hereditary 1,25-dihydroxyvitamin D-resistant rickets (HVDRR) is a rare disorder, caused by bialellic mutations of the vitamin D receptor (VDR) gene, sometimes associated with alopecia.	1,25-dihydroxyvitamin D	11-34	vitamin D receptor	Homo sapiens	55-58
27927781-6	2017	We discovered associations of SNPs from five independent regions with serum PTH concentration, including the strongest association with rs6127099 upstream of CYP24A1 (P=4.2 x 10-53), a gene that encodes the primary catabolic enzyme for 1,25-dihydroxyvitamin D and 25-dihydroxyvitamin D.	1,25-dihydroxyvitamin D	236-259	parathyroid hormone	Homo sapiens	76-79
28095044-4	2017	The majority of circulating 25(OH)D and 1,25-dihydroxyvitamin D is tightly bound to DBP and albumin, with less than 1% circulating in an unbound form.	1,25-dihydroxyvitamin D	40-63	D-box binding PAR bZIP transcription factor	Homo sapiens	84-87
27927781-6	2017	We discovered associations of SNPs from five independent regions with serum PTH concentration, including the strongest association with rs6127099 upstream of CYP24A1 (P=4.2 x 10-53), a gene that encodes the primary catabolic enzyme for 1,25-dihydroxyvitamin D and 25-dihydroxyvitamin D.	1,25-dihydroxyvitamin D	236-259	cytochrome P450 family 24 subfamily A member 1	Homo sapiens	158-165
27412293-2	2017	Previously, we reported how the human Vitamin-D receptor (VDR) and its ligand, 1,25-dihydroxyvitamin-D (1,25-D), are associated with many chronic inflammatory and autoimmune diseases.	1,25-dihydroxyvitamin D	79-102	vitamin D receptor	Homo sapiens	38-56
28183805-7	2017	Consequently, Prx1-Cre;KLfl/fl mice had significantly lower serum FGF23 and parathyroid hormone levels, and higher renal 1-alpha-hydroxylase expression, serum 1,25-dihydroxyvitamin D, and calcium levels than KLfl/fl mice.	1,25-dihydroxyvitamin D	159-182	peroxiredoxin 1	Mus musculus	14-18
28456639-6	2017	The loss of peripheral catabolism of vitamin D metabolites in patients with an inactivating mutation of CYP24A1 is responsible for persistent high levels of 1,25-dihydroxyvitamin D especially after sun exposure and a charge of native vitamin D.	1,25-dihydroxyvitamin D	157-180	cytochrome P450 family 24 subfamily A member 1	Homo sapiens	104-111
28089917-0	2017	microRNAs and DICER1 are regulated by 1,25-dihydroxyvitamin D in prostate stroma.	1,25-dihydroxyvitamin D	38-61	dicer 1, ribonuclease III	Homo sapiens	14-20
27412293-2	2017	Previously, we reported how the human Vitamin-D receptor (VDR) and its ligand, 1,25-dihydroxyvitamin-D (1,25-D), are associated with many chronic inflammatory and autoimmune diseases.	1,25-dihydroxyvitamin D	79-102	vitamin D receptor	Homo sapiens	58-61
28713755-3	2017	Paradoxical inappropriately normal or low levels of 1,25-dihydroxyvitamin D in the setting of hypophosphatemia is due to suppressive effect of FGF23.	1,25-dihydroxyvitamin D	52-75	fibroblast growth factor 23	Homo sapiens	143-148
27535551-0	2017	Fibroblast Growth Factor 23 Regulation by Systemic and Local Osteoblast-Synthesized 1,25-Dihydroxyvitamin D.	1,25-dihydroxyvitamin D	84-107	fibroblast growth factor 23	Mus musculus	0-27
27535551-8	2017	Therefore, in addition to the direct effect of high circulating concentrations of 25-hydroxyvitamin D, local osteoblastic conversion of 25-hydroxyvitamin D to 1,25-dihydroxyvitamin D appears to be an important positive regulator of FGF23 production, particularly in uremia.	1,25-dihydroxyvitamin D	159-182	fibroblast growth factor 23	Mus musculus	232-237
27936456-0	2017	1alpha,25-dihydroxyvitamin D inhibits de novo fatty acid synthesis and lipid accumulation in metastatic breast cancer cells through down-regulation of pyruvate carboxylase.	1,25-dihydroxyvitamin D	0-28	pyruvate carboxylase	Homo sapiens	151-171
27287609-0	2017	A Case of Vitamin-D-Dependent Rickets Type 1A with Normal 1,25-Dihydroxyvitamin D Caused by Two Novel Mutations of the CYP27B1 Gene.	1,25-dihydroxyvitamin D	58-81	cytochrome P450 family 27 subfamily B member 1	Homo sapiens	119-126
27838350-1	2017	BACKGROUND: By modulating the antiviral immune response via vitamin D receptor, the active form of vitamin D (1,25-dihydroxyvitamin D, calcitriol) could play a central role in protection against respiratory virus infections.	1,25-dihydroxyvitamin D	110-133	vitamin D receptor	Homo sapiens	60-78
29074823-4	2017	The D2 and D3, which are called native vitamin D, are hydroxylated at C25 in the liver by CYP2R1 and then at C1 in the kidney by CYP27B1, to be converted to an active vitamin D metabolite, 1,25-dihydroxyvitamin D[1,25(OH)2D].	1,25-dihydroxyvitamin D	189-212	cytochrome P450 family 27 subfamily B member 1	Homo sapiens	129-136
26690787-2	2016	However, measurement of 1,25-dihydroxyvitamin D is required when disorders of 1a-hydroxylation, extrarenal 1a-hydroxylation, or vitamin D receptor defects are suspected.	1,25-dihydroxyvitamin D	24-47	vitamin D receptor	Homo sapiens	128-146
27679579-7	2016	Functional cis-elements in the CASR promoters responsive to 1,25-dihydroxyvitamin D [1,25(OH)2D], proinflammatory cytokines, and the transcription factor glial cells missing-2 (GCM2) have been characterized.	1,25-dihydroxyvitamin D	60-83	calcium sensing receptor	Homo sapiens	31-35
27679714-6	2016	Serum FGF23 levels in patients with Fanconi syndrome might be regulated by novel factors other than serum phosphate and 1,25-dihydroxyvitamin D levels.	1,25-dihydroxyvitamin D	120-143	fibroblast growth factor 23	Homo sapiens	6-11
27526034-6	2016	Consistent with this, induction of M-CSF gene expression by TGFbeta and 1,25-dihydroxyvitamin D was impaired in dermal fibroblasts isolated from VDR KO mice.	1,25-dihydroxyvitamin D	72-95	colony stimulating factor 1 (macrophage)	Mus musculus	35-40
27526034-6	2016	Consistent with this, induction of M-CSF gene expression by TGFbeta and 1,25-dihydroxyvitamin D was impaired in dermal fibroblasts isolated from VDR KO mice.	1,25-dihydroxyvitamin D	72-95	vitamin D (1,25-dihydroxyvitamin D3) receptor	Mus musculus	145-148
26639637-2	2016	Previously, we have demonstrated that mechanism by which this occurs, may include the conversion of 25D to 1,25-dihydroxyvitamin D (1,25D) by osteoclasts, catalysed by the CYP27B1 enzyme.	1,25-dihydroxyvitamin D	107-130	cytochrome P450, family 27, subfamily b, polypeptide 1	Mus musculus	172-179
26513524-1	2016	BACKGROUND AND AIM: The vitamin D receptor (VDR) regulates immune responses and inflammation through binding with 1,25-dihydroxyvitamin D, the active form of vitamin D.	1,25-dihydroxyvitamin D	114-137	vitamin D receptor	Homo sapiens	24-42
27255724-4	2016	We examined a mechanistic link between 1,25-dihydroxyvitamin D-mediated suppression of nuclear factor-kappaB (NF-kappaB) transporter, karyopherin alpha4 (KPNA4) expression and NF-kappaB activation in preadipocytes.	1,25-dihydroxyvitamin D	39-62	karyopherin alpha 4 (importin alpha 3)	Sus scrofa	134-152
27255724-4	2016	We examined a mechanistic link between 1,25-dihydroxyvitamin D-mediated suppression of nuclear factor-kappaB (NF-kappaB) transporter, karyopherin alpha4 (KPNA4) expression and NF-kappaB activation in preadipocytes.	1,25-dihydroxyvitamin D	39-62	karyopherin alpha 4 (importin alpha 3)	Sus scrofa	154-159
27255724-10	2016	1,25-dihydroxyvitamin D inhibited NF-kappaB activation and reduced KPNA4 levels through increased vitamin D receptor expression.	1,25-dihydroxyvitamin D	0-23	karyopherin alpha 4 (importin alpha 3)	Sus scrofa	67-72
27255724-11	2016	Exogenous KPNA4 rescued 1,25-dihydroxyvitamin D-dependent suppression of NF-kappaB nuclear translocation and activation.	1,25-dihydroxyvitamin D	24-47	karyopherin alpha 4 (importin alpha 3)	Sus scrofa	10-15
27255724-13	2016	CONCLUSIONS: 1,25-dihydroxyvitamin D attenuates NF-kappaB activation by targeting KPNA4.	1,25-dihydroxyvitamin D	13-36	karyopherin alpha 4 (importin alpha 3)	Sus scrofa	82-87
27408766-2	2016	This disorder is caused by homogeneous or heterogeneous mutations affecting the function of the vitamin D receptor (VDR), which lead to complete or partial target organ resistance to the action of 1,25-dihydroxy vitamin D.	1,25-dihydroxyvitamin D	197-221	vitamin D receptor	Homo sapiens	96-114
27408766-2	2016	This disorder is caused by homogeneous or heterogeneous mutations affecting the function of the vitamin D receptor (VDR), which lead to complete or partial target organ resistance to the action of 1,25-dihydroxy vitamin D.	1,25-dihydroxyvitamin D	197-221	vitamin D receptor	Homo sapiens	116-119
26751835-2	2016	Increased FGF23 decreases renal brush border membrane sodium-dependent phosphate transporter IIa (Npt2a) causing renal phosphate wasting, impairs 1-alpha hydroxylation of 25-hydroxyvitamin D, and induces the vitamin D 24-hydroxylase, leading to inappropriately low circulating levels of 1,25-dihydroxyvitamin D (1,25D).	1,25-dihydroxyvitamin D	287-310	fibroblast growth factor 23	Mus musculus	10-15
26751835-2	2016	Increased FGF23 decreases renal brush border membrane sodium-dependent phosphate transporter IIa (Npt2a) causing renal phosphate wasting, impairs 1-alpha hydroxylation of 25-hydroxyvitamin D, and induces the vitamin D 24-hydroxylase, leading to inappropriately low circulating levels of 1,25-dihydroxyvitamin D (1,25D).	1,25-dihydroxyvitamin D	287-310	solute carrier family 34 (sodium phosphate), member 1	Mus musculus	98-103
27471744-1	2016	INTRODUCTION: Fibroblast growth factor-23 (FGF23) is found as a bone derived hormone which can influence the serum levels of parathormone, phosphorous and 1, 25-dihydroxyvitamin D.	1,25-dihydroxyvitamin D	155-179	fibroblast growth factor 23	Homo sapiens	14-41
27471744-1	2016	INTRODUCTION: Fibroblast growth factor-23 (FGF23) is found as a bone derived hormone which can influence the serum levels of parathormone, phosphorous and 1, 25-dihydroxyvitamin D.	1,25-dihydroxyvitamin D	155-179	fibroblast growth factor 23	Homo sapiens	43-48
26513524-1	2016	BACKGROUND AND AIM: The vitamin D receptor (VDR) regulates immune responses and inflammation through binding with 1,25-dihydroxyvitamin D, the active form of vitamin D.	1,25-dihydroxyvitamin D	114-137	vitamin D receptor	Homo sapiens	44-47
26462119-8	2016	Treatment of C2C12 muscle cells with 1,25-dihydroxyvitamin D (VD3) reduced FOXO1 expression, nuclear translocation, and activity.	1,25-dihydroxyvitamin D	37-60	forkhead box O1	Mus musculus	75-80
25792238-3	2016	In this study, we investigated whether phosphate can enhance Fgf23 expression using the rat osteoblastic cell line UMR-106, which has been shown to express Fgf23 in response to 1,25-dihydroxyvitamin D [1,25(OH)2D].	1,25-dihydroxyvitamin D	177-200	fibroblast growth factor 23	Rattus norvegicus	156-161
26774511-0	2016	1,25-Dihydroxyvitamin D induces the glutamate transporter SLC1A1 and alters glutamate handling in non-transformed mammary cells.	1,25-dihydroxyvitamin D	0-23	solute carrier family 1 member 1	Homo sapiens	58-64
26671181-0	2016	Ablation of the Stimulatory G Protein alpha-Subunit in Renal Proximal Tubules Leads to Parathyroid Hormone-Resistance With Increased Renal Cyp24a1 mRNA Abundance and Reduced Serum 1,25-Dihydroxyvitamin D.	1,25-dihydroxyvitamin D	180-203	GNAS (guanine nucleotide binding protein, alpha stimulating) complex locus	Mus musculus	16-51
26813504-2	2016	Fibroblast growth factor 23(FGF23)is a hormone that inhibits renal phosphate reabsorption and 1,25-dihydroxyvitamin D biosynthesis.	1,25-dihydroxyvitamin D	94-117	fibroblast growth factor 23	Homo sapiens	28-33
26073451-1	2016	In X-linked hypophosphatemia (XLH), serum fibroblast growth factor 23 (FGF23) is increased and results in reduced renal maximum threshold for phosphate reabsorption (TmP), reduced serum inorganic phosphorus (Pi), and inappropriately low normal serum 1,25 dihydroxyvitamin D (1,25[OH]2 D) concentration, with subsequent development of rickets or osteomalacia.	1,25-dihydroxyvitamin D	250-273	fibroblast growth factor 23	Homo sapiens	42-69
26073451-1	2016	In X-linked hypophosphatemia (XLH), serum fibroblast growth factor 23 (FGF23) is increased and results in reduced renal maximum threshold for phosphate reabsorption (TmP), reduced serum inorganic phosphorus (Pi), and inappropriately low normal serum 1,25 dihydroxyvitamin D (1,25[OH]2 D) concentration, with subsequent development of rickets or osteomalacia.	1,25-dihydroxyvitamin D	250-273	fibroblast growth factor 23	Homo sapiens	71-76
26671181-1	2016	PTH regulates serum calcium, phosphate, and 1,25-dihydroxyvitamin D (1,25(OH)2D) levels by acting on bone and kidney.	1,25-dihydroxyvitamin D	44-67	parathyroid hormone	Mus musculus	0-3
26585929-1	2016	BACKGROUND: Patients have been described with loss-of-function CYP24A1 (cytochrome P450, family 24, subfamily A, polypeptide 1) mutations that cause a high ratio of 25-hydroxyvitamin D to 24,25-dihydroxyvitamin D [25(OH)D/24,25(OH)2D], increased serum 1,25-dihydroxyvitamin D, and resulting hypercalcemia, hypercalciuria and nephrolithiasis.	1,25-dihydroxyvitamin D	252-275	cytochrome P450 family 24 subfamily A member 1	Homo sapiens	63-70
27403416-4	2016	The active form of vitamin D, 1,25-dihydroxyvitamin D (calcitriol), is biosynthesised in the kidney through the hydroxylation of 25-hydroxycholecalciferol by the CYP27B1 enzyme.	1,25-dihydroxyvitamin D	30-53	cytochrome P450 family 27 subfamily B member 1	Homo sapiens	162-169
26238339-1	2016	Our previous studies showed that the 1,25-dihydroxyvitamin D (1,25-D3) catabolizing enzyme, 1,25-dihydoxyvitamin D 24 hydroxylase (CYP24A1) was overexpressed in colorectal tumours and its level correlated with increased proliferation.	1,25-dihydroxyvitamin D	37-60	cytochrome P450, family 24, subfamily a, polypeptide 1	Mus musculus	131-138
27440690-5	2016	We found that higher serum concentrations of inorganic phosphorus and lower serum concentrations of 1,25-dihydroxy vitamin D as well as lower fat but higher phosphorus and calcium intake were weakly but significantly associated with high serum concentrations of FGF-23, adjusted for postmenarcheal age and body weight.	1,25-dihydroxyvitamin D	100-124	fibroblast growth factor 23	Homo sapiens	262-268
27314039-0	2016	Circulating Endothelial Microparticles and Correlation of Serum 1,25-Dihydroxyvitamin D with Adiponectin, Nonesterified Fatty Acids, and Glycerol from Middle-Aged Men in China.	1,25-dihydroxyvitamin D	64-87	adiponectin, C1Q and collagen domain containing	Homo sapiens	93-104
27314039-1	2016	The aim of the present study is (1) to determine the correlation between circulating 1,25-dihydroxyvitamin D [25(OH)D] and adiponectin, nonesterified fatty acids (NEFAs), and glycerol and (2) to determine the alterations in circulating endothelial microparticles (EMPs) in Chinese male subjects with increased body mass index (BMI).	1,25-dihydroxyvitamin D	85-108	adiponectin, C1Q and collagen domain containing	Homo sapiens	123-134
26585929-1	2016	BACKGROUND: Patients have been described with loss-of-function CYP24A1 (cytochrome P450, family 24, subfamily A, polypeptide 1) mutations that cause a high ratio of 25-hydroxyvitamin D to 24,25-dihydroxyvitamin D [25(OH)D/24,25(OH)2D], increased serum 1,25-dihydroxyvitamin D, and resulting hypercalcemia, hypercalciuria and nephrolithiasis.	1,25-dihydroxyvitamin D	252-275	cytochrome P450 family 24 subfamily A member 1	Homo sapiens	72-126
26588476-3	2015	We have shown that ERK1/2 signaling blockade suppresses renal egr-1 gene expression and prevents FGF23-induced hypophosphatemia and 1,25-dihydroxyvitamin D (1,25(OH)2D) suppression in mice.	1,25-dihydroxyvitamin D	132-155	mitogen-activated protein kinase 3	Mus musculus	19-25
26459742-6	2016	The elevation of serum FGF-23 has been recognized as a common feature in CKD to maintain normophosphatemia at the expense of declining 1,25-dihydroxyvitamin D values.	1,25-dihydroxyvitamin D	135-158	fibroblast growth factor 23	Homo sapiens	23-29
27394135-1	2016	BACKGROUND/AIMS: Loss-of-function mutations in the CYP24A1 gene, which encodes the vitamin D-24 hydroxylase, have been recognized as a cause of elevated 1,25-dihydroxyvitamin D concentrations, hypercalcemia, hypercalciuria, nephrocalcinosis and nephrolithiasis in infants and adults.	1,25-dihydroxyvitamin D	153-176	cytochrome P450 family 24 subfamily A member 1	Homo sapiens	51-58
27394135-1	2016	BACKGROUND/AIMS: Loss-of-function mutations in the CYP24A1 gene, which encodes the vitamin D-24 hydroxylase, have been recognized as a cause of elevated 1,25-dihydroxyvitamin D concentrations, hypercalcemia, hypercalciuria, nephrocalcinosis and nephrolithiasis in infants and adults.	1,25-dihydroxyvitamin D	153-176	cytochrome P450 family 24 subfamily A member 1	Homo sapiens	83-107
27012053-3	2016	In addition, FGF-23 was found to inhibit the extra-renal synthesis of 1,25-dihydroxyvitamin D by human monocytes.	1,25-dihydroxyvitamin D	70-93	fibroblast growth factor 23	Homo sapiens	13-19
27194998-1	2015	BACKGROUND: The osteocyte-derived hormone, fibroblast growth factor 23 (FGF23), regulates the phosphorus metabolism and suppresses 1,25-dihydroxyvitamin D production, thereby mitigating hyperphosphatemia in patients with renal disorders.	1,25-dihydroxyvitamin D	131-154	fibroblast growth factor 23	Homo sapiens	43-70
27194998-1	2015	BACKGROUND: The osteocyte-derived hormone, fibroblast growth factor 23 (FGF23), regulates the phosphorus metabolism and suppresses 1,25-dihydroxyvitamin D production, thereby mitigating hyperphosphatemia in patients with renal disorders.	1,25-dihydroxyvitamin D	131-154	fibroblast growth factor 23	Homo sapiens	72-77